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Abstract
The InterFeron Inducible TransMembrane proteins (IFITMs) are broad-spectrum
antiviral factors. In vitro, these proteins inhibit cellular entry of many enveloped
viruses. In vivo, mice lacking expression of all Ifitm genes, or Ifitm3 alone, have been
shown to have increased pathogenesis from influenza A, respiratory syncytial, West
Nile and chikungunya virus infections. While much is known about the breadth of
antiviral action of the IFITM proteins, and more is being learnt about function in
vivo, there is currently a poor understanding of aspects of their cell biology and their
precise mechanism(s) of antiviral action. The work presented here aims to further
understanding of both of these aspects of IFITM biology.
Using morphological and biochemical techniques, I first proposed a novel topol-
ogy model for the IFITMs, in which the N-terminal domain resides in the cytoplasm,
while the C-terminal domain resides in the extracellular/lumenal space. Building
on this knowledge, an analysis of the cellular distribution was performed to better
understand how the IFITMs interact with the viruses they inhibit. The alphavirus,
Semliki Forest virus (SFV) was, for the first time, established as a model system
to investigate the antiviral functions of the IFITMs. In these studies I established
that IFITM3 blocks viral entry following endocytosis and exposure of virus to low
pH and before virus release to the cytoplasm. Finally, the properties of IFITM
restriction of SFV were compared to those associated with other viruses that enter
cells by similar mechanisms. These experiments showed that related viruses exhibit
distinct patterns of IFITM restriction suggesting these different viruses may target
distinct membrane sub-domains for fusion.
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Overall, the work presented here extends our understanding of IFITM membrane
topology and cellular distribution, defines IFITM-mediated inhibition of alphavirus
infection and raises questions about the mechanisms of inhibition for different IFITM
proteins.
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Chapter 1
Introduction
Viral infections are a severe global health burden. However, viruses themselves are molec-
ularly inert and only generate pathological consequences by co-opting cellular machinery
to replicate and spread between infected and uninfected cells. The negative consequences
of viral replication have driven the evolution of protective antiviral mechanisms within
host cells and organisms. In multicellular organisms, the major countermeasure to viral
infection is the immune system. In humans, this system can be broadly divided into two
connected arms, the innate and adaptive immune responses. The innate immune response
is triggered by the cellular detection of pathogens and acts rapidly and non-specifically to
impair replication and spread. The adaptive immune response is triggered by the innate
response and is therefore more slow acting, but plays vital roles in clearance of infection to
further limit the severity of disease and provides immunological memory. The interferon
(IFN) response is the major innate antiviral immune response initiated in humans. Upon
detection of viral infection, cells can produce IFN as a danger signal to alert surrounding
cells, and produce a broad ‘antiviral state,’ associated with the IFN-induced expression of
hundreds of IFN stimulated genes (ISGs).
It is nearly 60 years since IFN was first identified by virtue of its ability to interfere with
influenza virus replication [1]. However, the full array of cellular genes induced by IFN,
and their roles in establishing an antiviral state remains largely unknown. Until recently,
only a handful of ISGs had been characterised and the encoded proteins generally have
very broad activity, such as 2’5’-oligoadenylate synthase/ribonuclease L and protein kinase
R (see [2] for review). However, in recent years many studies have used unbiased screening
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approaches to better investigate broad sets of ISGs, often finding genes with virus specific
functions (see [3–6] for some examples). Similar approaches have been used to identify host
factors that can modulate viral infection, which have also identified ISGs. One such screen
by Brass et al. used genome-wide siRNA-mediated knockdown of host factors to identify
genes that modulate influenza A virus (IAV) infection [7]. Amongst other proteins, this
screen identified interferon inducible transmembrane protein 3 (IFITM3). In the human
genome, IFITM3 is one of a group of five IFITM genes, although only IFITM1, 2 and 3
are induced by IFN. Knockdown of IFITM3 was found to enhance IAV infection, conversely
overexpression of IFITM1, 2 or 3 inhibited replication. Not only were the IFITM proteins
antiviral against IAV, they also inhibited replication of multiple flaviviruses, suggesting
they have broad-spectrum antiviral activity [7].
Since the initial identification of IFITM-mediated antiviral activity these proteins have
been extensively studied. Through multiple studies, the antiviral activity has been ex-
tended to numerous viruses; currently representatives of over 10 viral families have been
found to be inhibited by one or more IFITM proteins (see [8–11] for various reviews and
Tables 1.1 and 1.2). Shortly after the discovery of their antiviral activity, the IFITM pro-
teins were shown to restrict IAV infection by inhibiting delivery of incoming viral nucleic
acid to the nucleus, suggesting that IFITM expression affected virus entry [12]. IAV has
since become the most highly characterised virus for IFITM-mediated inhibition of entry,
which is suggested to occur at the point of fusion between viral and cellular membranes
[13, 14]. However the precise molecular mechanism(s) underlying IFITM-mediated re-
striction remain unknown. Furthermore, since few of the viruses shown to be inhibited by
IFITM proteins have been analysed in great detail, whether these proteins inhibit entry of
all viruses in the same way, or have different modes of action, is also unknown. Moreover,
many aspects of IFITM cell biology still lack proper definition.
The work presented in this thesis was designed to develop a better understanding of
both the cell biology and antiviral functions of the IFITM proteins. Work was performed
to define the membrane topology [15] and cellular distribution of the IFITM proteins.
Representatives of the previously untested alphavirus family were assessed for IFITM-
mediated antiviral activity, with the focus being on the well characterised Semliki Forest
virus (SFV). Finding that the alphaviruses are indeed inhibited by IFITM proteins, and
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thoroughly characterising this inhibition [16] provides a powerful tool for further defining
IFITM antiviral function. Building on the work with alphaviruses, further viral families
were tested. Flaviviruses were found to have different sensitivity towards IFITM isoforms
than alphaviruses while the poxvirus, vaccinia virus (VACV), was found to be insensitive
to all IFITM proteins. These differences in sensitivity suggest IFITM-mediated inhibition
may vary between viruses. Understanding these differences will also move towards a better
understanding of IFITM antiviral function.
In order to contextualise the work presented throughout this thesis, certain concepts
will be introduced in this chapter. Because the IFITM proteins inhibit viral entry, there
is a summary of the mechanisms used by enveloped viruses to enter cells, with a focus on
alphavirus entry and membrane fusion. The alphaviruses are the main system used in this
work to study IFITM-mediated inhibition of viral infection, so these viruses will also be
introduced. Finally, the IFITM proteins will be discussed to give appropriate background
to the questions addressed in this thesis.
1.1 Enveloped virus cell entry
To allow for viral replication, genetic material must be transferred from infected to unin-
fected cells. The lipid bilayers of cells, and enveloped viruses, are physical barriers to this
transit that must be overcome. Viruses therefore occupy an interesting ecological niche,
requiring stability within an extracellular environment, to protect the genome between
cells (or host organism), but also liability to penetrate cellular membranes, disassemble
and deliver their genetic payload. Viruses are therefore produced as metastable particles;
stable within an extracellular environment, but able to rapidly disassemble upon receiving
appropriate triggers from a potential host cell.
The first interaction viruses have with new host cells is at the plasma membrane. Many
of these interactions are non-specific, often through glycoprotein or glycolipid structures,
referred to as attachment factors. One such factor is heparan sulfate that is used by
multiple viruses (e.g. herpes simplex virus-1 [17], dengue virus [18], Sindbis virus [19], and
various others [20]). Binding to attachment factors promotes interaction with receptor
molecules to promote entry (see [21–23] for reviews). Receptors are essential for viral
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replication, while attachment factors facilitate infection. These interactions are often
dictated by the envelope glycoproteins that protrude on the surface of enveloped viruses.
Upon virus binding to receptors at the cell surface, one of two fates can ensue. Either
the virus can directly penetrate the plasma membrane, or can be internalised via one or
more of several endocytic mechanisms of the cell. As discussed previously, viruses are
produced as metastable particles, requiring triggers to transition into a state capable of
delivering genetic material into a cell. For viruses that can penetrate the plasma mem-
brane, this trigger is the binding of cell surface receptor(s). One classical example of this
is HIV-1, where binding to CD4, followed by binding to co-receptors (either C-C motif
chemokine receptor 5 [CCR5] or C-X-C motif chemokine receptor 4 [CXCR4]) promotes
conformational changes to the envelope glycoprotein to fuse the viral envelope with the
plasma membrane (reviewed in [24]). While some viruses can fuse at the cell surface, the
vast majority of studied viruses are taken into cells by endocytosis [22]. The changing en-
vironment within the endosomal system provides the trigger(s) for fusion: generally these
are low pH, protease activation of viral proteins and/or further receptor binding.
1.1.1 Endocytosis
Many animal viruses subvert endocytic mechanisms of cells [22]. One of the most highly
characterised endocytic pathways, and one used by alphaviruses, is clathrin-mediated en-
docytosis (CME), where clathrin acts as a coat protein for the formation of transport
vesicles [25]. When cell surface receptors are destined for CME, there are various stages
to the formation of a clathrin coated vesicle (CCV). Initially a membrane pit needs to
form through invagination of the plasma membrane. Clathrin is unable to bind directly
to lipids or cargo proteins, and therefore relies on adaptor proteins such as AP-2. It had
been thought that binding of AP-2 to the plasma membrane through interaction with
cargo proteins [26], and the lipid phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2; [27]),
resulted in the initial curvature to form a pit. However, it has since been suggested that
curvature may initially be induced by binding of Fer/Cip4 homology domain-only pro-
teins (FCHO), epidermal growth factor substrate 15 (Eps15) and intersectins [28]. Once
AP-2 has localised to the plasma membrane, it can recruit clathrin from the cytosol to
form polygonal networks of clathrin triskelia [29]. The forming clathrin coated pit ulti-
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mately needs to pinch off from the plasma membrane and release into the cytosol, which
is achieved by the GTPase action of dynamin [30]. Once the vesicle has been released,
the clathrin coat must be disassembled by the actions of the ATPase heat shock cognate
protein 70 (Hsc70; [31]), allowing the vesicle to fuse with the endosomal system.
Various other endocytic mechanisms have evolved [32], but a full discussion of most
of these is outside the scope of this work (see Fig. 1.1 for a summary diagram). CME
has been highlighted because alphaviruses subvert this system for uptake from the plasma
membrane and delivery to the endosomal system (discussed further below). However, it is
also pertinent to briefly discuss macropinocytic uptake as this is used by VACV and possi-
bly yellow fever virus 17D strain (YFV), both of which are investigated here for sensitivity
to IFITM proteins. Macropinocytosis is a form of large-scale uptake that involves actin
based protrusions from the plasma membrane that fuse with themselves, or back with the
plasma membrane. The closure of these protrusions by membrane fusion forms an encased
volume of extracellular fluid which can enter into the endosomal system. These protrusions
from the surface of cells gives a characteristic plasma membrane ruﬄing. Thus in contrast
to CME, where a pit invaginates towards the cytosol, in macropinocytic uptake, membrane
extends away from the cell to internalise extracellular fluid and molecules. Along with the
dependence on regulators of actin polymerisation such as p21 protein-activated kinase 1
(PAK1) and Ras-related C3 botulinum toxin substrate 1 (Rac1), macropinocytosis is also
dependent on PI(3)-kinase, Na+/H+ exchangers and various other cellular factors (see [22,
32] for reviews).
The endosomal system is a highly regulated, directional pathway for protein sorting.
Upon arrival at early endosomes, cargoes have one of three fates: recycling to the plasma
membrane, retrograde transport to the trans-Golgi network, or transport to later endo-
cytic compartments including the lysosomes. For the purposes of this introduction the
maturation of early endosomes into late endosomes and cargo degradation in lysosomes
will be discussed. The other fates will not be discussed because enveloped viruses generally
do not use the recycling or retrograde pathways for entry into cells.
Early endosomes are produced by the fusion of multiple incoming transport vesicles,
and are the initial sites of sorting to determine the fate of incoming cargo. The organelles
acquire a defined lipid and protein composition [34]. One of the master regulators of early
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Figure 1.1: Summary of endocytic internalisation mechanisms. Various mecha-
nisms have evolved to allow for internalisation of substrates from the cell surface or the
extracellular space of mammalian cells. Key features of the internalisation mechanisms
are summarised here, such as the dependence on coat proteins (e.g. clathrin or caveolin),
dynamin-dependence or a need for actin-based protrusions from the cell surface. The
CLIC/GEEC pathway is characterised by clathrin-independent carriers (CLICs) that form
at the plasma membrane and later mature into early endocytic compartments referred to
as glycosylphosphotidylinositol-anchored protein enriched compartments (GEECs). The
pathway labelled as IL-2 (interleukin-2) is a clathrin-independent, dynamin-dependent
internalisation pathway that has been best characterised for the internalisation of IL-2.
Viruses are capable of subverting these internalisation mechanisms as part of their entry
pathway, with most viruses using the clathrin-mediated endocytic pathway, some exam-
ples are provided. Larger viruses such as vaccinia virus and Ebola virus rely on on uptake
through macropinocytosis. Details adapted from [21, 22, 32, 33].
28 Chapter 1
Introduction
endosomal identity is the small GTPase Rab5, which localises to the plasma membrane
and early endosomal membranes [35], and is activated by Rabex-5 [36]. Once associated
with membranes in the active GTP bound form, Rab5 recruits various effectors that
define organelle identity and perform the sorting functions of early endosomes (reviewed
in [34, 37, 38]). One such group of proteins are PI3-kinases that generate PI(3)P on the
cytoplasmic surface of early endosomes [39]. PI(3)P can subsequently regulate recruitment
of additional proteins to endosomes such as early endosomal antigen 1 (EEA1), through
the FYVE domain (Fab1, YOTB, Vac1, EEA1) [40]. The vacuolar ATPase (vATPase)
is also recruited to early endosomes, which functions to pump H+ ions into the lumen
of the organelle, and cause gradual acidification. The lumen of early endosomes ranges
from pH 6.8 - 6.1 [34], and this acidification is often necessary for ligand release from
receptors as part of the sorting process of early endosomes. Lowered pH is also required
for the degradative pathway because hydrolyases in lysosomes have optimal activity in
acidic conditions. The gradual reduction of lumenal pH also plays roles in maturation
of early endosomes into late endosomes, and has been subverted by numerous viruses to
promote their entry into cells, as discussed in more detail below.
Concomitantly with the lowering of endosomal pH, various other switches occur as
early endosomes mature to late endosomes. Rab5 and a variety of effectors again helps
dictate these changes, and there is a switch from Rab5 to Rab7, which functions to define
late endosome identity [41, 42]. Initially, Rab7 is recruited to Rab5 containing endosomes,
and this in turn suppresses the action of Rab5. These Rab5/Rab7 hybrid endosomes gen-
erate Rab7 positive sub-domains which have then been observed to break away from Rab5
sub-domains in a fission event, producing Rab7 marked late endosomes [42]. Similarly, a
PI switch occurs, with PIKfyve being recruited to membranes rich in PI(3)P (early en-
dosomes), which promotes the formation of PI(3,5)P2 on the surface of late endosomes
(reviewed [34]). Late endosomes continue to mature, and the lumenal pH becomes more
acidic, ranging from pH 6.0 to 4.9 [34].
In conjunction with the various protein and lipid changes as endosomes mature, there
are also membrane remodelling events. Membrane proteins destined for degradation are
tagged with ubiquitin by cytosolic enzymes. This post-translational modification (PTM)
promotes the recruitment of the endosomal sorting complexes required for transport (ES-
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CRT) to form intralumenal vesicles (ILVs; reviewed [43]). ESCRT promotes inward bud-
ding and scission from the limiting membrane of late endosomes to produce multivesicular
bodies (MVBs). These late endosomes/MVBs will eventually fuse with lysosomes, expos-
ing the ILVs to the hydrolytic interior of lysosomal compartments, which can have a pH
as low as 4.5 [34, 43]. This endocytic pathway, and various proteins and lipids associated
with it has been summarised in Fig. 1.2.
Virus entry through the endocytic system
A large number of enveloped viruses have adapted to subvert endocytic uptake and traffick-
ing to mediate their entry into cells. By entering into the endocytic system, virus particles
can be transported through the cytosol towards the nucleus, which may be advantageous
to viruses that replicate in the nucleus. This transport may also allow for bypass of phys-
ical barriers to infection such as the actin cortex and may act as an immune avoidance
strategy since fusion with internal membranes will not leave any viral membrane proteins
exposed on the cell surface. This route of entry also provides many different triggers to
regulate membrane fusion and penetration to the cytosol, allowing precise timing of cell
entry and potentially escape from premature activation within extracellular spaces. As
will be discussed in more detail below, SFV only requires the trigger of low pH, with a
threshold at pH ≤ 6.2 [45–48]. Thus, CME of SFV particles and delivery to early en-
dosomal compartments is sufficient to provide a trigger for entry. Other viruses, such
as IAVs, have lower pH threshold (pH 5.2 - 4.9), requiring trafficking to late endosomal
compartments [49–51].
Low pH alone is not always sufficient to promote membrane fusion. Dengue virus
(DENV) appears to have a two stage activation process where low pH acts as an initial
trigger in early endosomes and anionic lipids in late endosomes act as the secondary trigger
to enable cellular entry [52]. Severe acute respiratory syndrome coronavirus (SARS-CoV)
requires proteolytic activation of envelope glycoproteins by cathepsins, which are optimal
at acidic pH. It appears that SARS-CoV only require access to low pH compartments for
optimal function of the proteases, rather than for low pH-induced conformational changes
to the viral envelope glycoproteins [53]. Ebola virus (EBOV) has a similar dependency on
cathepsins to activate the envelope glycoproteins, and like SARS-CoV, only requires access
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Figure 1.2: Summary of the endosomal maturation pathway. Clathrin-mediated
endocytic uptake from the cell surface delivers cargo into the endosomal system. The
organelles of this system can be broadly divided into early, recycling and multivesicular
endosomes, along with lysosomes. Various different cellular proteins and lipids define these
different organelles and regulate their function, with examples of these given. See Section
1.1.1 for further discussion of endosomal maturation. Details adapted from [22, 34, 38,
44].
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to low pH compartments for optimal function of these proteases [54]. However, EBOV
appears to have an interesting requirement for multiple intracellular receptors to facilitate
entry along with proteolytic processing. Both of the late endosomally localised Niemann-
Pick C1 [55] and two pore calcium channel [56] proteins are required for EBOV entry into
cells. Lassa fever virus (LASV) has a similar requirement for delivery into late endosomal
compartments to engage an intracellular receptor molecule. LASV initially binds to the
cell surface through interactions with α-dystroglycan [57], and is internalised through a
macropinocytic mechanism [58]. Upon transit through the endosomal system, low pH
induces conformational changes to the LASV envelope glycoprotein allowing interaction
with LAMP1 [59], and subsequent membrane penetration. There are a variety of triggers
used by viruses to promote their cellular entry.
1.1.2 Virus-cell membrane fusion
Regardless of the various triggers required by enveloped viruses, and the different routes
that are used to receive these, cytosolic entry is achieved by fusion of viral and cellular
membranes. Viral envelope glycoproteins mediate not only cell attachment but also the
membrane fusion reaction which results in coalescence of viral and cellular membranes
to produce a fusion pore, which allows delivery of viral genetic material into the cytosol.
The envelope glycoproteins responsible for merging lipid membranes are termed fusion
proteins and come in a variety of structures. Some viruses have only a single envelope
glycoprotein which is responsible for regulating cell attachment and membrane fusion (e.g.
vesicular stomatitis virus G protein [VSV-G]), while other viruses have a single glycopro-
tein which is proteolytically cleaved to allow receptor engagement and membrane fusion
(e.g. HIV-1 and IAV). Some viruses produce two glycoproteins which play different roles
in the entry pathway (e.g. alphavirus E1 [membrane fusion] and E2 [cell attachment] and
paramyxovirus H, HN or G [attachment] and F [membrane fusion] [60]). There can also
be even greater complexity; herpes simplex virus-1 (HSV-1) has five glycoproteins with
various roles (gB, gC, gD, gH and gL) although one of these (gC) is non-essential for infec-
tion [61]. Poxviruses have even more complexity, encoding eleven different proteins which
form the entry-fusion complex, along with four proteins which mediate cell attachment
[62]. Viral fusion proteins interact with the target membrane through a short hydrophobic
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sequence of amino acids, referred to as the fusion peptide [63]. Overall, fusion proteins
can be divided into three sub-categories, type I, II and III (see [24, 64] for more detailed
reviews).
Type I fusion proteins
Type I fusion proteins are characterised by their production as trimeric inactive precursors
that are proteolytically activated. The type I fusion proteins are predominantly composed
of α helices. The hemagglutinin (HA) protein of IAV is a highly characterised example.
HA is initially produced as a fusion inactive precursor, HA0, which is assembled into a
metastable trimeric complex in the endoplasmic reticulum (ER) of infected cells. Upon
exit from the ER into the secretory pathway, HA0 is cleaved by cellular proteases [65],
forming a disulphide linked C-terminal membrane anchor, HA2, and an N-terminal HA1,
which remain associated in a trimeric complex within membranes [66, 67]. Low pH causes
the HA1 heads of the trimer to dissociated and move apart to expose the fusion peptide
of HA2, which can insert into target membrane to drive fusion. These low pH-induced
conformational changes are irreversible. Additional examples of type I fusion proteins
include the HIV-1 Env protein, which is initially synthesised as a gp160 protein which is
proteolytically cleaved into gp120 and gp41 (analogous to HA1 and HA2, respectively)
and and the F protein of paramyxoviruses.
Type II fusion proteins
In contrast to type I fusion proteins, type II fusion proteins are produced as part of a
complex containing an N-terminal chaperone protein. The type II fusion proteins are pre-
dominantly composed of β strands. A pertinent example of a type II fusion protein is E1
of SFV. When initially synthesised in an infected cell, the E1 protein forms a heterodimer
with p62. Interaction of p62 with E1 produces a fusion incompetent complex [68] that
is protected from premature activation in low pH compartments of the secretory system.
En route to the cell surface, p62 is proteolytically processed to E2 and E3, which remain
associated with E1 [69]. E2 is a transmembrane protein, while E3 is a small peptide on
the periphery of the complex. E3 remains associated with E1/E2 on SFV particles, but
dissociates from Sindbis virus (SINV), and is unnecessary for fusion [70]. Upon receiving
Chapter 1 33
Introduction
a low pH trigger, E2 dissociates from the complex [71, 72], allowing E1 to undergo confor-
mational changes, insert into target membrane and become homotrimeric, to ultimately
promote fusion [72–74]. (See Section 1.2 for further discussion). As with type I fusion
machinery, the low-pH induced conformational changes are irreversible. Flaviviruses also
have type II fusion machinery.
Type III fusion proteins
Type III fusion proteins do not undergo proteolytic activation during their synthesis, nor
are they produced with a chaperone protein, separating them from both type I and type II
fusion proteins. There are other structural differences between type III and the other two
classes, but they are arranged as a trimer on the surface of cellular and viral membranes.
The type III fusion peptide faces the virus membrane, rather than being buried in the
envelope glycoprotein, as for type I. Upon receiving appropriate triggers, conformational
changes occur to extend and rotate the fusion protein, allowing interaction with target
membrane. Example for the type III fusion proteins are the G protein VSV [75] and
the gB protein of HSV-1 [76]. The low pH-induced changes to VSV-G are reversible, in
contrast to type I and II fusion machineries.
Membrane fusion
Given the various different structures of viral fusion proteins, the sequence of events under-
lying membrane fusion are believed to be remarkably similar (see Fig. 1.3 for a schematic
of type II fusion protein mediated fusion). Upon receiving the appropriate trigger (low
pH for alphaviruses) to initiate membrane fusion, individual viral envelope glycoprotein
complexes undergo large conformational changes to extend and interact with the target
membrane, through the fusion peptide (Fig. 1.3 C). Either before, or after the initial in-
sertion, fusion proteins trimerise and form an intermediate, pre-hairpin structure between
the two membranes (Fig. 1.3 D). This intermediate subsequently folds back on itself to a
more energetically favourable conformation to produce a hairpin structure, that pulls the
two membranes into close apposition. The energy released by the unfolding and re-folding
of the fusion proteins is enough to overcome the thermodynamic barrier of membrane
fusion, and produces a hemifusion intermediate (Fig. 1.3 E). At the stage of hemifusion,
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lipid mixing between outer leaflets has occurred, but the contents of the two systems are
still separated by the inner leaflets of each bilayer [77]. After hemifusion, a fusion pore
can start to open. The opening of such a pore can be transient, or more long lived [77].
However, once the pore has enlarged and become established, it is irreversibly open and
the viral genomic material can escape into the cytosol to initiate infection (see [24, 64,
78–80] for various reviews. More specific examples for SFV are provided in Section 1.2).
Virus entry summary
Without the ability to enter cells, viruses would be unable to replicate. The lipid bilayer
of cells imposes a physical barrier to this process, but viruses have evolved to subvert the
normal functioning of cells to overcome this. For enveloped viruses, the process of mem-
brane fusion allows penetration of lipid bilayers, and delivery of viral genetic material into
a cell. The membrane fusion reaction is regulated by viral fusion proteins, and initiated
after receiving appropriate triggers from the cellular environment. For some viruses this
trigger can be the binding of cell surface receptor proteins. However, the vast majority of
enveloped viruses have adapted to subvert the endocytic mechanisms of the cell, allowing
them to use the changing environment of the endocytic system to regulate their pene-
tration to the cytosol and provide other advantages as discussed previously. Regardless
of the required trigger, upon activation, the viral envelope glycoproteins undergo large
conformational changes to insert into a target membrane, while remaining anchored in the
viral membrane. Subsequently, the re-folding of these proteins brings the two membranes
into close apposition to allow them to fuse, via a hemifusion intermediate, and produce a
pore through which viral genetic material can escape. The routes of virus entry into cells
by CME and pH-induced membrane fusion have been introduced as these are the most
pertinent to the main virus system used in the work presented in this thesis, SFV.
1.2 Semliki Forest virus
The main virus used throughout the work on IFITM-mediated inhibition of viral infection
presented in this thesis is the alphavirus SFV, of the Togaviridae family. SFV was first
isolated in the Semliki forest of Uganda in 1944 [81]. SFV, and other alphaviruses are small
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Figure 1.3: A schematic of membrane fusion mediated by type II fusion proteins.
A) For clarity, the representation of an individual E1/E2 heterodimer on the surface of a
viral particle (E1 in red and E2 in purple). B) E1/E2 heterodimers are found as a trimeric
complex on the surface of a virus particle. C) Upon receiving appropriate triggers (in the
case of SFV, low pH), the E1/E2 complex dissociates allowing the E1 protein to undergo a
large conformational change to extend and interact with target membrane through the fu-
sion peptide. D) As part of the conformational changes E1 forms homotrimeric complexes.
These complexes begin to fold back on themselves, pulling the two membranes into close
apposition. E) A hemifusion intermediate is formed through the mixing of lipids of the
outer viral and cellular membrane leaflets. The re-folding of the fusion protein provides the
energy to overcome the thermodynamic barrier of membrane fusion. F) Small, transient
fusion pores can form following hemifusion and can eventually resolve into a full fusion
pore by the coalescence of the inner viral and cellular membrane leaflets. Content mixing
can then occur between the two systems, allowing deposition of viral genetic material into
the cytosol. Image adapted from [64].
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(∼70 nm diameter), icosahedral viruses with RNA genomes of ∼12 kb [82, 83]. These
viruses are encased in a host derived lipid bilayer, with the E1/E2 envelope glycoproteins
protruding on the surface. The icosahedral symmetry and ordered arrangement of the
virus gives rise to 80 copies of E1/E2 heterodimers that exist as trimers on the surface
of SFV and other alphaviruses [82–84]. Beneath the lipid bilayer, connected to the E2
protein, is the viral capsid (240 copies), in which a single strand of positive sense RNA is
found (the nucleocapsid).
SFV was the first virus shown to use CME for internalisation from the cell surface
and delivery into the endosomal system for infection [45, 85], following attachment to cells
through the E2 protein [86, 87]. The importance of CME for SFV infection has been
shown through various approaches such as inhibition of CME with monoclonal antibodies
[88] or dominant negative mutants of regulators of CME [89, 90]. While well established as
being internalised by CME, no cell surface receptor has been conclusively defined for SFV.
Major histo-compatilibity complex (MHC) antigens were suggested as a surface receptor
[91], but the virus has also been found to replicate in cells that lack MHC expression
[92]. SFV can infect a very broad range of host cells, and therefore likely has promiscuous
receptor usage, or targets highly conserved molecules [83].
Following CME from the cell surface, SFV is delivered into endosomes and uses the
low pH of these compartments as a trigger for penetration into the cytosol [45, 93–96].
Low pH has been suggested as the only necessary trigger for SFV membrane penetration
because the virus can fuse with protein-free liposomes following low pH treatment [47].
SFV also needs no other endosomal-specific triggers as low pH treatment of cell surface
bound virus can allow cytosolic penetration [47], at least in some cell types [97].
As discussed in Section 1.1.2, SFV produces type II fusion machinery made of the
E1 and E2 envelope glycoproteins. Following delivery into endosomes of sufficiently low
lumenal pH to activate the fusion machinery (pH ≤ 6.2; [45–48]) the E2 protein dissociates
from the E1 protein [71, 72], allowing for extension of the E1 fusion peptide and insertion
to target membranes [98]. Once inserted into the target membrane, E1 protein forms
homotrimeric complexes which become insensitive to digestion with trypsin [96, 98]. The
interaction of E1 with a target membrane depends on the presence of cholesterol and
sphingomyelin [99, 100]. As in other fusion mechanisms, E1 then folds back on itself into
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a post-fusion helical bundle [98]. Lipid mixing between viral and endosomal membranes
can be detected by spread of lipid dyes such as pyrene [101]. Hemifusion intermediates
produced by E1-induced fusion have also been detected in cell-cell fusion assays [102].
It therefore appears that as described previously, membrane fusion induced by SFV E1
proceeds through hemifusion intermediates before a full fusion pore allows for cytosolic
access. Experimental evidence suggests the nucleocapsid is released into the cytosol and
then uncoats through interaction with ribosomes [103]. Once uncoated, the positive sense
RNA genome can itself interact with ribosomes and start the replication cycle to produce
progeny virions (see Fig. 1.4 for subsequent detail to the SFV life cycle).
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Figure 1.4: SFV viral life cycle. A schematic representation of the SFV viral life cy-
cle. Following attachment to cells, SFV is internalised by clathrin-mediated endocytosis
(clathrin coat proteins displayed in dark green). Clathrin-coated vesicles uncoat after re-
leasing from the plasma membrane, and are delivered into the endosomal system. SFV
particles will then be subject to the changing environment within the lumen of endo-
somes. Fusion between viral and cellular membrane is stimulated at pH ≤ 6.2, promoting
release of the viral nucleocapsid into the cytosol. The nucleocapsid is uncoated through
an interaction with ribosomes (displayed in light green), releasing the positive sense RNA
genome. Translation can be initiated from this genomic RNA to produce the viral non-
structural proteins (nsPs). These nsPs then regulate the replication of the genome and
production of a sub-genomic 26S mRNA, from which the structural proteins are produced
(also see Fig. 1.5). The structural proteins are initially translated as a large polyprotein
which is co-translationally cleaved by the autoproteolytic activity of the capsid (C) pro-
tein. The release of capsid exposes a signal peptide sequence that directs insertion of the
envelope proteins into the endoplasmic reticulum (ER) membrane. The envelope proteins
are processed in the ER to form heterodimeric complexes of p62/E1. These heterodimeric
complexes are trafficked from the ER to the Golgi apparatus and continue through the
secretory pathway to be delivered to the plasma membrane. Through the secretory path-
way p62 is proteolytically cleaved to produce E2 and E3 which both remain associated
with E1. The capsid is loaded with genomic RNA and similarly delivered to the plasma
membrane where it can associated with envelope protein complexes. These interactions
promote the outward budding of the plasma membrane until virons are released into the
extracellular space to spread to new target cells. Image adapted from [83].
The SFV structural proteins are produced as a single polypeptide from a subgenomic
RNA (Fig. 1.5). This polyprotein contains the capsid and envelope proteins, along with a
small protein called 6K (whose function is poorly defined). The capsid protein has auto-
catalytic activity to allow release of this protein from the polypeptide during translation.
The released capsid can then associate with genomic RNA in the cytosol to produce viral
nucleocapsids. Cleavage of capsid exposes a signal peptide sequence at the N-terminal end
of the envelope proteins, which dictates co-translational insertion to the ER membrane
[104, 105]. The E1 and p62 proteins are processed in the ER along with 6K. E1 and p62
form heterodimeric complexes in the ER. This processes is dependent upon the E3 protein
segment of p62 as replacement of this amino acid sequence results in loss of heterodimeric
complexes [106]. The envelope proteins are subsequently delivered through the secretory
system to the plasma membrane. During this transit the p62 protein is cleaved to E2
and E3 by cellular furin [69, 107]. Again, E3 is necessary through this transport step
to provide protection from premature activation of the fusion machinery in the low pH
compartments of the secretory pathway [108]. Once delivered to the plasma membrane,
E2 proteins form a direct interactions with the nucleocapsid. This interaction promotes
40 Chapter 1
Introduction
the formation of virions, and there appears to be a requirement of cholesterol for viral
budding from the cell surface ([109–111], also see [82, 83, 112] for reviews and Fig. 1.4).
A wealth of experimental information has been generated describing the mechanisms
used by SFV to enter into cells. This alphavirus therefore provides a powerful tool with
which to study IFITM proteins, cellular antiviral factors capable of blocking virus entry.
SFV also has advantages in the ease with which it can be produced to high titres and its
safety to work with. Additionally, much work defining IFITM antiviral activity has been
performed with IAV (see Section 1.3.2), which enters cells by fusion with late endosomes,
while SFV enters cells by penetration of early endosomes. Using SFV as a new model
system therefore allows for the development of understanding of any similarities and dif-
ferences between inhibition of different viruses, especially with regards to the different
sites of entry into cells.
1.3 IFITM proteins
The human IFITM proteins were first identified over 30 years ago by virtue of their induc-
tion by interferon treatment [113]. The proteins were originally denoted 9-27 (IFITM1,
also referred to as Leu13 antigen), 1-8D (IFITM2) and 1-8U (IFITM3). Early work on
IFITM1 suggested potential roles in both B and T cells [114–119], while murine Ifitms were
suggested to have developmental functions [120–123]. The importance of IFITM1 function
in adaptive immune cells remains unclear, and the role of Ifitm proteins in murine devel-
opment has been questioned by the fact that Ifitm knockout mice show no developmental
defects [124].
While characterised as ISGs, the first suggestion of an IFITM protein having antivi-
ral activity was not made until 1996 when IFITM1 was found to inhibit replication of
VSV (but not IAV), albeit less potently than another ISG, MxA [125]. However, it was
not until 2009 that the IFITM proteins started to be studied intensively because of their
antiviral function [7]. Brass et al. designed a genome-wide siRNA screen to detect cel-
lular factors involved in the replication of IAV in the U2OS cell line [7]. Amongst many
other hits, the knockdown of IFITM3 was found to enhance IAV infection of U2OS cell.
Further investigation validated this result in various other cell lines [7]. Moreover, it was
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Figure 1.5: SFV genomic structure and protein production. A schematic represen-
tation of the SFV genomic structure and how the various structural and non-structural
proteins are produced. The genomic RNA has an 5’ 7-methylguanosine cap (Cap) and a
3’ polyadenylated tail (PolyA). Upon release into the cytosol, the positive sense genomic
RNA associates with ribosomes and the P1234 polyprotein is translated. The P1234
polyprotein is cleaved into the non-structural proteins (nsP) by the proteolytic activity of
the nsP2 unit. The non-structural proteins form the RNA dependent RNA polymerase
that produces negative (-ve) sense RNA from the template genomic RNA. From this -
ve sense RNA the subgenomic 26S mRNA encoding the structural proteins is produced.
These proteins are initially translated as a polyprotien. Capsid (C) has autoproteolytic
activity and can cleave the growing polypeptide chain. This cleavage releases capsid and
exposes a signal peptide sequence at the N-terminal end of the envelope proteins that al-
lows co-translational insertion to the ER membrane. Signalses cleave after p62 and again
after the small peptide 6K, releasing E1. The p62 protein is later cleaved in the secre-
tory pathway to produce E2 and E3 which associated with E1 to form the viral envelope
glycoprotein complex. Image adapted from [82, 83]. Also see Fig. 1.4.
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also demonstrated that overexpression of IFITM3, as well as IFITM1 and IFITM2, could
suppress replication of IAV in vitro. During this initial characterisation, the IFITM pro-
teins were suggested to impact viral entry by virtue of their ability to inhibit infection of
HA-pseudotyped retroviral particles. This antiviral function was not specific to IAV as
various members of the flavivirus family were also shown to be inhibited. However, no
antiviral activity was detected against the retrovirus murine leukaemia virus (MLV) nor
arenaviruses [7]. Since the work of Brass et al. many different viruses or pseudotyped
particles have been found to be inhibited by IFITM proteins (see Tables 1.1 and 1.2 and
Section 1.3.2), but how the IFITM proteins inhibit such a broad array of viruses is not
understood.
1.3.1 IFITM evolution
It has been suggested that the IFITM genes arose through gene duplication events early
in vertebrate evolution [126]. This early evolution in the vertebrate lineage is supported
by identification of an IFITM -like gene in lampreys [126]. The human genome contains
three IFN-inducible IFITM genes, however in addition to IFITM1, 2 and 3 (IFN-induced)
there are two additional IFITM genes, IFITM5 and IFITM10. IFITM1, 2, 3 and 5 are
found clustered within a 26 kb region of chromosome 11, while IFITM10 is located 1.4
Mb away [126–128]. IFITM5 is expressed primarily in osteoblasts and has roles in bone
mineralisation [129]. Little is known about the function of IFITM10 which, like IFITM5,
lacks a functional IFN-responsive sequence element. It is unknown whether IFITM5 or
IFITM10 have antiviral function. The murine genome encodes two further Ifitm genes
(Ifitm4 and Ifitm6 ), but most research has focused on the murine orthologues of IFITM1,
2 and 3. Various other mammalian species have been found to have IFITM genes and
antiviral function has been demonstrated for some of these [126–128, 130–133]. IFITMs
have also been identified and shown to have antiviral activity in some birds [134, 135].
The IFITMs are part of a larger protein family known as the dispanins which is found
in both eukaryotes and prokaryotes [127]. Interestingly, Mycobacterium IFITM-related
proteins have been proposed to have antiviral activity when expressed in human cells
[136]. This dispanin family is defined by the presence of a highly conserved CD225 domain,
which in the IFITMs occupies the central portion of the proteins (Fig. 1.6). In terms of
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Figure 1.6: Sequence alignment of human IFITM1, 2 and 3. The amino acid
sequences of IFITM1, IFITM2 and IFITM3 were aligned using the ClustalOmega tool
(EMBL-EBI; http://www.ebi.ac.uk/Tools/msa/clustalo/). * denotes identical amino
acids, : and . represent similarities between amino acids. The sequences have been divided
into the domains of the IFITM proteins; NTD (N-terminal domain), M1 (membrane do-
main 1), CIL (conserved intracellular loop), M2 (membrane domain 2), CTD (C-terminal
domain). See Fig. 1.8 for diagrams of the topological structures that have been proposed
for IFITM proteins. The position of the highly conserved CD225 domain is denoted.
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their amino acid sequences, IFITM2 and IFITM3 are very similar, with ∼91% sequence
identity. Comparatively, IFITM1 shares ∼81% and ∼84% identity with IFITM2 and 3,
respectively. Since the CD225 domain is so highly conserved, the variations between the
IFITM amino acid sequences reside in the N- and C-terminal domains (NTD and CTD).
IFITM1 has a 21 amino acid truncation compared to IFITM3 (20 amino acid compared
to IFITM2) at the NTD, while the CTD of IFITM1 is longer than those of IFITM2 and
IFITM3 (see Section 1.3.3 for a discussion of the implications of these differences and Fig.
1.6 for sequence alignments).
1.3.2 IFITM antiviral activity
In vitro
It has become well established that the IFITM proteins can act as broad-spectrum an-
tiviral factors in cell culture. Overexpression, knockdown and genetic knockout have all
been used to investigate antiviral activity against both full viruses and viral particles
pseudotyped with various envelope glycoproteins. A summary of published literature on
IFITM-sensitive viruses is provided in Tables 1.1 and 1.2. Since infection by pseudotyped
virus particles can be inhibited by IFITM proteins this gave the first indications that these
proteins could inhibit viral entry. However, there remains a lack of detailed understanding
regarding the mechanism(s) of antiviral activity. It is also unclear why some viruses are
insensitive to IFITM-mediated inhibition (Table 1.3), and what dictates the sensitivity of
different viruses to different IFITMs.
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Inhibition of pseudotyped virus particles strongly suggested IFITM proteins interfere
with viral entry. However, the work of Feeley et al. first started to develop a detailed
understanding of where in the IAV entry pathway IFITM proteins are targeting [12]. This
work made use of an IAV engineered to produce green fluorescent protein tagged nuclear
protein (GFP-NP) and demonstrated that IAV particles were able to bind to IFITM3
expressing cells and be internalised, but that the GFP-NP did not reach the nucleus.
Instead, the GFP signal appeared to accumulate in endosomal compartments, suggesting
that IFITM3 expression was blocking release of IAV genetic material into the cytosol.
This was further confirmed by the use of β-lactamase assays which showed that IFITM3
expression could block deposition of viral contents into the cytosol, suggesting IFITM3
may inhibit viral-cell membrane fusion [12].
As discussed previously, viral-cell membrane fusion is achieved through a complex se-
ries of events, from initial interaction of fusion proteins with target membrane, through
a hemifusion intermediate, and culminating in a fusion pore. It has been suggested that
IFITM expression can inhibit viral penetration into the cytosol, by blocking the establish-
ment of hemifusion [13]. This proposal was made based on assays using cell-cell fusion,
where donor cells expressing the envelope glycoproteins of a virus are loaded with aqueous
dye and then mixed with target cells lacking viral protein. In the work of Li et al. [13],
cells expressing representatives of each class of fusion protein were used (IAV and JSRV
[type I], SFV [type II] and VSV [type III]). Upon providing appropriate triggers (e.g. low
pH), the envelope glycoprotein can be activated to promote fusion of target and donor
cells (fusion from within), allowing the spread of aqueous dye into the target cells. Li
et al. made use of a cold arrested state in which low pH treatment at 4℃ can induce
hemifusion, but not full fusion [13]. The subsequent raising of temperature to 37℃, or
treating with chlorpromazine (CPZ) allows for the formation of a fusion pore, through
which dye can spread. Working with the envelope glycoproteins of the Jaagsiekte sheep
retrovirus (JSRV) and IAV, they found that in control cells, following the generation of
a cold arrested state, subsequent treatments could allow for dye spread. However, when
target cells were expressing IFITMs, CPZ treatment resulted in comparatively reduced
dye transfer. Raising the temperature to 37℃ gave a greater degree of dye spread than
CPZ treatment, but this was still lower than the dye transfer seen with target cells lacking
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IFITM expression. Additionally, it was shown that treating cells with oleic acid could
rescue the IFITM-mediated inhibition of cell-cell fusion. Hemifusion is promoted by neg-
ative curvature of lipid membranes, and oleic acid induces greater negative curvature,
suggesting that by promoting hemifusion, IFITM-mediated inhibition can be overcome.
This inhibition of the establishment of hemifusion intermediates suggests that the IFITM
proteins alter the properties of the membrane they reside in; indeed, it was suggested that
the presence of IFITM proteins in cell membranes reduces their fluidity by Li et al. [13],
and others [156], suggesting a higher energy barrier to the establishment of hemifusion
intermediates.
The work of Li et al. focused on cell-cell fusion [156]. There are differences between the
fusion of two plasma membranes and the fusion of viral and endosomal membrane. Firstly,
the level of membrane curvature could be higher when a virus and endosome fuse than
when cells fuse. Secondly, the lipid compositions of the plasma membrane and endosomes is
different [34, 172]. If IFITM proteins modulate membrane properties, the composition may
be an important consideration. Taking a different approach to study how IFITM proteins
block viral entry, Desai et al. used DiD-labelled virus [14], a well established system for
studying membrane fusion. DiD is a lipophilic dye whose fluorescence self-quenches at
high concentration, for instance when loaded into the envelope of a viral particle (IAV
in the work of Desai et al.). At lower concentrations, the self-quenching is removed and
DiD fluorescence intensity increases; for instance when the dye disperses into endosomal
membranes following viral-induced fusion. The initial stages of lipid mixing are all that
are required to dequench DiD and lead to an increase in fluorescence intensity. In order
to then determine whether content transfer has occurred (i.e. determine if hemifusion has
been resolved to a pore), viruses can also be loaded with content markers which will be
deposited into the cytosol. Using this system, Desai et al. [14] demonstrated that DiD-
labelled IAV particles dequench in the presence of IFITM3 but that the addition of oleic
acid had no impact (in contrast to results seen by Li et al. [13]). While IAV particles
could establish hemifusion in the presence of IFITM3, using HA pseudotyped retrovirus
particles, labelled with DiD and carrying fluorescent cargo, it was observed that there was
no content mixing after hemifusion. The work of Desai et al. [14] therefore suggested that
IFITM3 was blocking the establishment of fusion pores, after the formation of hemifusion
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intermediates, in contrast to the model proposed by Li et al. [13]. The differences seen
may be down to the different systems of cell-cell fusion and virus-cell fusion that were
used.
Whether or not hemifusion can be established when IFITM proteins are present re-
mains unclear, as does the mechanism(s) underlying any inhibition, and whether there
is any involvement of reduced fluidity of cellular membranes [13, 156]. It also remains
unknown wether all IFITM proteins operate through the same mechanism for all viruses
that are restricted. It has been suggested that IFITM proteins can directly interact with
vesicle-membrane-protein-associated protein A (VAPA) [152]. VAPA is an ER localised
protein involved in regulating cellular cholesterol levels. It was proposed that IFITM in-
teraction with VAPA out-competes binding of oxysterol-binding protein and results in an
accumulation of cholesterol in endosomal membranes. This cholesterol accumulation was
proposed to be responsible for IFITM-mediated inhibition of viral entry. How the ER
localised VAPA and IFITM proteins, which localise to endosomes and the plasma mem-
brane (discussed in more detail in Section 1.3.3), interact in cells is unclear. The results
of Amini-Bavil-Olyaee et al. [152] have also been challenged by other studies suggesting
that cholesterol accumulation does not play a role in IFITM-mediated inhibition [14, 156].
However, cholesterol may still play roles in IFITM function, as the cholesterol binding drug
amphotericin B (AmphoB), and derivatives, have been shown to negate IFITM3-mediated
inhibition of IAV [156] and simian immunodeficiency virus (African green monkey [SIVagm]
strain; [168]). However, AmphoB treatment had no impact on EBOV infection [142].
While most viruses have been proposed to be inhibited by IFITM proteins during
entry into new host cells, there are exceptions to this model. It has been suggested that
IFITM proteins can incorporate into budding HIV particles and reduce their infectivity
in subsequent cells [133, 166, 167]. In one of these studies, it was demonstrated in cell-cell
spread assays that when IFITM3 was expressed in target cells, there was only modest
inhibition of HIV-1 infection [166]. However, the expression of IFITM3 in donor cells
reduced infection of target cells, with the argument made that was as a result of reduced
infectivity of the released virus [166]. IFITM3 was found to be the most potent for
inhibiting infection in new target cells following incorporation into HIV-1 particles, which
is interesting given that HIV-1 generally buds from the plasma membrane but IFITM3 is
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generally localised to intracellular compartments [166, 167]. It has also been suggested that
IFITM protein expression in HIV-1 infected cells can alter the trafficking and processing
of Env [173], although this has been challeneged by a subsequent study [133].
The importance of IFITM incorporation into HIV-1 virions has been challenged by a
recent study, in which it was suggested that IFITM proteins can inhibit infection of HIV-
1 irrespective of incorporated IFITM protein [169]. Interestingly, this study found that
different strains of HIV-1 had differential sensitivity to IFITM proteins based on the co-
receptor usage; CXCR4 tropic lab-adapted viruses were found to be more sensitive to the
endosomal IFITM2 and IFITM3 (discussed in Section 1.3.3), while CCR5 tropic viruses
were found to be more sensitive to the plasma membrane localised IFITM1 (discussed in
Section 1.3.3; [169]). These differences in sensitivity to IFITM inhibition perhaps explain
some of the discrepancies between the various studies of HIV-1. These data also suggest
that the route of entry into the cell may alter the sensitivity to IFITM proteins, with it
being tempting to speculate that CXCR4 tropic viruses may fuse at endosomal membrane
sites, while CCR5 tropic viruses may fuse at the plasma membrane. In agreement with
this idea, mutation of IFITM2 or IFITM3 to cause accumulation of protein at the plasma
membrane (again see Section 1.3.3) altered the inhibition of the different HIV-1 strains
[169]. Finally, it was also demonstrated that HIV-1 transmitter founder viruses are re-
fractory to IFITM-mediated inhibition, but viruses collected from patients 6 months later
were sensitive, most likely as a result of mutations to Env which were associated with
evasion from neutralising antibodies [169]. The impact IFITM proteins have on HIV-1
infection therefore appear to be highly complex and potentially multifaceted.
In summary, while much has been learnt about the breadth of IFITM-mediated antivi-
ral activity in cell culture, there is currently a lack of understanding of the mechanism(s)
underlying this function. Most data point towards inhibition occurring at the stage of
entry, although there have been suggestions of an alternative function of IFITMs incorpo-
rating into nascent virions. IAV has been the most intensively studied virus for IFITM-
mediated inhibition, but there is debate over whether IFITMs inhibit fusion before, or
after the establishment of a hemifusion intermediate. There is a suggestion that choles-
terol may have some function in IFITM-mediated inhibition, though it remains unclear
what this is. Furthermore, whether all viruses are inhibited by the mechanisms described
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for IAV and whether all three human IFITM proteins inhibit through this mechanism, or
not, remains to be established, as do the reasons for certain viruses being refractory to
the antiviral function of IFITM proteins.
In vivo
Compared to the study of IFITM proteins in cell culture systems, there is relatively little
data on the impact they have in vivo. The first studies to show in vivo relevance of IFITM
proteins used mice genetically deleted for the whole Ifitm locus (Ifitm -/- or Ifitm3 alone
(Ifitm3 -/-). Both sets of mice were developmentally unaltered, but upon challenge with
IAV rapidly developed fulminant viral pneumonia and had to be euthanised as a result
of excessive weight loss [174, 175]. In contrast, after a brief loss of body weight, wild
type littermates recovered from the infection. Ifitm3 -/- mice showed similar severity of
disease as Ifitm -/- mice suggested that Ifitm3 may be the key protein for controlling IAV
infection in mice. Additionally, it has been demonstrated that both wild type and Ifitm3
-/- mice had increased pathogenesis from IAV infection when treated with a derivative of
AmphoB, validating the in vitro data [156].
A role for Ifitm3 in the murine adaptive immune response has also been suggested.
Wakim et al. demonstrated that after challenge with influenza, there was a prolonged ex-
pression of Ifitm3 in lung resident memory CD8+ T cells [176]. This prolonged expression
did not appear to be dependent on continued IFN production, but was associated with hy-
pomethylation of the Ifitm3 promoter in the IAV-specific memory T cells. The suggestion
was made that these Ifitm3 expressing CD8+ T cells were more resistant to subsequent
influenza challenge, potentially enhancing their efficacy in the memory response to viral
infection [176]. Whether similar epigenetic changes occur in humans following influenza
infection remains to be determined.
In addition to displaying enhanced pathogenesis in mice, the work of Everitt et al.
[174] also identified a potential genetic association between severe influenza infection and
a single nucleotide polymorphism (SNP - rs12252) in human IFITM3. The SNP codes
for a minor C allele which generally occurs at low frequency compared to the major T
allele, except in a Han Chinese population where the C allele has much higher frequency
[177]. In patients hospitalised by seasonal or pandemic influenza infection, there was a
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∼19 fold enrichment in the presence of the CC allele [174]. It was also found that 69%
of Chinese patients with severe pandemic IAV infection were CC positive, compared to
only 25% who had mild symptoms [177]. This minor allele was suggested to alter a splice
site in the IFITM3 gene which could result in a 21 amino acid truncation at the NTD
of IFITM3 [174]. However, this truncated protein was not detected in lymphoblastoid
cell lines expressing the CC variant, although a lower level of IFITM3 protein expression
was detected, as compared to the TT variant [174]. The exact consequence of the CC
allele remains unclear. The findings of Everitt et al. that rs12252-C associates with severe
influenza has been challenged [178], although other studies and a meta-analysis of data
have supported the initial work [177, 179, 180]. It has also been suggested that rs12252-C
is associated with more rapid progression to AIDS following HIV-1 infection [181]. To
date, no other viruses or IFITM SNPs have been associated with increased severity of
disease in humans.
Along with the above mentioned work analysing IAV infection of Ifitm3 -/- mice, var-
ious other pathogens have been tested [182]. This work suggested that the Ifitm3 -/- mice
had no altered sensitivity to bacterial (Salmonella typhimurium, Citrobacter rodentium,
Mycobacterium tuberculosis) nor protozoan (Plasmodium berghei) infections. However,
when challenged with respiratory syncitial virus (RSV), the mice showed more severe
disease, implicating Ifitm3 in the control of RSV infection. Subsequent work further
demonstrated that IFITM proteins could inhibit RSV in vitro [149].
Most recently, two papers from the Diamond and Farzan labs have shown that Ifitm
proteins are involved with control of West Nile virus and alphavirus infections (CHIKV
and VEEV) in mice [183, 184]. Both studies suggest that Ifitm3 is the major component
of controlling the early phases of infection. In the absence of Ifitm3, there were higher
viral titres at early time points following infection, enhanced inflammatory responses and
increased dissemination of virus [183, 184]. Ifitm3 -/- mice were found to have greater
morbidity and mortality to both VEEV and WNV [183, 184].
To date, five different viruses (from four families) have been shown to have enhanced
pathogenesis in Ifitm3 -/- mice, and a genetic link has been suggested between a SNP in
the IFITM3 gene with more severe IAV infection and more rapid progression to AIDS from
HIV-1 infection in humans. It therefore appears likely that at least IFITM3 has roles in
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control of viral infection in vivo. What roles IFITM1 and IFITM2 may be playing remains
unknown. In parallel with developing a more detailed understanding of the antiviral
function of the IFITM proteins in cell culture, future work directed at testing further
pathogens in mice and a better analysis of the potential genetic link between IFITM
SNPs and severe disease in humans are necessary to fully define the importance of these
proteins.
1.3.3 IFITM cell biology
Along with the knowledge that has been generated regarding the antiviral function of the
IFN-induced IFITM proteins, there has also been study of their cell biology. Precisely
connecting knowledge of the cell biology and regulation of IFITM proteins with their
antiviral function remains an on-going challenge.
Cellular localisation
The IFITM proteins inhibit viral entry into cells, therefore understanding their cellular
localisation is integral for understanding how they can impinge on the various viruses
they inhibit. Various different studies have made attempts to define the localisation of
the IFITM proteins. Much of this work has relied on immunofluorescence microscopy
and co-staining epitope-tagged forms of IFITM proteins with various markers of cellular
structures. A general consensus has emerged that the IFITM proteins are predominantly
endosomal, displaying varying degrees of co-localisation with many different endosomal
markers [12, 134, 139, 143, 146, 152, 154, 159, 160, 162, 163]. This is particularly true
for IFITM3, though IFITM2 has been less intensely studied. However, IFITM3 has also
been suggested to be localised to the ER [7, 150, 151], though the functional significance
of this is unclear.
Part of the work presented in this thesis was aimed at addressing the localisation
of the proteins. In A549 cells, IFITM1 is localised at the plasma membrane [15], while
IFITM2 and IFITM3 are dispersed through the endosomal system, but IFITM3 has greater
localisation to early endosomes, while IFITM2 has greater localisation to late endosomes
[16]. IFITM1 has also been suggested to be localised within the endosomal system by
others [159, 185]. Part of these discrepancies may come down to cell type variation or
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sample preparation. Based on the data within this thesis (and as in [15, 16]) a model
can be suggested whereby the three IFITM proteins occupy the major portals of entry
for many different viruses, be it the plasma membrane, or endo/lysosomal membranes
(see Fig. 1.7 and [10]). It is tempting to speculate that differences in localisation may
impact on the antiviral properties of each of the IFITM proteins. This will be discussed
throughout work presented here.
It is clear in A549 cells at least, that IFITM1 is primarily localised to the plasma
membrane, while IFITM2 and IFITM3 are primarily found within internal membrane
compartments. The major determinant for this difference in localisation appears to be
in the NTD. As discussed previously, IFITM1 has a 20 and 21 amino acid truncation
compared to IFITM2 and IFITM3, respectively. Within this additional stretch of amino
acids found on IFITM2 and IFITM3, there is a Yxxφ motif that acts as a sorting signal
for CME (where Y represents tyrosine, x represents any amino acid and φ represents a hy-
drophobic residue; 19-YEML-22 and 20-YEML-23, for IFITM2 and IFITM3, respectively.
See Fig. 1.6). Yxxφ motifs have been characterised through their ability to interact with
the clathrin adaptor AP-2 (Section 1.1.1), and therefore direct CME of proteins presenting
such a motif [186]. Indeed, deletion of the first 21 amino acids, or mutation of the Y residue
alone, results in accumulation of IFITM3 at the plasma membrane [163]. These mutant
forms of IFITM3 were found to have reduced antiviral activity against IAV and HIV-1
[163, 174]; this is interesting considering the apparent link between rs12252-C, which may
truncate IFITM3 by 21 amino acids, and the increased severity of IAV and HIV-1 infection
seen in humans [174, 177, 179–181]. However, the loss of antiviral function against IAV in
vitro has been challenged [187]. That the Yxxφ motif is indeed functioning as a membrane
trafficking signal was demonstrated by work showing that IFITM3 directly interacts with
AP-2, and mutation of this motif abolishes the interaction [143].
In addition to the work on sorting motifs in IFITM NTDs, it has been suggested
that there is a di-basic sorting motif (122-KRGY-125) in the IFITM1 CTD that can
regulate ubiquitination of IFITM1 and interaction with AP-3 [159]. It was proposed that
mutation of these resides could disrupt IFITM1 localisation and could alter IFITM1-
mediated antiviral activity against JSRV [159]. It has also been suggested that alterations
to the IFITM1 CTD can change cellular distribution and antiviral activity against HIV-
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Figure 1.7: IFITM cellular distribution and select viral entry sites. When ex-
pressed individually in A549 cells, the IFITM proteins are found to occupy various cel-
lular membrane compartments. As displayed in Chapter 3 and [15, 16], IFITM1 is pre-
dominantly localised at the plasma membrane, while IFITM2 and IFITM3 are dispersed
through the endosomal system. IFITM3 appears to have greater localisation to early en-
dosomal compartments than IFITM2, while IFITM2 appears to have greater localisation
to late endosomal compartments than IFITM3. Many different viruses (some examples
provided here) penetrate into the cytosol through the different membrane compartments
the IFITM proteins are found to be predominantly located in. It could therefore be hy-
pothesised that the localisation of the IFITM protein may influence its antiviral activity,
an idea which will be discussed throughout this thesis. Image adapted from [10].
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Figure 1.8: Topology models of the IFITM proteins. Model 1: The initially proposed
model for IFITM membrane topology placed both the N- and C-terminal domains (NTD
and CTD) on the extracellular/lumenal side of cellular membranes. The two termini are
connected by two transmembrane domains (M1 and M2) and a conserved intracellular
loop (CIL). Model 2: The second proposed model for IFITM membrane topology placed
both the NTD and CTD on the cytoplasmic side of membranes, connected by M1, CIL
and M2. This model necessitated M1 and M2 enter into but do not cross the lipid bilayer.
Model 3: The most recently proposed model suggests that the NTD is cytoplasmic, while
the CTD is extracellular/lumenal. M1 has enters into, but does not cross the bilayer,
while M2 is transmembrane.
1 [185]. The exact functional significance of the CTD and the potential di-basic motif
remains unclear, and will be discussed further in Chapter 6.
As previously alluded to, one outstanding question regarding the localisation of the
IFITM proteins is what role, if any, this plays in their antiviral action. This will be a
topic of discussion in Chapter 6.
Membrane topology
Another controversial aspect of IFITM proteins has been their membrane topology. When
the IFITM proteins were initially identified, they were characterised as dual-pass trans-
membrane proteins, with the membrane associated domains connected by a conserved
intracellular loop (CIL). Both the NTD and CTD were suggested to be in the extracel-
lular/lumenal space (Fig. 1.8; model 1). Early studies on the IFITM proteins pointed
towards the presence of extracellular regions of the proteins based on the binding of anti-
bodies and functions potentially necessitating extracellular domains [114–116]. This model
was further supported by the initial work of Brass et al. which suggested that both termini
were extracellularly available [7].
However, subsequent work identified multiple PTMs in the NTD of IFITM3 ([151, 163],
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and see Section 1.3.3), suggesting this part of the protein must be cytosolic. There was less
data regarding the localisation of the CTD. Using engineered murine Ifitm3 constructs,
Yount et al. suggested that a CTD NxT motif (H136T mutation) was not glycosylated in
the ER and that the CTD could be prenylated by addition of a CLVL motif [151]. The
argument was therefore made that the CTD resided on the cytosolic side of membranes.
Little other data was generated, but a second model was proposed in which both the NTD
and CTD resided in the cytoplasm, the CIL connects the two membrane domains, which
were suggested to enter into, but not cross the lipid bilayer (Fig. 1.8; model 2).
In Chapter 3 work is presented that characterised the membrane topology of hu-
man IFITM proteins and suggested a third model (Fig. 1.8; model 3). This work is
re-introduced at the start of the chapter, and is the source of discussion in Chapter 6. As
such, greater detail on the membrane topology of the IFITM proteins can be found there.
Post-translational modifications
Not long after the IFITM proteins were identified as antiviral factors, PTMs started to
be detected and were suggested to regulate the function of the proteins. Thus far, IFITM
proteins have been shown to be subject to palmitoylation, phosphorylation, ubiquitination
and methylation.
Palmitoylation
The first study that demonstrated PTM of IFITM3 was initially designed to identify
lipid modified proteins with functions in the immune response using a murine dendritic
cell line (DC2.4 cells) and mass-spectrometry. One of the hits detected in this screen as
being S-palmitoylated was Ifitm3 [150]. S-palmitoylation involves the covalent attachment
of palmitic acid to proteins, through thioester bonding to cysteine (C) residues. Ifitm3 was
found to be palmitoylated at three highly conserved cysteine residues in membrane proxi-
mal regions (C71, 77 and 105). Mutation of all three residues to alanine (C-A) resulted in
more diffuse immunofluorescence staining for Ifitm3, and caused a loss of antiviral activity
against IAV, suggesting there is a need for lipid modification of Ifitm3 for antiviral ac-
tivity [150]. Interestingly, the addition of an NTD myristolyation site (GARASVLS) and
CTD prenylation site (CLVL), in the context of the triple C-A mutant Ifitm3, restored
the clustered localisation of the protein and antiviral activity against IAV. Additionally,
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murine Ifitm1 was found to be palmitoylated at a non-conserved CTD C residue, and
this modification was necessary for stability and anti-IAV function of the protein [155]. It
therefore appears that lipid modifications are necessary to promote IFITM clustering and
antiviral activity.
Phosphorylation
Both human and murine IFITM3 have been found to be phosphorylated on NTD tyro-
sine residues [158, 163]. In human IFITM3, Y20 is the only site of phosphorylation [158],
with this residue forming part of the Yxxφ sorting motif discussed previously. Murine
Ifitm3 is additionally phosphorylated at an non-conserved Y27 [158]. Fyn was identified
as the kinase responsible for phosphorylation of Y20 [163]. It was subsequently demon-
strated that increased phosphorylation at this site, by Fyn overexpression, can result in
accumulation of IFITM3 at the plasma membrane [158], suggesting disruption of the inter-
action with AP-2 [143]. Since IFITM3 with a Y20A mutation, which cannot interact with
AP-2 and localises to the plasma membrane, has been suggested to have reduced anti-IAV
and HIV-1 activity [143, 158, 163, 174], it would appear that phosphorylation of IFITM3
Y20 may regulate antiviral function. In order to detect phophorylation of IFITM3 it
was necessary to treat cells with phosphatase inhibitors such as sodium orthovadate [158,
163], suggesting dynamic regulation of IFITM3 phosphorylation. How, and whether this
IFITM3 phosphorylation is modulated during IFN stimulation or infection, remains to be
explored.
Ubiquitination
IFITM3 has also been detected to be modified by ubiquitination at any of 4 lysine (K)
residues [150, 158]. The most strongly modified residue is K24 [150], which is located close
to a PPxY motif (17-PPNY-20) in the IFITM3 NTD. This motif was shown to interact
with the E3 ubiquitin ligase NEDD4 [160]. The other three residues are found in the
CIL (K83, 88 and 104). Along with mono- and di-ubiquitination that was detected by
overexposure of western blots, IFITM3 can also be poly-ubiquitinated with K48- and K63-
linked ubiquitin chains [150]. K48-linked chains are generally associated with targeting
proteins for proteasomal degradation, while K63-linked chains play non-degradative roles,
suggesting potential for ubiquitin-mediated regulation of IFITM3 function. It appears that
ubiquitination of IFITM3 is important for turnover of the protein since mutation of the K
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residues to A increased protein stability and enhanced anti-IAV activity [150, 160], most
likely as a consequence of decreased degradation. Interestingly, there appears to be an
interplay between IFITM3 phosphorylation and ubiquitination as it has been demonstrated
that overexpression of Fyn kinase reduced the level of ubiquitinated IFITM3 [158]. Since
phosphorylation of Y20 can block IFITM3 endocytosis from the plasma membrane, this
may play a role in the reduced ubiquitination, and indeed, Y20A mutant IFITM3 has
a reduced level of ubiquitination compared to wild type [150]. However, it may also be
the case that phosphorylation of Y20 disrupts NEDD4 association with the 17-PPxY-20
motif. Again, how, and whether ubiquitination is regulated during infection remains to
be explored.
Methylation
The final PTM that has been proposed for IFITM3 is methylation, which was suggested
to negatively regulate the antiviral activity of IFITM3 against IAV and VSV [157]. Mono-
methylation of IFITM3 was found to be controlled by the lysine methyltransferase Set7
which targets K88 [157]. IFN treatment of cells resulted in a decreased level of IFITM3
methylation, whereas infection with IAV or VSV appeared to enhance methylation. How
viral infection modulates the interaction of Set7 and IFITM3 remains unclear. In the work
of Shan et al. infection with VSV at a multiplicity of infection (MOI) of 0.02 appeared to
give a marked increase in the level of methylated IFITM3 at a population level, even within
the first 4 h of infection [157]. How infection at such a low MOI can modulate IFITM3
methylation status across a cell population is unclear. It also remains unknown how
methylation and ubiquitination at K88 may be interacting to modulate IFITM3 function.
Further work is required to define the importance of IFITM3 methylation.
Overall, it is clear that there are various PTMs that modulate IFITM cell biology
and antiviral function. The vast majority of work to analyse these PTMs has focused
on IFITM3, with much of that focusing on murine Ifitm3. The target residues for the
PTMs are largely conserved in the IFITMs, with the exception of the lack of a PPxY and
NTD phosphorylation site (Y20 of IFITM3) in IFITM1 because of the shorter NTD. Since
IFITM2 shares all of the sites of PTMs as IFITM3, and IFITM1 shares all but the NTD
sites, this suggests IFITM1 and IFITM2 are probably regulated in similar ways, though
this remains poorly defined. Additionally, as mentioned throughout, how these PTMs are
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modulated through an infection remains to be clearly established.
1.4 Summary
Much has been learnt about the breadth of antiviral function of IFITM proteins. However,
for the majority of viruses, there is a lack of detailed understanding over how the IFITM
proteins inhibit infection. IAV is the best characterised virus, with data pointing heav-
ily towards an inhibition of viral-cell membrane fusion; but there is debate over whether
IFITM proteins inhibit prior to, or after hemifusion has been established. Moreover, it
remains unclear whether all viruses are inhibited through the same mechanism(s) as IAV.
Infection by IAV in the presence of IFITM3 is modulated by AmphoB treatment, as is
the infection of SIVagm [156, 168]. In contrast, infection by EBOV is not modulated by
AmphoB treatment [142], perhaps suggesting different underlying mechanisms of antivi-
ral action (discussed in more detail in Chatper 6). Moreover, mutational analysis has
suggested that alteration to certain residues of IFITM3 can modulate anti-IAV activity,
without altering anti-DENV activity, and vice versa [154].
There are also questions regarding aspects of IFITM cell biology. A major point of
contention has been the membrane topology of the IFITM proteins, with two models being
debated when the work presented in this thesis was started. A third model has since been
proposed. Perhaps related to a lack of understanding about topology, there has also been
a lack of full understanding of cellular distribution of the IFITM proteins, and what, if
any, impact the different localisation of the IFITM isoforms may have on their antiviral
function and breadth.
The work presented in this thesis therefore aims to better characterise aspects of IFITM
cell biology and antiviral function. An investigation into the membrane topology has been
conducted and produced a model in which the NTD resides in the cytosol, while the CTD
resides in the extracellular or lumenal space. The first membrane segment enters into,
but does not cross lipid bilayers, while the second membrane domain is a transmembrane
segment ([15] and see Fig. 1.8; model 3). Building on the knowledge of the topology,
an evaluation of IFITM localisation was made and defined IFITM1 to be localised at the
plasma membrane, while IFITM2 and IFITM3 appeared to be dispersed throughout the
62 Chapter 1
Introduction
endosomal system. IFITM3 appeared to be more localised to early endosomal compart-
ments than IFITM2, which conversely was more localised to late endosomal compartments
than IFITM3. For the first time, alphaviruses were shown to be inhibited by IFITM pro-
teins, extending the breadth of IFITM antiviral activity. Using SFV, it was determined
that IFITM3 did not inhibit any aspect of viral entry into cells, up until the point of capsid
release into the cytosol, suggesting that, as with IAV, membrane fusion is being inhibited
[16]. Again, similarly to results with IAV, AmphoB treatment was found to modulate the
anti-SFV activity of IFITM3, suggesting that type I and type II fusion machineries may
be inhibited by similar mechanisms, at least between IAV and SFV. This work therefore
defines SFV as a new model virus system to work with to understand IFITM-mediated
inhibition of viral entry.
In contrast to many other viruses (Tables 1.1 and 1.2), alphaviruses were not inhibited
by IFITM1. However rather than this necessarily being as a result of the localisation of
IFITM1 compared to IFITM3, the data suggested there may be intrinsic differences in the
anti-SFV activity of IFITM1 and IFITM3. A comparison between the antiviral function
of IFITM proteins against SFV and flaviviruses was also made. These experiments fur-
ther argued that protein localisation may not be the main determining feature of antiviral
action. Flaviviruses enter cells through CME and have pH-dependent fusion in endo-
somes, but were found to be inhibited by all IFITMs, even the plasma membrane localised
IFITM1, which did not inhibit SFV. AmphoB treatment did not modulate the antiviral
function of IFITM proteins against flavivirus infection. An argument is made that the
difference in IFITM-sensitivity and the impact of AmphoB treatment on alphavirus and
flavivirus infection may be as a result of the membrane lipids required for viral fusion.
Finally, the archetypal poxvirus, VACV, was tested for IFITM-mediated inhibition and
found to be insensitive, further demonstrating that not all viruses entering cells through
the endocytic pathway are targets for IFITM inhibition. However, the work with VACV
did point towards a potentially interesting side effect of high IFITM protein expression,
in that cells appear to become more motile.
In toto, the work presented in this thesis develops a better understanding of IFITM
membrane topology and localisation. The previously unexplored alphavirus family is
shown to be inhibited by IFITM proteins and a precise definition of the stage of en-
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try inhibited is developed. A comparison is made between the inhibition of alphaviruses
and flaviviruses, which suggested there could be intrinsic differences in the sensitivity of
different viruses to the IFITM isoforms, and that this could be related to the lipid depen-
dences for viral-cell membrane fusion. Combined, these data further the understanding of
IFITM cell biology and antiviral function.
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Materials and Methods
2.1 Reagents
Below follows a list of the reagents used throughout this work along with a list of the
abbreviations through which they are referred to. Numbers in brackets refer to notes
which can be found after the table.
Reagent name Abbreviation Supplier
Ammonium chloride NH4Cl Sigma-Aldrich
Ammonium persulfate APS Sigma-Aldrich
Amphotericin B AmphoB Amresco
Bovine serum albumin BSA
Life Technologies (1) and
Sigma-Aldrich (2)
Bafilomycin A1 Baf A Sigma-Aldrich
Bromophenol blue - Sigma-Aldrich
Calcium chloride CaCl2 Fisons
Carboxymethylcellulose CMC VWR Chemicals
Complete protease
inhibitor cocktail
PIC Roche
Crystal violet - Sigma-Aldrich
DL-Dithiothreitol DTT Sigma-Aldrich
Dulbecco’s modified
Eagle medium
DMEM Life Technologies
Ethanol - Fisher Scientific
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Ethylenediaminetetraacetic acid EDTA Life Technologies
Epon resin - TAAB
EZ-Link Sulfo-NHS-SS-Biotin* - Thermo Scientific
Foetal calf serum FCS Life Technologies
FuGENE 6 F6 Promega
Gelatin - MP Biomedicals
Glasgow’s minimum
essential medium
GMEM Life Technologies
Glutaraldehyde - TAAB
Glycerol - Sigma-Aldrich
Glycine - Sigma-Aldrich
Ham’s F12 nutrient mixture F12 Life Technologies
Hepes -
Life Technologies (3) and
Sigma-Aldrich (4)
Hoechst 33258 Hoechst Sigma-Aldrich
Interferon beta IFN-β Rebif
Leibovitz-15 medium L-15 Life Technologies
Lead nitrate - TAAB
Magnesium chloride MgCl2 Sigma-Alrdrich
Medium 199 M199 Life Technologies
Methanol MeOH Fisher Scientific
Minimum essential medium MEM Life Technologies
Mowiol - Sigma-Aldrich
Methylcellulose - Sigma
MES - Sigma-Aldrich
NeutrAvidin agarose beads - Thermo Scientific
Non-essential amino acids NEAA Life Technologies
Opti-minimum essential media Opti-MEM Life Technologies
Osmium tetraoxide - TAAB
Penicillin/streptomycin Pen/Step Life Technologies
Paraformaldehyde FA
TAAB (5), TAAB (6)
and Sigma-Aldrich (7)
Phenylmethylsulfonyl fluoride PMSF Sigma-Aldrich
Potassium ferricyanide - Sigma
Proteinase K ProtK Sigma-Aldrich
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ProtoGel (30%) ProtoGel National Diagnostics
Roswell Park Memorial
Institute medium
RPMI Sigma-Aldrich (8)
Saponin - Sigma-Aldrich
Skimmed milk powder - Marvel
Sodium cacodylate - TAAB
Sodium chloride NaCl Fisons
Sodium citrate - Sigma
Sodium dodecyl sulfate SDS Sigma-Aldrich
Sodium pyruvate - Life Technologies
Soy bean trypsin inhibitor SBTI Sigma-Aldrich
Sucrose - Sigma
Subtilisin - Sigma-Aldrich
Tannic acid - TAAB
Tetramethylethylenediamine TEMED Sigma-Aldrich
Triton X-100 Tx100 Sigma-Aldrich
Trizma Base Tris Sigma-Aldrich
Trypsin - Sigma-Aldrich
Tryptose phosphate broth TPB Sigma-Aldrich
Tween-20 - VWR Chemicals
Uranyl acetate - Agar Scientific
Table 2.1: Reagents and supplier details. * NHS-SS-Biotin; N-hydroxysulfosuccinimide-
ester biotinylation reagent containing a disulfide bond. (1) Life Technologies supplied
BSA was a 7.5% (w/v) solution. (2) Sigma-Aldrich supplied BSA was a powder. (3) Life
Technologies supplied Hepes was a 1 mM solution. (4) Sigma-Aldrich supplied Hepes was
a powder. (5) TAAB supplied FA was a 36% (w/v) ‘EM-grade stock.’ This was used for
all fixation with the ensuing exceptions: (6) An additional TAAB supplied FA stock of
16% (w/v) described as ‘MeOH free,’ which was used for fixation before staining intact
cell (referenced when used), (7) Sigma-Aldrich supplied FA was a 36% (w/v) stock and
used only for making crystal violet stain. (8) RPMI with no bicarbonate supplied as a
powder by Sigma-Aldrich.
2.2 Buffer recipes
Below follows a list of the buffers used throughout this work and their composition. Where
applicable, abbreviations of solutions have been give which will be used throughout the
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rest of this thesis.
• 3x Laemmli sample buffer (LSB)
– 188 mM Tris pH 6.8
– 6% (w/v) SDS
– 30% (v/v) glycerol
– 0.0006% (w/v) Bromophenol blue
– 100 mM DTT (for reducing buffer)
• 6x Laemmli sample buffer (LSB)
– 300 mM Tris pH 6.8
– 12% (w/v) SDS
– 60% (v/v) glycerol
– 0.0006% (w/v) Bromophenol blue
– (only used as non-reducing)
• Crystal violet stain
– 0.1% (w/v) crystal violet
– 2% (w/v) FA
• Dulbecco’s phosphate buffered saline (DPBS)
– PBS
– 1 mM CaCl2
– 0.5 mM MgCl2
• Infection media
– Ham’s F-12 nutrient mixture (GluaMAX) media
– 10 mM Hepes (from 1 mM [pH 7] stock)
– 0.2% BSA (from 7.5% stock)
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• Overlay media
– 1.5% (w/v) CMC
– 1 x MEM
• SFV binding media (BM)
– RPMI media (without bicarbonate)
– 0.2% (w/v) BSA
– 10 mM Hepes (powdered stock)
– 10 mM MES
– pH 6.8 (also adjusted to pH 5.5)
• TE buffer
– 10 mM Tris
– 5 mM EDTA
• TN buffer
– 100 mM NaCl
– 50 mM Tris
– pH 7.6
• Tris buffered saline (TBS)
– 20 mM Tris
– 137 mM NaCl
– pH 7.6
• TBS-Tween (TBST)
– TBS (as above)
– 0.05% (v/v) Tween-20
• Triton-X100 lysis buffer (Tx100 lysis buffer)
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– 1% (v/v) Tx100
– 150 mM NaCl
– 50 mM Tris
– pH 8
• Western blot resolving gel (15%)
– 2.3 ml ddH2O
– 2.5 ml 1.5 mM Tris pH 8.8
– 5 ml Protogel
– 100 µl 10% SDS
– 100 µl APS
– 4 µl TEMED
• Western blot resolving gel (10%)
– 4 ml ddH2O
– 2.5 ml 1.5 mM Tris pH 8.8
– 3.3 ml Protogel
– 100 µl 10% SDS
– 100 µl APS
– 4 µl TEMED
• Western blot stacking gel (4%)
– 7.18 ml ddH2O
– 1.25 ml 1 mM Tris pH 6.8
– 1.36 ml Protogel
– 100 µl 10% SDS
– 100 µl APS
– 8 µl TEMED
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• Western blot running buffer (purchased through SLS Life Science)
– 25 mM Tris
– 192 mM Glycine
– 0.1% (w/v) SDS
• Western blot transfer buffer
– 25 mM Tris
– 192 mM glycine
– 20% (v/v) MeOH
– 0.005% (w/v) SDS
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2.3 Cell Culture
2.3.1 Cell lines
A549 cells stably expressing individual C-terminally HA-tagged IFITM proteins were
acquired from the Kellam Lab (Sanger Institute, Cambridge, UK) and were produced
by Sarah Smith, Rachael Wash and Carmen Diaz-Soria. Stable protein expression was
achieved through lentiviral transfection (discussed in Section 2.3.2), and selected in two
different ways. There were three sets of stable A549 cells which are denoted as original
set (OS), puromycin 1 and puromycin 2 (P1 and P2, respectively). Transfected cells in
the OS set were selected by single cell cloning as described [134]. Transfected P1 and P2
cells were selected by virtue of a puromycin resistance gene cassette within the lentiviral
vector. See Table 2.2 for the different cells within each group.
Original Set (OS) Puromycin 1 (P1) Puromycin 2 (P2)
A549 A549 empty puro. A549 GFP
IFITM1 IFITM1 -
IFITM2 IFITM2 -
IFITM3 IFITM3 IFITM3
- - IFITM3-Y20A
Table 2.2: Composition of OS, P1 and P2 IFITM cell groups
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Cell line
Culture
media
FCS (v/v)
Pen/Strep
(v/v)
Additional (v/v)
A549 Ham’s F12 10% 1% -
BSC-40 DMEM 10% 1%
1% NEAA and
sodium pyruvate
C6/36 L15 10% 1% 10% TPB
BHK-21 GMEM 5% 1% 5% TPB
HEK293T DMEM 10% 1% -
Vero E6 M199 10% 1% -
Table 2.3: Cell culture conditions. All media was Life Technologies ‘GlutaMAX’ media.
All % values are (v/v).
Cell culture conditions are displayed in Table 2.3. Cells were maintained on plastic
10 cm dishes (Corning), 15 cm dishes (Sigma-Aldrich) or tissue culture flasks of various
sizes (Corning) as stated where appropriate through this chapter. Cells were also cultured
in 6 x 35 mm well dishes, 24 x 1.5 mm well dishes (both Thermo Scientific) or black 96
well plates (PerkinElmer). Any other culture conditions are discussed where appropriate.
Cells were maintained at 37℃ and 5% CO2.
2.3.2 Stable cell line production
Stable cell lines were produced through lentiviral (HIV based) transduction (as described
[134]). Lentivirus particles were produced by transient transfection of HEK293T cells
with the p8.9, pMDG2 and pSIN vectors. pSIN vectors were used to carry the gene
of interest while p8.9 provides the structural proteins for producing HIV particles and
pMDG2 encodes the vesicular stomatitis virus glycoprotein (VSV-G) to mediate viral
entry into cells (all constructs were kind gifts from the Kellam Lab [Sanger Institute]).
HEK293T cells were plated at a density of 2 x 106 in 10 cm dishes and incubated overnight.
The following day, cells were transfected with the three constructs in DMEM (transient
transfection further detailed in Section 2.3.3 and Table 2.4); 1 µg of p8.9 and pMDG2 and
1.5 µg pSIN (DNA concentrations optimised by members of the Kellam Lab) and incubated
for 24 hours (h). Subsequently, media were changed for fresh 10% FCS supplemented
DMEM (with no Pen/Strep) and incubated for a further 24 h. After 48 h transfection,
media were collected from the cells, filtered through 0.45 µm pores and stored at -80℃
prior to use.
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2.3.3 Transfection
For all transfections FuGENE 6 (F6) transfection reagent was used. Cells were cultured
overnight on 6 x 35 mm well dishes or 10 cm dishes depending on the assay. Cells were
plated to achieve roughly 60-70% confluency as per the Promega F6 instruction. For all
transient transfections, a F6 and OptiMEM transfection mix was made (see Table 2.4)
and incubated for 5 minutes (min) at room temperature (RT). DNA was added to the
transfection mix at an appropriate concentration (see Table 2.4). The F6:OptiMEM:DNA
ratio for a 6 x 35 mm dish was suggested by Promega F6 instructions and scaled up based
on plate area for 10 cm dishes (with the exception of the mix to produce lentiviruses as
discussed in Section 2.3.2). The F6:OptiMEM:DNA mix was incubated for 20 min at room
temperature (RT) prior to addition to cells in 10% FCS supplemented DMEM with no
Pen/Strep. Cells were then incubated for either 24 or 48 h prior to use. For all transient
transfections, the pcDNA3.1 vector was used. All constructs were provided by the Kellam
Lab (Sanger Institute), having been purchased from GeneArt (Thermo Scientific).
Culture plate FuGENE 6 OptiMEM DNA
6 x 35 mm 6 µl 200 µl 2 µg
10 cm 39 µl 1.3 ml 13 µg
10 cm (lenti.) 10 µl 200 µl 1 µg p8.9
1 µg pMDG2
1.5 µg pSIN
Table 2.4: Transfection reagent mixes.
2.3.4 Scratch assay
Cells were plated onto glass coverslips (LabTech glass coverslip chambers, 8 well) and
cultured overnight to form a confluent monolayer. Cells were imaged on an inverted
microscope, a scratch was made through the middle of the monolayer with a sterile plastic
P200 pipette tip, and were then imaged again. Cells were then incubated for various times
and closure of the wound monitored by further imaging.
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2.4 Antibodies
Details of primary antibodies and usage can be found in Table 2.5. WB: western blot,
IF: immunofluorescence, EM: electron microscopy. Details of secondary antibodies can be
found in Table 2.6. AF: AlexaFluor and abbreviations as above.
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2.5 Viruses Stock Preparation
2.5.1 Alphaviruses
Semliki Forest (SFV) and Sindbis virus (SINV) stocks were prepared from the CB3 and
AR339 virus preparations, respectively (SFV CB3 was produced by Prof. Mark Marsh,
SINV AR339 was a kind gift from Dr. Penny Powell, University of East Anglia, Norwich,
UK). Stocks for both alphaviruses were prepared in the same way. BHK-21 cells were
grown in T75 or T175 flasks for 2 days to form a confluent monolayer and infected with
0.05 pfu/cell (in GMEM supplemented with 0.2% [w/v] BSA and 10 mM Hepes [from
powder, pH 7] containing Pen/Step). Cells were incubated with virus for 1 h at 37℃, prior
to removal of media and replacement with fresh GMEM (supplemented as before). Cells
were cultured at 37℃ to allow infection for 22 h. Following incubation, flasks were placed
on ice for 30 min and media were collected to polypropylene Falcon tubes. Cellular debris
was removed by centrifugation for 15 min at 2500 x g (4℃). Supernatant was collected and
subject to ultracentrifugation for 2.5 h at 100000 x g (4℃). Following ultracentrifugation,
supernatant was removed and the pellet placed on ice. The virus pellet was re-suspended
in TN buffer and centrifuged for 5 min at 200 x g (RT) to remove any large clumps of
virus. Samples were snap frozen with liquid nitrogen and stored at -80℃. Virus titre was
determined by serial dilution plaque assay on BHK-21 cells (see Section 2.6.1).
2.5.2 Flaviviruses
Dengue (serotype 2; DENV), Zika (African strain; ZIKV) and yellow fever (17D strain;
YFV) virus stocks were all produced by Dr. Michela Mazzon (MRC LMCB).
Dengue virus
C6/36 mosquito cells were grown in T175 flasks overnight, to ∼80% confluency, and in-
fected with 0.5 pfu/cell (in L-15 media supplemented with 10% TPB and 2% FCS; referred
to as ‘2% L15’). Cells were incubated with virus for 2 h at 37℃, prior to removal of media
and replacement with fresh 2% L-15. Cells were incubated for 3 days before harvesting.
The media were collected from flasks (and replaced) twice a day (morning and evening)
for 2 days. At each collection, cellular debris was pelleted by centrifugation at 300 x g
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for 10 min, filtered through 0.45 µm pores and stored at 4℃. After the final collection, all
media were pooled and concentrated by centrifugation (Vivaspin column 20) at 4℃ for 1
h at 600 x g. The concentrated supernatant was transferred to ice and the concentrator
rinsed with 2% L-15. Hepes (pH 7) was added to a final concentration of 25 mM (from 1
mM solution) and samples were snap frozen with liquid nitrogen prior to storage at -80℃.
DENV titre was determined by immunofocus assay (performed by Dr. Michela Maz-
zon). Vero cells were plated on 24 x 1.5 mm dishes and grown overnight, to ∼90% con-
fluency, then infected with DENV across a 10 fold dilution series of appropriate range for
the expected virus yield. Virus was added to cells in MEM supplemented with 2% FCS
and incubated for 1 h at 37℃. Media were then removed and a CMC overlay was added.
Cells were incubated for 3 days at 37℃. Following this period, the overlay was removed
and the wells were washed with PBS. The cells were fixed with 5% (v/v) FA in PBS for
30 min at RT. Cells were permeabilised with 2% (v/v) Tx100 in PBS and incubated for
5 min at RT. Samples were then blocked with 2% (w/v) skimmed milk in PBS (block-
ing solution) for 30 min at RT. The blocking solution was removed and replaced with
anti-DENV antibody diluted in blocking solution and incubated for 1 h at 37℃. Samples
were washed 3x with PBS, to remove unbound antibody and subsequently incubated with
HRP-conjugated anti-mouse secondary antibody, diluted in blocking buffer, for 1 h at RT.
Wells were washed 4x with PBS to remove unbound antibody. Single SIGMAFAST tablets
(SIGMAFAST 3-3-Diaminobenzidine tablet, D44418-50 Set) were diluted in 15 ml ddH2O
and at least 200 µl was added to each well and incubated at room temperature until well
defined foci were visible. Plaques were then counted to determine the viral titre.
Yellow fever virus
Vero cells were grown in T75 flasks overnight to be about 70% confluent and infected with
YFV (in M199 media supplemented with 2.5% FCS). The YFV stock was a kind gift from
Dr. Joachim Bugert (University of Cardiff, UK), 300 µl was provided, and 150 µl was
used for the innoculum (titre not determined). Cells were incubated with virus for 2 days.
Media were collected and centrifuged at 600 x g for 8 min and filtered through 0.45 µm
pores. Hepes (pH 7) was added to a final concentration of 25 mM (from 1 mM stock)
and virus stored at -80℃. Virus titre was determined by infection and immunofluorescence
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staining of A549 cells (see Section 2.8 for details on immunofluorescence).
Zika virus
ZIKV stocks were prepared and titre determined in the same way as YFV.
2.5.3 Vaccinia virus
VACV Western Reserve (WR) strain and VACV WR expressing EGFP from an early/late
fusion promoter were a kind gift from Dr. Jason Mercer (MRC LMCB).
2.6 Virus Infections
2.6.1 Plaque assay
To determine alphavirus titre, serial dilution plaque assays were performed. BHK-21 cells
were grown for 1 day in 6 x 35 mm well dishes to form a confluent monolayer. Virus
stocks were diluted in GMEM supplemented with 10 mM Hepes (from powder) and 0.2%
(w/v) BSA and a 10 fold dilution series made, over an appropriate range for the expected
virus yield. Cells were inoculated with 0.5 ml virus containing media and incubated at
37℃ for 2 h with occasional manual agitation to ensure no cells dried out. After 2 h,
virus containing media were removed and 2 ml CMC overlay media was added to the cells,
before incubating at 37℃ for 2 days with minimal movement. Following infection, overlay
media was removed and 1 ml crystal violet stain was added to cells and incubated for 30
min at RT. Crystal violet stain was removed following incubation and the plates washed
in tap water. Crystal violet stains live cells. Plaques were detected, and counted, as clear
areas within each well to determine viral titre.
VACV titres were also determined by serial dilution plaque assay with a slightly ad-
justed protocol. BSC-40 cells were grown overnight in 6 x 35 mm well dishes to form a
confluent monolayer. Virus was diluted in unsupplemented DMEM across a 10 fold dilu-
tion series, over an appropriate range for the expected virus yield. Virus was incubated
with cells for 30 min at 37℃, prior to removal of inoculation media and addition of 2 ml
DMEM (supplemented as for maintenance of BSC-40 cells; see Table 2.3). Infection was
80 Chapter 2
Materials and Methods
allowed to proceed for 2 days prior to crystal violet staining as above.
2.6.2 Alphavirus and flavivirus infections
Cells were grown overnight in various cell culture dishes to achieve 70-80% confluency. For
infection of A549 cells, virus was diluted to the required MOI (listed for each experiment)
in F-12 infection media. Cells were incubated for 5.5 - 6 h to allow infection prior to
fixation with 3% FA for 15 min at RT for the alphaviruses. For flaviviruses, cells were
infected using the same media as for alphaviruses and incubated for 27 h prior to fixation.
Following fixation, infection level was determined by immunofluorescence staining for the
E1/E2 envelope proteins of the alphaviruses or antibodies against the flaviviruses (see
Table 2.5 for antibody details, Section 2.8 for details on immunofluorescence staining and
Section 2.6.8 for details on infection quantification).
2.6.3 SFV binding to the cell surface
Many of the experiments subsequently described required SFV to be bound to the cell
surface, without being internalised through endocytosis. This was achieved by adding
virus at 4℃, which blocks endocytic uptake and therefore viral entry. Virus could then be
allowed to enter cells by synchronous endocytic uptake (as described in Section 2.6.4) or
experimentally induced to infect cells by fusion with the plasma membrane (as described
in Section 2.6.7). Cells were grown on plastic plates of various size, or glass coverslips
(VWR International) overnight to be 80-90% confluent. After overnight culture, cells
were washed 1x with 4℃ binding media (BM) and placed on ice. Virus was diluted to the
required MOI (as indicated) in 4℃ BM, added to cells and incubated for 1 h, on ice and
at 4℃, with gentle agitation. Subsequently, the media were removed and the cells rinsed
twice with 4℃ BM to remove unbound virus. Appropriate further treatments were then
performed (detailed below).
2.6.4 SFV internalisation
In order to analyse SFV internalisation into cells, biochemical immunofluorescence mi-
croscopy or electron microscopy (EM) were used. Virus was added to cells at an MOI of
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50 or 200 pfu/cell (as indicated) for IF analysis, and 1000 or 5000 pfu/cell for EM analysis,
and allowed to bind at the cell surface. Endocytosis of virus was stimulated by incubating
cells in 37℃ infection media for the indicated times. Cells were fixed with 3% FA and
processed for immunofluorescence microscopy (Section 2.8).
Subtilisin resistance assay
To investigate SFV internalisation biochemically, a protease resistance assay was used.
Virus was added to cells at an MOI of 200 pfu/cell and allowed to bind at the cell surface
for 1 h, then allowed to internalise for the indicated times. Cells were returned to ice and
treated with 2 mg/ml subtilisin in PBS for 1 h at 4℃ with gentle shaking. Subtilisin can
remove virus remaining at the surface without impacting intracellular pools. Subtilisin
was inactivated by addition of 1 mM PMSF and 30 mg/ml BSA in PBS (containing 1x
complete PIC). Cells were collected (by scraping for samples not treated with protease),
and centrifuged to form a pellet (300 x g for 5 min at 4℃.) The supernatant was removed
and the cell pellet resuspended in 0.2% BSA in PBS to wash. Cells were again pelleted
under the same centrifuge conditions and washed a final time in PBS. After removing the
final wash, cells were lysed with Tx100 lysis buffer and analysed by SDS-PAGE and western
blot (see Section 2.7) for the E1/E2 proteins, to determine the amount of cell-associated
virus.
2.6.5 Time course of SFV penetration
The kinetics of SFV endosomal penetration were determined in A549 cells. SFV was
bound to the surface of cells. Media at 37℃ were then added to cells to allow endocytic
uptake of virus. The pre-warmed F12 infection media added to cells contained DMSO
or 10 µM monensin. Monensin is an ionophore which dissipates low pH gradients thus
inhibiting SFV fusion with endosomes. Addition of monensin can therefore be used to
determine the time at which SFV passes the acid-sensitive stage of entry. At time points
between 3 and 30 min, media containing DMSO were removed and replaced with media
containing monensin. Cells were then incubated for 5.5 - 6 h at 37℃ to allow infection,
prior to fixation and immunofluorescence analysis of infection (Section 2.8 and Section
2.6.8).
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2.6.6 SFV E1 trypsin insensitivity
Cells were grown in 6 x 35 mm well plates overnight and pre-incubated with DMSO or
100 nM Baf A in BM for 15 min at 37℃. Cells were then placed on ice and washed with
cold BM containing DMSO or Baf A to match the pre-incubation (as in all subsequent
steps) prior to addition of SFV (200 pfu/cell). Virus was incubated with cells for 1 h
on ice to allow binding to the cell surface. Subsequently, unbound virus was removed by
washing with cold BM. Cells were then either incubated with 37℃ BM for the indicated
times to allow virus internalisation, incubated at 37℃ with BM adjusted to pH 5.5, or left
on ice as control. Cells were washed twice with ice cold PBS and lysed with 60 µl/well
1% (v/v) Tx100 in PBS for 15 min on ice. Nuclei were removed by centrifugation (16000
x g, 20 min, 4℃) and lysate was aliquoted to 2 x 20 µl samples. One sample was mixed
with 20 µl trypsin at 800 µg/ml in 1% Tx100, while the other was mixed with 20 µl
1% Tx100, and incubated for 10 min at 37℃. Both samples were mixed with 20 µl soy
bean trypsin inhibitor, to inactivate the enzyme, at 2 mg/ml in 1% Tx100. Finally, 6x
non-reducing LSB was added to a final concentration of 1x. The samples were not heated
as this can dissociate the E1 homotrimer. An equal volume of each sample was separated
by SDS-PAGE and analysed by western blot (Section 2.7).
2.6.7 SFV plasma membrane fusion
Cells were grown overnight in 96 well plate format and pre-incubated with DMSO or 100
nM Baf A prior to adding SFV (5 pfu/cell) as described for SFV E1 trypsin insensitivity.
Unbound virus was removed by washing with cold BM (2 washes) and the cells were then
treated with 37℃ BM adjusted to pH 5.5 to activate the virus fusion machinery (or as
control, remaining at pH 6.8) and incubated at 37℃ for 3 min. Media were removed and
replaced with F-12 infection media (pH 7) containing DMSO or Baf A and incubated for
5.5 - 6 h to allow infection, prior to fixation and analysis of infection by immunofluorescence
microscopy (Section 2.8 and Section 2.6.8).
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2.6.8 Infection quantification
Two approaches were used to detect the percentage of infected cells, both using immunoflu-
orescence staining and microscopy (see Section 2.8). Either, cells were imaged using an
Opera automated, high-throughput confocal microscope system (PerkinElmer): Cells were
detected and counted based on Hoechst staining and infected cells were detected and
counted based on viral protein staining by the Columbus software (PerkinElmer), allow-
ing calculation of percentage infected cells. The Opera microscope was set up to image
12 fields of view at 20x magnification for each well. Or, cells were imaged with a Leica
DMIRB epifluorescence microscope (also see Section 2.8.4 for further detail) and total cells
and total infected cells were detected using ImageJ software. For this quantification of
infection, 3 random fields of view were collected at 20x magnification per well. The images
were separated to their component channels to give images of nuclei and staining of viral
protein to mark infected cells. Nuclei were segmented and counted to determine the total
number of cells per field of view. The segmented nuclei were then super-imposed on the
image of the fluorescent channel for infected cells and a ring of 10 pixels was expanded
around each nucleus area. The fluorescence intensity within this area was then used to
score cells as infected or uninfected and the percentage of infected cells determined. The
second approach was used as the Opera system was not always available. A direct compar-
ison indicated very little difference in the data generated by the two methods. GraphPad
Prism software was used for significance testing.
2.7 Western blotting
To produce whole cell lysates, cells were rinsed twice with ice cold PBS prior to addi-
tion of Tx100 lysis buffer (unless otherwise indicated) and incubated for 15 min on ice.
Cells were scraped in order to collect all sample. Nuclei were pelleted by centrifugation
(16000 x g, 20 min, 4℃) and the supernatant collected. Protein content was determined
using the bicinchoninic acid method (Thermo Scientific), as per the manufacturer’s in-
structions. Unless indicated otherwise, 20 µg of protein was used in each gel and mixed
with 3x reducing or non-reducing LSB (final concentration of 1x), heated at 95℃ for 5
min. Proteins were separated by SDS-PAGE with constant voltage, using either 10% or
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15% gels depending on the molecular weight of the protein being analysed. Proteins were
transferred to PVDF membrane (Immobilon-FL, Millipore; activated with MeOH as per
the manufacturers instructions) with constant current using a semi-dry approach (BioRad
Trans Blot SD Semi-Dry Transfer Cell). Membranes were dried at 37℃ for 30 min, then
re-wetted by 15 s incubation in MeOH, followed by washing with water for 2 min and
TBST for 2 min. Membranes were then blocked using 5% (w/v) skimmed milk in TBST
(block buffer) for 1 h and incubated with primary antibody (diluted in block buffer) at 4℃
overnight. Membranes were washed 3 x 5 min with TBST and incubated with Li-COR
secondary antibodies diluted in block buffer for 1 h at RT. Membranes were washed 6
x 5 min with distilled water and dried by 30 min incubation at 37℃ prior to imaging
on a Li-COR Odyssey system. Quantification of band intensity was performed using the
Odyssey software.
2.7.1 Protease cleavage assays to investigate topology
A trypsin cleavage assay was performed to analyse IFITM1 topology. Cells were grown
overnight on 6 x 35 mm well plates to be 80-90% confluent, washed twice with PBS at
RT and treated with 100 µg/ml trypsin in PBS for 5-30 min at 37℃. Cells in suspension
were collected and transferred to microcentrifuge tubes, on ice. The wells were rinsed
with 1 mg/ml soy bean trypsin inhibitor (SBTI) in PBS, to collect any remaining cells,
and this rinse was added to the microcentrifuge tubes on ice to inactivate the trypsin.
The untreated control cells were incubated with PBS for 30 min at 37℃, prior to scraping
to detach cells which were then collected into microcentrifuge tubes on ice. Wells were
similarly washed with SBTI. As a further control, samples were incubated with inactivated
trypsin (1:1 mix between trypsin and SBTI) for 30 min at 37℃ and collected as for the
untreated control samples. Cells were pelleted by centrifugation (600 x g, 5 min, 4℃),
washed with soy bean trypsin inhibitor then directly lysed in 1x reducing LSB (diluted
from the 3x LSB stock - see Section 2.2) prior to SDS-PAGE and western blotting.
A similar protease cleavage assay was used to investigate the topology of IFITM3-
Y20A, however IFITM3 lacks trypsin cleavage sites in the CTD. As a consequence pro-
teinase K (ProtK) was used instead. Cells were set up as for the trypsin cleavage assay
and treated with 500 µg/ml ProtK in DPBS for 10 or 30 min at 37℃ (DPBS used as
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ProtK requires calcium ions for activity). PMSF was added (1 mM final) following each
incubation to terminate the reaction. Cells in suspension were collected and transferred to
microcentrifuge tubes on ice. Wells were rinsed with 1 mM PMSF in PBS, to collect any
remaining cells, and this rinse was added to the microcentrifuge tube. Untreated control
cells were incubated with DPBS for 30 min at 37℃, prior to collection by scraping; PMSF
was added (1 mM final) and wells were similarly rinsed as for collection of other samples.
For the inactivated control sample, PMSF was added to ProK (1 mM final) in DPSB prior
to addition to cells and incubation for 30 min at 37℃. This inactivated control was col-
lected in the same way as the untreated control. Cells were pelleted as above and washed
with 1 mM PMSF then lysed with Tx100 lysis buffer prior to analysis by western blotting.
2.7.2 Biotin labelling and pulldown
HEK293T cells were grown on 10 cm dishes and transfected with pcDNA3.1 plasmids
containing untagged IFITM1 or IFITM1-Vstop (Section 2.3.3). The cells were incubated
for 24 h then detached with 5 mM EDTA and re-plated on 6 x 35 mm well plates. After a
further 24 h, the cells were washed twice with PBS then labelled for 45 min at 37℃ with
1 mg/ml EZ-link Sulfo-NHS-SS-Biotin. The label was washed off with TBS and the cells
were lysed with 100 µl Tx100 lysis buffer. Whole cell lysate (70 µl) was added to 25 µl
of NeutrAvidin agarose beads and rotated for 3 h at 4℃. The beads were then pelleted
by centrifugation (200 x g, 1 min) and the supernatant collected to assess the unbound
material. The pelleted beads were washed with Tx100 lysis buffer, TBS and TE buffer,
pelleting and removing the supernatant between each wash. Proteins were eluted from the
beads by addition of 70 µl of 1x reducing LSB (diluted from 3x LSB stock) and heating at
95℃ for 10 min. The beads were again pelleted and the supernatant containing the eluted
proteins was collected. A second round of elution was performed to ensure all protein had
been collected. Equivalent volumes of the remaining whole cell lysate, unbound material
and both protein elutions were separated by SDS-PAGE and analysed by western blot.
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2.8 Immunofluorescence and Flow Cytometry
2.8.1 Immunofluorescence staining of permeabilised cells
Cells were cultured on glass coverslips, or plastic tissue culture dishes prior to any im-
munofluorescence staining. All processing was performed at RT. Cells were fixed for 15
min with 3% FA diluted in PBS. Samples were rinsed with PBS and free aldehyde was
quenched by incubation with 50 mM NH4Cl in 0.2% (w/v) BSA in PBS (PBS/BSA) for
15 min. Cells were again rinsed with PBS and then permeabilised with 0.05% saponin
in PBS/BSA (permeabilisation buffer [PB]), and incubated for 30 min. Samples were
subsequently incubated with appropriate primary antibodies diluted in PB for 1 h, prior
to washing to remove any unbound antibody (3 x 5 min washes with PB). Secondary
antibodies were similarly diluted in PB and incubated with samples for 45 min prior to
washing (4 x 5 min). Details of all antibodies and their usage are given in Tables 2.5 and
2.6. Nuclei were labelled by 5 min incubation with 5 µg/ml Hoechst (in PB). Samples
were finally washed 3 x 5 min in PBS and mounted to glass slides (Thermo Scientific or
VWR International) in Mowiol prior to imaging. All samples in culture dishes were left
in PBS.
For detection of flavivirus infection and SFV capsid by immunofluorescence staining,
the above procedure was altered to use 0.1% (v/v) Tx100 in PBS for permeabilisation.
In this variation, permeabilisation was carried out for 10 min, and PBS/BSA (without
Tx100) was used for all subsequent steps.
2.8.2 Immunofluorescence staining of intact cells
Where indicated immunofluorescence staining was performed on intact cells using one of
two approaches. For the first approach, cells were incubated on ice with cold PBS/BSA
for 10 min prior to incubation with primary antibody diluted in ice cold PBS/BSA for 1 h.
Unbound antibody was removed by washing with cold PBS/BSA (3 x 5 min) and the cells
were fixed with cold 3% FA for 1 h (30 min on ice and 30 min at RT). Subsequent steps
were performed as for permeabilised immunofluorescence, using PBS/BSA for diluting all
reagents. An alternative approach was to fix cells with 3% MeOH free FA and perform
all steps at RT, as described for permeabilised immunofluorescence, in the absence of
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detergent (PBS/BSA for all steps).
2.8.3 Antibody feeding
Cells were cultured on coverslips overnight and incubated with 5 µg/ml rat anti-HA an-
tibody for 3 h at 37℃ (diluted in culture media). Unbound antibody was removed by
rinsing the cells 2x with media and 1x with PBS prior to fixation with 3% FA. Cells were
then processed for immunofluorescence staining with permeabilisation (Section 2.8.1).
2.8.4 Microscopy
For imaging cells in tissue culture dishes, a Leica DMIRB epifluorescence microscope
connected to a Hammamatsu C4742-95 Orca CCD camera was used. Images were ac-
quired using OpenLab software (PerkinElmer). Cells on coverslips were imaged using
either epifluorescence or confocal microscopy. For epifluorescence microscopy either a
Zeiss AxioImager (connected to a QImaging Retiga EXi camera), or a Zeiss Axioplan
(connected to a QImaging QIClick camera) were used, with images acquired through
OpenLab software. For confocal microscopy a Leica SPE system was used with images
acquired through the LAS AF software (Leica). As discussed in Section 2.6.8, an Opera
automated, high-throughput confocal microscope system (PerkinElmer) was also used for
analysis of infection percentages.
2.8.5 Flow cytometry
Samples were prepared as described for the immunofluorescence staining with the alter-
ations described subsequently. Flow cytometry was performed with an LSR-II (BD Bio-
science) with cells being gated on forward and side scatter and analysed for fluorescence
intensity. Data was processed with FlowJo software (TreeStar).
Cell surface IFITM staining and flow cytometry
Cells grown on 6 x 35 mm dishes were detached by incubation at 37℃ with 5 mM EDTA
in PBS. The detached cells were collected, pelleted by centrifugation (600 x g 5 min at
RT) and the supernatant removed. Cell pellet was resuspended in 3% FA and incubated
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at RT for 15 min to fix. Cells were again pelleted by centrifugation, and resuspended in
50 mM NH4Cl and incubated at RT for 15 min (as described for cells on coverslips in
Section 2.8). Samples were then either permeabilised with 0.05% saponin or left intact by
incubation with PBS/BSA only (30 min incubation). Cells were labelled with rat anti-HA
antibody followed by appropriate secondary antibody. The staining procedure was carried
out to mimic that of cells on coverslips as described in Section 2.8, with centrifugation
and supernatant removal at each step. As controls, samples were either incubated without
antibodies present (PBS/BSA only) or incubated with secondary antibody only.
HA-tag trypsin cleavage and flow cytometry
Cells were grown in 6 x 35 mm dishes and treated with trypsin for 10 or 30 min (as
described in Section 2.7.1). Cells were collected and processed as above.
2.9 Image analysis
2.9.1 Co-localisation analysis
All microscope image analysis was performed using ImageJ. For calculation of Pearson’s
R-value and Mander’s correlation coefficients M1 and M2, individual cells were manually
segmented and analysed using the JACoP plugin [189]. For the M1 and M2 values a
Costes’s automatic threshold was applied, as described [189]. The process of calculating
relative areas of overlap is detailed in Fig. 2.1. All significance testing was performed used
GraphPad Prism software.
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Figure 2.1: Work flow for co-localisation analysis. 1) To analyse co-localisation, single
confocal sections were acquired through the centre of cells. 2) The component channels of
the image were separated and the nuclei (blue channel) were discarded, leaving magenta
and green channels. 3) An ‘AND’ function was performed on the two channels to produce
a new image made up of pixels containing both magenta and green signal. 4) A threshold
was set to remove background signal and the area of the magenta and green (‘overlap’)
pixels was measured. 5) ‘Overlap’ pixels were removed from the individual magenta and
green channels. 6) As in 4, a threshold was set to remove background and measure the
magenta only pixels. 7) Magenta only pixels were removed from the green channel. 8)
The remaining green pixel area was measured. Three values were therefore produced per
confocal section, overlap pixel area, magenta only pixel area and green only pixel area.
These values were set relative to total pixel area and analysed across multiple images to
determine co-localisation.
2.9.2 Analysis of cytosolic SFV capsid immunofluorescence
staining
All microscope image analysis was performed using ImageJ. The process of quantifying
the immunofluorescence associated with SFV capsid release into the cytosol is detailed in
Fig. 2.2. GraphPad Prism software was used for significance testing.
2.10 Statistical analysis
All statistical analysis was performed using GraphPad Prism software. All analyses were
performed as unpaired student’s t-tests to compare difference between control A549 cells
and IFITM expressing cells, or drug treated cells and untreated cells.
2.11 Electron Microscopy
All sample preparation for EM was performed by Dr. Ian White (MRC LMCB). All sam-
ples were imaged using a transmission electron microscope (Tecani T12; FEI), equipped
with a charge-coupled device camera (SIS Morada; Olympus).
Epon section EM
Cells were grown on coverslips overnight prior to addition of SFV (1000 pfu/cell) for
cell surface binding and internalisation as described in Section 2.6.3. Cells were fixed
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Figure 2.2: Work flow for analysis of cytosolic capsid fluorescence. 1) To analyse
cytosolic capisd fluorescence, single confocal sections were acquired through the centre of
cells. 2) The component channels were split and nuclei areas were manually segmented.
3) Any fluorescence in the capsid channel associated with the nuclei area was deemed to
be background and was therefore removed. 4) A threshold was set to detect the large flu-
orescent puncta. 5) The large puncta were judged to be virus particles within endosomes,
rather than staining of capsid in the cytosol and as such, these pixels were also removed.
6) Individual cell areas were segmented and the mean grey value within each area was
measured to determine cytosolic fluorescence intensity.
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with EM-grade 2% FA / 2% glutaraldehyde in 0.1 M sodium cacodylate (pH 7.4) for
30 min. Samples were further fixed for 1 h in 1% osmium tetraoxide/1.5% potassium
ferricyanide at 4℃ then treated with 1% tannic acid in 0.1 M sodium cacodylate for 45
min at RT. Samples were dehydrated in sequentially increasing concentrations of ethanol
and embedded in Epon resin. The coverslips were inverted onto prepolymerised Epon
stubs and polymerised by baking at 60℃ overnight. A Diatome 45° diamond knife and an
ultramicrotome (UC7; Leica) were used to cut 70 nm ultrathin sections. These sections
were collected on 1 x 2 mm formvar-coated slot grids and stained with Reynolds lead
citrate [190].
Immunogold labelling of cryosections and EM
When analysing SFV internalisation by immunogold labelling, virus was added to cells at
5000 pfu/cell for binding at the plasma membrane, prior to warming to allow internalisa-
tion (as described in Section 2.6.4), prior to fixation. Alternatively, cells were grown on
coverslips overnight prior to fixation. Cells were fixed with 4% FA in 0.1 M phosphate
buffer (pH 7.4), infused with 2.3 M sucrose, supported in 12% (w/v) gelatin and frozen
in liquid nitrogen. Ultrathin (70 nm) cryosections were cut at -120℃ and picked up in
1:1 2% sucrose:methylcellulose. Sections were labelled with primary antibodies (detailed
in Table 2.5) and where necessary a bridging antibody (rabbit anti-mouse intermediate
[1:180; DAKO] - required for detection of mouse anti-HA antibody) and protein A-gold.
For double labelling experiments, sections were treated with 1% glutaraldehyde in PBS
after the first protein A-gold incubation then quenched in 15 mM glycine before repeat-
ing the single labelling procedure with the second primary antibody and different sized
protein-A gold [191]. The antibody order was anti-HA followed by anti-E1/E2. Sections
were contrast stained in a 1:9 solution of 4% uranyl acetate:2% methylcellulose pH 4.0.
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IFITM Protein Membrane
Topology and Localisation
3.1 Introduction
When the IFITM proteins were identified as having antiviral function by Brass et al. [7],
their data suggested that the IFITMs had a dual-pass transmembrane topology. The
N- and C-terminal domains (NTD and CTD) were both suggested to reside in the ex-
tracellular/lumenal space, connected by two transmembrane domains and the conserved
intracellular loop (CIL; Fig. 3.1; model 1). This model was in agreement with older
suggestions of IFITM membrane topology [114–116]. However, subsequent studies were
published suggesting that both the NTD and CTD were in fact on the cytoplasmic side
of cellular membranes, necessitating two intramembrane loops (Fig. 3.1; model 2; [150,
163]).
At the commencement of this work, there was debate over the topology of the IFITMs.
Therefore, biochemical and cell biological experiments were performed to define the mem-
brane topology in a stable A549 cell system. These investigations produced data to suggest
a third membrane topology model in which the NTD is on the cytoplasmic side of mem-
branes, while the CTD is on the extracellular/lumenal side (Fig. 3.1; model 3). Our
work was published [15], and much of the data presented in this chapter can also be
found there. During the course of our studies, the same topology model was proposed
for murine Ifitm3 [153]. Another more recent study has further supported this topology
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Figure 3.1: Topology models of the IFITM proteins. Model 1: The initially proposed
model for IFITM membrane topology placed both the N- and C-terminal domains (NTD
and CTD) on the extracellular/lumenal side of cellular membranes. The two termini are
connected by two transmembrane domains (M1 and M2) and a conserved intracellular
loop (CIL). Model 2: The second proposed model for IFITM membrane topology placed
both the NTD and CTD on the cytoplasmic side of membranes, connected by M1, CIL
and M2. This model necessitated M1 and M2 enter into but do not cross the lipid bilayer.
Model 3: The most recently proposed model suggests that the NTD is cytoplasmic, while
the CTD is extracellular/lumenal. M1 enters into, but does not cross the bilayer, while
M2 crosses the bilayer. (N.B. This figure has previously been displayed in Chapter 1 and
is repeated here as an aide-memoire).
model for human IFITM3 using the methods of nuclear magnetic resonance (NMR) and
electron paramagnetic resonance (EPR; [192]). Defining a membrane topology in which
the CTD resides in extracellular/lumenal spaces has implications for understanding the
distribution of IFITM proteins within the endosomal system. Consequently, work is pre-
sented analysing the cellular distribution of the IFITM proteins by immunofluorescence
microscopy with antibodies against the NTD. Developing an understanding of the topol-
ogy and localisation may also have implications for understanding the antiviral activity of
the proteins, as will be discussed in subsequent chapters.
3.2 Results
3.2.1 The IFITM1 C-terminal domain resides in the extra-
cellular space
To investigate the topology and cellular distribution of the IFITM proteins, A549 cells
stably expressing C-terminally HA-tagged proteins were analysed by immunofluorescence
microscopy. When cells were permeabilised with saponin and labelled with anti-HA anti-
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Figure 3.2: Cellular distribution of the IFITM proteins and HA-tag localisation.
Control A549 and C-terminally HA-tagged IFITM1, 2 and 3 expressing cells were labelled
with an anti-HA antibody following saponin permeabilisation or with intact cell mem-
branes (antibody added on ice prior to fixation). The anti-HA antibody was visualised
with anti-rat AF488 antibody. A and E) Permeabilised and intact A549 cells showed no
specific staining for HA. B-D) In permeabilised cells, the HA-tag could be detected and
the labelling showed that IFITM1, 2 and 3 have distinct distributions. F) The HA-tag
was accessible on intact IFITM1 expressing cells. G) Intact IFITM2 expressing cells show
no specific staining. H) A minority (<1%) of intact IFITM3 expressing cells had low level
HA signal detectable at the plasma membrane. Nuclei were labelled with Hoechst. All
images are maximum intensity projections of confocal sections through the depth of the
cells. All images were acquired with the same microscope settings and brightness and
contrast have been adjusted uniformly. Scale bar represents 15 µm.
body, all three IFITM proteins were found to have distinct distributions (Fig. 3.2 B-D).
There was no background staining in the control A549 cells (Fig. 3.2 A). IFITM1 ap-
peared to be primarily at the plasma membrane, while IFITM2 and IFITM3 were mostly
seen in punctate, intracellular compartments. Intact cells were also stained to assess the
extracellular availability of the C-terminal HA-tags. In order to ensure the integrity of the
plasma membrane, anti-HA antibody was added to cells on ice prior to fixation. IFITM1
could be detected on intact cells (Fig. 3.2 F), and the staining appeared very similar to
that seen on saponin treated cells. There was no detection of IFITM2, probably as a re-
sult of localisation to intracellular membrane compartments (Fig. 3.2 G). A small fraction
(<1%) of IFITM3 expressing cells showed some signal at the plasma membrane, however
most cells lacked any positive staining (Fig. 3.2 H). These data suggested that IFITM1
(and perhaps IFITM3) have a CTD HA-tag that is exposed in the extracellular space.
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To ensure that cytoplasmic antigens were not being labelled, the integrity of the plasma
membrane to antibodies was assessed. Tubulin could be detected in saponin permeabilised
cells (Fig. 3.3 A), and IFITM1-3 showed the same distributions displayed in Fig. 3.2. How-
ever, when antibodies were added on ice prior to fixation there was no detectable tubulin
staining (Fig. 3.3 B). Comparatively, IFITM1 could be detected and a low percentage of
IFITM3 expressing cells again stained positively (Fig. 3.3 B). These data suggest that
intracellular antigens are not detected under the ‘intact’ condition, suggesting the HA-tag
is extracellularly exposed.
Finally, to test the apparent plasma membrane localisation of IFITM1 and a minority
of IFITM3, intact cells were co-labelled with wheat germ agglutinin conjugated to a fluo-
rophore. These results suggest that IFITM1 and IFITM3 are indeed at the plasma mem-
brane (Fig. 3.4). Overall, the data suggest that in A549 cells, IFITM1 is localised at the
plasma membrane and the CTD HA-tag is extracellularly accessible to antibody labelling.
IFITM2 and IFITM3 are predominantly found within internal membrane compartments,
however, on a low number of cells the CTD HA-tag of IFITM3 could be detected at the
plasma membrane, suggesting that similarly to IFITM1, the CTD is in the extracellular
space.
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Figure 3.3: IFITM1 and IFITM3 can be labelled on intact cells, while tubulin
cannot. C-terminally HA-tagged IFITM1, 2 or 3 expressing cells were co-stained for
the HA-tag and tubulin following saponin permeabilisation or in intact conditions. The
HA-tag was visualised with AF488 (green), while tubulin was visualised with AF594 (ma-
genta). A) Permeabilised cells showed positive labelling for tubulin and all three IFITMs.
B) When antibodies were added to cells on ice, prior to fixation to maintain the integrity
of the plasma membrane, no tubulin was detected. Conversely, IFITM1 and a minority of
IFITM3 expressing cells were positive for HA. No IFITM2 was detected in the absence of
permeabilisation. Nuclei were labelled with Hoechst. All images are maximum intensity
projections of confocal sections through the depth of the cells. All images were acquired
with the same microscope settings and brightness and contrast have been adjusted uni-
formly. Scale bar represents 15 µm. (Immunofluorescence staining and microscopy was
performed by Stephanie Czieso).
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3.2.2 Analysis of IFITM localisation and HA-tag orienta-
tion by electron microscopy
To further define the localisation of the IFITM proteins, ultrathin (70 nm) cryosections
of IFITM expressing cells were prepared and labelled using antibodies against the HA-tag
and protein A-gold and analysed by electron microscopy (EM). The majority of IFITM1
labelling was detected at the plasma membrane (Fig. 3.5), supporting the immunofluo-
rescence data (Fig. 3.2). It also appeared that many of the gold particles were on the
extracellular side of the plasma membrane, further suggesting the extracellular localisation
of the CTD. Additional IFITM1 labelling was detected in endosomes and multivesicular
bodies (MVBs; Fig. 3.5B and C) and the Golgi apparatus (Fig. 3.5 D), indicating the
presence of protein in the endocytic and biosynthetic pathways.
There was generally low labelling for the HA-tag in IFITM2 expressing cells. The
labelling that was seen appeared to be predominantly on MVBs, with much of that la-
belling being on intra-lumenal vesicles (ILV), rather than on the limiting membrane (Fig.
3.6 B). In contrast to IFITM1, only a low level of IFITM2 HA labelling was detected at
the plasma membrane (Fig. 3.6 A). Similarly to IFITM1, IFITM2 HA labelling was also
found at the Golgi apparatus (Fig. 3.6 C).
Some IFITM3 HA labelling could be detected at the plasma membrane (Fig. 3.7 A).
This was less common than seen for IFITM1, but more common than seen for IFITM2.
Similarly to IFITM2, the majority of IFITM3 HA labelling was found on MVBs, and
specifically the ILVs (Fig. 3.7 B). Labelling was again observed at the Golgi apparatus
(Fig. 3.7 C). Similarly to IFITM1, in IFITM3 expressing cells, plasma membrane localised
gold particles appeared to be predominantly on the extracellular side of membranes (Fig.
3.7 A).
Overall, the data from the EM further defines that IFITM1 is predominantly found
at the plasma membrane, while IFITM2 and IFITM3 are mostly found within intracel-
lular compartments, particularly MVBs. However, these localisations are not exclusive
as protein was found in compartments of the endocytic and biosynthetic pathways. It is
therefore possible to infer some details of IFITM protein trafficking. IFITM proteins may
traffic through the Golgi apparatus and the secretory pathway to reach the plasma mem-
brane, from where they may be internalised to endocytic compartments. Alternatively,
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Figure 3.4: IFITM1 and IFITM3 labelling on intact cells co-localises with wheat
germ agglutinin. IFITM expressing cells were co-labelled with anti-HA antibody (de-
tected with AF488; green) and wheat germ agglutinin (WGA) directly conjugated to
AF647 (magenta). WGA labels the plasma membrane, under these intact conditions, and
acts as a marker to show that the C-terminal HA-tag of IFITM1 and IFITM3 can be
detected at the cell surface of intact cells. There was no HA-tag detection on the IFITM2
expressing cells. Images are single optical sections. Nuclei were labelled with Hoechst.
Scale bars represent 15 µm.
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Figure 3.5: IFITM1 localisation analysed by electron microscopy. Cryo-sections of
IFITM1 expressing cells were labelled with anti-HA antibody and Protein A-gold and anal-
ysed by electron microscopy. A) Labelling for IFITM1 localised at the plasma membrane.
B and C) IFITM1 labelling at the plasma membrane and within multivesicular bodies. D)
Further plasma membrane labelling and Golgi apparatus labelling. As suggested from the
images, the majority of IFITM1 protein was found at the plasma membrane, but some
protein was also localised in intracellular compartments. Scale bars represent 200 nm.
(Sample preparation and microscopy were performed by Dr. Ian White).
there could be direct trafficking from the Golgi apparatus to compartments of the endo-
cytic pathway. Additionally, the immuno-gold labelling of the HA-tag appears to support
the notion that this C-terminal epitope is on the extracellular face of membranes.
3.2.3 The IFITM1 N-terminal domain resides intracellu-
larly
Having determined that the CTD of IFITM1 was accessible at the plasma membrane on
intact cells, the topology of the IFITM proteins was further analysed through the use of
antibodies targeting the NTD. Two commercially available antibodies that were raised
against the ‘IFITM1-NTD’ or the ‘IFITM3-NTD’ were used. The anti-IFITM1-NTD
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Figure 3.6: IFITM2 localisation analysed by electron microscopy. Cryo-sections of
IFITM2 expressing cells were labelled with anti-HA antibody and Protein A-gold and anal-
ysed by electron microscopy. A) A rare example of plasma membrane localised labelling
for IFITM2. B) Four examples of IFITM2 labelling in endosome and multivesicular bod-
ies. Most of IFITM2 labelling was seen on such compartments. C) Labelling of IFITM2 in
the Golgi apparatus. Scale bars represent 200 nm. (Sample preparation and microscopy
were performed by Dr. Ian White).
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Figure 3.7: IFITM3 localisation analysed by electron microscopy. Cryo-sections
of IFITM3 expressing cells were labelled with anti-HA antibody and Protein A gold and
analysed by electron microscopy. A) Labelling for IFITM3 at the plasma membrane and
an internal membrane compartment. Compared to IFITM2 (Fig. 3.6), more examples
of IFITM3 at the plasma membrane were seen. B) Four examples of IFITM3 labelling
on multivesicular bodies. Most of the IFITM3 labelling was seen in such compartments.
C) Labelling of IFITM3 in the Golgi apparatus. Scale bars represent 200 nm. (Sample
preparation and microscopy were performed by Dr. Ian White).
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antibody was raised against the first 35 amino acids of IFITM1. This region has 69% and
75% amino acid identity with IFITM2 and IFITM3, respectively (see Fig. 1.6 [page 44],
for sequence alignments). The anti-IFITM3-NTD antibody was raised against the first 30
amino acids of IFITM3. There is 90% amino acid identity between IFITM2 and IFITM3
in the first 30 amino acids, however IFITM1 has a 21 amino acid truncation compared to
IFITM3 and therefore has only 9 amino acids overlapping with this sequence (Fig. 1.6).
The two antibodies were tested for cross-reactivity against the three IFITM proteins
by western blotting whole cell lysates from each of the stable cell lines, and by immunofluo-
rescence. By western blot, the anti-IFITM1-NTD antibody was found to cross-react with
IFITM3, but did not detect IFITM2 (Fig. 3.8), while the anti-IFITM3-NTD antibody
showed cross-reactivity with IFITM2 but not IFITM1 (Fig. 3.8). Multiple bands were
seen in the range of 12-17 kDa when analysing the NTD, while only one band was seen
for the HA-tag. This suggested that there could be some form of post-translational modi-
fication of the protein (discussed further in Section 3.2.6). When the two NTD antibodies
were used for immunofluorescence on permeabilised cells, the labelling largely matched the
western blot results. The anti-IFITM1-NTD antibody detected IFITM1 and IFITM3, and
there was only minimal detection of IFITM2 (Fig. 3.9 B-D). No staining was observed in
control A549 cells (Fig. 3.9 A). The anti-IFITM3-NTD antibody did not detect IFITM1,
but did detect IFITM3 and IFITM2 (Fig. 3.9 F-H). Some background fluorescence was
seen in control A549 cells using the anti-IFITM3-NTD antibody (Fig. 3.9 E), but this was
clearly lower than when IFITM proteins were stably expressed.
Using the NTD antibodies for immunofluorescence microscopy on permeabilised cells
showed distributions of IFITM proteins that matched those seen when using antibodies
against the HA-tag (Fig. 3.2). There was more, and brighter labelling for IFITM2 with
the anti-IFITM3-NTD than the HA-tag (discussed in further Section 3.2.6). When intact
cells were labelled with anti-IFITM1-NTD antibody neither IFITM1 nor IFITM3 could
be detected, unlike results seen after labelling for the HA-tag (Fig. 3.9 J and L, compared
to Fig. 3.2 F and H). These data therefore suggest a topology in which the NTD is on the
cytosolic side of membranes, while the CTD is in the extracellular space.
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Figure 3.8: Analysis of IFITM NTD antibodies by western blot. Two commer-
cially available antibodies were tested for their cross-reactivity between IFITM proteins
by western blot of whole cell lysates from A549 cells, or IFITM1-3 expressing A549 cells
(M1, M2 and M3). Equivalent amounts of protein were separated by SDS-PAGE on 15%
gels, transferred to PVDF membranes and western blotted with antibodies against the
IFITM-NTD, HA-tag and VDAC (as a loading control). Blots were imaged using the
Li-COR Odyssey system that uses far-red fluorophore conjugated secondary antibodies,
displayed in magenta (NTD) and green (HA). A) Anti-IFITM1-NTD probed western blots
show this antibody detects IFITM1 and cross-reacts with IFITM3. B) Anti-IFITM3-NTD
probed western blots show this antibody detects IFITM3 and cross-reacts with IFITM2.
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Figure 3.9: Cellular distribution of IFITM proteins and NTD localisation. Im-
munofluorescence microscopy of control A549 cells, or cells expressing IFITM1-3 using
anti-IFITM1-NTD or anti-IFITM3-NTD antibodies. A) Saponin permeabilised A549 cells
show no specific staining with the anti-IFITM1-NTD antibody. B-D) IFITM1, 2 and 3 can
be detected with the anti-IFITM1-NTD antibody and have distinct cellular distributions,
when cells were permeabilised. E and F) The anti-IFITM3-NTD antibody detects a low
level of background protein in permeabilised A549 and IFITM1 expressing cells. G and H)
IFITM2 and IFITM3 were detected by the anti-IFITM3-NTD antibody in permeabilised
cells. I-L) No specific staining was detected with the anti-IFITM1-NTD antibody when
cell membranes were intact. Hoechst was used to label the nuclei. All images are maxi-
mum intensity projections of confocal sections through the depth of the cells. All images
were acquired using the same microscope settings and brightness and contrast have been
adjusted uniformly. Scale bar represents 15 µm.
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3.2.4 The IFITM1 C-terminal domain is accessible to ex-
tracellular proteases
The data have shown that IFITM1 is predominantly localised at the plasma membrane
making it highly amenable to further analysis of its membrane topology. The hypothesis
was made that because the HA-tag was accessible to antibodies, it would also be accessible
to extracellular proteases. The IFITM1 CTD amino acid sequence was analysed with the
ExPASy Peptide Cutter tool (http://web.expasy.org/peptide_cutter/). There are
two trypsin cleavage sites in the IFITM1 CTD (Fig. 3.10 A) and there is a suitable
inhibitor to terminate trypsin activity (soy bean trypsin inhibitor; SBTI); trypsin was
therefore chosen as an appropriate enzyme to test accessibility of the HA-tag.
IFITM1 expressing cells were incubated with trypsin for between 5 and 30 min at 37℃,
or incubated for 30 min with PBS alone. The reaction was terminated by addition of SBTI
after each incubation period. Samples were then collected, lysed, separated by SDS-PAGE
and analysed by western blot for loss of HA signal, and a change in the molecular weight
(MW) of the protein. As previously seen in Fig. 3.8, untreated IFITM1 displayed two
bands when detected with anti-IFITM1-NTD antibody. The high MW band corresponded
to the HA-tagged form of the protein, based on overlap of the bands (Fig. 3.10 Bi-iii).
Following treatment with trypsin, the intensity of the HA band decreased, and there was
a concomitant increase in the intensity of the lower MW NTD band (Fig. 3.10 Bi and
ii). By 30 min there was ∼8% of the HA-tag signal remaining, compared to the untreated
control. This incomplete loss of the HA-tagged form of the protein was probably due to
the intracellular pool that was inaccessible to the enzyme (Fig. 3.5). When trypsin was
mixed with SBTI prior to addition to cells there was no cleavage of the HA-tag, indicating
the reaction was effectively terminated and there was no cleavage following lysis of the
cells (Fig. 3.10 B). The NTD and the CIL of IFITM1 both have trypsin cleavage sites
(2 and 5 sites, respectively), therefore if either of these were extracellularly available,
more fragments of IFITM1 would be expected on the western blots. These results further
suggest that IFITM1 has a topology in which the CTD HA-tag is accessible at the cell
surface, while the NTD is located on the cytoplasmic side of membranes.
Cleavage of the IFITM1 HA-tag was also assessed by flow cytometry. Cells were
incubated with trypsin for 10 or 30 min, and the enzyme was inactivated by addition
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of SBTI. Cells were subsequently fixed and labelled with anti-HA antibody, which was
detected with fluorophore-conjugated secondary antibody. Untreated IFITM1 expressing
cells showed clear HA labelling, compared to A549 control cells, as judged by the higher
mean fluorescence intensity (MFI) and shift in peak fluorescence intensity (Fig. 3.10 C and
D). When cells were treated with trypsin, there was a lower peak fluorescence intensity
and reduced MFI, with greater reduction at 30 min than 10 min of treatment (Fig. 3.10
C and D). Overall, the data from trypsin cleavage experiments argue that the IFITM1
C-terminal HA-tag is accessible to extracellular proteases, while the NTD and CIL are
protected.
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Figure 3.10: Trypsin cleavage of HA-tagged IFITM1. A) Schematic representation
of the trypsin cleavage assay and the predicted cleavage sites in the IFITM1 CTD. B)
IFITM1 expressing cells were treated with trypsin (100 µg/ml) for up to 30 min at 37℃.
The reaction was terminated by addition of soy bean trypsin inhibitor (SBTI; 1 mg/ml)
at each time point. Cells were lysed and samples separated by SDS-PAGE. Proteins were
detected by western blot using antibodies against the IFITM1-NTD (i), the HA-tag (ii) and
VDAC (iv; as a loading control). Secondary antibodies conjugated to far-red fluorophores
were used for visualisation and allowed overlay of the IFITM1-NTD (magenta) and HA
(green) labelling (iii). Control samples were untreated (UN; PBS only) or samples treated
with SBTI-inactivated trypsin (IN; 1:1 mix of trypsin and SBTI), and both were incubated
with cells at 37℃ for 30 min. C) IFITM1 expressing cells were treated with trypsin for
10 or 30 min, at 37℃, fixed and immunofluorescence stained for the HA-tag prior to
analysis by flow cytometry. The anti-HA labelling was detected with anti-rat AF647. A
representative histogram is displayed with the fluorescence intensity of HA labelling being
plotted against cell count. D) Mean fluorescence intensity (MFI) of HA labelling with data
averaged from two independent experiments. Error bars represent standard deviation.
3.2.5 Topology of untagged IFITM1
To exclude the possibility that the addition of a CTD epitope influenced the topology of
IFITM1, we made use of C-terminal residues amenable to biotinylation (Fig. 3.11 A).
HEK293T cells were used for transient expression of untagged IFITM1 and were chosen
by virtue of their ease of transfection, high protein expression and lack of background
IFITM protein when using the anti-IFITM1-NTD antibody (Fig. 3.11 Biii). Following
transfection, cells were incubated with the membrane impermeable Sulfo-NHS-SS-Biotin
for 45 min at 37℃. This incubation period was used in an attempt to allow for effective
labelling at the plasma membrane, and may also label some intracellular pools of protein.
Following labelling, cells were lysed and incubated with NeutrAvidin beads to precipitate
biotinylated protein. There was no dilution of the sample added to the beads, allowing
analysis of bound and unbound material. Samples were eluted from the beads and analysed
by western blot using the anti-IFITM1-NTD antibody. Following the labelling procedure
it was possible to elute IFITM1 protein from the beads as seen in the pulldown lane (PD;
Fig. 3.11 Bi). The elution procedure appeared to be efficient as a second round of elution
did not retrieve any additional protein (PD2). While it was possible to collect IFITM1
from the NeutrAvidin beads, a large proportion of the protein was detected in the unbound
fraction (UB; Fig. 3.11 Bi). The pulldown appeared to be specific for biotinylated IFITM1
as no bands were detected in the pulldown fraction of unlabelled samples, but there was
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high recovery of protein in the unbound fraction (Fig. 3.11 Bii).
The low level of pulldown could have been a result of IFITM1 not being localised
at the plasma membrane in HEK293T cells, in contrast to results seen in A549 cells;
but this did not appear to be the case by immunofluorescence microscopy (Fig. 3.11
C). The immunofluorescence staining of IFITM1 in HEK293T cells appeared very similar
to that seen in A549 cells (Fig. 3.2 and 3.9). In the A549 cells, intracellular pools of
protein were found by EM (Fig. 3.5) and similar pools may exist in HEK293T cells.
Therefore the relatively low level of protein pulldown could arise from a combination of
some intracellular pools of IFITM1 that are inaccessible to the cell impermeable biotin
labelling reagent and/or inefficiencies in labelling and precipitation. It can also not be
ruled out that there may be forms of the protein with a topology in which the CTD is on
the cytoplasmic side of cell membranes.
To further control for the specificity of the observed IFITM1 biotin labelling, a CTD
truncation mutant of IFITM1 was used. This mutant form of IFITM1 has a stop codon
after valine 109 (IFITM1-Vstop), thus removing residues that could be biotinylated (Fig.
3.11 A). When IFITM1-Vstop was transiently expressed in HEK293T cells there was a
clear difference in MW compared to wild type IFITM1, indicative of the protein being
truncated (Fig. 3.11 D). When HEK293T cells expressing IFITM1-Vstop were incubated
with Sulfo-NHS-SS-Biotin and subject to the previously described pulldown assay, no
IFITM1-Vstop was detected as being eluted from NeutrAvidin beads (Fig. 3.11 E). These
results suggest that precipitation of IFITM1 seen in Fig. 3.11 B is specifically due to
labelling of amino acid residues in the CTD, beyond valine 109. Moreover, since there are
residues in the NTD that could be biotinylated, the lack of IFITM1-Vstop precipitation
additionally suggests that the NTD is not exposed on the extracellular side of membranes.
Overall, these biotinylation and pulldown experiments suggest that untagged IFITM1 has
a topology in which the CTD can be extracellularly accessible, and therefore that the HA
epitope does not influence membrane topology. However, in HEK293T cells, there appears
to be a large pool of protein that is inaccessible to biotinylation.
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Figure 3.11: Biotin labelling and pulldown of untagged IFITM1. Untagged wild
type IFITM1 or IFITM1-Vstop expression plasmids were transfected into HEK293T cells.
After 2 days the cells were labelled with membrane impermeable Sulfo-NHS-SS-Biotin for
45 min at 37℃. Excess labelling reagent was washed out with Tris buffered saline. Whole
cell lysates were produced and incubated with NeutrAvidin agarose beads (without any
dilution) to precipitate biotinylated proteins. The unbound material was collected from
the beads and precipitated proteins were eluted by incubation with reducing Laemmli
sample buffer. A) A schematic representation of the IFITM membrane topology to show
the hypothesised exposed CTD residues of IFITM1 and IFITM1-Vstop. B) Western blots
were probed with anti-IFITM1-NTD; WCL - whole cell lysates, UB - unbound material
following incubation with NeutrAvidin beads, PD and PD2 - two rounds of elution from
the NeutrAvidin beads. Gel i - samples from biotinylated cells. Gel ii - samples from
unlabelled cells. Gel iii - samples from mock transfected biotinylated HEK293T cells. The
elution step detached some NeutrAvidin monomers from the beads which have a molecular
weight of ∼14 kDa, this background has been labelled. Calreticulin was used as a loading
control and negative control for the pulldown. C) HEK293T cells, transfected with IFITM1
were fixed, permeabilised and labelled for the presence of IFITM1 using the anti-IFITM1-
NTD antibody (detected with AF488). Two representative images are shown, both being
maximum intensity projections of confocal sections through the depth of the cells. Scale
bar represents 15 µm. D) Western blot comparing wild type IFITM1 (M1), IFITM1-Vstop
and mock transfected HEK293T cells. E) HEK293T cells transfected with IFITM1-Vstop
and subject to the same biotinylation procedure. Four independent transfection samples
are displayed, one of which is unlabelled. Gel i - whole cell lysate samples from the four
transfections. Gel ii - samples retrieved from the unbound fraction. Gel iii - samples
eluted from the NeutrAvidin beads. As previously NeutrAvidin monomers were eluted,
which run at ∼14 kDa. The NeutrAvidin monomers have a very similar molecular weight
to IFITM1-Vstop, but due to the presence of a band in the unlabelled sample in Gel iii,
these bands are considered to be background, not IFITM1-Vstop.
3.2.6 Conservation of the IFITM1 topology in IFITM2 and
IFITM3
IFITM1 is localised at the plasma membrane in A549 cells, making it highly amenable
to the experiments used to define the topology. In comparison, IFITM2 and IFITM3
appear to be mostly associated with intracellular membrane compartments, necessitating
alternative approaches to investigate if the topology observed for IFITM1 is conserved.
Antibody feeding
To test the topology of IFITM2 and IFITM3 and to investigate certain aspects of pro-
tein trafficking, an antibody feeding assay was used. Live cells were cultured in media
containing anti-HA antibody for 3 h, prior to washing, fixation, permeabilisation and la-
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belling with secondary antibody for immunofluorescence microscopy. In this experiment,
if IFITM2 or IFITM3 traffic to the plasma membrane, and have an extracellularly exposed
HA-tag, this should bind antibody. IFITM2 or IFITM3 may then be detectable at the
plasma membrane, or within internal compartments following internalisation of antibody
bound protein. Control A549 cells showed no labelling when incubated with anti-HA anti-
body for 3 h, suggesting that there was no non-specific uptake of antibody (Fig. 3.12 A).
As a negative control, IFITM3 expressing cells were incubated for 3 h in media without
anti-HA antibody. These cells were then fixed, permeabilised and labelled with a fluores-
cent secondary antibody, but showed no fluorescence signal (Fig. 3.12 C), suggesting there
was no non-specific labelling with the secondary antibody. IFITM1 expressing cells acted
as a positive control as the protein is localised at the plasma membrane and the HA-tag
is accessible at the cell surface (Fig. 3.12 B).
When IFITM2 and IFITM3 cells were incubated with anti-HA antibody for 3 h, the
majority of cells had little, if any staining for HA. However, ∼25% of IFITM3 and ∼10%
of IFITM2 expressing cells did have punctate fluorescence (Fig. 3.12 D and E; values
calculated from 30 random fields of view at 40x magnification). This suggested that, in
some cells, the IFITM2 and IFITM3 proteins are trafficked to the plasma membrane, where
the extracellularly available HA-tag can bind anti-HA antibody. Both proteins appear to
then be internalised, along with antibody.
HA-tag loss
IFITM2 and IFITM3 are found in puncta within cells when assessed by immunofluores-
cence microscopy (Fig. 3.2 and 3.9) and appear to localise to MVBs by EM (Fig. 3.6
and 3.7), strongly suggesting predominant localisation within the endosomal system. If
the topology observed for IFITM1 is conserved in the other two IFITM proteins, this
would suggest that the C-terminal HA-tags reside in the lumen of endosomal compart-
ments. It was therefore hypothesised that the HA-tag could be subject to cleavage by
endosomal/lysosomal proteases, similar to the exogenous addition of trypsin for cleavage
of the HA-tag from IFITM1 (Fig. 3.10). This hypothesis was supported by western blots
that showed lower levels of HA labelling for IFITM2 and IFITM3 than IFITM1 (Fig.
3.8). Moreover, these western blots showed multiple bands when probed with anti-NTD
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Figure 3.12: Antibody feeding of IFITM expressing cells. Live IFITM expressing
cells were incubated with anti-HA antibody (5 µg/ml) for 3 h at 37℃. This incubation
should allow antibody to bind to any extracellularly exposed HA epitopes and potentially
be internalised to cells by endocytosis. Following the feeding period, cells were fixed,
permeabilised with saponin and incubated with anti-rat AF488 to detect any anti-HA
antibody. A) Control A549 cells show no specific HA labelling, suggesting no non-specific
uptake of antibody. B) The majority of IFITM1 HA labelling is at the cell surface. C)
IFITM3 expressing cells not incubated with anti-HA antibody, but labelled with secondary
antibody show no staining, acting as a control for the specificity of the secondary anti-
body. D and E) For the majority of IFITM2 and IFITM3 expressing cells no staining
was seen. However, ∼10% of IFITM2 and ∼25% of IFITM3 cells (each counted from
30 random fields of view at 40x magnification. Counted data are from n = 1 experi-
ment, representative of two individual experiments) showed punctate labelling, suggesting
binding of anti-HA antibody and internalisation. Nuclei were labelled with Hoechst. All
images were acquired using the same microscope settings and brightness and contrast have
been adjusted uniformly. Scale bars represent 15 µm. (Experiment and microscopy was
performed by Stephanie Czieso).
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antibodies, suggesting forms of the protein that may have lost the HA-tag (Fig. 3.10).
To test for loss of the HA-tag from IFITM2 and IFITM3, cells were co-labelled with
antibodies against the HA-tag and the NTD and analysed by immunofluorescence mi-
croscopy. Since the IFITM proteins are relatively small (125, 132 and 133 amino acids for
IFITM1, 2 and 3, respectively), it would be expected that labelling the NTD and CTD
should have a high degree of overlap. This was indeed seen to be the case for IFITM1
expressing cells where ∼70% of pixels were detected as overlapping and there was a high
value for the Mander’s correlation coefficients M1 and M2 (Fig. 3.13 and Table 3.1).
The lack of complete overlap may in part be explained by some endosomal IFITM1, as
visualised by EM (Fig. 3.5), where the HA-tag may be lost.
In contrast to IFITM1, IFITM2 expressing cells had a lower proportion of overlapping
pixels (∼49%) and lower M1 and M2 values (Table 3.2). This is best seen with the
anti-IFITM3-NTD antibody (Fig. 3.14) because the anti-IFITM1-NTD antibody has low
detection of IFITM2 (Fig. 3.8, Fig. 3.13 and Table 3.1). Similarly, IFITM3 had a lower
proportion of overlapping pixels between the NTD and HA-tag than IFITM1, when either
of the NTD antibodies were used (Fig. 3.13, 3.14, Table 3.1 and Table 3.2). Importantly,
in both IFITM2 and IFITM3 expressing cells there were distinct magenta only puncta,
indicative of compartments in which the NTD is intact, but the HA-tag has been lost.
Through image quantification it was also seen that there was an increased proportion of
magenta (NTD) only pixels in IFITM2 and IFITM3 expressing cells compared to IFITM1
expressing cells. This higher level of magenta only pixels for IFITM2 and IFITM3 is
indicative of a larger extent of HA-tag loss, presumably as a result of the predominant
endosomal distribution of these proteins, compared to the predominant plasma membrane
localisation of IFITM1. It is also noted that green only pixels were detected. It is unclear
whether this was due to antibody accessibility issues, issues with the image analysis or as
a consequence of protein that has an intact CTD but an NTD that could not be detected
by antibody.
Overall, these results suggest that IFITM2 and IFITM3 have a topology that allows
for extracellular binding of anti-HA antibodies and that there are pools of protein in which
the HA-tag has been lost from the CTD, but the NTD is intact. The interpretation of this
loss is that the epitope tag faces the lumen of endocytic organelles where it can be cleaved
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in the acidic/proteolytic environment. Therefore it appears that the topology displayed
for IFITM1 may be conserved in IFITM2 and IFITM3.
Cell line # of cells imaged Pearson’s R value Mander’s M1 Mander’s M2
IFITM1 58 0.85 (±0.05) 0.97 (±0.12) 0.99 (±0.01)
IFITM2 53 0.60 (±0.10) 0.83 (±0.17) 0.82 (±0.12)
IFITM3 57 0.81 (±0.05) 0.75 (±0.19) 0.77 (±0.19)
Table 3.1: Image analysis of anti-IFITM1-NTD antibody and anti-HA antibody
co-staining. Individual cells were segmented and analysed to assess the Pearson’s R-
value and Mander’s correlation coefficients. The data are collected from two independent
experiments and the mean values and standard deviation across cells are displayed. The
Pearson’s R-value assesses the correlation between intensity of magenta (NTD) and green
(HA) fluorescent signals. The Mander’s correlation coefficients, M1 and M2, represent the
proportion of magenta pixels in pixels that are green, and the proportion of green pixels
in pixels that are magenta, respectively. See also Fig. 3.13 for example images and further
image analysis.
Cell line # of cells imaged Pearson’s R value Mander’s M1 Mander’s M2
IFITM2 57 0.73 (±0.13) 0.85 (±0.16) 0.86 (±0.14)
IFITM3 49 0.72 (±0.04) 0.75 (±0.21) 0.77 (±0.17)
Table 3.2: Image analysis of anti-IFITM3-NTD antibody and anti-HA antibody
co-staining. Individual cells were segmented and analysed to assess the Pearson’s R-
value and Mander’s correlation coefficients. The data are collected from two independent
experiments and the mean values and standard deviation across cells are displayed. The
Pearson’s R-value assesses the correlation between intensity of magenta (NTD) and green
(HA) fluorescent signals. The Mander’s correlation coefficients, M1 and M2, represent the
proportion of magenta pixels in pixels that are green, and the proportion green pixels in
pixels that are magenta, respectively. See also Fig. 3.14 for example images and further
image analysis.
3.2.7 The IFITM3-Y20A C-terminal domain resides in the
extracellular space
IFITM3 is predominantly found within endosomal compartments (see Section 3.2.8). This
endosomal localisation is in part determined by the presence of a Yxxφ sorting motif (where
Y is a tyrosine, x is any amino acid and φ represents a hydrophobic residue) present in the
NTD (20-YEML-23), which has been shown to interact with the clathrin adaptor AP-2
[143]. IFITM2 has a similar Yxxφ motif in the NTD (19-YEML-22), but IFITM1 does
not because of a 21 amino acid truncation at the NTD (compared to IFITM3, see Fig. 1.6
[page 44], for sequence alignment). The difference in the presence of the Yxxφ motif may
explain the differences in localisation of IFITM2 and IFITM3 compared to IFITM1. That
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Figure 3.13: Co-staining of IFITM expressing cells with anti-IFITM1-NTD and
anti-HA antibodies indicates HA-tag loss. A) IFITM1, 2 and 3 expressing cells
were saponin permeabilised and labelled with the anti-IFITM1-NTD antibody and anti-
HA antibody, which were detected with AF647 (magenta) and AF488 (green), respectively.
Images are single optical sections. Nuclei were stained with Hoechst. Scale bars represent
15 µm. B) Quantification of relative pixel areas across 14 (IFITM1 and IFITM2) and
15 (IFITM3) random fields of view at 63x magnification, collected from 2 independent
experiments. A total of 58 IFITM1, 53 IFITM2 and 57 IFITM3 expressing cells were
analysed. Values plotted are relative mean area and error bars are standard deviation
across images. (N.B. see Table 3.1 for further image analysis of the same data set).
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Figure 3.14: Co-staining of IFITM expressing cells with anti-IFITM3-NTD and
anti-HA antibodies indicates HA tag loss. A) IFITM2 and IFITM3 expressing cells
were saponin permeabilised and labelled with anti-IFITM3-NTD and anti-HA antibodies,
which were detected with AF647 (magenta) and AF488 (green), respectively. Images are
single optical sections. Scale bars represent 15 µm. B) Quantification of relative pixel areas
across 13 (IFITM2) and 14 (IFITM3) random fields of view at 63x magnification, collected
from 2 independent experiments. A total of 57 IFITM2 and 49 IFITM3 expressing cells
were analysed. Values plotted are relative mean area and error bars are standard deviation
across images. (N.B. see Table 3.2 for further image analysis of the same data set).
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Figure 3.15: IFITM3-Y20A localises to the plasma membrane. P2-IFITM3 and
Y20A cells were saponin permeabilised and labelled with anti-IFITM1-NTD antibody
which was detected with AF488. Images were collected on an epifluorescence microscope
with equivalent exposure time. Nuclei were labelled with Hoechst. Scale bar represents
15 µm.
20-YEML-23 of IFITM3 acts as a functional sorting motif has been shown by the fact
that when Y20 was replaced with an alanine (A) residue (Y20A), this mutant IFITM3
accumulated at the plasma membrane and could no longer interact with AP-2 [143, 163].
In the work presented here, a cell line was produced that stably expresses IFITM3-Y20A
and is part of the P2 cell set, which also contains a cell population expressing wild type
IFITM3 (see Materials and Methods; Table 2.2 [page 72]). To confirm published data,
the mutant IFITM3 was tested by immunofluorescence staining of permeabilised cells.
As expected, IFITM3-Y20A appeared to be primarily localised at the plasma membrane
(Fig. 3.15), while wild type IFITM3 was found in an intracellular punctate distribution.
Owing to the plasma membrane localisation, the Y20A protein acts as a tool to further
investigate IFITM3 topology.
It was previously seen that the CTD HA-tag of IFITM1 was accessible at the cell
surface, such that cells could be labelled for immunofluorescence microscopy in the absence
of permeabilisation. A similar approach was used to test the extracellular availability of
the CTD HA-tag on IFITM3-Y20A expressing cells. The previous protocol was slightly
altered to fix cells with methanol free formaldehyde prior to addition of antibodies (i.e.
cells were not incubated on ice at any point). It was found that fixation before addition
of antibody resulted in a degree of background fluorescence for both tubulin and the
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IFITM NTD (potentially non-specific), but the HA-tag still clearly showed extracellular
availability for both IFITM1 and IFITM3-Y20A (Fig. 3.16 A). It therefore appears that
like IFITM1, IFITM3-Y20A has a CTD HA-tag that is available to antibody binding at
the cell surface, while the NTD appears to be on the cytosolic side of membranes.
To further assess the topology of IFITM3-Y20A, a protease cleavage assay was per-
formed, as for IFITM1 (Fig. 3.10). IFITM3 lacks trypsin cleavage sites in the CTD,
therefore proteinase K (ProtK) was used instead (Fig. 3.16 Bi). ProtK treatment of
IFITM3-Y20A cells for 10 or 30 min resulted in a clear weight shift when detected by the
anti-IFITM1-NTD antibody (Fig. 3.16 Bii). After each time point phenylmethylsulfonyl
fluoride (PMSF) was added to inactivate ProtK. The observed weight shift was not seen
when ProtK was inactivated by addition of PMSF prior to incubating with cells for 30
min, suggesting that the cleavage did not occur following lysis of the cells (Fig. 3.16 Bii).
As was the case with IFITM1 and trypsin, ProtK has multiple cleavage sites in both the
NTD (26 sites) and CIL (12 sites) of IFITM3, suggesting that both of these domains are
protected from proteolytic cleavage as more fragments of IFITM3-Y20A would be expected
otherwise.
Overall these data suggest that IFITM3-Y20A has the same type II transmembrane
topology as IFITM1. This, coupled with the data on IFITM2 and wild type IFITM3
suggests that the type II transmembrane topology may be conserved across the human
IFN-inducible IFITM proteins.
3.2.8 IFITM3 preferentially localises to early endosomes and
IFITM2 to late endosomes
Having observed that the CTD HA-tag on IFITM2 and IFITM3 can be lost in endosomal
compartments, any analysis of the localisation based on immunostaining the epitope tag
would most likely miss pools of protein that may be functionally important. Therefore, an
analysis of the localisation of IFITM2 and IFITM3 was performed to better define their
distribution within the endosomal system using anti-NTD antibody. Cells were co-stained
for the IFITM protein, using the anti-IFITM3-NTD antibody, and markers of early and
recycling endosomes (early endosomal antigen 1 [EEA1] and transferrin receptor [TfR])
or late endosomes and lysosomes (CD63 and lysosomal associated protein 1 [LAMP1]),
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Figure 3.16: IFITM3-Y20A has an extracellular CTD HA-tag. A) IFITM1 or
IFITM3-Y20A cells were fixed with methanol free formaldehyde prior to labelling with
anti-HA, anti-IFITM1-NTD and anti-tubulin antibodies without permeabilisation. Pri-
mary antibodies were detected with AF488 (HA; green), AF594 (NTD; magenta) and
AF647 (tubulin; blue) conjugated secondary antibodies. Anti-IFITM1-NTD and anti-
tubulin antibodies acted as controls for permeabilisation from fixation and show some
background, but no specific staining, suggesting the plasma membrane was largely intact.
Nuclei were labelled with Hoechst and are displayed in white. Images are confocal sec-
tions. Scale bar represents 15 µm. B) Schematic of the Proteinase K (ProtK) cleavage
assay showing the predicted cleavage sites in the IFITM3 CTD. C) IFITM3-Y20A express-
ing cells were treated with ProtK (500 µg/ml) for 10 or 30 min at 37℃. The reaction was
terminated by addition of 1 mM PMSF. Samples were western blotted for IFITM3-Y20A
using the anti-IFITM1-NTD antibody and tubulin as a loading control. Control samples
were either untreated (UN) or treated with ProtK that was inactivated (IN) with 1 mM
PMSF prior to incubation with cells for 30 min.
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and analysed by confocal microscopy. IFITM3 was found to have greater overlap with
the early/recycling endosomal markers than IFITM2, while IFITM2 had greater overlap
with the markers of late endosomes and lysosomes than IFITM3. Images were analysed to
quantify these differences. A large fraction of each IFITM does not overlap with any single
endosomal marker, suggesting that the proteins are distributed throughout the endosomal
system and other compartments (such as the plasma membrane and Golgi apparatus as
seen by EM, Fig. 3.6 and 3.7). Accepting that early endosomes are heterogeneous and
neither EEA1 nor TfR mark the entire population, and that IFITM2 and IFITM3 have
somewhat overlapping distribution, the conclusions from these analyses are that IFITM3
shows greater association with markers of early endosomal compartments, while IFITM2
shows greater association with markers of late endosomal and lysosomal compartments.
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Figure 3.17: Endosomal distribution of IFITM2 and IFITM3. IFITM2 and IFITM3
expressing cells were fixed and permeabilised with saponin prior to labelling with anti-
IFITM3-NTD antibody and endosomal markers. A) Confocal sections of cells co-stained
for IFITM protein and transferrin receptor (TfR) as a marker of early and recycling endo-
somes. IFITM protein were detected with AF488 (green) and TfR with AF647 (magenta).
B) Confocal sections of cells co-stained for IFITM protein (green) and LAMP1 (magenta)
as a marker of late endosomes and lysosomes. Nucleic were detected with Hoechst. A549
cells are displayed as a control for lack of IFITM protein expression. Scale bars rep-
resent 15 µm. C and D) Analysis of the overlap between green and magenta pixels of
IFITM2 or IFITM3 with markers of early/recycling endosomes (C; EEA1/TfR) and late
endosomes/lysosomes (D; CD63/LAMP1). Data are from three independent experiments
with between 18 and 21 fields of view collected at 63x magnification (displaying a total
of between 155 and 308 cells in each staining condition). In all cases there are pixels that
are only green or only magenta, indicating the IFITM proteins do not occupy a single
compartment. However, overlap is detected and there are significant differences between
the co-localisation of IFITM2 and IFITM3 with early or late endosomal markers. IFITM3
has greater overlap with early markers, while IFITM2 has greater overlap with late mark-
ers. Bars show the relative mean pixel area and error bars are standard deviation between
images. Significance test relates to the difference in overlap area between IFITM2 and
IFITM3. **** p < 0.0001.
3.3 Conclusions and Discussion
The membrane topology of the IFITM proteins had been a contentious issue. The IFITMs
had initially been suggested to be dual-pass transmembrane proteins with extracellular
NTDs and CTDs (Fig. 3.1 model 1; [7, 114–116]). However, later work suggested that
the proteins could be post-translationally modified by intracellular enzymes, placing the
terminal domains on the cytoplasmic side of membranes (Fig. 3.1 model 2; [150, 163]).
Experimental data for the localisation of the CTD was generally lacking, however murine
Ifitm1 was shown to have a non-conserved cysteine residue in the CTD which could be
palmitoylated, suggesting cytosolic localisation [155]. The work presented here was de-
signed to better understand the membrane topology of the human IFITM proteins; a third
membrane topology model (Fig. 3.1) has since been proposed by ourselves and others [15,
153, 192].
The work of Bailey et al. first defined the type II transmembrane topology model us-
ing murine Ifitm3 [153]. Their work used similar approaches to those presented here. As
with our own experiments, it was demonstrated that epitope tags at the C-terminal end of
Ifitm3 were exposed extracellularly and could be detected on intact cells using immunoflu-
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orescence microscopy and flow cytometry. The work of Bailey et al. also demonstrated
that the CTD of Ifitm3 enters into the lumen of the ER as the addition of a KDEL mo-
tif resulted in ER retention. As with work presented here (Fig. 3.13 and 3.14), epitope
tags at the C-terminal end of Ifitm3 were localised to the lumen of lysosomes, and conse-
quently lost [153]. Finally, Bailey et al. demonstrated that the constructs they analysed
had antiviral activity against IAV and VSV, arguing that the proteins with this topology
were functionally active. In Chapters 4 and 5, the IFITM proteins analysed in this work
are also displayed to have antiviral function. Ling et al. took the analysis of IFITM3
membrane topology further by reconstituting the protein in artificial lipid membranes and
used the approaches of NMR and EPR for structural analysis [192]. These approaches
demonstrated the presence of an α helical transmembrane domain at the C-terminal end
of the protein, and a membrane interacting domain made of two α helices that did not
cross lipid bilayers at the N-terminal end [192]. These structural data thus support the
type II transmembrane topology shown through biochemical and cell biological approaches
used by Bailey et al. [153] and ourselves ([15] and results in this chapter).
Our experiments largely focused on defining the topology of human IFITM1 as this
protein was found to be localised predominantly at the plasma membrane when expressed
in A549 cells, making it easily accessible. The IFITM1 C-terminal HA-tag could be labelled
with antibody at the surface of non-permeabilised cells (Fig. 3.2) and be proteolytically
removed by addition of trypsin (Fig. 3.10). Conversely, an antibody targeting the IFITM1
NTD could only label the protein following saponin permeabilisation (Fig. 3.9). Moreover,
based on the molecular weight shift seen by western blot following trypsin treatment of
cells, the NTD appeared to be protected, suggesting cytosolic localisation (Fig. 3.10).
Much of the experimental data was generated using cells that stably expressed IFITM1
with a C-terminal HA-tag, which acted as a good substitute for the lack of CTD targeting
antibodies. However, data was presented suggesting that it was possible to biotin label
C-terminal residues of untagged IFITM1, when transiently expressed in HEK293T cells,
arguing that the tag does not influence the topology (Fig. 3.11). Relatively little IFITM1
was precipitated with NeutrAvidin beads in these experiments which is thought to be due
to a combination of intracellular protein that may not be biotinylated (seen by EM in A549
cells [Fig. 3.5], and expected to be present in HEK293Ts), and potential label accessibility
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issues at the plasma membrane, possibly due to the short CTD length of IFITM1.
Interestingly, experimental data appears to suggest that murine Ifitm1 may adopt a
different topology to human IFITM1. The work of Hach et al. demonstrated that a
cysteine residue present in the murine Ifitm1 CTD could be palmitoylated; this residue is
not conserved in the human orthologue of the protein [155]. The enzymes responsible for
palmitoylation are thought to be cytosolic, suggesting that the murine Ifitm1 CTD faces
the cytosol. Murine Ifitm1 was shown to have antiviral activity against IAV [155], and
multiple studies have demonstrated human IFITM1 has antiviral activity (see Tables 1.1
and 1.2). Furthermore, results presented in Chapter 5 demonstrate that human IFITM1
can inhibit infection by three different flaviviruses in this A549 cell system. What impact
the apparent different topology of human and murine IFITM1 has on antiviral activity
remains to be explored.
The topology proposed for IFITM1 appears to be conserved in IFITM2 and IFITM3,
though these proteins were harder to assess due to their predominant intracellular localisa-
tion. Antibody feeding assays and analysis of HA-tag loss suggested that for both IFITM2
and IFITM3 the HA-tag may face the extracellular space and the lumen of cellular or-
ganelles (Fig. 3.12, 3.13, 3.14). Additionally, the mutant form of IFITM3, IFITM3-Y20A,
which localises to the plasma membrane, gave very similar results in experiments used
to define IFITM1 membrane topology (Fig. 3.16). The work of Ling et al., discussed
above, independently supports the suggestion that human IFITM3 has a topology with a
transmembrane domain present at the second membrane interacting domain.
Since it appeared that the C-terminal HA-tag can be lost from IFITM2 and IFITM3
(Fig. 3.13 and 3.14), any analysis of the localisation of these proteins using C-terminal
tags has the potential to not detect pools of protein that may be functionally important.
Therefore, immunofluorescence experiments were used to define the endosomal localisation
of IFITM2 and IFITM3 by co-staining the NTD with various markers of early and late
endosomes (Fig. 3.17). These experiments suggest that there is more IFITM3 associated
with early endosomes, and more IFITM2 associated with late endosomes and lysosomes, as
compared with each other. With IFITM1 localised at the plasma membrane, it therefore
appears that the three different IFITM proteins occupy the main membrane compartments
that need to be crossed by different viruses to enter cells (see Fig. 3.18). Understanding
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IFITM localisation may aid in understanding the antiviral activity, which will be discussed
in more detail in subsequent chapters.
An important caveat should be noted; these localisations have been determined in
cells expressing each IFITM protein in isolation. During an IFN response, it is likely that
all three antiviral IFITM proteins will be expressed. It has been suggested that IFITM
proteins form homo- and heteromeric complexes [154]; what impact expression of multiple
IFITM proteins may have on their cellular distribution and antiviral activity remains to
be fully explored. However, investigating the function of the IFITM proteins individually
provides a simpler system for analysis which can then be built upon to better understand
any changes that occur as a consequence of expression of multiple proteins.
In summary, the work presented in this chapter suggests that the IFITM proteins have
a type II transmembrane topology in which the NTD faces the cytoplasm while the CTD
faces the extracellular/lumenal space. The two terminal domains are connected by two
membrane interacting regions and the CIL. The precise functional consequence of this
topology remains unclear, and will be discussed in greater detail in Chapter 6. IFITM1
is predominantly localised at the plasma membrane while IFITM2 and IFITM3 are pre-
dominantly found within intracellular compartments. Having developed an understanding
of the membrane topology, a more thorough analysis of IFITM2 and IFITM3 localisation
could then be performed, suggesting these proteins are found throughout compartments of
the endosomal system. It is hypothesised that these differences in distribution may influ-
ence the antiviral function of the IFITM proteins, which will be the topic of the following
chapters.
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Figure 3.18: IFITM cellular distribution and select viral entry sites. When ex-
pressed individually in A549 cells, the IFITM proteins are found to occupy various cel-
lular membrane compartments. As displayed in this chapter and [15, 16], IFITM1 is
predominantly localised at the plasma membrane, while IFITM2 and IFITM3 are dis-
persed through the endosomal system. IFITM3 appears to have greater localisation to
early endosomal compartments than IFITM2, while IFITM2 appears to have greater lo-
calisation to late endosomal compartments than IFITM3. Many different viruses (some
examples provided here) penetrate into the cytosol through the different membrane com-
partments the IFITM proteins are found to be predominantly located in. It could therefore
be hypothesised that the localisation of the IFITM protein may influence its antiviral ac-
tivity, an idea which will be discussed throughout this thesis. Image adapted from [10].
(N.B. This figure has previously been displayed in Chapter 1 and is repeated here as an
aide-memoire).
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4.1 Introduction
A precise understanding of the mechanism(s) of IFITM-mediated antiviral activity remain
elusive. Alphaviruses, particularly Semliki Forest virus (SFV), have been used extensively
to study clathrin-mediated endocytosis and pH-dependent virus entry into cells [45, 47,
85]. Due to the wealth of experimental data on SFV entry, this virus is an attractive
model system to study IFITM-mediated inhibition of viral infection. While the majority
of viruses shown to be inhibited by the IFITM proteins enter cells through similar pathways
to SFV, there had been little study as to whether IFITMs inhibit alphavirus infection.
An overexpression screen suggested IFITMs inhibit Chikunguna virus (CHIKV), but have
limited impact on Venezuelan equine encephalitis virus (VEEV) [3]. Additionally, it has
been suggested that IFITM1 and IFITM3 can inhibit cell-cell fusion driven by cellular
expression of the SFV E1/E2 envelope glycoproteins [13]. Nevertheless, there was also a
view that alphaviruses are not inhibited by IFITM proteins [9, 11].
The work presented in this chapter shows that IFITM3, and to a lesser extent IFITM2,
can inhibit SFV and Sindbis virus (SINV, another alphavirus) when virus enters through
the endocytic pathway, and that IFITM1 had no effect. Focusing on SFV, IFITM3 was
found to block capsid release from endosomal compartments, without any inhibition of
earlier events in the entry pathway. When SFV fusion was triggered directly at the plasma
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membrane, IFITM1 could inhibit infection to a minor extent. However, surprisingly, the
predominantly endosomal localised IFITM3 could still potently inhibit infection when
virus was fused at the cell surface, even though there are low levels of the protein at this
site, especially compared to IFITM1. In Chapter 3, it was speculated that the different
localisation of the IFITM proteins may influence the range of viruses they inhibit, however,
from the data presented here, the conclusion made is that IFITM3 can inhibit alphavirus
infection more potently than IFITM1, regardless of localisation. This suggests intrinsic
differences in IFITM1 and IFITM3. Much of the work presented in this chapter has been
published in [16].
4.2 Results
4.2.1 IFITMs can restrict alphavirus infection
To initially investigate whether IFITM proteins inhibit alphavirus infection, stably ex-
pressing A549 cells were used (as in Chapter 3). Cells were infected with SFV or SINV
at a range of input between 0.1 and 1000 pfu/cell for 5.5 - 6 h. Cells were then fixed and
labelled for newly synthesised envelope glycoproteins (E1/E2) as a read-out of infection.
IFITM3 inhibited infection by both viruses (Fig. 4.1). At 1 pfu/cell, ∼80% of A549 cells
were positive for E1/E2, but only ∼3% of IFITM3 expressing cells were infected (p <
0.0001). A549 cells seemed less permissive to SINV than SFV with ∼40% of cells infected
at 10 pfu/cell. IFITM3 inhibited SINV infection, with only ∼5% infection at 10 pfu/cell
(p < 0.0001). IFITM3-mediated inhibition of both viruses was reduced at higher input
of virus with ∼20% inhibition at 100 pfu/cell (still a statistically significant difference
compared to A549 cells; p < 0.0001) and <10% inhibition at 1000 pfu/cell (p = 0.0155)
for SFV, and ∼10% inhibition at 100 pfu/cell for SINV (p = 0.0008). IFITM2 also in-
hibited SFV infection, though not as efficiently as IFITM3 (∼50% inhibition at 1 pfu/cell
[p = 0.0006], compared to ∼95% with IFITM3), but showed no statistically significant
inhibition of SINV infection. IFITM1 did not inhibit either virus.
These data indicate that IFITM3, and to a lesser extent IFITM2, can restrict al-
phavirus infection of A549 cells, while IFITM1 has no apparent inhibitory effect. This
restriction seemed to become saturated as the level of input virus was increased.
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Figure 4.1: Alphavirus infection is inhibited by IFITM proteins. A549 cells stably
expressing HA-tagged IFITM1, 2 or 3 were infected with SFV (A) or SINV (B). Cells
were infected at the indicated level of input virus for 5.5 - 6 h, then fixed and labelled
for the production of the respective viral envelope glycoproteins as a marker of infection.
The percentage of infected cells was determined by immunofluorescence microscopy using
a high-throughput Opera confocal microscope. SINV did not infect A549 cells as effi-
ciently as SFV, however both viruses show reduced infection when IFITM3 was expressed.
IFITM2 expression had some inhibitory effect on SFV, but little impact on SINV infec-
tion. IFITM1 had no apparent affect on either virus. These data are from a representative
experiment (n = 3 for SFV and 2 for SINV) performed in 96 well plate format with trip-
licate wells of infection. Each bar shows the mean infection percentage with error bars
representing the standard deviation between the three wells.
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4.2.2 IFITM3 endosomal localisation and expression levels
impact on antiviral activity
The IFITM expressing cell lines used in Fig. 4.1 were produced through single cell cloning
of lentivirally transduced cells (OS cells - see Materials and Methods Table 2.2 [page
72]). To further define SFV restriction by IFITM proteins, and rule out the potential for
inhibition being a consequence of using clonal cells, two further groups of stable IFITM
expressing cells, produced through puromycin selection, were tested (P1 and P2 cell groups
- Table 2.2 [page 72]).
Initially, the IFITM expression levels in each of the different cells were tested by western
blot (Fig. 4.2 A). Antibodies against the NTD were used, as the HA-tag can be lost in
endosomal compartments (Fig. 3.13 and 3.14, pages 120 and 121). The OS cell group
had the highest levels of IFITM expression. P1 and P2 cells had expression levels that
were similar to each other. OS- and P1-IFITM1 had similar expression levels. OS- and
P1-IFITM2 had low expression or poor detection with the anti-IFITM3-NTD antibody.
The expression levels for the three groups of cells were compared to the expression level
induced by interferon (IFN)-β treatment of A549 cells. It appears that the majority of
IFITM protein produced in A549 cells following IFN-β treatment is IFITM1 (Fig. 4.3); a
band was detected using the anti-IFITM1-NTD antibody but there was only a weak protein
band detected with the anti-IFITM3-NTD antibody (which does not detect IFITM1; Fig.
3.8 [page 107]). The apparent IFITM1 band that was detected by IFN-β treatment of
A549 cells suggests that the P1 and P2 cells have IFITM expression levels closest to the
levels induced in A549 cells (Fig. 4.3).
When infected with SFV, the P1-IFITM expressing cells showed a similar restriction
pattern as OS-IFITMs. P1-IFITM3 inhibited infection most potently (∼70% inhibition at
1 pfu/cell [p < 0.0001]), with IFITM2 having some inhibitory affect (∼50% inhibition at 1
pfu/cell [p = 0.0001]), while IFITM1 did not inhibit infection (Fig. 4.2 B). P1-IFITM3 was
less restrictive of SFV infection than OS-IFITM3, with inhibition only occurring between
0.1 - 10 pfu/cell, compared to 0.1 - 100 pfu/cell for OS-IFITM3. At 1 pfu/cell where
OS-IFITM3 had ∼95% inhibition of infection, P1-IFITM3 inhibited infection by ∼70%.
Similar levels of inhibition were seen with P2-IFITM3. These lower levels of restriction
correlate with the lower expression level of IFITM3 in the P1 and P2 cells (Fig. 4.2 A),
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matching with the apparent saturation of inhibition that occurs with higher input of virus
(Fig. 4.1 and 4.2 B).
As previously discussed, IFITM3-Y20A is localised primarily to the plasma membrane
(Fig. 3.15 [page 122]), similarly to IFITM1 (Fig. 3.2 [page 97] and Fig. 3.9 [page 108]).
While endosomal localised IFITM3 inhibited SFV infection, IFITM3-Y20A did not (Fig.
4.2 B), matching IFITM1. Therefore it appears that the endosomal localisation of IFITM3
is essential for inhibition of SFV infection when the virus enters through the normal
endosomal route.
For clarity, unless otherwise indicated, all work presented from here was performed
with OS-IFITM cells.
4.2.3 IFITM3 expression does not block SFV binding or
endocytosis
IFITM3 can inhibit SFV infection of cells, and the endosomal localisation of the protein
is essential for this function. Since SFV enters cells by fusion in early endosomes, it was
hypothesised that IFITM3 inhibited infection by blocking SFV entry. In order to enter
and infect a cell, SFV must initially bind to the cell surface, prior to internalisation by
clathrin-mediated endocytosis (CME). Once internalised, virus is trafficked to endosomes
where the low pH environment triggers conformational changes in the E1/E2 glycoprotein
complex that promotes fusion between viral and endosomal membrane, allowing release of
the viral capsid into the cytosol. Each of these aspects of the entry pathway were tested
to determine at which stage IFITM3 inhibits infection.
Initially, SFV binding to the cell surface of IFITM expressing cells was tested. Equal
amounts of virus were added to IFITM expressing cells for 1 h at 4℃ (conditions at which
virus has been found to effectively bind to BHK-21 cells [45, 86]), prior to production
of lysates which were separated by SDS-PAGE and analysed for the E1/E2 proteins by
western blot. Similar amounts of E1/E2 were detected in lysates from A549 and IFITM1, 2
and 3 expressing cells, suggesting that IFITM expression does not impact on SFV binding
to the cell surface (Fig. 4.4 A).
Following binding, SFV must be internalised by the cell through CME. To test whether
IFITM3 inhibits CME of SFV particles, a protease resistance assay was used. Virus was
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Figure 4.2: IFITM expression level and endosomal localisation affect SFV re-
striction. P1- and P2-IFITM expressing cell lines were analysed for IFITM expression
levels and SFV restriction (see Materials and Methods Table 2.2 [page 72], for a description
of the cells). A) Western blots to compare the IFITM expression levels of OS- (the original
set used in Fig. 4.1), P1- and P2-IFITM cells. A, M1, M2, M3 denote A549, IFITM1,
IFITM2 and IFITM3, respectively. The anti-IFITM1-NTD and anti-IFITM3-NTD anti-
bodies were used to detected IFITM proteins (as described in Chapter 3). Tubulin was
used as a loading control. Proteins were detected using secondary antibodies conjugated to
far-red fluorophores and imaged on a Li-COR Odyssey system. The fluorescence intensity
(int.) of the IFITM and tubulin bands was quantified using Li-COR Odyssey software.
IFITM band intensities were normalised to the tubulin loading controls and set relative
to the highest band intensity in each blot (OS-IFITM3 for both). B) P1- and P2-IFITM
cells were infected with SFV at an input between 0.1 and 1000 pfu/cell. Cells were incu-
bated for 5.5 - 6 h to allow infection, prior to fixation and labelling for production of de
novo E1/E2 protein as a read-out of infection, which was analysed by immunofluorescence
microscopy. Concomitantly with the lower expression in the P1- and P2-IFITM cells (A),
there were reduced levels of SFV restriction compared to OS-IFITM cells (Fig. 4.1). The
data are a representative experiment (n = 2) performed with triplicate wells in a 96 well
plate format. Each bar shows the mean infection percentage of the three wells and errors
bars are the standard deviation.
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Figure 4.3: IFN-β treatment induces IFITM expression in A549 cells. OS-A549
cells were treated with 200 ng IFN-β for 24 h prior to production of whole cell lysates
for western blotting. Samples were separated by SDS-PAGE and blotted with the anti-
IFITM1-NTD (A) or anti-IFITM3-NTD (B) antibodies and for VDAC as a loading control.
Lysates from IFN-β treated A549 cells were western blotted alongside samples produced
from OS-, P1- and P2-IFITM cell sets (M1, M2, M3 and A20 denote IFITM1, IFITM2,
IFITM3 and IFITM3-Y20A, respectively). Proteins were detected using secondary anti-
bodies conjugated to far-red fluorophores and imaged on a Li-COR Odyssey system. The
fluorescence intensity (int.) of the IFITM and VDAC bands was quantified using Li-COR
Odyssey software. IFITM band intensities were normalised to the tubulin loading controls
and set relative to the band intensity of IFN-β treated A549 samples. It appears that the
majority of IFITM protein produced by A549 cells is IFITM1 as the band intensity is low
with the anti-IFITM3-NTD antibody (which does not detect IFITM1), compared to the
band intensity seen with the anti-IFITM1-NTD antibody.
bound to the surface of cells, which were then warmed to 37℃ for 5, 15 or 30 min, or left
on ice. The shift from 4℃ to 37℃ promotes endocytosis of bound virus [45, 85]. After
each period of warming, cells were shifted back to 4℃, to prevent further trafficking events,
then treated with subtilisin for 1 h. Subtilisin treatment can remove virus particles bound
at the cell surface, without impacting intracellular pools [193]. Thus, following subtilisin
treatment, only virus particles internalised by endocytosis will remain associated with the
cells, which can be analysed by western blot for the E1/E2 proteins. Without warming,
subtilisin treatment removed ∼78% of bound virus from A549 cells (Fig. 4.4 B and C).
Following warming, there was an increase in the amount of cell-associated E1/E2, which
peaked at 15 min with >75% of virus internalised (Fig. 4.4 B and C). Very similar kinetics
of uptake were observed on IFITM3 expressing cells (Fig. 4.4 B and C), indicating that
IFITM3 does not inhibit SFV internalisation to A549 cells.
4.2.4 Internalised SFV co-localises with IFITM3
Seeing that SFV can be endocytosed to IFITM3 expressing cells, that IFITM3 localises
primarily to endosomal membranes (Fig. 3.17 [page 127]), and with the knowledge that
Chapter 4 139
Alphavirus restriction by IFITM proteins
Figure 4.4: SFV binding and internalisation into IFITM expressing cells. A)
Cell surface binding: SFV (200 pfu/cell) was added to A549 or IFITM expressing cells (A,
M1, M2 and M3) at 4℃, and incubated for 1 h to allow virus binding to the cell surface.
Cells were washed to remove unbound virus and lysed to analyse the level of viral protein
(E1/E2) associated with cells by western blot. A representative western blot (n = 4) is
displayed. Tubulin was used as a loading control. B) Virus endocytosis: SFV was bound
to A549 or IFITM3 expressing cells as in (A). Cells were washed to remove unbound virus,
media at 37℃ was added and the cells incubated at 37℃ for the indicated times to promote
virus endocytosis. Cells were subsequently incubated with subtilisin at 4℃ to proteolyti-
cally remove any virus remaining at the plasma membrane, without impacting on internal
pools. Cells were lysed and analysed for cell-associated viral protein (E1/E2) by west-
ern blot. Control samples that were not treated with subtilisin were analysed to indicate
the total cell-associated virus. (The experiments were performed by Stephanie Czieso).
C) Fluorescence intensity of E1 (bottom), E2 (top) and tubulin bands were measured to
quantify the level of subtilisin resistant E1/E2 across 3 - 4 independent experiments (n
= 4 for A549 and n = 3 for IFITM3). Band intensity of E1/E2 were adjusted based on
tubulin loading. A measure of the total cell-associated virus was determined by averaging
the band intensity for all untreated time points and setting the intensity of E1 or E2 at
each treated time relative to this total. These relative intensities were averaged across all
experiments and plotted to display the percentage E1/E2 that was subtilisin resistant at
each time point.
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SFV fusion occurs in these compartments, we investigated whether internalised SFV en-
tered into IFITM3-positive endosomes. As described previously, virus was bound to the
surface of cells grown on glass coverslips at 4℃ for 1 h and the cells then shifted to 37℃
to promote endocytic uptake of bound virus. At time points between 0 and 30 min,
cells were fixed and processed for immunofluorescence microscopy. Cells were stained for
SFV using antibodies directed against E1/E2, and the IFITM3 HA-tag (Fig. 4.5). While
some pools of IFITM3 may be missed due to loss of the HA-tag in endosomes (Fig. 3.13
[page 120], and Fig. 3.14, [page 121]), it was necessary to use rat anti-HA antibody as
both IFITM-NTD antibodies were rabbit polyclonal preparations, and the SFV E1/E2
anti-serum was also from rabbit. As a control, comparable experiments were performed
in A549 cells, which were stained for E1/E2 and EEA1, as a marker of early endosomes
(Fig. 4.7). On cells kept at 4℃, E1/E2 staining was seen as small puncta primarily
around the periphery of cells, and there was little overlap with either IFITM3 (Fig. 4.5)
or EEA1 (Fig. 4.7). After 10 min at 37℃ and at later time points, overlap was detected
between E1/E2 and the cellular proteins (Fig. 4.5 and 4.7). The E1/E2 positive puncta
also appeared to increase in size and fluorescence intensity suggesting particles may be
accumulating within endosomes. An increase in the size and fluorescence intensity over
time of warming was also observed for EEA1 (Fig. 4.7), but this was similarly seen in
mock infected cells (data not shown), suggesting it is probably a consequence of cooling
and warming, rather than an affect induced by SFV internalisation. The time dependent
increase in overlap between SFV and IFITM3 (Fig. 4.6) or EEA1 (Fig. 4.8) was observed
over multiple experiments. These data indicate that when SFV is taken up by CME, it is
delivered into IFITM3-positive endosomes.
These observations were further confirmed by electron microscopy (EM). As before,
virus particles were bound to cells and allowed to internalise, prior to processing for EM
analysis. SFV particles were found within coated vesicles and multivesicular bodies in both
A549 and IFITM3 expressing cells (Fig. 4.9 and 4.10), further supporting the suggestion
that IFITM3 expression does not inhibit SFV internalisation or trafficking. As with the
immunofluorescence experiments, SFV and IFITM3 were found in the same compartments
by immuno-gold labelling of cryo-sections (Fig. 4.10 B), further arguing that virions are
delivered to IFITM3-positive endosomes.
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Figure 4.5: Internalised SFV co-localises with IFITM3. SFV (50 pfu/cell) was
added to IFITM3 expressing cells and allowed to bind for 1 h at 4℃. Unbound virus
was removed by washing. Media pre-warmed to 37℃ was added to cells, which were
then incubated for the indicated times to allow internalisation. Cells were then fixed
and labelled with antibodies against SFV E1/E2 (detected with AF488; green) and HA
(detected with AF647; magenta) following permeabilisation. Single confocal sections are
displayed. E1/E2 labelling was seen as small puncta primarily around the periphery of
cells after 0 and 5 min at 37℃, and had little overlap with HA. With longer periods
of warming, larger and brighter puncta of E1/E2 were seen and overlap was observed
with HA. Nuclei were detected with Hoechst. Scale bar represents 15 µm. All images
were acquired with the same microscope settings and brightness and contrast have been
adjusted uniformly. See Fig. 4.6 for analysis of the overlap between SFV and IFITM3
staining.
Figure 4.6: Internalised SFV co-localisation with IFITM3 (quantification). Anal-
ysis of overlap between E1/E2 (green) and HA (magenta) pixels as displayed in Fig. 4.5.
Data were quantified over three independent experiments, with six images at 63x magnifi-
cation for each sample per experiment (displaying a total of between 131 and 163 cells per
condition). The average ratio of relative area of overlapping pixels to green only pixels is
plotted, with error bars displaying the standard deviation (see Section 2.9.1 [page 89] for
further detail).
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Figure 4.7: Internalised SFV co-localises with EEA1. SFV (50 pfu/cell) was added
to A549 cells and allowed to bind for 1 h at 4℃. Unbound virus was removed by washing.
Media pre-warmed to 37℃ was added to cells, which were then incubated for the indicated
times to allow internalisation. Cells were then fixed and labelled with antibodies against
SFV E1/E2 (detected with AF488; green) and EEA1 (detected with AF647; magenta)
following permeabilisation. Single confocal sections are displayed. E1/E2 labelling was
seen as small puncta primarily around the periphery of cells after 0 and 5 min at 37℃,
and had little overlap with EEA1. With longer periods of warming, larger and brighter
puncta of E1/E2 were seen and overlap was observed with EEA1. There also appeared
to be an increase in the brightness of EEA1 puncta over time that was similarly seen
in mock-infected samples (data not shown), and may be due to cooling and warming
the cells. Nuclei were detected with Hoechst. Scale bar represents 15 µm. All images
were acquired with the same microscope settings and brightness and contrast have been
adjusted uniformly.
Figure 4.8: Internalised SFV co-localisation with EEA1 (quantification). Anal-
ysis of overlap between E1/E2 (green) and EEA1 (magenta) pixels as displayed in Fig.
4.5. Data were quantified over three independent experiments, with six images at 63x
magnification for each sample per experiment (displaying a total of between 150 and 213
cells per condition). The average ratio of relative area of overlapping pixels to green only
pixels is plotted, with error bars displaying the standard deviation (see Section 2.9.1 [page
89] for further detail).
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Figure 4.9: Electron microscopy imaging of SFV uptake to A549 and IFITM3
expressing cells. SFV (1000 pfu/cell) was added to A549 or IFITM3 expressing cells
and allowed to bind for 1 h at 4℃. Unbound virus was removed by washing. Media
pre-warmed to 37℃ was added to cells to allow internalisation of virus for the indicated
times. Samples were fixed and processed for Epon section electron microscopy. After
binding, virus particles could be detected at the plasma membrane (0 min), based on their
characteristic morphology. With 5 min of warming virus particles could be detected in
coated vesicles and at the plasma membrane. By 20 and 30 min, virus particles appeared
in endosomal structures, but it became hard to differentiate virions form intralumenal
vesicles, which have a similar size. These internalisation patterns appeared similar in
A549 and IFITM3 expressing cells. Scale bars represent 200 nm. Sample preparation and
imaging was performed by Dr. Ian White.
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Figure 4.10: Immuno-gold labelling of cryo-sections and electron microscopy
of SFV uptake to A549 and IFITM3 expressing cells. SFV (5000 pfu/cell) was
added to A549 or IFITM3 expressing cells and allowed to bind for 1 h at 4℃. Unbound
virus was removed by washing. Media pre-warmed to 37℃ was added to cells for the
indicated times to allow internalisation of virus. Samples were fixed and processed for
cryo-sectioning and immuno-gold labelling. A) Sections were labelled with antibodies
against SFV E1/E2. After binding, virus particles were detected at the cell surface. With
30 min of warming, gold particles were found within multivesicular bodies in both A549
and IFITM3 expressing cells. B) Sections were labelled with antibodies against SFV E1/E2
(detected with 10 nm colloidal gold) and the HA-tag (detected with 15 nm colloidal gold).
Minimal background to the HA-tag was detected in A549 cells: The majority of labelling
in IFITM3 expressing cells was found in multivesicular bodies (as seen in Chapter 3, Fig.
3.7). As in (A), SFV particles were detected in multivesicular bodies following 30 min
internalisation, and were seen in the same compartments as IFITM3 (as based on the HA
labelling). Scale bars represent 200 nm. Sample preparation and imaging was performed
by Dr. Ian White.
4.2.5 Kinetics of SFV capid release into A549 cells
To ensure that the investigations of virus internalisation were at time points relevant to
infection, the kinetics of SFV capsid release into A549 cells was determined. Delivery of
the capsid into the cytosol is dependent on virion endocytosis and low pH-induced fusion
in endosomes. Therefore, disruption of pH gradients can inhibit SFV infection, up until
the point of membrane fusion. After membrane fusion, disruption of low pH gradients
will not impact SFV infection of cells. To investigate the time for SFV penetration of
endosomes to occur, the fast acting ionophore monensin was used to dissipate the low pH
gradient across endosome membranes. Virus particles were bound at the cell surface and
allowed to internalise by shifting cells to 37℃. Monensin was added at times between 0 and
30 min, and left through the 5.5 - 6 h infection period. E1/E2 production, as detected by
immunofluorescence microscopy, was used as a read-out of infection (with infection being
a surrogate of successful fusion with endosomes). The percentage of infected cells was then
determined and compared to untreated control cells. When monensin was added at 0 min,
there was nearly a complete loss of infection (Fig. 4.11). However, when added at later
times an increasing number of cells were infected. Adding monensin at 30 min had almost
no inhibitory affect (Fig. 4.11). These data suggest that the majority of infectious virus
had penetrated cells by 30 min. Therefore the previous analysis of SFV internalisation
within the first 30 min is relevant to infection in A549 cells.
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Figure 4.11: Kinetics of SFV penetration into A549 cells. SFV (5 pfu/cell) was
added to A549 cells and allowed to bind for 1 h at 4℃. Unbound virus was removed by
washing. Media pre-warmed to 37℃ containing DMSO (as control) or 10 µm monensin
was added to the cells to allow internalisation of virus. At times between 3 and 30 min,
control media were replaced with monensin-containing media. After 5.5 - 6 h infection,
cells were fixed and analysed for infection by immunofluorescence microscopy. The data
are presented as the percentage infected cells in monensin treated samples relative to
control samples. The data are the mean infection percentage (relative to DMSO controls)
from three independent experiments (containing duplicate wells). Error bars represent the
standard deviation between experiments.
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4.2.6 SFV is exposed to acidic pH in IFITM3 expressing
cells
Since SFV was effectively endocytosed into IFITM3 expressing cells, the next question was
whether virus particles were being delivered to low pH compartments to activate the fusion
machinery. Following exposure to low pH, E1 undergoes conformational changes to form a
homotrimer (HT) that is insensitive to SDS and digestion with trypsin [96], changes that
can be seen by SDS-PAGE and western blotting. As a positive control for the acid-induced
conformational changes, virus particles bound at the cell surface were treated with pH 5.5
media for 3 min at 37℃. To test for SFV delivery to acidic compartments of cells, virus
was bound to the cell surface and allowed to internalise for 0, 5, 15 and 30 min at 37℃.
As a negative control, cells were pre-treated with bafilomycin A1 (Baf A) for 15 min at
37℃, prior to virus binding at 4℃, and internalisation for 30 min, all in the presence of
Baf A. Baf A is an inhibitor of the vacuolar ATPase proton pump and therefore inhibits
endosomal acidification. After all treatments, cells were lysed, the lysates where split in
two, and one half treated with trypsin. The E1/E2 proteins were then analysed by western
blot. Heat can dissociate the E1 HT, so unlike in other western blots, the samples were
not heated prior to SDS-PAGE.
With 0 min of internalisation, the monomeric forms of E1/E2 were detected with a
molecular weight (MW) of ∼50 kDa (Fig. 4.12 lane 1). These monomeric forms of E1/E2
are sensitive to trypsin digestion as the bands became undetectable following incubation
with the protease (lane 2). Treatment of surface bound virus with pH 5.5 media for 3 min
prior to lysis induced the formation of a higher MW fragment, which was insensitive to
trypsin digestion, and therefore concluded to be the E1 HT (lanes 3 and 4). This higher
molecular weight, trypsin-insensitive band, was also detected when virus was internalised
into A549 cells. The intensity of the band increased over the three time points, indicating
a time-dependent increase in the appearance of the E1 HT (lanes 7 - 12). When virus
was internalised for 30 min into cells that were treated with Baf A, the higher MW
band was not detected (lanes 5 and 6), arguing that this band is indeed induced by an
acidic environment. Virus internalised to IFITM3 expressing cells displayed the higher
MW band of E1 with similar kinetics to those in A549 cells (lanes 13 - 18). It can
therefore be concluded that IFITM3 does not interfere with endosomal acidification, SFV
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Figure 4.12: SFV is exposed to acidic pH in IFITM3 expressing cells. Cells
were pre-treated at 37℃ for 15 min with media containing 100 nm bafilomycin A1 (Baf
A) or untreated (DMSO control), prior to addition of media at 4℃ (containing Baf A
or DMSO) and placing on ice. SFV (200 pfu/cell) was added to A549 (lanes 1 - 12) or
IFITM3 expressing cells (lanes 13 - 18) for 1 h at 4℃. Unbound virus was removed by
washing and pre-warmed media were added to the cells prior to incubation at 37℃ for
the indicated times (lanes 5 - 18), or kept at 4℃ (lanes 1 - 4). In lanes 3 - 4, cells with
bound virus were treated with pH 5.5 media for 3 min at 37℃. In lanes 5 - 6 cells were
treated with 37℃ media, containing 100 nm bafilomycin A1 (Baf A), and incubated for
30 min. Cells were placed on ice and lysed with 1% Triton X-100 (Tx100) in PBS for 15
min. Nuclei were removed by centrifugation and the lysate was split into two aliquots and
one sample was treated with 800 µg/ml trypsin in 1% Tx100. After 10 min incubation
at 37℃, soy bean trypsin inhibitor (2 mg/ml) in 1% Tx100 was added to all samples to
inactivate the protease. All samples were then analysed by non-reducing SDS-PAGE and
western blotting for E1/E2, and tubulin as a loading control. Samples were not heated
prior to SDS-PAGE as this can dissociate the E1 homotrimer (HT).
internalisation to these compartments, or conformational changes of E1/E2.
4.2.7 IFITM3 inhibits release of SFV capsid to the cytosol
SFV can be delivered into acidic compartments, and the E1 glycoprotein can undergo
conformational changes in IFITM3 expressing cells. Therefore, it was investigated whether
the viral capsid could be released from endosomes into the cytosol. To determine if capsid
was being released from endosomes, virus was bound to cells and internalised for up to 60
min. At each time point, cells were fixed, peremeabilised with Triton X-100, and labelled
with antibodies against the SFV capsid for analysis by immunofluorescence microscopy.
Between 0 and 20 min, in both A549 and IFITM3 expressing cells, the capsid staining
was detected as small puncta initially around the cell periphery, then seemingly within
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intracellular compartments, which were most likely endosomes (Fig. 4.13). The staining
pattern observed with the capsid appeared to be very similar to that seen with E1/E2 at
these earlier time points (Fig. 4.5 and 4.7). The labelling was generally weak, presumably
owing to the tight packaging of the capsid protein within virions limiting access of anti-
capsid antibodies. With 40 min of internalisation to A549 cells, diffuse cytosolic capsid
fluorescence was seen that increased in intensity after 60 min warming (Fig. 4.13 and 4.14).
This diffuse fluorescence was thought to be capsid protein that had been released from
endosomes into the cytosol. Monensin raises the pH of acidic organelles and inhibits SFV
infection by preventing membrane fusion (Fig. 4.11). When A549 cells were treated with
monensin, the diffuse cytosolic fluorescence was not detected, supporting the idea that
the cytosolic staining pattern was associated with capsid release into the cytosol (Fig.
4.13 and 4.14). Even though there was little difference in the capsid staining on A549
and IFITM3 expressing cells up to 20 min, at later time points, there was no detection
of diffuse cytosolic fluorescence in the IFITM3 expressing cells (Fig. 4.13 and 4.14). The
similar staining pattern between monensin treated A549 cells and IFITM3 expressing
cells suggests that IFITM3 blocked capsid release into the cytosol, and therefore blocked
infection.
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Figure 4.13: IFITM3 expression inhibits SFV capsid release into the cytosol.
SFV (200 pfu/cell) was added to A549 or IFITM3 expressing cells and allowed to bind for
1 h at 4℃. Unbound virus was removed by washing. Media at 37℃ (containing 10 µM
monensin where indicated) was added and cells incubated for up to 60 min. Cells were
fixed, permeabilised with 0.1% Triton X-100 and labelled with rabbit anti-SFV capsid
anti-serum (detected with AF594). With longer times of incubation at 37℃, staining for
the SFV capsid was detected as increasingly bright puncta, indicative of virus trafficking
to endosomes. In untreated A549 cells, by 40 min, diffuse cytosolic fluorescence was also
seen, indicating release of the SFV capsid into the cytosol. Monensin treatment dissipates
low pH gradients and inhibits SFV infection (see Fig. 4.11). In monensin treated A549s,
the diffuse cytosolic fluorescence was not seen, even though puncta of SFV were, suggesting
inhibition of capsid release into the cytosol. IFITM3 expressing cells showed a very similar
staining pattern to monensin treated A549 cells, with endosomal puncta of SFV detected,
but a lack of diffuse cytosolic fluorescence. Nuclei were detected with Hoechst. Scale bar
represents 15 µm.
Figure 4.14: IFITM3 expression inhibits SFV capsid release into the cytosol
(quantification). Quantification of cytosolic fluorescence associated with SFV capsid
release from endosomes (as displayed in Fig. 4.13 and significance testing, as described
in Chapter 2 (page 91). Briefly, nuclei were segmented and any fluorescence in the capsid
channel associated with that area was removed as background. Large puncta of capsid
staining were detected by application of a threshold and removed, as these were considered
to be virus particles in endosomes. The remaining signal was deemed to be cytosolic,
and the mean fluorescence intensity of individual cells determined. The mean average of
these fluorescence intensity values was calculated from cells imaged across 3 independent
experiments with 3 - 7 images at 63x magnification from each. A total of between 67
and 153 cells were analysed across all conditions. The plotted data are the averaged
fluorescence intensity, normalised to background intensity at 0 min of warming. * p <
0.05, ** p < 0.01.
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4.2.8 Amphotericin B treatment reduces IFITM3-mediated
inhibition of SFV infection
IFITM3 has been shown to inhibit influenza A virus (IAV) infection by blocking fusion
between viral and endosomal membranes [13, 14], and thus block nuclear translocation of
the genetic material [12]. However, there is debate over the precise mechanisms underlying
the block to membrane fusion [13, 14] (see Chapter 1 for more extensive discussion). The
data presented thus far suggest that a similar mechanism may be associated with the
restriction of SFV infection, since inhibition of membrane fusion can explain the lack of
SFV capsid release into the cytosol. One characteristic of IFITM3-mediated IAV inhibition
is that the antifungal drug amphotericin B (AmphoB) promotes IAV infection of IFITM3
expressing cells, without altering IFITM3 expression levels or distribution [156]. The
precise mechanism(s) underlying this disruption are unclear, but AmphoB can bind to
cholesterol, and was suggested to alter the properties of cellular membranes [156].
It was therefore tested whether IFITM3-mediated inhibition of SFV is similarly sen-
sitive to AmphoB treatment. In the study of Lin et al. [156], it was reported that
pre-treating cells with AmphoB for 1 h, prior to addition of virus, gave the greatest en-
hancement of IAV infection of IFITM3 expressing cells. To test the effects of AmphoB
treatment in the context of SFV infection, cells were pre-treated with 1 µM AmphoB (as in
[156]) at 37℃ for 1 h prior to infection with SFV (in the presence of drug). Alternatively,
there was no pre-treatment step, and SFV was added to cells with 1 µM AmphoB. Cells
were incubated for 5.5 - 6 h to allow infection prior to immunofluorescence staining for
production of E1/E2. Treatment of cells with AmphoB had very little impact on infection
of A549 cells. However, with infection at 10 pfu/cell, the AmphoB treatment resulted
in a small but statistically significant decrease in percentage of infected cells (Fig. 4.15).
While AmphoB had little impact on infection of A549 cells, there was a large increase in
the number of infected IFITM3 expressing cells (Fig. 4.15). When cells were pre-treated
with AmphoB, there was a ∼6.5 fold increase in the percentage of IFITM3 infected cells
(at 1 pfu/cell). When AmphoB was added with SFV, there was a ∼4.7 fold increase in
infection (Fig. 4.15). These data suggest that the pre-treatment step, can to an extent
enhance the impact of AmphoB treatment on IFITM3 expressing cells, although there was
no statistically significant difference between the two treatments (Fig. 4.15). To further
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Figure 4.15: Amphotericin B treatment enhances SFV infection of IFITM3 ex-
pressing cells. A549 or IFITM3 expressing cells were treated with 1 µM AmphoB for 1
h at 37℃ prior to infection with SFV in the presence of AmphoB (-1 h), or 1 µM AmphoB
was added to cells with SFV (0 h). Cells were incubated for 5.5 - 6 h to allow infection,
prior to fixation and immunofluorescence staining for E1/E2 as a read-out of infection.
The percentage of infected cells at 1 pfu/cell (A) and 10 pfu/cell (B) are displayed. The
data are from a representative experiment (n = 2; the data are from an infection per-
formed by Stephanie Czieso), performed in a 96 well plate format with triplicate wells for
each condition. Bars represent the mean infection percentage across the three wells with
error bars representing the standard deviation between these. Significance tests relate to
the difference in mean infection percentage for each compared condition using student’s
unpaired t-tests. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
confirm these results, the P1 and P2 cell groups were similarly treated with AmphoB
and infected with SFV. As with OS-IFITM3 expressing cells, AmphoB treatment of P1-
and P2-IFITM3 expressing cells enhanced SFV infection (Fig. 4.16), with no impact on
infectivity of control A549 cells. In sum, it appears that AmphoB can indeed abrogate
IFITM3-mediated inhibition of SFV, similarly to results previously seen with IAV [156].
Addition of AmphoB at the same time as virus (0 h; Fig. 4.15 and 4.16) gave a lower
level of enhanced infection than when pre-incubated for 1 h. These data suggest that
AmphoB may enhance SFV infection by altering IFITM3-mediated inhibition of entry.
To further test this hypothesis, and investigate whether any later aspects of the SFV
life cycle were impacted by AmphoB, a time of addition assay was used, as previously
described with monensin (Fig. 4.11). SFV was bound to the cell surface at 4℃, prior to
shifting cells to 37℃ to promote synchronous uptake of virus. AmphoB was added to cells
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Figure 4.16: Amphotericin B treatment enhances SFV infection of P1 and P2-
IFITM3 cells. P1- and P2-A549 or IFITM3 expressing cells were treated with 1 µM
AmphoB for 1 h at 37℃ prior to infection with SFV in the presence of AmphoB (-1 h),
or 1 µM AmphoB was added to cells with SFV (0 h). Cells were incubated for 5.5 - 6
h to allow infection, prior to fixation and staining for E1/E2 as a read-out of infection.
The percentage of P1 cells infected with SFV at 1 pfu/cell (A) or 10 pfu/cell (B) and
the percentage of P2 cells infected with SFV at 1 pfu/cell (C) or 10 pfu/cell (D) are
displayed. The data are from one experiment (performed by Stephanie Czieso), in a 96 well
plate format with triplicate wells for each condition. Bars represent the mean infection
percentage across the three wells with error bars representing the standard deviation
between these. Significance tests relate to the difference in mean infection percentage for
each compared condition using student’s unpaired t-tests. * p < 0.05, ** p < 0.01, *** p
< 0.001.
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either when first shifting to 37℃, or at time points between 10 min and 120 min after
warming. While AmphoB could enhance SFV infection when added at 0 min, addition
even after 10 min internalisation did not increase SFV infection of IFITM3 expressing
cells (Fig. 4.17). These results suggest that 1 µM AmphoB enhances SFV infection by
disrupting IFITM3-mediated inhibition of entry, and does not impact later stages of the
virus life cycle.
To further examine the effect of AmphoB on IFITM3-mediated restriction of SFV, a
range of concentrations were examined. Initially, 1 µM AmphoB was used as in [156],
however it was noted that when treating IFITM3 expressing cells with this concentration
the level of infection did not reach that seen in A549 cells (at 1 pfu/cell; Fig. 4.15 and 4.16).
Higher concentrations of AmphoB were therefore examined to test if there was any further
enhancement of infection. At higher concentrations of AmphoB (12.5 µM - 50 µM), SFV
infection in both the IFITM3 expressing and A549 control cells was inhibited (Fig. 4.18).
There were no clear signs of cytotoxicity when cells were examined by microscopy (data not
shown), even at the highest concentration of AmphoB (this is further supported by data
presented in Chapter 5), suggesting a drug-mediated inhibition of infection. Enhancement
of SFV infection in the presence of IFITM3 was detectable across the range of 0.5 µM to
3.125 µM, therefore 1 µM as used previously appeared to be optimal for promoting SFV
infection in the presence of IFITM3 (Fig. 4.18).
SFV requires cholesterol for fusion [100], therefore it was hypothesised that high con-
centrations of AmphoB were binding to the lipid and disrupting entry. This hypothesis
was tested by performing another time of addition experiment. As above, virus was bound
at the cell surface and allowed to enter cells by shifting to 37℃. At time points between
0 and 120 min, 50 µM AmphoB was added to the cells. Addition of the drug at all time
points potently inhibited SFV infection (Fig. 4.19). These results are in stark contrast to
monensin, which did not inhibit infection after the first 30 min at 37℃ (Fig. 4.11). There-
fore, although high concentration AmphoB may inhibit entry, it may also have additional
effects on later steps of the replication process.
Overall, AmphoB treatment of cells reduced the anti-SFV function of IFITM3, as has
been published for anti-IAV activity, suggesting similarities in the mechanism of inhibition
for both viruses. Following 10 min internalisation to cells, AmphoB no longer impacted
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Figure 4.17: Amphotericin B does not enhance SFV infection of IFITM3 ex-
pressing cells after virus internalisation. SFV (5 pfu/cell) was added to A549 or
IFITM3 expressing cells and incubated for 1 h at 4℃. Cells were washed to remove un-
bound virus and then treated with media pre-warmed to 37 ℃, with or without 1 µM
AmphoB. At the indicated times between 10 and 120 min, media were replaced with me-
dia containing AmphoB. Cells were incubated for a total of 5.5 - 6 h to allow infection,
prior to immunofluorescence analysis. Data presented are percentage of infected cells
normalised to untreated cells (A549 ∼70%, IFITM3 ∼5% infection). Data is from one
experiment performed in 96 well plate format using triplicate wells.
IFITM3-mediated inhibition of SFV, suggesting that even though AmphoB can act rapidly,
once virus is internalised to cells, infection is inhibited by IFITM3. High concentrations
of AmphoB can inhibit SFV infection, which was hypothesised to be as a result of the
dependency of SFV on cholesterol for fusion. However it appears that AmphoB may
disrupt later aspects of the SFV life cycle (potentially in addition to early aspects).
4.2.9 AmphotericinB does not appear to alter properties of
SFV virions
It appears that AmphoB treatment has a negative impact on the antiviral function of
IFITM3 against SFV and IAV [156]. A possibility that was not explored by Lin et al. is
that AmphoB may have direct affects on virus particles, rather than IFITM3 expressing
cells. An experiment was therefore set up to investigate whether AmphoB treatment was
impacting SFV particles or having a cellular affect. For this experiment 1 µM AmphoB
was used to boost SFV infection in the presence of IFITM3, while 1 nM was used as
a concentration which was expected to have little impact (and indeed did not, see Fig.
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Figure 4.18: Higher concentrations of AmphoB inhibit SFV infection. A549 or
IFITM3 expressing cells were pre-treated with AmphoB at concentrations between 0 and
50 µM for 1 h at 37℃. SFV was added to cells at 1 pfu/cell in the presence of AmphoB at
the appropriate concentration. Cells were incubated for 5.5 - 6 h to allow infection, prior
to analysis of infection. Data presented are the mean infection percentage across three
independent experiments, each consisting of triplicate wells in a 96 well plate format.
Error bars are the standard deviation between the experiments.
Figure 4.19: High concentration AmphoB inhibits SFV infection. SFV (5 pfu/cell)
was added to A549 or IFITM3 expressing cells and incubated for 1 h at 4℃. Cells were
washed to remove unbound virus. Media containing 50 µM AmphoB, or media alone,
at 37℃, were added to cells. Cells were incubated at 37℃ for between 10 and 120 min.
At each indicated time, control media were replace with fresh media containing 50 µM
AmphoB. Cells were incubated for a total of 5.5 - 6 h to allow infection prior to analysis
of infection by immunofluorescence staining and microscopy. Data presented are infec-
tion percentage normalised to untreated cells (A549 ∼54% infection). Data is from one
experiment performed in 96 well plate format using triplicate wells.
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4.20). To investigate the possibility that AmphoB treatment impacted SFV particles
directly, virus was incubated with 1 µM for 10 min at 37℃ at an MOI 1000 fold higher
than was to be used for infection. Following the incubation period, the virus was diluted
1000 fold in media lacking AmphoB, thus diluting AmphoB to 1 nM and then added to
cells and allowed to infect for 5.5 - 6 h (Fig. 4.20 A). If 1 µM AmphoB directly impacted
SFV particles, this incubation process would be expected to enhance SFV infectivity in the
presence of IFITM3. However, this 1 µM to 1 nM infection was not seen to be any different
to untreated samples, suggesting no impact from treating virus with 1 µM AmphoB (Fig.
4.20 B).
While the 1 µM AmphoB diluted to 1 nM treated virus did not show any enhanced
infection in the presence of IFITM3, it may be the case that this dilution of AmphoB
negated the enhancing affect. To test this possibility, IFITM3 expressing cells were incu-
bated with 1 µM for 10 min at 37℃. Media were removed from the cells, and virus was
added to the cells in 1 nM AmphoB media (with minimal exposure to the media prior to
addition to cells; Fig. 4.20 A). These samples were again allowed to infect for 5.5 - 6 h
and analysed for the percentage of infected cells. As can be seen in the ‘1 µM to 1 nM
cells’ sample, this process enhanced infection in the presence of IFITM3 (Fig. 4.20 B).
The enhancement was not as large as that seen when virus and cells were both incubated
with 1 µM AmphoB through the infection (though only statistically different at MOI =
5, and not at MOI = 1), but there was a statistically significant increase over the control
level of infection (Fig. 4.20 B). This indicates that incubating cells for 10 min with 1 µM
AmphoB could impact SFV infection of IFITM3 expressing cells. Since 1 nM AmphoB did
not increase SFV infection in the presence of IFITM3, it is unlikely that mixing virus with
1 nM AmphoB was responsible for the increase see in the ‘1 µM to 1 nM cells’ sample. It
is speculated that the difference between cells and virus being treated with 1 µM AmphoB
and the ‘1 µM to 1 nM cells’ sample is as a result of AmphoB being diluted to the lower
concentration, allowing greater inhibition from IFITM3.
The data suggest that AmphoB does not directly alter the infectivity of SFV particles
in the presence of IFITM3. Additionally, as seen in previous (Fig. 4.15 and 4.16), AmphoB
treatment did not alter SFV infectivity of A549 cells. It therefore appears that AmphoB
treatment is altering IFITM3 expressing cells to allow a higher level of SFV infection.
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Figure 4.20: AmphoB treatment does not appear to alter properties of SFV
virions. A) A diagram to display the experimental set up. In all cases there was a 10
min incubation at 37 ℃ of virus and cells separately. The first diagram represents the
control conditions of treating cells and virus with 1 µM or 1 nM AmphoB. The middle
diagram represents the set up for treating virus with 1 µM AmphoB and then diluting
this to 1 nM to investigate whether 1 µM AmphoB impacts virus instead of the cells.
The final diagram represents a control to test the impact of treating cells with 1 µM
AmphoB and then diluting this to 1 nM, as it was unknown whether this dilution would
cause a loss of the AmphoB enhancing affect. B) Percentage of SFV infected cells in the
various conditions displayed in (A), with the addition of the untreated controls (Unt.).
The data are from a representative experiment (n = 2) performed in a 96 well plate with
triplicate wells of infection. The error bars represent the standard deviation between wells.
The right hand graph displays the relative infection of IFITM3 expressing cells for each
condition (normalised to untreated controls at each MOI). Significance tests relate to the
difference in mean infection percentages as assess by unpaired student’s t-tests. Stars
directly above bars represent comparison of untreated and treated samples at each MOI
(where no stars are displayed there was no statistically significant difference). Stars above
the bars, connected by lines represent a comparison on the 1 µM and ‘1 µM to 1 nM cells’
samples. * p < 0.05, ** p < 0.01, *** p < 0.001.
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4.2.10 IFITM1 and IFITM3 can inhibit SFV infection by
fusion at the plasma membrane
The data presented Fig. 4.1 and 4.2 indicated that IFITM3 could inhibit SFV infection
when virus enters through the endocytic route, while IFITM1 and IFITM3-Y20A could
not. The difference in restriction between these IFITM proteins could be related to their
localisation within a cell, with IFITM3 being localised to early endosomes, from where
SFV normally penetrates to the cytosol, while IFITM1 and IFITM3-Y20A are mostly at
the plasma membrane. It was therefore investigated whether IFITM3-mediated restriction
could be bypassed by fusion of SFV at the cell surface, and whether this route of entry
into the cell would be sensitive to the plasma membrane localised IFITM proteins.
SFV can enter cells by fusion directly at the plasma membrane following a transient
low pH treatment (pH 5.5; [46]). To ensure that any infection of cells was as a result
of fusion at the plasma membrane, and not low pH-dependent entry through endosomes,
cells were pre-treated for 15 min at 37℃ with Baf A as described in Section 4.2.6 (page
151) and Chapter 2 (Section 2.6.7 [page 83]). Virus was bound to the cell surface at 4℃
for 1 h, as previously described. Cells were subsequently treated with media (containing
Baf A) at pH 5.5 for 3 min at 37℃, to activate the E1/E2 fusion machinery at the cell
surface (as seen in Fig. 4.12) and induce fusion of the plasma membrane and viral lipid
envelope. Following the transient low pH treatment, cells were returned to pH 6.8 media,
containing Baf A, and incubated for 5.5 - 6 h to allow production of de novo E1/E2 as
a read-out for infection. As controls, cells were treated with pH 6.8 media for 3 min or
treated with DMSO instead of Baf A.
When virus was bound at the cell surface (5 pfu/cell input), then allowed to internalise
and fuse with early endosomes (pH 6.8 DMSO), ∼65-80% of A549 cells (OS, P1 and P2)
were infected with SFV (Fig. 4.21 A). When cells were treated with Baf A, and no low
pH pulse was given at the cell surface (pH 6.8 Baf A), infection was inhibited by >90%
(Fig. 4.21 A). When A549 cells were pre-treated with Baf A, and given a 3 min low pH
pulse (pH 5.5 Baf A), ∼20-50% of cells were infected (Fig. 4.21 A). Treating cells with
Baf A prior to the low pH pulse did no affect the result since pre-treatment with DMSO,
followed by Baf A in the infection media (pH 5.5 DMSO/Baf A [D/B]) gave similar levels
of infection. This bypass of Baf A inhibition seen with low pH treatment is the level of
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infection by direct plasma membrane fusion. This route is not as efficient as infection
through the endocytic route, but has some variability based on the cell line used [97].
In order to make direct comparisons, the level of infection through plasma membrane
fusion and the endocytic route were compared. Within each independent experiment,
infection percentages from low pH treatment were set relative to the pH 6.8 DMSO control
(endocytic infection) for each individual cell line. The relative infection for both pH
5.5 treatments (pH 5.5 Baf A and pH 5.5 D/B) showed very little difference, and were
therefore considered equivalent by averaging the two. These relative infection levels were
then averaged across three independent experiments to give a value that can be used to
assess the efficiency of infection by plasma membrane fusion in each cell line. In OS-
A549 cells the relative infection level from plasma membrane fusion was 0.34. In P1- and
P2-A549 cells, these values were 0.62 and 0.44, respectively. It therefore appeared that
there was some variability in the efficiency of plasma membrane fusion even in different
A549 cell lines, which may be due to the different derivation of these cells (OS-A549 are
parental, P1-A549 have an empty puromycin resistant vector stably transfected, P2-A549
stably express GFP).
As seen previously, IFITM1 did not inhibit the endosomal route of SFV infection in
either OS- or P1-IFITM1 cells, with both showing similar infection levels to their respective
A549 controls (Fig. 4.21 A). Baf A potently inhibited SFV infection of IFITM1 expressing
cells. When virus bound to the surface of IFITM1 expressing cells was given a low pH
pulse to promote entry at this membrane site, the infection percentage was consistently
lower than that observed in the comparable A549 cells (Fig. 4.21 A). In the OS cell set,
the fact that the efficiency of infection by plasma membrane fusion in the A549 control
cells was low meant that the inhibition by IFITM1 was modest, and not statistically
significant. However, in the P1 set, the difference between infection percentage of A549
and IFITM1 cells was much greater, and statistically significant. The relative infection
levels of plasma membrane fusion, compared to endocytic entry were 0.19 and 0.15 for
OS- and P1-IFITM1, respectively, compared to 0.34 (OS) and 0.62 (P1) in the A549 cells.
Overall, from these data it is concluded that IFITM1 can inhibit infection by SFV through
fusion at the plasma membrane, but that effect is modest.
Plasma membrane localised P2-IFITM3-Y20A did not inhibit SFV infection through
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the endocytic route (Fig. 4.21 A and 4.2 B). However, when virus was fused at the plasma
membrane, P2-IFITM3-Y20A inhibited infection by ∼95% (Fig. 4.21 A). This relative
infection level is lower than that seen for either OS- or P1-IFITM1 (0.05 compared to
0.19 and 0.15, respectively). It has previously been noted that IFITM expression levels
are important for the anti-SFV function (Section 4.2.2, Fig. 4.2). P2-IFITM3-Y20A
expression levels are similar to, or lower than those seen for either OS- or P1-IFITM1(Fig.
4.2), suggesting that P2-IFITM3-Y20A has greater potency for inhibiting SFV plasma
membrane fusion than IFITM1.
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Figure 4.21: IFITM1 and IFITM3 can inhibit SFV infection by fusion at the
cell surface. A) Infection by plasma membrane fusion: OS, P1 and P2 cells were pre-
treated with media containing 100 nM bafilomycin A1 (Baf A; pH 5.5 Baf A and pH 6.8
Baf A samples) for 15 min at 37℃ (or DMSO as a control; pH 6.8 DMSO and pH 5.5
D/B samples [see further detail below]). Cells were then cooled by addition of media
at 4℃ (with or without Baf A) and placed on ice. SFV (5 pfu/cell) was added and
allowed to bind to the cell surface for 1 h at 4℃. Unbound virus was removed by washing.
Cells were treated with media (with or without Baf A) pre-warmed to 37℃ for 3 min
to promote fusion at the cell surface (pH 5.5 Baf A and pH 5.5 D/B [see further detail
below]). As a control, cells were incubated with pH 6.8 media for 3 min, which would
not activate the fusion machinery. Following the 3 min incubation periods, all media were
replaced with pH 6.8 media with or without Baf A. Cells were then incubated for 5.5 -
6 h to allow infection, prior to fixation and immunofluorescence staining for the E1/E2
proteins as a marker of infection. As a control for the Baf A pre-treatment steps, cells
were incubated with control media up to the pH 5.5 treatment, and then incubated with
pH 6.8 media containing Baf A through the 5.5 - 6 h incubation period (pH 5.5 D/B).
The bars represent mean infection percentage from three independent experiments (each
containing triplicate wells for each sample). Error bars represent the standard deviation
between experiments. Statistical significance was determined using normalised infection
values, comparing pH 5.5 D/B (green) or pH 5.5 Baf A (magenta) of A549 samples, with
IFITM samples (described in Materials and Methods). * p < 0.05, ** p < 0.01, *** p <
0.001, **** p < 0.0001. B) Analysis of IFITM expression by flow cytometry: OS-, P1- or
P2-IFITM cells were labelled with anti-HA antibodies either intact (I) or following saponin
permeabilisation (P). Anti-HA antibody was detected with AF647 and analysed by flow
cytometry to determine the relative levels of cell surface IFITM protein. To control for the
specificity of labelling, cells were either incubated with no antibody, or without anti-HA
antibody (i.e. AF647 secondary antibody only). The mean fluorescence intensity (MFI),
relative to the no antibody control displayed for each cell line. Plots are representative of
3-4 independent experiments.
SFV infection by the endocytic route of entry was low in all three IFITM3 cell groups,
with OS-IFITM3 being the most restrictive (Fig. 4.21, as seen in Fig. 4.1 and 4.2).
Treatment of IFITM3 expressing cells with Baf A reduced the infection level to <1%. It
was hypothesised that fusion of virus at the plasma membrane would not only bypass the
inhibition imposed by Baf A, but also that of IFITM3. It was therefore surprising to see no
increase in the level of infection following low pH treatment, and that these infection levels
were consistently lower than those seen in all A549 cells (Fig. 4.21 A). As above, to make
comparisons, the relative infection levels of plasma membrane fusion against the endocytic
route were analysed. If SFV could bypass inhibition from IFITM3, these values would be
expected to be above 1 as a result of comparison to the endocytic route of entry (which is
blocked by IFITM3). The OS-IFITM3 cells showed the greatest inhibition of infection by
fusion at the plasma membrane, with a relative infection level of 0.01, compared to the
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A549 control cells which had a relative infection level of 0.34. The P1-A549 cells had a
relative infection level of 0.62, compared to 0.2 for the P1-IFITM3 expressing cells. While
the P2-IFITM3 expressing cells had a relative infection level of 0.24, compared to 0.44 of
the P2-A549 controls.
Overall, it appears that, even though predominantly localised to early endosomes (Fig.
3.17 [page 127]), IFITM3-mediated inhibition of SFV was not bypassed through fusion at
the plasma membrane, and therefore the protein could still inhibit infection. The infection
percentages seen by plasma membrane fusion in OS-IFITM3 cells were lower than observed
for any other set of cells. The P1- and P2-IFITM3 cells show similar levels of infection
as the OS- and P1-IFITM1 cells. Together, these data suggest that IFITM3 inhibits SFV
infection by plasma membrane fusion to a similar, or greater extent than IFITM1.
It was interesting to see that IFITM3 could inhibit SFV infection through plasma mem-
brane fusion, even though much of the protein appeared to be localised in the endosomal
system (Fig. 3.17 [page 127] and Fig. 3.7 [page 105]). To further investigate the levels of
IFITM protein at the plasma membrane, cells were labelled with anti-HA antibody either
intact, or following saponin permeabilisation and were analysed by flow cytometry. The
mean fluorescence intensity of labelled OS-IFITM1, P1-IFITM1 and P2-IFITM3-Y20A
was similar on intact and permeabilised cells, suggesting the majority of the HA-tag is
present at the cell surface (Fig. 4.21 B). For all three sets of IFITM3 expressing cells,
significant fluorescent signal was only detected following permeabilisation, suggesting the
majority of the protein is within intracellular pools (Fig. 4.21 B). Nevertheless, the MFI
of intact IFITM3 expressing cells was slightly above background, suggesting some IFITM3
protein is present at the cell surface (as previous described in Chapter 3, e.g. Fig. 3.2
[page 97]). This may be sufficient to explain the efficient inhibition of infection through
plasma membrane fusion by IFITM3.
In summary, despite low levels of protein at the plasma membrane, IFITM3 appeared
to be able to inhibit SFV fusion at the cell surface to an equivalent, or greater extent
than IFITM1; and that IFITM3-Y20A also appeared to inhibit to a greater extent than
IFITM1. It therefore seems that IFITM3 may be a more potent inhibitor of SFV infection
than IFITM1.
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4.3 Conclusions and Discussion
While the IFITM proteins have been suggested to inhibit infection by a wide range of
viruses (Tables 1.1 and 1.2), there had been little work to investigate whether they could
inhibit alphaviruses, and there had been the suggestion that they do not [9, 11]. The
work presented in this chapter indicates that IFITM3, and to a lesser extent IFITM2, can
inhibit infection of A549 cells by the alphaviruses SFV and SINV. When virus entered
through the endocytic route, neither IFITM1 nor IFITM3-Y20A, inhibited infection, ini-
tially suggesting the endosomal localisation of IFITM proteins may be required for their
anti-SFV function. Focusing on SFV, it was demonstrated that IFITM proteins do not im-
pact on virus binding. Moreover, IFITM3 was found to not inhibit endocytosis or delivery
to acidic compartments of the cell where the envelope protein could undergo pH-induced
conformational changes. However, while E1 could trimerise, the viral capsid was not re-
leased into the cytosol of IFITM3 expressing cells. These results suggest that IFITM3
inhibits fusion between viral and cellular membranes, and/or uncoating of the viral cap-
sid. Shortly after the publication of this work [16], a study was published showing that
IFITM3 could inhibit the alphaviruses CHIKV, O’nyong nyong, VEEV, SFV and SINV
[184], further supporting our own findings. Additionally, this second study also suggesting
that IFITM3 was important for control of the early stages of CHIKV infection and mor-
tality from VEEV infection in mice, pointing towards in vivo relevance for this antiviral
function.
IFITM3 was not found to block the formation of the E1 HT within the endosomal
system (Fig. 4.12). This suggests that IFITM3 does not inhibit viral infection by altering
endosomal acidification, and does not directly impact conformational changes of the viral
envelope glycoprotein. A suggestion has been made that formation of the E1 HT, is
dependent on interaction with membrane [194], perhaps suggesting that IFITM3 is also
not inhibiting this process. It is noted that only a small fraction of the E1 protein becomes
trimeric, either upon endocytic internalisation to cells, or when given a low pH treatment
at the cell surface, regardless of IFITM expression (Fig. 4.12). This result could be
explained either if the E1 HT is unstable and therefore mostly in a monomeric form, or if
there is indeed a requirement for membrane interaction, which is suggested because only
a low fraction of the envelope proteins on the surface of an SFV virion will be in contact
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with a target membrane. The low proportion of trimeric E1 may therefore further suggest
that membrane interaction is required, and therefore not inhibited by IFITM3.
Much of the work defining IFITM proteins as inhibitors of viral entry has been through
the use of pseudotyped virus particles (Tables 1.1 and 1.2). IFITM3-mediated inhibition
of IAV has been much more highly characterised with work suggesting that inhibition oc-
curs either prior to membrane fusion [13], or at the point of hemifusion to block resolution
to a full fusion pore [14]. Additionally, Lin et al. have suggested that IFITM3-mediated
inhibition of IAV infection can be modulated by treatment with the antifungal drug Am-
phoB [156]. The precise mechanism(s) of this effect remains unclear, but the suggestion
was made that by binding to cholesterol, AmphoB may modulate the fluidity of cellu-
lar membranes to disrupt IFITM-mediated inhibition. Similarly to the results with IAV,
IFITM3-mediated inhibition of SFV is also sensitive to AmphoB treatment, suggesting a
similar mechanism of restriction for both viruses. SFV is amenable to various assays to
investigate whether fusion is occurring, for instance, labelling with lipophilic dyes such
as DiD (as has been done for IAV [14]), and therefore can be used to better understand
whether IFITM proteins inhibit before, or after hemifusion.
It was observed that the antiviral action of IFITM3 could be saturated by increasing
the amount of virus, or by lowering the level of IFITM expression. This ability to saturate
IFITM3-mediated inhibition of SFV infection could be explained if there is a need for
direct interaction between IFITM3 and sites at which SFV fusion occurs. Since SFV
fusion requires cholesterol in the target membrane, and IFITM3-mediated inhibition of
SFV is diminished in the presence of AmphoB, it is possible that IFITM3 may cluster
to cholesterol-rich regions of cellular membranes, where it can disrupt membrane fusion
events.
It was interesting to see that IFITM1 did not effectively inhibit SFV infection. Even
though the majority of viruses shown to be inhibited by the IFITM proteins fuse in
endosomes, many of these show at least some sensitivity to IFITM1 (Tables 1.1 and
1.2). It was speculated that the endocytic uptake of SFV allows it to escape the plasma
membrane localised IFITM1 in this A549 cell system; however why other endocytosed
viruses would be sensitive to IFITM1 remains unclear. A potentially contributing factor
to the lack of IFITM1-mediated inhibition of SFV may be as a result of intrinsic differences
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in the potency of IFITM1 and IFITM3 for inhibiting SFV infection. Even though there are
relatively low levels of IFITM3 at the plasma membrane, when SFV fusion was triggered
at this site, IFITM3 could inhibit infection to a similar or greater extent than IFITM1. If,
as suggested above, IFITM3 clusters to cholesterol-rich regions of cellular membranes, this
may explain how a relatively low level of protein at the plasma membrane can still inhibit
SFV fusion. However, a caveat should be noted when interpreting the results of plasma
membrane fusion and surface levels of IFITM3; whether Baf A treatment can alter IFITM3
levels at the cell surface has not been tested. An alternative explanation for the observed
inhibition of SFV infection by plasma membrane fusion may be that Baf A treatment could
cause IFITM3 accumulation at the cell surface. However, it still appears that IFITM1
has limited anti-SFV activity compared to IFITM3. Future research could be aimed at
investigating what regulates these apparent differences between IFITM1 and IFITM3. All
IFITM proteins contain a highly conserved CD225 domain which spans the first membrane
interacting domain and the CIL (Fig. 1.6 [page 44]). The second membrane domain is
also highly conserved. The differences between IFITM1 and IFITM3 are therefore mostly
in the NTD and CTD. SFV will act as a good model system to work with to investigate
how the NTD and CTD of IFITM1 and IFITM3 may regulate their apparent differential
antiviral potency, for instance, through the use of chimeric IFITM proteins. Investigating
these differences may help to better understand the antiviral function of the human IFITM
proteins.
Many of the ideas suggested here will be built on further in the subsequent chapter
with an investigation of IFITM-mediated inhibition of flavivirus infection, and how this
differs to that seen for inhibition of alphaviruses.
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5.1 Introduction
In the previous chapter, IFITM proteins were shown to inhibit alphavirus infection (fo-
cusing on SFV), with IFITM3 seemingly being the most potent inhibitor. This inhibition
was sensitive to treatment with the antifungal drug amphotericin B (AmphoB) and a
suggestion was made that there could be a link between IFITM3 and cholesterol for the
anti-SFV activity. In this chapter, work is presented comparing the antiviral function of
IFITM proteins against alphaviruses with other viruses, members of the Flaviviridae and
vaccinia virus (VACV) of the Poxviridae. The flaviviruses used here and VACV are inter-
nalised to cells through endocytic mechanisms, and have low pH-induced membrane fusion
with endosomes, similarly to alphaviruses. The flaviviruses are also structurally similar
to alphaviruses and have a type II fusion protein machinery for penetration of cellular
membranes. Work has previously been published to analyse IFITM-mediated inhibition
of flaviviruses, with all three of the IFITM proteins shown to have at least some antiviral
function [7, 144, 147, 154]. In contrast VACV has not been analysed in any great detail
for IFITM-mediated inhibition, although the IFITM proteins were not detected as hits in
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an RNAi screen for host factors that modify VACV infection in HeLa cells [195].
The experiments presented in this chapter are divided into two parts. Firstly, a com-
parison between the inhibition of alphaviruses and flaviviruses is made. In agreement with
previous studies, all IFITM proteins were found to inhibit infection by different flaviviruses,
in contrast to results with alphaviruses which were insensitive to the plasma membrane
localised IFITM proteins. Additionally, IFITM-mediated inhibition of flavivirus infection
was found to be insensitive to AmphoB treatment, perhaps suggesting different underlying
mechanisms of antiviral function. In the second part of this chapter, VACV is suggested to
be insensitive to IFITM-mediated inhibition, arguing that not all viruses that enter cells
through the endocytic system are sensitive to IFITM proteins. However, the experiments
with VACV led to the identification of a potentially interesting feature of high levels of
IFITM expression, which appear to enhance cell motility.
5.2 Comparison of alphavirus and flavivirus inhi-
bition by IFITM proteins
5.2.1 IFITM proteins inhibit flavivirus infection and this is
not altered by AmphoB treatment
To test whether IFITM proteins can inhibit flavivirus infection, dengue (serotype 2;
DENV), Zika (African strain; ZIKV) and yellow fever (17D strain; YFV) viruses were
used (most work focused on DENV). Cells were infected with DENV at an input of 1 or
0.3 pfu/cell and incubated for 27 h prior to fixation and labelling to determine infection
percentage by immunofluorescence microscopy. In OS-A549 controls ∼57% of cells were
infected with 1 pfu/cell, and ∼21% of cells were infected with 0.3 pfu/cell (Fig. 5.1 A).
As with SFV, OS-IFITM3 inhibited DENV infection of A549 cells; with 1 pfu/cell there
was ∼8% infection (p = 0.0001). OS-IFITM2 could also inhibit infection, though not as
potently as OS-IFITM3 (∼30% infection with 1 pfu/cell [p = 0.0009, compared to A549]),
again similarly to the results seen with alphaviruses. In contrast to alphaviruses, OS-
IFITM1 was also able to inhibit DENV infection, and in fact showed greater potency than
OS-IFITM2, with ∼20% infection (p = 0.0005, compared to A549) at 1 pfu/cell (Fig. 5.1
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A).
To further investigate similarities and differences in IFITM-mediated inhibition of
alphaviruses and flaviviruses, the impact of AmphoB treatment was also tested. Treating
cells with 1 µM AmphoB (using 1 h pre-treatment as previously in Chapter 4) did not
boost DENV infection of the OS-IFITM cells. There were no significant differences in
the infection percentage of treated and untreated IFITM1 (p = 0.1886) and IFITM3
(p = 0.6372) expressing cells (Fig. 5.1 A). While IFITM2 expressing cells treated with
AmphoB appeared to show a small decrease in infection percentage following treatment
with AmphoB (p = 0.0005 [Fig. 5.1 A]). This is in clear contrast to results with SFV
where a ∼6.5 fold increase in infection of IFITM3 expressing cells was observed following
treatment with AmphoB (Fig. 4.15 [page 157]).
P1-IFITM cells showed largely similar results to OS-IFITM cells, with IFITM3 being
the most potent inhibitor (p = 0.0007, compared to A549 at 1 pfu/cell) of DENV followed
by IFITM1 (p = 0.0019, compared to A549 cells at 1 pfu/cell) then IFITM2 (p = 0.0146,
compared to A549 at 1 pfu/cell [Fig. 5.1 B]). P2-IFITM3 also inhibited DENV infection
(p = 0.0001 compared to A549 cells at 1 pfu/cell) to a similar extent as P1-IFITM3. P2-
IFITM3-Y20A was capable of inhibiting DENV infection (p < 0.0001, compared to A549
cell at 1 pfu/cell) even though, like IFITM1, it did not inhibit SFV infection through the
endocytic route (Fig. 5.1 C). P2-IFITM3-Y20A expressing cells did not inhibit infection
as potently as any of the IFITM3 expressing cells, but had similar inhibition to OS- and
P1-IFITM1 cells. P1- and P2-IFITM-mediated inhibition of DENV was also unaffected by
treatment with AmphoB (Fig. 5.1 B and C). Therefore, in contrast to SFV, all IFITMs in-
hibited DENV infection, even those localised at the plasma membrane, and the mechanism
of DENV inhibition was insensitive to treatment with AmphoB.
Chapter 5 175
Comparing IFITM-mediated alphavirus restriction with other viral families
176 Chapter 5
Comparing IFITM-mediated alphavirus restriction with other viral families
Figure 5.1: All IFITM proteins inhibit DENV and this is insensitive to AmphoB
treatment. A549 control, or IFITM expressing cells were pre-incubated for 1 h at 37℃
with 1 µM AmphoB, or left untreated (UN), and then infected with DENV (serotype 2)
using 1 or 0.3 pfu/cell (with AmpohoB as labelled). Cells were incubated for 6 h prior
to AmphoB media being replaced with infection media lacking AmphoB, to mimic the
incubation time of cells with AmphoB used for SFV experiments. Infection was allowed to
proceed for a total of 27 h, prior to fixation and staining to determine infection percentage
by immunofluorescence microscopy. A) OS-IFITM cells. B) P1-IFITM cells. C) P2-
IFITM cells. AmphoB did not alter DENV infection of IFITM expressing cells. The same
AmphoB stock was used as for SFV infections in Chapter 4, and SFV infections were run
in parallel to confirm the AmphoB affect on SFV (data not shown). Data presented are
from representative experiments (n = 3 for UN and n = 2 for AmphoB) performed in a 96
well plate format with triplicate wells of infection. Bars are the mean infection percentage
with error bars representing the standard deviation. (All DENV infections performed by
Dr. Michela Mazzon.)
ZIKV showed a similar pattern of restriction as DENV. Both OS-IFITM1 and IFITM3
expressing cells inhibited ZIKV (p = 0.0005 and 0.0003, respectively, as compared to A549
cells at 1 pfu/cell [Fig. 5.2 A]). OS-IFITM2 only had a minor impact on ZIKV infection,
which did not show a statistically significant difference compared to infection of A549 cells
(Fig. 5.2 A). All of P2-IFITM3, P2-IFITM3-Y20A and P1-IFITM1 inhibited ZIKV to a
similar extent as each other (all three p < 0.0001, compared to A549 cells at 1 pfu/cell
[Fig. 5.2 B]). Therefore, as for DENV, it seems that IFITM1 and IFITM3 can both
inhibit ZIKV, and the endosomal localisation of IFITM3 is not essential for this function,
in contrast to results seen with SFV (Fig. 4.1 and 4.2, pages 135 and 138). Like DENV,
AmphoB treatment had limited impact on ZIKV infection of IFITM expressing cells.
YFV 17D showed similar restriction patterns as the two other flaviviruses, with one ex-
ception. IFITM3 and IFITM1 inhibited YFV 17D (Fig. 5.3), with statistically significant
differences compared to A549 cells (OS-IFITM3 and OS-IFITM1 p < 0.0001, P2-IFITM3
p = 0.0066 and P1-IFITM1 p = 0.0089). Within the OS cell set, OS-IFITM2 expressing
cells had the lowest level of inhibition, but still demonstrated a statistically significant de-
crease compared to A549 cells (p = 0.0042). In comparison, P2-IFITM3-Y20A expressing
cells did no inhibit YFV 17D as potently as the other two flaviviruses tested, and did not
show statistically significant differences compared to A549 cells (Fig. 5.3 B compared to
Fig. 5.1 C and Fig. 5.2 B). The lack of IFITM3-Y20A-mediated inhibition was probably
not as a result of expression levels since P1-IFITM1, which has similar population level
expression (see Fig. 4.2 [page 138]) could potently inhibit YFV 17D (Fig. 5.3 B). Similarly
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to results with DENV and ZIKV, AmphoB treatment had no impact on IFITM-mediated
inhibition of YFV 17D (Fig. 5.3), suggesting similar properties for inhibition of three
different flaviviruses.
5.2.2 Higher concentrations of AmphoB do not inhibit DENV
infection
In the experiments described in Fig. 5.1, 5.2 and 5.3, AmphoB treatment was performed to
mimic that of the SFV infections described in Chapter 4. To that end, cells were incubated
with 1 µM AmphoB for 1 h at 37℃, prior to addition of virus in AmphoB containing
media. Virus and AmphoB were incubated with cells for 6 h and media was then replaced
for normal infection media. This replacement was made to match the time period that
cells were incubated with AmphoB for SFV infections to avoid any potential toxic affects.
However, there is a clear difference in that the SFV replication cycle is completed within 6
h, while the flavivirus replication cycle takes much longer (27 h infection period used here).
This raised the question of whether removal of AmphoB was responsible for the lack of
impact on IFITM-mediated inhibition of flavivirus infection. Time of addition experiments
with SFV suggested that AmphoB only impacted IFITM3-mediated inhibition at early
time points (Fig. 4.17 [page 160]), therefore it seemed unlikely that removing AmphoB
would alter the flavivirus life cycle in the context of IFITM-mediated inhibition. However,
to test this, cells were pre-treated with AmphoB, and incubated with virus for 6 h, prior
to media changing, or left in AmphoB media for the full 27 h. A549 cells incubated with
AmphoB containing media for 27 h showed no decrease in infection percentage, suggesting
cells could effectively produce viral protein (as used to detect infected cells) and that
there were presumably no cytotoxic affects from the longer incubation with drug. IFITM
expressing cells incubated with AmphoB for 27 h inhibited infection to a similar extent
as the cells incubated with AmphoB for 6 h (no statistically significant difference seen),
further arguing that AmphoB treatment does not alter IFITM-mediated inhibition of
DENV (Fig. 5.4 A). The lack of AmphoB impact on DENV infection does not appear to
be as a result of not having the drug present through the full virus replication cycle.
For SFV infection, it was determined that 1 µM AmphoB gave the largest increase of
infection in the presence of IFITM3. It may have been the case that higher concentrations
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Figure 5.2: IFITM proteins inhibit ZIKV and this is insensitive to AmphoB
treatment. A549 control, or IFITM expressing cells were pre-incubated for 1 h at 37℃
with 1 µM AmphoB, or left untreated (UN), and then infected with ZIKV (African strain)
using 1 or 0.1 pfu/cell (with AmphoB as labelled). Cells were incubated for 6 h prior
to AmphoB media being replaced with infection media lacking AmphoB, to mimic the
incubation time of cells with AmphoB used for SFV experiments. Infection was allowed to
proceed for a total of 27 h, prior to fixation and staining to determine infection percentage
by immunofluorescence microscopy. A) OS-IFITM cells. B) P2-IFITM cells and P1-
IFITM1 cells. Treating cells with AmphoB had minimal impact on ZIKV infection. The
same AmphoB stock as used for other experiments was used here. Data presented are
from representative experiments (n = 2 for UN and n = 1 for AmphoB) performed in a
96 well plate format with triplicate wells of infection. Bars are the mean infection with
error bars representing the standard deviation.
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Figure 5.3: IFITM proteins inhibit YFV 17D and this is insensitive to AmphoB
treatment. A549 control, or IFITM expressing cells were pre-incubated for 1 h at 37℃
with 1 µM AmphoB, or left untreated (UN), and then infected with YFV (17D strain)
using 3 or 0.3 pfu/cell (with AmphoB as labelled). Cells were incubated for 6 h prior
to AmphoB media being replaced with infection media lacking AmphoB, to mimic the
incubation time of cells with AmphoB used for SFV experiments. Infection was allowed to
proceed for a total of 27 h, prior to fixation and staining to determine infection percentage
by immunofluorescence microscopy. A) OS-IFITM cells. B) P2-IFITM cells and P1-
IFITM1 cells. Treating cells with AmphoB had minimal impact on YFV 17D infection.
The same AmphoB stock as used for other experiments was used here. Data presented
are from representative experiments (n = 3 for UN and n = 2 for AmphoB) performed in
a 96 well plate format with triplicate wells of infection. Bars are the mean infection with
error bars representing the standard deviation.
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were needed to impact flavivirus infection. To test this, cells were treated with a range of
different AmphoB concentrations and infected with DENV (similarly to experiments with
SFV; Fig. 4.18 [page 161]). These data showed that even at higher concentrations of Am-
phoB, IFITM3-mediated inhibition of DENV was not altered (Fig. 5.4 B). Interestingly,
unlike with SFV, the higher concentrations of AmphoB did not inhibit DENV infection
in either A549 controls, or IFITM3 expressing cells, except for maybe a small impact at
the highest concentration of 50 µM (Fig. 5.4). Overall, it appears that treating cells with
AmphoB does not impact IFITM-mediated inhibition of DENV, even with longer time of
treatment, or at higher concentrations.
5.2.3 Discussion
IFITM1, 2 and 3 were all found to inhibit flavivirus infection. IFITM3 had the most
potency, followed by IFITM1, and IFITM2 had the least potency. Like alphaviruses,
flaviviruses are internalised to cells through endocytic mechanisms and enter the cytosol
through pH-induced fusion with endosomes. IFITM1 did not inhibit SFV infection and
this was initially speculated to be as a result of localisation at the plasma membrane, away
from the site of SFV fusion. However, data from plasma membrane fusion experiments
(Fig. 4.21 [page 168]) suggested that there may be intrinsic differences between IFITM1
and IFITM3 for their potency against SFV. The results with flaviviruses further argue that
the basal localisation of IFITM proteins is not the main determining feature of restriction.
IFITM1 is predominantly localised to the plasma membrane, and yet can still inhibit
flavivirus infection. By electron microscopy minor pools of IFITM1 were detected within
the endocytic pathway (see Chapter 3). These pools of protein may, to an extent, be
responsible for IFITM1-mediated inhibition of flavivirus infection, but it may also be the
case that protein is internalised with the virus from the cell surface.
Like IFITM1, IFITM3-Y20A localises to the plasma membrane and did not inhibit
SFV infection. IFITM3-Y20A was able to inhibit DENV and ZIKV infection, but had
little impact on YFV 17D. It can be speculated that there are some intracellular pools of
IFITM3-Y20A, similarly to IFITM1, and that protein may be internalised with endocy-
tosed virus, perhaps explaining inhibition of DENV and ZIKV. However, why IFITM3-
Y20A has comparatively little impact on YFV 17D, while IFITM1 does is unclear. The
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Figure 5.4: High concentrations of AmphoB do not inhibit DENV infection. A)
For the experiments described in Fig. 5.1, 1 µM AmphoB containing media were removed
after 6 h incubation of cells with virus (plus 1 h pre-treatment) and replaced with media
lacking drug and virus. To control for any lack of AmphoB affect being as a result of
removing the drug, a direct comparison was made between replacing AmphoB media after
6 h, or leaving it for the full infection time of 27 h (using OS-IFITM cells). All cells were
pre-incubated with AmphoB for 1 h (or left untreated [UN]) prior to addition of DENV
at the labelled MOI and incubated for a total of 27 h to allow infection. Data is from
a representative experiment (n = 2) performed in a 96 well plate format with triplicate
wells of infection. Bars represent the mean infection percentage and error bars represent
the standard deviation. B) OS-IFITM cells were pre-treated with the indicated AmphoB
concentrations for 1 h, prior to addition of 1 pfu/cell DENV in the presence of AmphoB.
Virus was incubated with cells for 6 h prior to replacing AmphoB containing media with
infection media lacking AmphoB. Cells were incubated for a total of 27 h, prior to fixation
and analysis of infection by immunofluorescence microscopy. Data is from a representative
experiment (n = 2) performed in a 96 well plate format with triplicate wells of infection.
Data points represent the mean infection percentage and error bars represent the standard
deviation. (All DENV infections performed by Dr. Michela Mazzon.)
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17D strain of YFV is a live attenuated form of the virus used for vaccination. Many of the
mutations responsible for the attenuation have been found to be in the viral envelope (E)
protein [196]. The E protein regulates YFV entry, and it has been suggested that these
attenuating mutations of E have altered the entry route of the virus [197]. Like DENV,
wild-type YFV is internalised to cells through CME (DENV; [198–201], wild-type YFV;
[197]), however, YFV 17D was found to enter HeLa cells through a clathrin-independent,
dynamin-dependent, caveolae-independent pathway [197]. Whether this different route of
internalisation is altering the sensitivity towards IFITM proteins (sensitive to IFITM1, but
insensitive to IFITM3-Y20A) is an interesting possibility that remains to be investigated.
It was suggested that the difference in potency for inhibiting SFV between IFITM1
and IFITM3 may have a link to cholesterol in cellular membranes. SFV requires choles-
terol at the site of membrane fusion [100], therefore if IFITM3 preferentially localises to
cholesterol-rich regions of cellular membranes, this may explain its potency for inhibiting
SFV, particularly at the plasma membrane were there are relatively low levels of IFITM3.
The suggested importance of cholesterol is supported by the fact that AmphoB, which
binds sterols, can disrupt IFITM3-mediated inhibition of SFV, and at high concentrations
can even disrupt SFV infection. In contrast, DENV has been suggested to not require
cholesterol for fusion [100]. Indeed, AmphoB treatment did not impact IFITM-mediated
inhibition of DENV, and high concentrations of the drug had no inhibitory affect. The
experiments of flaviviruses also suggest that 50 µM AmphoB did not cause cytotoxic af-
fects (which were again not observed by microscopy [data not shown]). Furthermore, since
A549 cells treated with 50 µM AmphoB could effectively produce viral protein (as used to
determine infection), this suggests that 50 µM AmphoB was not killing cells, and therefore
this was not the cause of lack of SFV infection (Fig. 4.19 [page 161]).
While AmphoB is suggested to alter SFV but not flavivirus infection of IFITM ex-
pressing cells through binding to cholesterol and disrupting IFITM function, an alter-
native explanation can be made. AmphoB treatment of cells may alter the entry path-
ways of viruses, which may allow certain viruses to enter at sites which do not have
inhibitory IFITM proteins, similarly to the proposed explanation for YFV 17D insensi-
tivity to IFITM3-Y20A. It may therefore be the case that SFV can enter cells through
an alternative pathway, which is insensitive to IFITM-mediated inhibition, following Am-
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phoB treatment. Comparatively, AmphoB treatment may not alter the route of flavivirus
entry, therefore maintaining IFITM sensitivity. Analysing the impacts AmphoB treatment
has on the entry pathways of these different viruses may aid in understanding how this
antiviral drug can modular IFITM antiviral function.
In the same manner that comparatively low levels of IFITM3 at the plasma membrane
inhibited SFV infection through fusion at this site, comparatively low levels of IFITM1 at
endosomal membranes appear to inhibit flavivirus infection. It can therefore be suggested
that IFITM1 may have enhanced potency towards inhibiting flaviviruses. While DENV
does not require cholesterol for fusion, there is a dependency on anionic lipids [52], perhaps
this has some impact on sensitivity towards IFITM1. As was discussed with regards to
SFV, the determinants of these apparent differences remain to be explored, but the use of
chimeric IFITM proteins with terminal domain swaps may be informative.
In summary, there are clear differences between the features of IFITM-mediated in-
hibition of alphaviruses and flaviviruses, which potentially suggests differences in the un-
derlying mechanisms of antiviral activity. Developing a better understanding of these
differences may help to further the understanding of IFITM-mediated antiviral activity
(as will be discussed in further detail in Chapter 6).
5.3 Comparison of alphavirus and poxvirus inhi-
bition by IFITM proteins
5.3.1 IFITM proteins do not inhibit vaccina virus infection
To further test IFITM-mediated inhibition of viral infection, VACV was tested for sensi-
tivity to IFITM-mediated inhibition in the stable A549 cells. Infection with VACV was
initially assessed by plaque assay across a range of MOI following 48 h infection with the
Western Reserve strain (mature virions; MVs - see Fig. 5.5 for example images). When
cells were infected with an input of 50 pfu/well (titred on BSC-40 cells), an average (n =
3) of 38 plaques were detected on A549 cells, with 34 on IFITM1 expressing cells (Fig.
5.6). This minimal difference suggested no IFITM1-mediated inhibition of VACV infec-
tion. IFITM2 expressing cells appeared to have an increased number of plaques, with
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Figure 5.5: Images of enlarged VACV plaques. A549 cells or IFITM expressing cells
were infected with Western Reserve strain of VACV (mature virions) for 48 h, in a 6 x
35 mm well plate format, prior to plaque assay using crystal violet staining. Images of
representative wells infected with 500 pfu/well VACV. The data in in Fig. 5.6 is from
infection with 50 pfu/well VACV, the images here are from the higher MOI to display a
larger number of example plaques.
an average of 56 plaques detected, perhaps suggesting some enhancement of infection in
IFITM2 expressing cells, although this difference was not statistically significant (Fig.
5.6). IFITM3 expressing cells had a decrease in the number of plaques, with an average
of 19 per well (Fig. 5.6), which was a statistically significant difference to the A549 con-
trol cells, but not compared to the other IFITM expressing cells. While there were fewer
plaques on the IFITM3 expressing cells, these were significantly larger than those seen on
A549 cells, with a ∼3.5 fold increase in the mean plaque area (see Fig. 5.6 A for measures
of plaque area and Fig. 5.5 for example plaques from 500 pfu/well input). It was therefore
unclear whether IFITM3 was in fact inhibiting VACV infection. When plaque areas were
measured a small, but significant, increase in plaque size was also detected in IFITM1
expressing cells (1.4 fold increase; Fig. 5.6 A and Fig. 5.5). Very little difference in plaque
size was detected between A549 cells and IFITM2 expressing cells (1.1 fold increase; Fig.
5.6 A and Fig. 5.5).
To further test whether there was any inhibition of VACV infection by IFITM proteins,
cells were infected with 1 pfu/cell, and virus production was analysed at 8, 16 and 24 h
(Fig. 5.7). During the VACV life cycle, two infectious forms of virus are produced, an
extracellular enveloped virion (EEV) and MVs. EEVs are produced in an infected cell and
wrapped in three lipid bilayers prior to transport to, and fusion with the plasma membrane.
A double membrane wrapped form of virus is then released into the extracellular space,
or transported to neighbouring cells along virus-induced actin tails (see [202] for review
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Figure 5.6: VACV plaques are enlarged in IFITM expressing cells. A549 cells
or IFITM expressing cells were infected with Western Reserve strain of VACV (mature
virions) for 48 h, in a 6 x 35 mm well plate format, prior to plaque assay using crystal
violet staining. A) Measurements of VACV plaque area were made using ImageJ. Data
presented are from three independent experiments. All plaques were measured from wells
infected with 50 pfu/well VACV. Total data - A549; n = 115, µ = 0.46 mm2, σ = 0.26
mm2. IFITM1; n = 103, µ = 0.63 mm2, σ = 0.44 mm2. IFITM2; n = 168, µ = 0.52
mm2, σ = 0.34 mm2. IFITM3; n = 56, µ = 1.60 mm2, σ = 1.21 mm2. See Fig. 5.5
for images of plaques. Significance tests relate to the difference in plaque areas between
A549 and IFITM expressing cells. *** p < 0.001, **** p < 0.0001. B) Graph displaying
the average number of plaques for each cell line (infected with 50 pfu/well VACV) across
the three independent experiments (error bars display standard deviation). This data are
taken from A and the graph used to more clearly display the average number of plaques
per well. Significance tests relate to difference in mean plaque counts between experiments
as assessed by unpaired student’s t-tests (* p < 0.05). For all other comparisons there
were no statistically significant differences.
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of VACV replication cycle). EEVs start to be released from cells around 6 - 8 h post
infection. In contrast, MVs are retained in the cytosol of infected cells until these lyse,
around 72 h post infection. Production of both forms of virus was analysed. To assess
EEV production, media were collected from infected cells at each time point. For analysis
of MV production, cells were collected from plates at each time point, by scraping, and
lysed by three rounds of freeze-thawing (-80℃ to 37℃). Each form of collected virus was
then titred on BSC-40 cells. These data suggested that IFITM1 may have a minor affect
on VACV production, resulting in close to half a log drop in virus titre at each collection
time. IFITM2 and IFITM3 showed only minor differences in virus titre compared to the
A549 control cells (Fig. 5.7). Importantly, at 8 h there were only minor differences between
A549 controls and IFITM3 expressing cells, suggesting there was no inhibition of a single
round infection. Therefore, even though there were fewer plaques on IFITM3 expressing
cells (Fig. 5.6), IFITM3 expression does not inhibit VACV production, suggesting there is
no inhibition of infection. While IFITM2 expressing cells appeared to have more plaques
than A549 cells (Fig. 5.6), there was no clear change to virus production, suggesting
IFITM2 is not enhancing VACV infection. Finally, while IFITM1 expression appeared to
result in a small drop in VACV production at each of the three time points, there was no
clear difference in plaque number (Fig. 5.6), suggesting that IFITM1 has limited, if any,
inhibitory activity against VACV.
5.3.2 IFITM3 enhances cell motility in the absence of VACV
infection
It appeared that IFITM proteins did not inhibit VACV infection, based on production
of infectious virus, however this left the question of why enlarged plaques were detected
on IFITM expressing cells. To investigate the cause of the increased plaque size, a re-
combinant VACV expressing EGFP from an early/late fusion promoter was used because
the spread of EGFP can be used to analyse spread of virus in the monolayer. Cells were
infected for 24 or 48 h and EGFP was analysed by immunofluorescence microscopy (Fig.
5.8 A). IFITM3 and IFITM1 expressing cells showed a larger EGFP area than A549 cells,
while IFITM2 showed no clear difference (and if any difference, there may have been a
minor decrease; Fig. 5.8 B). It appeared that as the EGFP infection zone increased in size,
Chapter 5 187
Comparing IFITM-mediated alphavirus restriction with other viral families
Figure 5.7: IFITM expression does not alter VACV production. A549 or IFITM
expressing cells were infected with 1 pfu/cell VACV Western Reserve strain (mature virions
[MVs]). Media were collected at 8, 16 or 24 h post infection to analyse extracellular
envelope virion production (EEV). At the same time points, cells were collected from
plates by scraping and lysed by three rounds of freeze-thawing (-80℃ to 37℃) to collect
progeny MVs. The titre of the collected virus was determined on BSC-40 cells by plaque
assay after 48 h infection. A) MV production from 8 and 16 h infections (i) and 24 h
infections (ii). B) EEV production from 8 and 16 h infections (i) and 24 h infections (ii).
All data presented is the mean average titre (log pfu/ml) from 3 independent infections
with the standard deviation given as error bars.
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so too did the clearance zone at the centre of the plaque (Fig. 5.8 A). Nuclei bunching
at the edge of large plaques was also observed (most clear for IFITM3 expressing cells
[Fig. 5.8 A]). Both of these features of the plaques suggested that there may be enhanced
motility in IFITM3 and IFITM1 expressing cells.
To test whether IFITM expressing cells were indeed more motile, a scratch assay was
performed in the absence of VACV infection. Cells were plated on glass coverslips to form
a monolayer and a scratch was made through this with a P200 tip. Migration of cells
into this wound was then monitored over a 36 h period (imaging at 24 and 36 h after the
scratch). The results showed that IFITM3 expressing cells closed the wound more rapidly
than A549 expressing cells (Fig. 5.9). IFITM1 expressing cells also appeared to have
enhanced motility, though little difference between A549 and IFITM2 expressing cells was
detected (Fig. 5.9). The migration of cells into the scratch matched with the cells that
produced the largest plaques; IFITM3 expressing cells had the highest motility and largest
plaques, followed by IFITM1 expressing cells, and IFITM2 expressing cells showed little
difference to A549 controls (Fig. 5.9 and Fig. 5.6).
An important caveat to the apparent increase in cell motility should be noted. These
results were generated using the OS-IFITM cell lines which were produced by clonal se-
lection. It is therefore possible that the increased cell motility is as a result of the clonal
nature of the stable cell line production, rather than as a consequence of IFITM3 (or
IFITM1) expression. In an attempt to test this, similar scratch assays were performed in
P1-IFITM3 cells. As seen in Fig. 5.10, the P1-IFITM3 cells did not show enhanced motil-
ity, as observed for OS-IFITM3 cells. The motility of OS-IFITM3 cells could therefore be
a consequence of clonal selection. However, it should also be noted that the OS-IFITM3
expressing cells have higher expression of IFITM3 (Fig. 4.2 [page 138]), so it could be the
case that high IFITM3 expression is necessary for increasing cell motility.
Overall, it appears that IFITM3, and to a lesser extent, IFITM1 highly expressing
cells have enhanced motility, which is made evident by VACV infection. Although it
cannot be ruled out that there could be affects from the clonal nature of the OS-IFITM
cells. However, it does appear that IFITM proteins, do not inhibit VACV infection, unlike
results with alphaviruses and flaviviruses which were IFITM-sensitive.
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Figure 5.8: Enlarged VACV plaques associated with enhanced cell motility. A549
or IFITM expressing cells were infected with VACV Western Reserve strain (50 pfu/well),
engineered to express EGFP from an early/late (E/L) fusion promoter. At 24 or 48 h post
infection cells were fixed, permeabilised and immunofluorescence stained with anti-GFP
antibody (detected with AF488) to boost signal, and Hoechst to detect nuclei. Plaques
were then imaged using an epifluorescence microscope. Representative images from 24 (A)
and 48 h (B) infection. C) GFP infection zone size was measured using ImageJ. The mean
values were calculated and set relative to A549 control cells at each time point. Data are
form a single experiment.
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Figure 5.9: Scratch assays show enhanced cell motility in IFITM3 and IFITM1
expressing cells. A549 or IFITM expressing cells were plated to glass coverslips in
LabTech chambers and grown to form a confluent monolayer. Cells were then imaged,
scratched with a P200 tip and imaged again. Cells were incubated under normal culture
conditions for 36 h, taking images at 24 h and 36 h to monitor closure of the wound.
Representative images are displayed from n = 3 experiments, 5 wells each for A549 and
IFITM3, and n = 2 experiments, 2 wells each for IFITM1 and IFITM2 (all images are
from the same experiment).
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Figure 5.10: Comparison of OS- and P1-IFITM3 cell motility. A549 or IFITM3
expressing cells were plated to glass coverslips in LabTech chambers and grown to form
a confluent monolayer. Cells were then imaged, scratched with a P200 tip and imaged
again. Cells were incubated under normal culture conditions for 24 h and imaged again.
Representative images are displayed from n = 2 wells for each cell line.
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5.3.3 Discussion
Very few viruses have been shown to be insensitive to IFITM-mediated inhibition, com-
pared to those that have. To date, only areanaviruses, a retrovirus (murine leukaemia
virus), papillomaviruses, cytomegalovirus and adenoviruses have been shown to be insen-
sitive (see Table 1.3 [page 48]). The papillomaviruses and adenoviruses are non-enveloped,
and therefore do not use membrane fusion to enter cells, perhaps explaining their insen-
sitivity to IFITM-mediated inhibition. Why other enveloped viruses are not inhibited
remains to be fully explored. Here, data is presented suggesting that VACV, an enveloped
virus, which enters cells by fusion with internal membranes following macropinocytic up-
take from the cell surface, is not inhibit by IFITM expression. However, the studies of
VACV demonstrated that OS-IFITM1 and IFITM3 expressing cells have enlarged VACV
plaques. A potential explanation for enlarged plaques (that has not been investigated in
this work) may be that IFITM proteins interfere with spread of VACV through a mono-
layer, to restrict infection to neighbouring cells. Alternatively, being that VACV activates
cell motility upon infection, for instance through an interaction of the viral F11L protein
with RhoA [203], the enlarged plaques may be explained by an increase to cell motil-
ity. Indeed, VACV-induced motility led to the observation that OS-IFITM1 and IFITM3
expressing were more motile compared A549 control cells even in the absence of VACV
infection. It cannot be ruled out that this increased motility is a consequence of the clonal
selection of these cells. However, IFITM proteins have been linked to an increase in inva-
siveness and metastatic potential of cancer cells (reviewed in [204], see also [205–207]). It
could therefore be the case that at the higher levels of IFITM3 expression, there may be
disruption of normal cellular function which has the knock-on affect of enhancing cellular
motility, however the precise mechanism(s) underlying this effect have not been explored.
5.4 Conclusions and Discussion
In summary of the work presented in this chapter, it appears that not all viruses that enter
cells by endocytosis and pH-dependent fusion with endosomal membranes are equally sen-
sitive to IFITM-mediated inhibition. In contrast to the alphaviruses, which were inhibited
by IFITM3 and IFITM2, DENV and ZIKV appeared to be sensitive to all IFITM pro-
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teins. YFV 17D appeared to be sensitive to IFITM1, 2 and 3, but IFITM3-Y20A had little
affect. These differences further suggest that protein localisation may not be a key deter-
minant of IFITM restriction of viral infection. Additionally, IFITM-mediated inhibition
of flaviviruses is insensitive to treatment with AmphoB, unlike the alphaviruses and IAV
[156], but similarly to EBOV [142]. These differences perhaps point towards mechanistic
differences within the IFITM proteins in the modes of antiviral function. Furthermore,
it has been shown that VACV is not inhibited by IFITM proteins, further supporting
previously published data that the IFITM proteins do not inhibit all viruses. While there
was no inhibition of VACV, the data suggested a possible role of high IFITM expression in
enhancing cell motility, perhaps point towards consequences of sustained high expression.
The IFITM proteins have been linked to cancer invasiveness and metastatic potential, in
agreement with a potential role in promoting cell motility, perhaps suggesting why the
proteins need to be IFN-inducible.
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The work presented in this thesis has helped to develop an understanding of IFITM protein
membrane topology, better define the localisation of the IFITM proteins in A549 cells, and
defined how IFITM3 can inhibit SFV infection. The data have also suggested that there
are potential differences in the potency of IFITM isoforms towards different viruses, and
that the mechanisms of antiviral activity may vary. Furthermore, a suggestion was made
that high IFITM expression may enhance cell motility, so could have negative consequences
outside of an in vitro scenario.
6.1 Topology and Localisation
The membrane topology of the IFITM proteins had been a contentious issue at the com-
mencement of this work, with two models being debated. Before the IFITM proteins
were studied for antiviral function, they were suggested to have roles in embryonic de-
velopment, germ cell migration, and proliferation of immune cells [114–116]. These early
studies pointed towards extracellular regions of IFITM proteins based on the ability of
antibodies to bind, and proposed interactions between IFITMs on different cells, although
no thorough analysis was undertaken. The IFITM proteins were initially suggested to have
a dual-pass transmembrane topology with both the N- and C-terminal domains (NTD and
CTD) exposed extracellularly/lumenally (see Fig. 3.1 [page 96], Model 1). When Brass et
al. later identified the IFITM proteins as having antiviral function, their work suggested
a similar structure based on the extracellular availability of a CTD HA-tag, and the NTD
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to antibodies for FACS labelling [7]. However, this work was limited in the controls used
and left questions about the topology.
Subsequent studies suggested there were post-translational modification to the IFITM3
NTD, leading to the suggestion of an intramembrane topology model (see Fig. 3.1 [page
96], Model 2). A tyrosine residue in the IFITM3 NTD (Y20) was shown to be phospho-
rylated by Fyn kinase, which resides on the cytosolic leaflet of cell membranes [163]. The
Y20 residue was later shown to be part of a functional Yxxφ sorting motif (where Y is
tyrosine, x is any amino acid and φ is a hydrophobic residue), which could interact with
AP-2 [143]. Similarly, IFITM3 can be ubiquitinated at any of four lysine resides [151]; one
of which (K24) resides in the NTD, while the others reside in the conserved intracellular
loop (CIL; K83, 88, 104). Since all known ubiquitinases are cytosolic, this further argued
for an intracellular NTD. Indeed, it was later demonstrated that the cytoslic E3 ubiqui-
tin ligase NEDD4 could interact with the IFITM3 NTD PPxY motif (17-PPNY-20) to
regulate ubiquitination [160].
While published data strongly supported a cytosolic NTD, the data for the CTD was
weaker, relying largely on engineered constructs. Murine Ifitm3 altered to have a CTD
NxT motif (H136T mutation) was not detected as being glycosylated in the ER. Another
Ifitm3 construct demonstrated prenylation of an engineered CTD CLVL motif [151]. The
results from both of these mutant proteins were used to first suggest the cytosolic CTD.
Additionally, murine Ifitm1 was later shown to have a non-conserved CTD cysteine that
could be palmitoylated [155]. With debate over the two models, the initial investigations
of the work presented here were designed to define the topology of human IFITM proteins
in A549 cells.
Through the course of the work presented in Chapter 3, a third membrane topology
model was produced. The work largely focused on IFITM1 as this protein is localised at
the plasma membrane and is therefore amenable to many experimental approaches to in-
vestigate topology. The data presented suggested that IFITM1 has a membrane topology
in which the NTD resides in the cytoplasm, while the CTD resides in the extracellu-
lar/lumenal space. IFITM2 and IFITM3 are found within internal membrane compart-
ments, and are therefore less amenable to topological analysis than IFITM1. However, im-
munofluorescence staining and antibody feeding experiments (Fig. 3.2 [page 97], 3.4 [page
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102], 3.3 [page 100] and 3.12 [page 117]) suggested that, at least in some cells, IFITM2 and
IFITM3 have extracellularly available CTDs. This led to the hypothesis that the CTD
HA-tags may be lost in the acidic/proteolytic environment of endosomal compartments,
which was indeed found to be the case (Fig. 3.13 [page 120] and 3.14 [page 121]), further
supporting the notion of a lumenal CTD. Finally, making use of the plasma membrane
localised IFITM3-Y20A mutant, data was generated demonstrating that IFITM3 topology
matches that of IFITM1 (Fig. 3.16 [page 124]). In sum, the data presented in Chapter 3
suggest that all three human IFN-inducible IFITM proteins have a type II transmembrane
topology. This model has been supported by others who have shown murine Ifitm3 [153]
and human IFITM3 [192] to have the same topological structure.
It appears that the cytosolic localisation of the NTD of IFITM proteins is functionally
important. IFITM2 and IFITM3 have Yxxφ sorting motifs that have been shown to
interact with AP-2 and regulate the endosomal localisation of the proteins [143, 163, 169].
The disruption of this motif by Y20A mutation, or deletion of the first 21 amino acids
of the IFITM3 NTD, causes accumulation of the protein at the plasma membrane and
a reduced antiviral activity against IAV, HIV-1 and SFV ([16, 143, 158, 163, 174], and
work presented in this thesis). Mutations of IFITM2-Y19F and IFITM3-Y20F have also
been found to alter localisation and antiviral activity against different strains of HIV-1
[169]. The cytosolic NTD and ability to interact with AP-2 therefore appears essential for
antiviral activity, at least in some cases. The Y20 residue of IFITM3 has additionally been
proposed to be a site of phosphorylation by Fyn kinase, which seems to regulate IFITM3
membrane trafficking [158, 163].
In addition to phosphorylation of the NTD, K24 has been shown to be a ubiquitinated
and play a role in turnover of IFITM3 [151]. K24 is also a site of K63-linked polyubiq-
uitination, suggesting additional roles besides protein turnover [151]. The 17-PPxY-20
motif in the IFITM3 NTD determines the interaction between IFITM3 and the E3 ubiq-
uitin ligase NEDD4 [160]. What interplay there may be between phosphorylation of Y20
and NEDD4 interaction with IFITM3 at the 17-PPxY-20 motif remains to be explored.
Interestingly, loss of ubiquitination by mutation of IFITM3 lysine resides to alanine or
loss of interaction with NEDD4 (through mutation to IFITM3 or knockdown/knockout
of NEDD4) was seen to reduce IFITM3 turnover and enhance IFITM3 antiviral activity
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against IAV [151, 160]. It will be interesting to investigate whether the phosphorylation
status of Y20 can impact NEDD4 interaction with IFITM3, and whether this is modulated
during an infection. Seeing that reduced turnover, and subsequent protein accumulation,
enhances IFITM3 antiviral function is in agreement with data presented here suggesting
that higher levels of IFITM3 have greater antiviral activity against SFV (Section 4.2.2
[page 136]). The enhanced antiviral function of IFITM3 in the context of NEDD4 knock-
down led to the suggestion that pharmacological inhibition NEDD4 may have therapeutic
value. However, high IFITM3 levels may cause an increase in cell motility, as implied
by the data here (Fig. 5.9 [page 191]), meaning such intervention may have side affects.
Overall, it appears that an intracellular NTD is important for regulating IFITM cellular
distribution, protein turnover, and potentially other facets of their cell biology.
While the cytosolic NTD appears to regulate IFITM function, the consequences of
other aspects of the proposed membrane topology are less clear. In the suggested model,
the first membrane domain enters into, but does not cross lipid bilayers, perhaps resulting
in alterations to membrane curvature which could influence membrane fusion events. Func-
tionally important residues have been found within the highly conserved CD225 domain,
which spans the first membrane domain and CIL [154]. For instance, two phenylalanine
residues (F75 and F78 found in the first membrane domain of IFITM3) were suggested to
be important for IFITM protein-protein interaction; mutation of both residues to alanine
(F75A/F78A) resulted in a loss of IFITM3-mediated inhibition of IAV infection [154].
Perhaps this intramembrane structure is important interaction of IFITM proteins and
antiviral function.
The work of John et al. [154] also had the interesting result that a chimeric protein with
the IFITM3 NTD and all other parts of IFITM1 did not confer anti-IAV function, even
though the localisation of the chimeric protein was on internal membranes, rather than the
plasma membrane (i.e. localisation to endosomal membranes was not sufficient to inhibit
IAV; [154]). The CD225 domain is very highly conserved, suggesting the determinants
of the lack of anti-IAV function for the chimeric protein are in the second membrane
domain and/or the CTD. These results suggest functional importance for these regions of
IFITM proteins. Additionally, it has been proposed that IFITMs can interact with vesicle-
associated membrane protein-associated protein A (VAPA) through the second membrane
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spanning domain [152], the transmembrane structure of this domain could be important
for that interaction.
The CTD has been suggested to be important for control of coronavirus (CoV) infec-
tion. IFITM2 and IFITM3 were found to enhance CoV-OC43 infection, while IFITM1
did not. Chimeras with altered CTDs changed these phenotypes, and it was suggested
that the shorter length of the IFITM2 and IFITM3 CTDs, compared to IFITM1, were
responsible [140]. However, the precise functional role of the CTDs for modulating CoV
infection remains unclear. It is also unclear why CoV-OC43 is enhanced by IFITM2 and
IFITM3, while SARS-CoV [139, 140] and many other viruses are restricted (Tables 1.1
[page 46] and 1.2 [page 47]). Finally, it has been suggested that there is a di-basic sorting
motif (122-KRXX-125) in the IFITM1 CTD that can interact with AP-3 [159] and that
the CTD can alter IFITM1 localisation and restriction of HIV-1 [185]. An AP-3 inter-
action seems at odds with an extracellular/lumenal orientation of the CTD, and even in
that work evidence was found for such a topology [159]. It is therefore unclear what role
such an interaction may play. Overall, how the extracellular/lumenal orientation of the
CTD can modulate IFITM cell biology remains to be established.
While defining the type II transmembrane topology for the IFITM proteins, it became
clear that analysing protein distribution within cells using a C-terminal HA-tag may be
flawed. The HA-epitope can be lost from the C-terminus, particularly of IFITM2 and
IFITM3, meaning functional pools of protein may potentially be missed when basing
analysis on such a tag. Therefore a thorough investigation of the IFITM2 and IFITM3
cellular distribution was performed by co-staining cells for the NTD and makers of early,
recycling and late endosomes as well as lysosomes (Fig. 3.17 [page 127]). These data
suggested that IFITM3 is more closely associated with markers of early and recycling
endosomes than IFITM2, while IFITM2 is more closely associated with markers of late
endosomes and lysosomes.
When analysing IFITM3 protein distribution at an EM level (Fig. 3.7 [page 105]), it
appeared that most of the HA labelling was on the intra-lumenal vesicles (ILVs) of multi-
vesicular bodies (MVBs). This EM analysis used the HA-tag because the NTD antibodies
only gave weak labelling (data not shown), therefore pools of protein were potentially
missed, or tag no longer attached to the IFITM protein may have been observed. Nev-
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ertheless, it remains intriguing that the majority of IFITM3 was found in MVBs with
many ILVs, as these are typically considered to be late endosomal, staining positively for
markers such as CD63, rather than EEA1 and TfR. Therefore, there appears to be some
discrepancy between the immunofluorescence and EM localisation analysis. It could be
hypothesised that IFITM3 expression may have an impact on the normal trafficking of
proteins used as markers such as EEA1 and TfR. It has been suggested that IFITM3
expression results in enlarged and more acidic endosomal compartments [12, 137, 208],
perhaps further supporting the notion that this protein can disrupt normal trafficking
events. As discussed, IFITM3 is ubiquitinated by NEDD4, and ubiquitination of mem-
brane proteins has been shown to direct their trafficking into ILVs [43]. Whether having
a high concentration of ubiquitinated IFITM3 can influence the formation of MVBs and
what affect this may have on inhibition of incoming viruses could be an interesting sub-
ject for future research. It is also tempting to speculate that if IFITM3 is disrupting the
endosomal system, this may have negative consequences for the normal functioning of the
cell, perhaps being linked to the apparent increased motility of cells expressing high levels
of IFITM3.
6.2 Antiviral action
The data presented in Chapter 4 demonstrated for the first time that IFITM3 could inhibit
alphavirus infection (SFV and SINV) by blocking release of the capsid into the cytosol.
Shortly after we published this [16], additional research was published demonstrating that
IFITM3 could inhibit infection from SFV, SINV, chikungunya (CHIKV), O’nyong nyong
and Venezuelan equine encephalitis (VEEV) viruses [184]. This second study also demon-
strated relevance of this antiviral function in vivo, with IFITM3 appearing to be important
for control of CHIKV and VEEV infections in mice [184]. The two studies complement one
another and suggest that IFITM proteins, in particular IFITM3, can inhibit alphavirus
infection of cells and are important to control pathogenesis of infections in mice. It has
been suggested that a single nucleotide polymorphism (SNP) in IFITM3 (rs12252-C) is as-
sociated with severe IAV infection [174, 177, 179, 180]. It will be interesting to investigate
whether there is any genetic link between the severity of alphavirus infection in humans
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and IFITM3 SNPs.
The antiviral function of IFITM proteins has been most highly characterised using
IAV. Studies have shown that IFITM3 expression blocks nuclear translocation of the viral
ribonuclear proteins, causing them to accumulate in endosomes [12]. It therefore appears
that IFITM3 is capable of blocking fusion of IAV with cellular membranes, however,
there is debate over whether this occurs before hemifusion [13] or after establishment of
hemifusion but before resolution to a fusion pore [14]. Much of the other published data on
IFITM restriction of virus infection has used pseudotyped viruses (see Tables 1.1 and 1.2)
to argue that IFITM proteins are inhibiting the glycoprotein-mediated fusion reaction,
though these studies rarely investigate earlier events in the virus entry pathway. From
the data presented here, it appears that IFITM3 inhibits alphavirus infection by blocking
fusion between viral and cellular membranes, as proposed for other viruses. While SFV
could be internalised to acidic cellular compartments in IFITM3 expressing cells, and the
E1 glycoprotein could undergo conformational changes, the capsid was not released into
the cytosol. It has been suggested that the formation of the E1 homotrimer (HT) is
dependent on the presence of membrane [194], and a relatively small proportion of E1 was
found in the HT form in our experiments (Fig. 4.12 [page 152), perhaps supporting the
notion of membrane interaction being necessary for the stabilisation of the HT. The E1
HT could form in IFITM3 expressing cells, leading to the suggestion that IFITM3 may not
be blocking interaction of E1 with endosomal membranes. However, even though the E1
HT could form, and potentially interact with membrane, the capsid was not released into
the cytosol, suggesting an inhibition of membrane fusion imposed by IFITM3; similarly
to the IFITM3 function characterised for anti-IAV activity. There are further similarities
between the inhibition of IAV and SFV in that treating cells with AmphoB diminishes the
antiviral activity of IFITM3 against both viruses ([156], Fig. 4.15 [page 157], Fig. 4.16
[page 158] and Fig. 4.20 [page 163]). These similarities may suggest similar underlying
mechanisms of orthomyxovirus and alphavirus inhibition. SFV may therefore provide
a powerful tool to better establish whether IFITM3 inhibits hemifusion formation, or
resolution of hemifusion intermediates.
It was noted that increasing the amount of input virus reduced the level of IFITM-
mediated inhibition of both SFV and SINV (Fig. 4.1 [page 135]), suggesting that high
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levels of virus can saturate the antiviral action of IFITM proteins. The converse was also
the case, such that cells with lower IFITM expression were less restrictive of SFV infection
(Fig. 4.2 [page 138]). If there is a need for direct interaction between IFITM protein and
the sites of SFV fusion, this may explain the saturability. With a higher level of input
virus there will be more fusion events and therefore a greater chance of successful fusion.
Conversely, with lower IFITM protein expression there is potentially a reduced likelihood
of IFITM protein being at sites of fusion. Developing an understanding of whether, and
how, IFITM proteins localise to sites of virus binding and fusion may help to develop a
better understanding of the mechanism(s) of antiviral activity.
While IFITM3 could inhibit SFV infection through the endocytic route, IFITM1 could
not, in contrast to many other viruses tested (Tables 1.1 and 1.2). The hypothesis was that
because IFITM1 is localised at the plasma membrane, internalisation and fusion of SFV
in early endosomes means low levels of IFITM1 at sites of fusion. In agreement, plasma
membrane localised IFITM3-Y20A similarly failed to inhibit SFV infection through the
endocytic route. Comparatively, IFITM3 is localised to early endosomal compartments,
and therefore presumably present at high concentration where viral fusion occurs (virus
and IFITM3 were indeed found to co-localise; Fig. 4.5 [page 143]). This initial hypothesis
was challenged by the results of plasma membrane fusion experiments (Fig. 4.21 [page
168]) that suggested there may be additional complexity. IFITM3 has relatively low
abundance in the plasma membrane, yet it was able to inhibit SFV infection by fusion
at the cell surface to a similar or greater extent than IFITM1. These results argue that
IFITM3 may have intrinsically higher potency for inhibiting SFV infection than IFITM1.
IFITM3-Y20A also appeared to have greater anti-SFV action than IFITM1 when virus
was fused at the cell surface.
It is speculated that the increased potency of IFITM3 for inhibiting SFV may be as
a consequence of its interaction with cholesterol. SFV requires cholesterol at the site
of membrane fusion [100], therefore if IFITM3 preferentially clusters to cholesterol-rich
regions of cell membranes this may explain how relatively low levels of protein can inhibit
viral fusion at the plasma membrane. The converse argument would be that while IFITM1
is at high abundance at the plasma membrane, if it does not associate with cholesterol-rich
regions of membrane there may be lower likelihood of being at the site of SFV fusion. It
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could be speculated that IFITM1 preferentially localises to other regions of cell membranes,
which could influence its antiviral function (as discussed below with regards to flaviviruses).
That cholesterol may play a role is supported by the fact that AmphoB treatment can
disrupt IFITM3-mediated inhibition of SFV. Perhaps AmphoB binding to cholesterol is
capable of disrupting IFITM3 association with the lipid, without interfering with the
SFV E1-mediated fusion reaction (at least at lower concentrations; Fig. 4.18 [page 161]).
However, as discussed in Chapter 4, an alternative explanation for the inhibition of SFV
infection through plasma membrane fusion may be that Baf A treatment could be causing
accumulation of IFITM3 at the plasma membrane, which remains to be examined.
It seems likely that there would be some uptake of IFITM3-Y20A from the plasma
membrane to endosomal compartments, even without the functional Yxxφ motif. This
raises the question of why low levels of IFITM3-Y20A didn’t inhibit SFV through the
endocytic route, in the same way IFITM3 could inhibit plasma membrane fusion. It is
possible that the concentration of IFITM3-Y20A at internal sites is too low to see any anti-
SFV activity. Alternatively, since IFITM3-Y20A lacks interaction with AP-2, perhaps the
internal pools are within different endosomal sub-populations, and therefore not present
at the sites of SFV fusion (as may also be true for IFITM1).
While IFITM1 was unable to inhibit the SFV endocytic route of infection, it was
capable of inhibiting infection by the flaviviruses DENV, ZIKV and YFV 17D. Flaviviruses
are very similar to alphaviruses in that both rely on clathrin-mediated endocytosis (CME)
and pH-dependent activation of type II fusion machinery for entry into cells [198, 199, 201].
There have been suggestions of DENV using alternate routes of entry, but in A549 cells
it appears the virus uses CME and pH-dependent fusion [200]. However, while the entry
pathways are very similar, there are clear differences in sensitivity to IFITM proteins.
How IFITM1, a protein predominantly localised at the plasma membrane, is able to block
the entry of viruses which fuse in the endosomal system remains unclear. As detected by
EM, there are pools of IFITM1 within endosomal compartments (Fig. 3.5 [page 103]).
However, since the expression level of IFITM proteins appears to influence their antiviral
activity (Section 4.2.2), it seems unlikely that this low level of protein would be responsible
for the observed inhibition. Unlike SFV, IFITM-mediated inhibition of flaviviruses was not
altered by treatment with AmphoB (Fig. 5.1 [page 177], 5.2 [page 179] and 5.3 [page 180]),
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and high concentrations of AmphoB had no impact on DENV infection (Fig. 5.4 [page
182). In agreement, previous studies have suggested that nystatin, a similar cholesterol
binding compound, does not inhibit DENV infection of A549 cells [200] and that DENV
does not require cholesterol for fusion [100]. It is therefore tempting to speculate that
while IFITM3 appears to have enhanced potency towards SFV, potentially through the
viral dependency on cholesterol, IFITM1 may have similarly lipid-based enhanced potency
against flaviviruses. DENV has been shown to require anionic lipids for fusion [52], perhaps
this plays a role in determining sensitivity to IFITM1.
Understanding whether there are indeed differences in the way IFITM proteins interact
with membrane lipids, and what the determining features of these differences are will be
an interesting source of future study. The CD225 domain of IFITM proteins is very highly
conserved between all isoforms, and it is therefore speculated that that any IFITM protein
determinants of these differences would reside in the NTD, CTD or second membrane
interacting domain. Having developed the alphavirus and flavivirus systems in this work,
there is now a platform to investigate these aspects of IFITM function, for instance,
through the use of chimeric IFITM proteins.
As discussed in Chapter 1, relatively few viruses have been assessed for sensitivity
towards IFITM proteins in vivo, compared to the work performed in vitro. However,
a flavivirus, West Nile virus (WNV), has been examined. The work of Gorman et al.
demonstrated that mice lacking Ifitm3 expression (Ifitm3 -/-) were more vulnerable to
lethal WNV infection; implicating Ifitm3 in regulation of WNV pathogenesis [183]. This
would be in keeping with results presented here showing that IFITM3 can inhibit the three
flaviviruses in this work. It would be interesting to see if Ifitm1 -/- mice similarity suffer
a more severe WNV infection, or whether Ifitm -/- have exacerbated severity to Ifitim3
-/- mice, to determine whether Ifitm1 plays roles for control of flavivirus infection in vivo,
as suggested by the in vitro data here.
While the results with AmphoB potentially provide interesting insight into different
underlying mechanism(s) of IFITM-mediated antiviral function, a caveat needed to be
examined. It could have been the case that AmphoB treatment directly impacted the
virus particle, either instead of, or potentially in addition to influencing IFITM activity.
SFV has been shown to require cholesterol at sites of budding, and has cholesterol in the
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host-derived lipid envelope [110]. It could therefore be the case that AmphoB is binding
to SFV and altering the properties of the viral envelope, to make the virus more infectious
in the presence of IFITM3 (although not of control A549 cells). This possibility was
examined in Fig. 4.20 (page 163). In those experiments, treatment of IFITM3 expressing
cells with 1 µM AmphoB for 10 min, prior to dilution to 1 nM for infection with SFV
showed enhanced infection. Treating cells with 1 nM AmphoB alone had no impact on
SFV infection of IFITM3 expressing cells, suggesting that the 10 min incubation with 1
µM AmphoB was enough to reduce IFITM3 anti-SFV activity. Conversely, treating SFV
particles with 1 µM AmphoB for 10 min, then diluting to 1 nM for infecting cells did
not boost SFV infection of IFITM3 expressing cells, arguing that AmphoB is not directly
impacting the infectivity of SFV particles.
It is currently unclear why IFITM3-Y20A can inhibit DENV and ZIKV, but not YFV
17D infection. All three viruses fuse within endosomes, and are sensitive to IFITM3. There
are high levels of IFITM3 in endosomes, perhaps explaining why this protein can inhibit
all three viruses. As suggested above, the inhibition of flaviviruses by IFITM1 could be as
a consequence of enhanced potency of IFITM1, so that even low levels of protein in endo-
somes can inhibit infection. However, the variable sensitivity of DENV/ZIKV and YFV
17D towards IFITM3-Y20A is puzzling. The 17D strain of YFV, as used here, has been
shown to enter HeLa cells through a clathrin-independent, dynamin-dependent, caveolae-
independent pathway [197], unlike DENV and wild-type YFV, which are internalised by
CME [197–201]. It is therefore possible that these different routes of internalisation into a
cell may alter sensitivity towards IFITM proteins; it would be an interesting experiment
to determine whether wild-type YFV is sensitive to IFITM3-Y20A-mediated inhibition.
Why the different IFITM isoforms may have impacts on different endocytic pathways
remains to be explored.
While IFITM proteins could inhibit alphaviruses and flaviviruses, to varying extents,
the results in Chapter 5 further extended published data that not all viruses which enter
cells through endocytosis and pH-dependent fusion in endosomal compartments are inhib-
ited by IFITM proteins (Table 1.3). The prototypical poxvirus VACV (Western Reserve
strain mature virions) was not inhibited by any of the IFITMs tested in this study. Similar
results have also been found in an RNAi screen for host factor influencing VACV replication
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[195]. VACV has been suggested to enter cells by fusion directly at the plasma membrane
[209], as well as through a pH-dependent mechanism [210] following macropinocytic up-
take from the cell surface [211]. The ability of VACV to enter cells through two routes
may influence the lack of IFITM-mediated inhibition. Alternatively, the membrane fusion
mechanism used by VACV may be insensitive to the affects of IFITM proteins.
Relatively few viruses have been shown to be insensitive to IFITM-mediated inhibition,
but one family consistently shown to have such a property are the arenaviruses. It has
been suggested that arenaviruses enter cells through macropinocytic mechanisms [58, 212],
similarly to VACV. It could therefore be speculated that viruses entering cells through
this route may be refractory to IFITM-mediated inhibition, perhaps as a consequence of
trafficking to different endosomal sub-populations. However, EBOV, which has also been
shown to use macropinocytosis to internalise to cells [213, 214], is inhibited by IFITM
proteins [139]. Therefore, why VACV and arenaviruses are refractory to IFITM-mediated
inhibition remains unclear.
While VACV was insensitive to IFITM-mediated inhibition, an interesting phenotype
was noticed in that VACV infection of IFITM expressing cells resulted in an enlarged
plaque phenotype (Fig. 5.6 [page 186]). Upon infection of cells, VACV activates signalling
pathways leading to cell motility (for instance [203]). However, the work presented in
Fig. 5.9 (page 191) suggested that IFITM expressing cells are already intrinsically more
motile than the non-expressing A549 controls. This increased motility likely accounts for
the enlarged plaque phenotype, rather than IFITM proteins having a direct affect on the
VACV-induced signalling. An enhancement of cell motility as a result of IFITM expression
is interesting as IFITM proteins have been linked to cancer in numerous studies, although
there is no clear consensus on the role they play; much of this work is reviewed in [204].
Additionally to the work cited in [204], IFITM proteins have been implicated in enhanced
migration of gliomal cells [205, 206] and the progression and invasiveness of breast cancer
[207]. It is currently unclear how IFITM protein expression enhances cell motility and,
as discussed in Chapter 5, further work is required to confirm the phenotype. However,
there could be interesting links between high levels of IFITM protein expression and a
disruption to normal cell physiology which may be worth exploring.
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6.3 Concluding Remarks
Through the work presented here a more detailed understanding of IFITM cell biology
and antiviral activity has been generated. Clarity has been drawn over the membrane
topology of the human IFN-inducible IFITM proteins and with this knowledge, a more
detailed understanding of the cellular distribution of IFITM proteins, in A549 cells, has
emerged. IFITM3 has been shown to inhibit alphavirus infection. A detailed analysis of
the inhibition mechanism demonstrated that SFV is internalised by cells and delivered to
acidic compartments, to activate the E1 fusion protein, but capsid release into the cytosol
is prevented. The interpretation is that IFITM3 blocks fusion between SFV and cellular
membranes. This mechanism of inhibition is the same as is proposed for inhibition of IAV
and has the similar property of being modulated by AmphoB treatment. Studies with SFV,
and flaviviruses, have provided interesting clues as to potential differences in the mode of
action between different IFITMs. IFITM1 only modestly inhibited SFV infection when the
virus fused at the plasma membrane, and had no impact on the endocytic route of entry.
Comparatively, even though IFITM3 has a low abundance at the plasma membrane it still
inhibited SFV infection by fusion at this site, suggesting a greater potency for inhibition
compared to IFITM1. Conversely, flaviviruses entering cells through the normal endocytic
route were sensitive to IFITM1, even though the majority of the protein is at the plasma
membrane, suggesting IFITM1 may preferentially inhibit flavivirus infection. AmphoB
treatment of cells had no impact on IFITM-mediated inhibition of flaviviruses, perhaps
pointing towards differences in the fusion reactions between alphaviruses and flaviviruses,
and/or differences in the mechanisms of IFITM antiviral function. Moreover, interesting
results were found even within the flaviviruses tested since IFITM3-Y20A could inhibit
DENV and ZIKV but not YFV 17D, perhaps suggesting differences in the fusion reactions
between these viruses, or that different endocytic routes into the cell can alter IFITM
sensitivity. Finally, even though SFV, DENV, ZIKV and YFV 17D, all of which enter cells
through endocytic mechanisms and pH-dependent fusion, had some sensitivity to IFITM
proteins, the poxvirus VACV did not. Understanding why certain viruses are sensitive to
IFITMs while others are not, and understanding the sensitivity of different viruses towards
different IFITMs will hopefully generate a far more detailed understanding of the precise
molecular mechanisms underlying IFITM-mediated inhibition of viral infection.
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Appendix
Please find attached within this appendix, articles that have been published from data
presented in this thesis. These have been referenced throughout the thesis [10, 15, 16].
The articles are presented in chronological order of publication.
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IFITM proteins — cellular inhibitors of viral entry
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Interferon inducible transmembrane (IFITM) proteins are a
recently discovered family of cellular anti-viral proteins that
restrict the replication of a number of enveloped and non-
enveloped viruses. IFITM proteins are located in the plasma
membrane and endosomal membranes, the main portals of
entry for many viruses. Biochemical and membrane fusion
studies suggest IFITM proteins have the ability to inhibit viral
entry, possibly by modulating the fluidity of cellular
membranes. Here we discuss the IFITM proteins, recent work
on their mode of action, and future directions for research.
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Introduction
In recent years, studies of innate defence mechanisms
have identified a number of cellular proteins that inter-
fere with the replication of human and animal viruses.
Many of these so-called ‘restriction factors’ have been
most intensively studied for human immunodeficiency
virus (HIV-1). For example, tripartite motif-containing
protein 5 (TRIM5) [1], APOBEC3G [2], 20,30-cyclic-
nucleotide 30-phosphodiesterase [3] and tetherin [4] have
been found to affect uncoating, reverse transcription,
virus assembly and virus release, respectively. A new
addition to this antiviral repertoire is myxoma resistance
protein B (MxB/Mx2) [5] that inhibits HIV-1 at a late
post-entry step. However, restriction factors for other
viruses have also been identified, including: RNA-acti-
vated protein kinase (PKR), that restricts Hepatitis C and
other viruses [6]; MX1, that restricts influenza A virus
(IAV) and measles virus [7]; and 20-50-oligoadenylate
synthase/RNase L, that restricts Hepatitis C and other
viruses [8]. Many of these factors are components of the
broad antiviral response induced by interferons, collec-
tively known as interferon stimulated genes (ISGs: for
review see [9]).
Although recognised to act at different stages in viral
replication cycles, most of the well-characterised restric-
tion factors affect steps following virus entry. Recently, a
new family of proteins has been identified that appears to
act specifically on virus entry, the interferon inducible
transmembrane (IFITM) proteins. Here we review the
antiviral capacity of three of these proteins, IFITM1–3.
Identification of IFITMs
The IFITM gene family was initially identified more
than 20 years ago [10], with particular interest in the
interferon-stimulated response elements (ISREs) they
contained. The IFITM transcripts were originally named
9-27, 1-8D and 1-8U, however, the antiviral properties of
the encoded proteins were only identified in 2009 in an
RNAi screen for host factors that influence IAV replica-
tion. Knock-down of IFITM3 led to enhanced viral
replication. Conversely, overexpression of IFITM1, 2,
or 3 inhibited early viral replication [11].
Subsequent genome analyses have indicated that the
IFITM genes are likely to have arisen by gene dupli-
cation very early in vertebrate evolution [12], since
‘lower’ vertebrates, such as lampreys, possess at least
one IFITM-like gene [13]. To date, five IFITM genes
have been identified in humans, of which IFITM1, 2, 3
and 5 are clustered within a 26 kb region towards the
telomere on the short arm of chromosome 11. IFITM5 is
not IFN inducible and is involved in bone mineralis-
ation [14]. The fifth gene, IFITM10, is located 1.4 Mb
towards the centromere, but little is known about its
function. IFITM4 is not present in humans, but is
located close to Ifitm1, 2, 3, and 5 in the mouse genome
[15], in which the locus has expanded to encode seven
Ifitm genes. Analogous genes have also been found in
other mammals [12], including marsupials [13], and
avian species [16].
Although the molecular function of these proteins has
been largely studied in cell culture systems, studies in
mice and humans suggest IFITM proteins, and IFITM3
in particular, restrict IAV infection in vivo. Ifitm3/mice
fail to control infection by mildly-pathogenic strains of
IAV compared to their wild type littermates, developing
fatal fulminant viral pneumonia [17,18]. Everitt et al.
also found that the minor C allele of human IFITM3
(synonymous single nucleotide polymorphism (SNP)
rs12252) was enriched in a cohort of Caucasian patients
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hospitalised with either IAV H1N1/09 or influenza B in the
2009 pandemic [17]. Although the C allele is rare in
Caucasians, replication of this genetic association was
shown in a cohort of Han Chinese patients (the SNP is
more prevalent in this population) with severe symptoms
following influenza infection. The minority CC genotype
was found in 69% of patients with severe disease compared
to only 25% with mild symptoms [19], further suggesting
that deleterious changes in the IFITM3 gene can influence
the severity of influenza infection. It is currently unclear
how this allele impacts IAV pathogenesis, but the altera-
tion of a splice acceptor site may lead to the synthesis of a
truncated IFITM3 protein that lacks the N-terminal 21
amino acids, and is expressed primarily on the cell surface
rather than in endosomes (see below) [17,20]. Aside from
rs12252, little investigation has been carried out into other
SNPs reported for IFITM3. One study carried out by John
et al. [21] made alterations of non-synonymous SNPs
H3Q/rs1136853, D56G/rs55794999, H57D/rs1553883,
N69D/rs12778, and G95R/rs61744108, with only G95R
showing a small reduction in IAV restriction compared
to wild type.
Broad-spectrum antiviral function
Using cell culture systems, and often pseudotype viruses,
several groups demonstrated that, in addition to IAV,
entry and infection by representatives of multiple virus
families (including filoviruses, rhabdoviruses and flavi-
viruses) [22,23,24] were also inhibited by overexpression
of IFITMs, particularly IFITM3 (see Table 1). Interest-
ingly, these restricted viruses are all enveloped, with
ssRNA genomes, and considered to enter cells by mem-
brane fusion following endocytosis. However, some retro-
viruses (e.g. Moloney leukaemia virus (MLV)) and
several arenaviruses were apparently not restricted.
Although restriction of HIV-1 infection was not initially
detected [11], several more recent studies have reported
some restriction of cell infection [20,25,26]. Most
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Table 1
Summary of viruses IFITM proteins have been tested against
Family Virus pH
dependent
Restricts
infectivity
Prevents
cell–cell
fusion
Pseudotyped
virions (P) or
live virus (L)
Restriction
status
Reference
Enveloped
Orthomyxoviridae Influenza A virus UU U U P L M1–3 Brass et al. [11],
Smith et al. [16]
Influenza B virus UU U L M1–3 Everitt et al. [17]
Flaviviridae West Nile virus U U P M1–3 Brass et al. [11]
Dengue virus UU U P M1–3 Brass et al. [11]
Hepatitis C virus U U/ P L M3 — no,
M1 — yes
Brass et al. [11],
Wilkins et al. [24]
Rhabdoviridae Vesicular stomatitis virus U U U P L M1–3 Weidner et al. [23]
Rabies virus UU U P M2–3 Smith et al. [16]
Lagos Bat virus UU U P M2–3 Smith et al. [16]
Filoviridae Marburg virus D U P L M1–3 Huang et al. [22]
Ebola virus D U P L M1–3 Huang et al. [22]
Coronaviridae SARS coronavirus D U P L M1–3 Huang et al. [22]
Retroviridae HIV-1  U/ P L Mixed results Brass et al. [11],
Lu et al. [26],
Jia et al. [20]
Moloney leukaemia virus   P L No Brass et al. [11],
Huang et al. [22]
Jaagsiekte sheep retrovirus U U U P M1 best Li et al. [28]
Arenaviridae Lassa virus U  P No Brass et al. [11]
Machupo virus U  P No Brass et al. [11]
Lymphocytic choriomeningitis
virus
U  P No Brass et al. [11]
Alphaviridae Semliki Forest virus U U U L M2 and M3
best
Li et al. [28]
Bunyaviridae La Crosse virus UU U L M1-3 Mudhasani et al. [30]
Hantaan virus UU U L M1-3 Mudhasani et al. [30]
Andes virus UU U L M1-3 Mudhasani et al. [30]
Rift Valley fever virus UU U L-attenuated M2 and M3 Mudhasani et al. [30]
Crimean–Congo haemorrhagic
fever virus
UU  L No Mudhasani et al. [30]
Non-enveloped
Reoviridae Reovirus UU U L M3 Anafu et al. [27]
U, fuses at pH >6; UU, fuses at pH <6; , does not require fusion; D, requires cathespin L in lysosome.
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recently, evidence that IFITM3 can also restrict a non-
enveloped reovirus has been published [27], suggesting
the range of viruses influenced by the IFITM proteins is
not limited to those with an envelope.
Using a pseudotype virus carrying the Jaagsiekte sheep
retrovirus (JSRV) envelope protein (Env), for which
fusion requires initial Env priming by receptor binding
and subsequent exposure to pH 6.3, IFITM1 seems to
restrict replication more potently than IFITM2 and 3
[28]. As IFITM1 appears to be located earlier in the
endocytic pathway, where the pH is higher [29], these
data suggest that the cellular location of different IFITM
proteins determines the range of viruses that each
restricts. Although not strictly pH-related, restriction
correlates with the cellular compartment where fusion
or penetration occurs. Differential restriction of viruses in
the vector-borne Bunyaviridae family has also been found
[30] (Table 1); only IFITM 2 and 3 were capable of
restricting Rift Valley fever virus (RVFV) and none of the
IFITM proteins prevented replication of Crimean–
Congo haemorrhagic fever virus (CCHFV). The reason(s)
underlying this difference in susceptibility are unclear as
the bunyaviruses share similar morphologies and glyco-
proteins (GN and GC) on their envelopes.
IFITMs: protein structure and cellular
distribution
IFITM3 is expressed constitutively in cells of the upper
airway and visceral pleura [18], but otherwise its expres-
sion, and that of IFITM1 and 2, in vivo is poorly under-
stood. In both cell lines and primary cells ex vivo, IFITM
protein expression is upregulated by IFNs, though the
relative levels of each protein in a given cell type or tissue
has yet to be determined. All three IFN-inducible human
IFITM proteins show high amino acid sequence sim-
ilarity and all are membrane located, though their topol-
ogies remain to be clearly established [31]. Initially
proposed as transmembrane proteins (Figure 1), with
both the N-termini and C-termini located externally,
subsequent studies suggested both the N-termini and
C-termini, as well as the so-called conserved intracellular
loop (CIL), are located cytoplasmically, with the hydro-
phobic domains interacting with the membrane but not
spanning it [31]. More recently, a model for IFITM3 in
which the N-terminal and CIL domains are located in the
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IFITM protein topology and domain organisation. Panel (a) Topological models for IFITM proteins. (I) Represents an initial model for the proteins as
transmembrane molecules with both the N-terminal and C-terminal domains (NTD and CTD) extracellular and the conserved intracellular loop (CIL)
facing the cytoplasm [33]. Subsequently, an alternative model (II) was proposed with the NTD, CTD and CIL all positioned intracellularly, and neither
membrane domain (M1 and M2, blue and purple respectively) spanning the bilayer [31]. The most recent model (III) combines models I and II,
positioning the NTD and CIL in the cytoplasm and the CTD extracellularly. Currently, the topology represented by III is only established for murine
IFITM3 [32]. Panel (b) Linear representation of human IFITM1, 2 and 3 showing key amino acids. In all cases, modifications and functional activities
have only been established with IFITM3, but conserved residues in IFITM1 and 2 are shown.
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cytoplasm and the C-terminal domain is extracellular,
suggested a type II transmembrane topology for the
second hydrophobic domain [32]. Our own work suggests
a similar topology for human IFITM1 (S Weston et al.,
unpublished data). This topology is consistent with obser-
vations that all three IFN-inducible IFITM proteins
contain conserved cysteine residues at the junctions of
the CIL domain, and the putative membrane interacting
domains. These cysteines (C71, 72 and 105 in human
IFITM3) are palmitoylated, and this modification is
required for full viral restriction [33]. Substitution of
the cysteines for alanines in IFITM3 inhibits protein
clustering in membranes and reduces its antiviral function
[21]. IFITM3 can also be ubiquitinated on any of four
lysines in the N-terminal and CIL domains. Ubiquitina-
tion enhances IFITM3 turnover [31], thus substitution of
the lysines with alanines slows the protein’s degradation
and increases its antiviral activity [25].
The N-terminal domains of IFITM2 and 3 are 20 and
21 amino acids longer, than IFITM1, respectively
(Figure 1). These N-terminal extensions include a key
tyrosine (Y20 in IFITM3 that appears to control the
cellular distributions of the two longer IFITMs)
[17,20,21]. Thus IFITM1 is predominantly at the
plasma membrane, while IFITM2 and 3 are located
mainly in intracellular compartments. IFITM3 is
reported to reside primarily in endosomal organelles,
identified by co-labelling with endosomal markers, in-
cluding Lamp1, Rab7 and CD63 [21,34,35], but the
location of IFITM2 remains to be clearly established
(Figure 2). Therefore, Y20 may be a component of a
YxxØ-type sorting signal for clathrin-mediated traffick-
ing [20]. Significantly, Y20 has also been identified as a
target for Fyn-mediated  phosphorylation, suggesting
that perhaps the activity of this motif as a trafficking
signal can be regulated [20,36].
It is important to note that studies of the subcellular
location of the IFITMs to date have for the most part used
epitope-tagged proteins, where tagging and/or overex-
pression (in transient systems) may have an impact on
protein localisation and/or detection. Recently John et al.
[21] showed that IFITM3 can interact with itself, as well
as IFITM1 and 2, and that phenylalanine residues (F75
and F78) are required for this interaction. Although the
significance of this association is unclear, the formation of
homo-oligomers and/or hetero-oligomers might also influ-
ence the distribution and functional activities of these
proteins.
Mode of action
Reovirus subvirus particles (ISVPs), in contrast to replica-
tion competent reovirus, do not require endosomal acid-
ification for entry and are not inhibited by IFITM3
expression, suggesting that IFITM3 may perturb endo-
somal acidification [27]. However, studies with various
enveloped viruses suggest a different mode of action.
Morphological analysis of IFITM3-restricted IAV in cells
showed the accumulation of viral particles in acidified
endosomal compartments, suggesting there is no effect on
receptor-binding, endocytosis or acidification [22,34].
Studies using cell-cell fusion assays suggest that IFITM3
blocks enveloped virus entry by preventing fusion of the
viral membrane with a limiting membrane of the host cell,
either the plasma membrane and/or endosomal mem-
branes [28]. Fusion is an essential step in enveloped
virus entry, and results in the transfer of viral capsids into
the cytoplasm of a target cell. This process is extremely
well characterised for a number of viruses, in particular
IAV. Low pH in the endosomal lumen triggers confor-
mational changes in one of the viral envelope proteins,
haemagglutinin (HA). This change results in fusion of the
outer leaflet of the viral membrane with the luminal
leaflet of endosomal membranes forming a short-lived
hemifusion intermediate. Resolution of the hemifusion
intermediate allows fusion of the viral membrane inner
leaflet with the cytoplasmic leaflet of endosomal mem-
branes and the opening of a stable fusion pore [37].
Although often not a reflection of the pathway of infec-
tious virus entry, a commonly used approach to studying
viral fusion mechanisms is the formation of syncytia by
cell-cell fusion. This requires the presence of viral fusion
proteins in the plasma membrane of cells and appropriate
signals, such as receptor-bearing cells and/or a transient
change in the pH of the medium. Using the JSRV Env
discussed previously, the IFITMs had no effect on either
priming or pH-induced conformational changes [28].
Moreover, syncytia formation induced by representatives
of all three classes of viral fusion proteins [38] could be
blocked by IFITM1. Using cold to arrest fusion at the
hemifusion state, and chlorpromazine to resolve this,
IFITM proteins were found to inhibit the early stages
of viral envelope fusion with cellular membranes [28].
The mechanism(s) through which the IFITMs inhibit the
early stages of fusion is unclear. Two-photon laser scan-
ning and fluorescence lifetime imaging (FLIM) of Laur-
dan-labelled cells, together with the effects of oleic acid
treatment on cell-cell fusion, suggest that IFITM
proteins may reduce membrane fluidity and increase
spontaneous positive curvature in the outer leaflet of
membranes [28]. Such changes might be expected to
impact on fusion, but how IFITMs affect membrane
fluidity, and whether this has consequences for other
membrane functions in the absence of infection, is
unclear. One mechanism, however, has been suggested
from experiments on IFITM3. Amini-Bavil-Olyaee et al.
show IFITM3 interacts with vesicle membrane protein
associated protein A (VAPA) and disrupts its association
with an oxysterol binding protein that regulates the
cholesterol content of endosomal membranes. Overex-
pression of IFITM3 increases endosomal cholesterol,
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Figure 2
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IFITM proteins inhibit virus entry at different stages of cell trafficking. Viruses enter cells by fusing with or penetrating a limiting cellular membrane. For
most enveloped viruses fusion occurs either at the cell surface or, following uptake by endocytosis, from within endosomes. Acid-dependent viruses
require acidification of the endosomal lumen by the membrane-associate vacuolar proton ATPase for fusion (shown in red). Trafficking through the
endocytic system, from early to late endosomes, exposes virions to increasingly acidic environments. IFITM proteins (green) can inhibit entry and
infection by a number of viruses that fuse/penetrate at the cell surface or from within endosomes. IFITM1 is expressed primarily at the cell surface,
while IFITM2 and 3 are primarily intracellular. IFITM3 has been localised to endosomal compartments, but the distribution of IFITM2 still needs to be
clearly established.
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which may impact on viral fusion through a corresponding
decrease in endosomal membrane fluidity [35].
Although other mechanisms may contribute to IFITM
inhibition of virus entry [39], analysis of changes in the
physical properties of cellular membranes induced by
IFITM expression is likely to shed light on the processes
underlying the broad anti-viral effects of these proteins,
as well as the mechanisms involved in the fusion/penetra-
tion and entry of a number of viruses.
Conclusions and outlook
Knock-down of IFITM proteins in cell culture can
increase infection by a range of enveloped and non-
enveloped viruses, and knock-out of IFITM genes in vivo
can influence pathogenesis. By contrast, overexpression
of the proteins in human cells can inhibit infection at an
early stage of the replication cycle. Although the mech-
anism of IFITM antiviral activity remains unclear,
possible IFITM induced decreases in membrane fluidity,
or increased outward curvature, may inhibit the initial
stages of enveloped virus fusion. Why each protein can
exhibit variable restriction on viruses of the same family,
for instance the Bunyaviridae, and how a virus that does
not require fusion for entry (reovirus) is restricted under
the proposed mechanisms remains unclear.
In many cases viruses have evolved mechanisms to
antagonise the activity of a number of cellular restriction
factors (e.g. see [2,4]). As yet no mechanisms to inhibit the
activity of the IFITM proteins have been identified,
though the indication that the IFITM proteins do not
inhibit the entry of some viruses suggests that these
agents are either refractory to the effects of the IFITM
proteins, or have indeed evolved mechanisms to antagon-
ise their function.
Although questions about the topology and intracellular
distribution of the IFN-induced IFITMs remain, when
taken together a model emerges suggesting that these
proteins may have evolved to provide coverage of the
main cellular membrane systems that have been impli-
cated in virus entry, that is, the plasma membrane and
compartments of the endocytic pathway. The implication
is that perhaps IFITM1 primarily restricts viruses that
fuse or penetrate at the cell surface, whereas IFITM2 and
3 primarily restrict viruses entering from endocytic orga-
nelles. That two IFITM proteins appear to function
intracellularly may reflect the fact that endocytosis has
been implicated in the entry of an increasing number of
both pH-dependent and independent vertebrate viruses
[40]. While there is some suggestion that this pattern may
be true (see Table 1), there are exceptions. It is clear that
there is much to be learned about the mechanisms
through which these newly identified cellular proteins
inhibit virus entry, and their full potential to restrict viral
transmission in vivo.
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Abstract
InterFeron Inducible TransMembrane proteins 1–3 (IFITM1, IFITM2 and IFITM3) are a family of proteins capable of inhibiting
the cellular entry of numerous human and animal viruses. IFITM1-3 are unique amongst the currently described viral
restriction factors in their apparent ability to block viral entry. This restrictive property is dependant on the localisation of
the proteins to plasma and endosomal membranes, which constitute the main portals of viral entry into cells. The topology
of the IFITM proteins within cell membranes is an unresolved aspect of their biology. Here we present data from
immunofluorescence microscopy, protease cleavage, biotin-labelling and immuno-electron microscopy assays, showing
that human IFITM1 has a membrane topology in which the N-terminal domain resides in the cytoplasm, and the C-terminal
domain is extracellular. Furthermore, we provide evidence that this topology is conserved for all of the human interferon-
induced IFITM proteins. This model is consistent with that recently proposed for murine IFITM3, but differs from that
proposed for murine IFITM1.
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Introduction
The InterFeron Inducible TransMembrane (IFITM) protein
family of viral restriction factors was defined in 2009 in a screen
for host-modifying proteins of influenza A virus (IAV) infection
[1]. Initially identified over 30 years ago [2], and named 9–27
(IFITM1), 1-8D (IFITM2) and 1-8U (IFITM3) [3], these proteins
received little attention until human IFITM3 depletion was found
to enhance IAV infection in cell culture assays. Conversely, over-
expression of IFITM3, or the closely related IFITM1 and
IFITM2, could inhibit IAV replication [1]. Studies in mice and
humans have suggested that IFITM3, at least, also protects against
IAV infection in vivo [4,5]. However, the IFITM proteins are not
IAV-specific and, in cell culture at least, have broad-spectrum
antiviral activity [6], though in some systems they may enhance
cellular infection of human coronavirus OC43 [7] and human
papillomavirus 16 [8].
Shortly after the identification of IFITM1-3 as antiviral factors,
over-expression of IFITM3 was shown to cause an accumulation
of intact IAV particles in endocytic organelles [9], suggesting that
IFITM3 interfered with viral entry following endocytosis.
Furthermore, this activity was dependent on localisation of
IFITM3 to endosomes [10]. More recent studies suggested that
IFITM over-expression may increase membrane rigidity and
positive curvature, preventing the early events in membrane fusion
[11]. Alternatively, IFITM protein interaction with vesicle
membrane protein associated protein A (VAPA), disrupts choles-
terol homeostasis and may increase membrane rigidity [12].
However, more recent work has questioned the role of cholesterol
[13,14]. Thus, the precise molecular mechanism(s) for IFITM
inhibition of viral entry remains to be established.
From their first descriptions, the IFITM proteins were thought
to be membrane proteins [15]. Indeed, sequence analyses
identified two hydrophobic, putative membrane interacting
domains in each of the proteins. Additional studies demonstrated
palmitoylation of cysteine residues adjacent to the hydrophobic
domains, a post-translational modification indicative of membrane
proteins [16]. However, the membrane topology of the IFITM
proteins has remained ambiguous. Initially, they were suggested to
be dual pass, transmembrane proteins with both N- and C-
terminal domains (NTD and CTD) exposed extracellularly and a
conserved intracellular loop (CIL) (Fig. 1, model 1). This model
was based on the ability of antibodies against unknown IFITM1
external epitopes to aggregate leukaemia cells [15,17], immuno-
precipitation of extracellular radiolabelled IFITM1 [18] and the
accessibility of IFITM3 NTD and CTD epitope tags at the cell
surface by FACS and immunofluorescence assays, respectively [1].
This topology was subsequently challenged by studies demon-
strating that the NTD and CIL domain of IFITM3 are post-
translationally modified by cytoplasmic enzymes [10,19]. More-
over, engineered myristoylation and prenylation sites at the NTD
and CTD of murine IFITM3 can be detected as lipidated with
selective chemical reporters alk-12 and alk-FOH, respectively [19].
These data suggested that both the NTD and CTD of IFITM3 are
intracellular, and that the two hydrophobic sequences, enter, but
do not span, the lipid bilayer [19] (Fig. 1, model 2). Murine
IFITM1 was also proposed to have this topology [20].
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Based on multiple approaches a third model has since been
proposed for mu IFITM3, with the NTD and CIL facing the
cytoplasm and the CTD located in the extracellular space, or
within the lumen of vesicular organelles [21] (Fig. 1, model 3).
While this manuscript was under revision, an additional study
suggested a similar topology for human IFITM3 [22]. However, it
remains unclear whether C-terminal epitope tags influence the
topology, and whether the proposed topology applies to other
human IFITM proteins.
Using immunofluorescence microscopy, protease cleavage
assays, immuno-electron microscopy and biotin-labelling ap-
proaches, our data support the notion that the NTD of human
IFITM1 is located in the cytoplasm, while the CTD is extracellular
(Fig. 1, model 3). We provide evidence that the presence of a HA-
tag at the IFITM1 C-terminus does not induce this topology. We
also show that, although human IFITM2 and IFITM3 reside
predominantly in intracellular membranes, they adopt the same
topology. Together our data are consistent with the recently
proposed model for mu IFITM3 [21], but not with that proposed
for mu IFITM1 [20].
Materials and Methods
Cell lines and constructs
A549 (adenocarcinoma of human lung epithelia) cell lines stably
expressing C-terminally HA-tagged human (hu) IFITM1, IFITM2
or IFITM3, as well as untransfected A549 cells [23], were cultured
in Ham’s F-12-GlutaMAX media (tissue culture reagents were
from Life Technologies, unless indicated otherwise) supplemented
with 10% (v/v) foetal calf serum (FCS) (PAA) and 1% (v/v)
Penicillin/Streptomycin (Pen/Strep, 10,000 unit/ml/10,000 mg/
ml). HEK293T cells were cultured in DMEM-GlutaMAX
supplemented with 10% (v/v) FCS and 1% (v/v) Pen/Strep. All
cell lines were maintained at 37uC and 5% CO2. Untagged
IFITM1 and IFITM1-Vstop (a construct with a stop codon after
Val109) were purchased from GeneArt and cloned into BamH1/
Not1 sites of pcDNA3.1. Constructs were confirmed by sequenc-
ing (Source BioScience).
Antibodies
Rat anti-HA (100 mg/ml, clone 3F10, Roche), mouse anti-HA
(1 mg/ml, clone HA.11, 16B12 Covance), rabbit anti-IFITM1-
NTD (100 mg/ml, Sigma), rabbit anti-IFITM3-NTD (250 mg/ml,
Abgent), rabbit anti-VDAC (1 mg/ml, Abcam), rabbit anti-
calreticulin (Thermo Scientific), mouse anti-tubulin (clone
DM1A, ascites fluid, Sigma), goat anti-rat Alexa-488, goat anti-
rabbit Alexa-488, goat anti-mouse Alexa-594 and goat anti-rabbit
Alexa-647 (all 2 mg/ml, Life Technologies), goat anti-rabbit
IRDye 680 and goat anti-mouse IRDye 800 (1 mg/ml, Li-
COR), and wheat germ agglutinin (WGA) conjugated to Alexa-
647 fluorophore (1 mg/ml, Invitrogen), were used at the dilutions
given below.
Permeabilised immunofluorescence
Cells cultured on coverslips were fixed in 3% (w/v) formalde-
hyde (FA) (TAAB) in phosphate buffered saline (PBS) for
15 minutes (min), quenched with 50 mM NH4Cl and 0.2% (w/
v) bovine serum albumin (BSA, Sigma) in PBS (PBS/BSA) for
15 min and then permeabilised in PBS/BSA and 0.05% (w/v)
saponin (Sigma) (permeabilisation buffer [PB]) for 30 min at room
temperature (RT). Primary antibodies were diluted in PB and
incubated with the coverslips for 1 hour (h). Unbound antibody
was washed off with PB (365 min). Primary antibodies were
detected with appropriate secondary antibodies conjugated to
Alexa-488, Alexa-594 or Alexa-647, again, diluted in PB.
Coverslips were mounted on Mowiol (Sigma) and imaged using
a Leica TSC SPE confocal microscope.
Intact cell immunofluorescence
Cells cultured on coverslips were washed with ice cold PBS/
BSA then incubated with primary antibodies on ice for 1 h in ice
cold PBS/BSA. Cells were washed to remove unbound antibody
and fixed in ice cold 3% FA for 1 h (30 min on ice and 30 min at
RT). Primary antibodies were detected with appropriate second-
ary antibodies in PBS/BSA. Cells were processed and imaged as
described above.
Figure 1. IFITM membrane topology models. In Model 1, the N- and C-terminal domains are extracellular and are connected by two
transmembrane domains (M1 and M2) and the conserved intracellular loop (CIL). In Model 2 the two hydrophobic domains (M1, M2) do not span the
membrane, resulting in NTD, CTD and CIL domain being located in the cytoplasm. In Model 3, the NTD and CIL domain are intracellular, suggesting
M1 does not span the membrane, but the CTD is located on the extracellular side of the membrane and requires that M2 spans the membrane.
doi:10.1371/journal.pone.0104341.g001
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Wheat germ agglutinin staining
WGA-Alexa-647 was bound to cells on ice for 10 min. The cells
were then washed four times with PBS/BSA and labelled using the
intact cell staining procedure described above.
Antibody feeding
Cells cultured on coverslips were incubated in media containing
rat anti-HA for 3 h at 37uC. Unbound antibody was removed, and
the cells then rinsed in PBS, fixed and permeabilised (as above)
before incubation with anti-rat Alexa-488 in PB. Cells were
mounted and imaged as described above.
For all immunofluorescence, the antibodies were used as
follows: rat anti-HA 1:100, rabbit anti-IFITM1-NTD 1:200,
rabbit anti-IFITM3-NTD 1:200, mouse anti-tubulin 1:100, goat
anti-rat Alexa-488, goat anti-rabbit Alexa-488, goat anti-mouse
Alexa-594 and goat anti-rabbit Alexa-647 all 1:500 and WGA-
Alexa-647 1:200. Nuclei were stained with Hoechst-33258
(Sigma).
Image analysis
To calculate the Pearson’s R-value and Mander’s correlation
coefficients, M1 and M2, individual cells were segmented and
analysed using the JACoP plugin on ImageJ software [24]. For M1
and M2 values, a Costes’ automatic threshold was applied (as
described [24]). To calculate the relative areas of yellow, red and
green signals, images were initially split into the red and green
component channels. These two images were then processed with
the ‘AND’ function in ImageJ (producing an image of pixels that
are only both red AND green). This image was subject to a
manual threshold to observe only cellular structures and remove
background noise. The pixel area was then calculated and these
pixels defined as ‘‘yellow.’’ The ‘‘yellow’’ pixels were then super-
imposed on the red and green single channel images, and removed
from each of these (such that a pixel defined as ‘‘yellow’’ cannot be
considered ‘‘red or ‘‘green’’). The same approach of applying a
threshold was then taken on the red channel to calculate the pixel
area, with these being defined as ‘‘red.’’ Again, once calculated,
these ‘‘red’’ pixels were super-imposed on the green channel image
and removed. This allowed a threshold to be applied to the green
channel and the area of the remaining pixels calculated. The
relative area for each colour was calculated for each field of view
and the mean average of all values calculated.
qRT-PCR
The endogenous levels of IFITM1, 2, and 3 mRNA in A549
and HEK293T cells were measured by QuantiTect SYBR green
qRT-PCR (Qiagen) using the primers described in Table 1 and
the following thermocycling conditions: RT step - 50uC for
30 min. PCR steps - 95uC for 15 min, 94uC for 15 s; 35 cycles of
(94uC, 15 s; 60uC, 30 s; 72uC, 30 s) in a reaction volume of 50 ml.
Total RNA was extracted from a known number of cells
(between 2.46105 and 5.96105) and quantitated (RNeasy minikit):
100 ng was used as a template in each qRT-PCR reaction.
Five standards from 107–103 copies were made using plasmids
encoding the transcripts of human IFITM1, 2, and 3, using the
following formula:
x g =½plasmid length| 660| 6:022| 1023 ~ y molecules
Using the standards for each transcript, the quantity of
transcript was determined relative to the standard curve for
100 ng input RNA. The number of copies per cell was estimated
by dividing the total number of cells by the total RNA extracted,
multiplied by 100. This gave the equivalent number of cells that
produced 100 ng of RNA and from this the RNA copy number
per cell was inferred.
Western blotting
Cells were lysed in Triton X-100 lysis buffer (1% [v/v] Triton
X-100, 150 mM NaCl, 50 mM Tris-HCl pH 8.0 and 16
complete protease inhibitor cocktail [Roche]). Protein concentra-
tions were determined using the BCA method (Thermo Scientific)
following the manufacturer’s instructions. Equal amounts of
protein were mixed with reducing 36 Laemmli sample buffer
(LSB), heated at 95uC for 5 min, separated by 15% SDS-PAGE
and semi-dry transferred to a PVDF membrane (Immobilon-FL,
Millipore). Membranes were blocked in TBST (Tris-buffered
saline pH 7.4 [TBS] with 0.05% [v/v] Tween 20) containing 5%
(w/v) dried skimmed milk (Marvel) for 1 h and incubated with
primary antibodies at 4uC overnight. For trypsin cleavage assays,
samples were collected (as described below) and lysed directly in
16 reducing LSB then heated at 95uC for 5 min. Equal volumes
of cell lysates were loaded.
Antibodies used for protein detection were as follows: rabbit
anti-IFITM3-NTD 1:500, rabbit anti-IFITM1-NTD 1:1000,
mouse anti-HA 1:1000 and rabbit anti-VDAC 1:3000. The
primary antibodies were detected using goat anti-rabbit IRDye
680 or goat anti-mouse IRDye 800 secondary antibodies, both at
1:10,000 (in 5% milk-TBST), then imaged and quantified using an
Odyssey system (Li-COR).
Trypsin treatment
IFITM1-HA expressing A549 cells, grown in 6635 mm well
plates, were treated with 100 mg/ml trypsin (Sigma) for 5–30 min
at 37uC. Subsequently, the cells were transferred to microcen-
trifuge tubes on ice, the wells were rinsed with 1 mg/ml soybean
trypsin inhibitor (SBTI) (Sigma) in PBS, and the rinse added to the
microcentrifuge tubes. Untreated control cells, as well as cells
treated with inactivated trypsin (1:1 volume ratio of SBTI to
trypsin), were also collected. All samples were pelleted (5 min,
3000 RCF, 4uC) and washed with SBTI before direct lysis in LSB
and western blotting, as described above.
Flow cytometry
Cells in 35 mm dishes were treated with trypsin for 10 and
30 min or PBS for 30 min (as described above). The cells were
then fixed, quenched (as previously) and washed with PBS/BSA
prior to labelling with rat anti-HA antibody in PBS/BSA for 1 h at
RT. The cells were then washed 36with PBS/BSA and labelled
Table 1. qRT-PCR primers.
Primer name Sequence (59 to 39)
F’Human_IFITM3 ACTGTCCAAACCTTCTTCTCTC
R’Human_IFITM3 AGCACAGCCACCTCGTGCTC
F’Human_IFITM2 ATTGTGCAAACCTTCTCTCCTG
R’Human_IFITM2 ACCCCCAGCATAGCCACTTCCT
F’Human_IFITM1 AGCACCATCCTTCCAAGGTCC
R’Human_IFITM1 TAACAGGATGAATCCAATGGTC
A list of the primers used for qRT-PCR. F9 and R9 stand for forward and reverse,
respectively.
doi:10.1371/journal.pone.0104341.t001
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with goat anti-rat Alexa-647 in PBS/BSA for 45 min. Cells were
washed 36with PBS and subject to flow cytometry (LSR-II; BD
Bioscience). Cells were gated on forward and side scatter and
analysed for fluorescence labelling. The data were processed using
FlowJo vX.0.7 software (Tree Star). Antibodies were diluted as for
immunofluorescence staining.
Biotin labelling and pulldown
HEK293T cells, grown in 10 cm dishes, were transfected with
untagged IFITM1 or IFITM1-Vstop expressing plasmids using
FuGENE6. After 24 h, cells were detached with 5 mM EDTA
and re-plated into 6635 mm well plates. After a further 24 h, cells
were labelled with 1 mg/ml EZ-link Sulfo-NHS-SS-Biotin
(Thermo Scientific) for 45 min at 37uC. The biotin label was
washed off with TBS and the cells lysed with 100 ml Triton X-100
lysis buffer (as previously). The whole cell lysate (70 ml) was added
to a 25 ml NeutrAvidin agarose bead pellet (Thermo Scientific)
and incubated for 3 h at 4uC on a rotor. Beads were then pelleted
and the unbound material collected. The bead pellet was then
washed with Triton X-100 lysis buffer, TBS and a TE buffer
(10 mM Tris, 5 mM EDTA), prior to elution of proteins in 70 ml
of 16 reducing LSB and heating at 95uC for 10 min. Eluate was
collected and the elution procedure repeated. Equivalent volumes
of whole cell lysate, unbound material and eluate from the
NeutrAvidin beads were separated by 15% SDS-PAGE and
western blotted as previously. Calreticulin was used as a loading
control and detected with an anti-calreticulin antibody diluted
1:5000 in 1% BSA-TBST.
Electron microscopy
Cells were fixed with 4% (w/v) FA in 0.1 M phosphate buffer
pH7.4, infused with 2.3 M sucrose, supported in 12% (w/v)
gelatin and frozen in liquid nitrogen. Ultrathin (70 nm) cryosec-
tions were cut at 2120uC and picked up in 1:1 2% sucrose:-
methylcellulose. Sections were labelled with primary antibody
(mouse anti-HA 1:400), followed by rabbit anti-mouse intermedi-
ate antibody (DAKO) and protein A gold, as described [25,26].
Images were obtained using a Tecnai T12 transmission electron
microscope (FEI) and captured using a Morada CCD camera
(Olympus-SIS).
Results
The human IFITM1 C-terminal domain resides
extracellularly
To investigate the cellular distributions of human (hu) IFITM1,
2 and 3 we used C-terminally HA-tagged proteins, stably
expressed in A549 cells, and immunofluorescence microscopy.
When cells were permeabilised and labelled with anti-HA
antibodies, all three IFITM proteins were detected, and each
had a different cellular distribution. IFITM1-HA was seen
primarily at the plasma membrane (Fig. 2B). By contrast,
IFITM2-HA and IFITM3-HA were seen mostly in intracellular
compartments with distinct distributions. IFITM2-HA localised in
a tight cluster of punctae close to the nucleus, while IFITM3-HA
had a more dispersed, punctate distribution (Fig. 2C and D).
Cells were also stained in the absence of detergent, thus
maintaining the integrity of the plasma membrane. For IFITM1,
anti-HA labelling was very similar on intact and detergent-
permeabilised cells (compare Fig. 2F and Fig. 2B). As a control for
the integrity of the plasma membrane, cells were co-stained with
an anti-tubulin antibody (Fig. S1). Detection of IFITM1-HA on
non-permeabilised cells further demonstrated that the protein is
located primarily at the cell surface in stable transfected A549
cells. Furthermore, the C-terminal HA-tag is accessible on intact
cells and therefore located on the extracellular surface of the
plasma membrane. Co-staining cells with fluorescent wheat germ
agglutinin further confirmed this plasma membrane localisation
(Fig. S2).
No anti-HA labelling was seen on intact IFITM2-HA express-
ing cells, in keeping with the notion that this protein is located on
intracellular membranes (Fig. 2G). A similar result was seen for
IFITM3-HA, although a low number of cells (,1%) did show
some surface labelling with anti-HA antibodies (Fig. 2H and Fig.
S3). This suggested that although the majority of IFITM3-HA is
located on intracellular membranes (Fig. 2D), in some cells
IFITM3-HA is either mis-sorted and/or is expressed at the cell
surface where the C-terminal HA epitope is accessible.
IFITM N-terminal domains reside intracellularly
The observation that the HA-tag of IFITM1 is accessible at the
surface of intact cells prompted us to investigate the topology of
the protein. We used two commercially available antibodies
against the hu IFITM1 and IFITM3 NTDs. The IFITM1 NTD
antibody (anti-IFITM1-NTD) was raised against a peptide
encoding the first 35 amino acids of hu IFITM1. This domain
has 69% and 75% amino acid identity with hu IFITM2 and
IFITM3, respectively. The IFITM3 NTD antibody (anti-IFITM3-
NTD) was raised against a peptide with a sequence corresponding
to the first 30 amino acids of hu IFITM3. Hu IFITM1 has an N-
terminal 21 amino acid truncation compared to IFITM3, so
contains only 9 amino acids overlapping with this domain.
However, there is 90% amino acid identity between the first 30
amino acids of hu IFITM3 and IFITM2.
To determine the specificity of the NTD antibodies, both were
tested on samples from the HA-tagged IFITM1-3 expressing A549
cells by western blot analysis. Anti-IFITM1-NTD detected
IFITM1-HA and IFITM3-HA, but not IFITM2-HA (Fig. 3A).
Anti-IFITM3-NTD detected both IFITM3-HA and IFITM2-HA,
but not IFITM1-HA (Fig. 3B). No IFITM protein was detected in
control A549 cells with either antibody by western blot. Multiple
bands in the range of 12–17 kDa were seen with the NTD
antibodies, but not the anti-HA, indicating possible post-transla-
tional modification of the proteins (see below).
When intact IFITM1, 2 or 3 cells were labelled with anti-
IFITM1-NTD antibody, no staining was seen, suggesting intra-
cellular NTDs (Fig. 4J, K and L). Following detergent treatment,
all three IFITM expressing lines were labelled (Fig. 4B, C and D),
though a weaker signal was seen for IFITM2, as expected from the
western blot (Fig. 3A). By immunofluorescence, the anti-IFITM3-
NTD antibody gave a low signal in the untransfected A549 control
and IFITM1-HA cells (Fig. 4E and D), consistent with the low
level of endogenous IFITM2 expression detected by qRT-PCR
(Fig. S4). However, the antibody clearly detected IFITM2-HA and
IFITM3-HA (Fig. 4G and H). The observed cellular distributions,
using the anti-NTD antibodies, agree with those seen using anti-
HA antibodies (Fig. 2), and the inaccessibility of the IFITM1-
NTD to labelling on intact cells indicates the domain is on the
cytoplasmic side of the plasma membrane.
The IFITM1 C-terminal domain is accessible to
extracellular proteases
Immunofluorescence microscopy (Fig. 2 and 4) suggested that
the IFITM1 C-terminal HA-tag resides on the extracellular face of
the plasma membrane, while the NTD is cytoplasmic. To further
investigate this topology, we used protease cleavage assays. Since
IFITM1-HA is primarily localised to the plasma membrane we
hypothesised that the CTD, and HA-tag, might be accessible to
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digestion by extracellular proteases. Following analysis of the
human IFITM1 CTD sequence with the ExPASy ‘PeptideCutter’
tool (http://web.expasy.org/peptide_cutter/) we chose to use
trypsin, which was predicted to cleave at two positions close to the
C-terminus of hu IFITM1 and thus expected to release the HA-tag
(Fig. 5A).
IFITM1-HA cells were incubated with trypsin for up to 30 min
at 37uC. The trypsin was then inactivated by addition of excess
soybean trypsin inhibitor (SBTI) and the cells analysed by western
blot using antibodies against both the C-terminal HA-tag and the
NTD. Analysis of samples from untreated cells with anti-IFITM1-
NTD indicated two IFITM1 bands (Fig. 5Bi), as previously seen
(Fig. 3A). In samples from trypsin-treated cells the higher
molecular weight band was rapidly lost, with a concomitant
increase in the intensity of the lower band (Fig. 5Bi). This
suggested that the higher molecular weight band is IFITM1-HA
(confirmed in an anti-HA and anti-IFITM1-NTD overlay analysis
[Fig. 5Biii]), and that the lower band is a cleavage product that has
lost the HA-tag. We noted that about 8% (relative to untreated
samples) of the HA-tagged protein was not digested by trypsin,
even after long periods, suggesting that a small pool of IFITM1-
HA protein was inaccessible to the protease (see below).
We also analysed trypsin cleavage of the HA epitope by flow
cytometry. Cells were treated with trypsin for 10 or 30 min and
the trypsin inactivated with SBTI. Cells were then fixed and
labelled with an anti-HA antibody and detected with an Alexa-647
conjugated secondary antibody. Untreated IFITM1-HA cells
showed a high level of staining that was lost upon treatment with
trypsin, as determined by a shift in the peak fluorescence intensity
and decrease in mean fluorescence intensity (Fig. S5).
Topology of untagged IFITM1
To exclude the possibility that C-terminal tagging influences the
topology of IFITM1, we made use of a lysine residue (K122)
present in the CTD that, if the observed topology is correct, will be
accessible to labelling with NHS-biotin (Fig. 6A). To investigate
this hypothesis, HEK293T cells were transfected with an untagged
IFITM1 expression plasmid and incubated with cell impermeable
Sulfo-NHS-SS-Biotin for 45 min at 37uC. While HEK293T cells
appear to have a low level of IFITM1 mRNA (Fig. S4), no protein
was detected by western blot of mock transfected cells (Fig. 6Biii).
Following biotin labelling of untagged IFITM1, cell lysates were
precipitated using NeutrAvidin beads and analysed by western
blot. IFITM1 labelled by biotin, and precipitated, is readily
detected compared to unlabelled samples (Fig. 6B). The detection
of IFITM1 in the biotin labelled, but unbound, fraction suggested
that either the precipitation is not efficient, or only a proportion of
IFITM1 has a CTD that is accessible to cell surface labelling.
To control for the specificity of labelling, a plasmid encoding an
IFITM1 protein with a stop codon after the V109 codon (referred
to as IFITM1-Vstop) that removes K122 (Fig. 6A), was transfected
into HEK293T cells (Fig. 6C). After cells expressing this protein
were incubated with Sulfo-NHS-SS-Biotin, none of the IFITM1-
Vstop was absorbed to the beads (Fig. 6D).
Figure 2. Cellular distribution of the human IFITM proteins. C-terminal domain HA-tagged IFITM1, IFITM2, IFITM3 and control A549 cell lines
were stained intact, or following permeabilisation, with an anti-HA antibody and a secondary anti-rat Alexa-488 antibody. A) Permeabilised A549 cells
show no specific staining. B-D) IFITM1-HA, IFITM2-HA and IFITM3-HA have distinct cellular distributions in permeabilised cells. E) Intact A549 cells (no
detergent treatment) show no specific staining. F) Intact IFITM1-HA cells show positive cell surface HA staining. G) Intact IFITM2-HA cells show no
detectable HA staining. H) Although the majority of intact IFITM3-HA cells show no anti-HA labelling, a minority (,1%) show low-level positive
staining. Nuclei were labelled with Hoechst. All images are maximum projections of 0.25 mm optical sections taken through the depth of the cells
using a confocal microscope. All images were taken using the same microscope settings and the levels adjusted uniformly. Scale bar represents
15 mm.
doi:10.1371/journal.pone.0104341.g002
Figure 3. Analysis of IFITM NTD antibodies. Two commercially
available antibodies targeting either the IFITM1-NTD or the IFITM3-NTD
were screened by western blot to assess specificity using HA-tagged
IFITM1-3 (M1, M2 and M3) cell lines along with control A549 cells.
Proteins were also identified using the HA epitope. Blots were imaged
on a Li-COR Odyssey system that uses far-red fluorophore conjugated
secondary antibodies. In the overlay image, red represents anti-IFITM-
NTD labelling and green represents anti-HA labelling. A) Anti-IFITM1-
NTD detects IFITM1 and shows cross-reactivity with IFITM3. B) Anti-
IFITM3-NTD detects IFITM3 and has cross-reactivity with IFITM2. VDAC
was used as a loading control.
doi:10.1371/journal.pone.0104341.g003
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Figure 4. Analysis of the cellular distribution of the human IFITM proteins using anti-N-terminal domain antibodies.
Immunofluorescence of A549 cells expressing HA-tagged IFITM1, IFITM2 and IFITM3 (or control A549 cells) using anti-IFITM1-NTD and anti-IFITM3
NTD antibodies. A) Permeabilised A549 cells show no specific staining. B-D) IFITM1-HA, IFITM2-HA and IFITM3-HA show distinct distributions in
permeabilised cells. E and F) Anti-IFITM3-NTD detects low levels of endogenous protein in control A549 and IFITM1-HA cell lines. G and H) Anti-
IFITM3-NTD detects IFITM2-HA and IFITM3-HA in permeabilised cells. I-L) No specific staining was seen on intact cells labelled with anti-IFITM1-NTD
antibody. Nuclei were labelled with Hoechst. All images are maximum projections of 0.25 mm optical sections taken through the depth of the cells on
a confocal microscope. All images were taken using the same microscope settings and the levels adjusted uniformly. Scale bar represents 15 mm.
doi:10.1371/journal.pone.0104341.g004
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The IFITM1 CTD HA-tag resides on the outer leaflet of the
plasma membrane
To analyse hu IFITM1 in more detail, cryo-sections of IFITM1-
HA cells were immuno-gold labelled for the HA-tag and examined
by electron microscopy. As expected, labelling was seen predom-
inantly at the plasma membrane (Fig. 7A and B). Close
examination indicated that the majority of gold particles resided
on the extracellular face of the plasma membrane, consistent with
the notion that the hu IFITM1 CTD is located extracellularly.
Labelling was also seen in the Golgi apparatus and in multi-
vesicular bodies (Fig. 7C and D). These intracellular pools
presumably indicate IFITM1 trafficking in the biosynthetic and
endocytic pathways. This material would be inaccessible to
extracellular proteases and labelling reagents, explaining the
failure to completely digest IFITM1-HA with trypsin (Fig. 5B)
and to fully label IFITM1 with biotin (Fig. 6B).
Conservation of the observed hu IFITM1 topology in hu
IFITM2 and IFITM3
Our results indicate that hu IFITM1 is located predominantly
in the plasma membrane, making it highly amenable to the
topological analysis described above. Conversely, we show that hu
IFITM2-HA and IFITM3-HA are primarily intracellular and less
accessible to these investigative methods. Alternative approaches
were therefore adopted to determine the location of the HA-
tagged CTD of hu IFITM2 or IFITM3.
An antibody-feeding approach was used in which live cells were
cultured in medium containing anti-HA antibody for 3 h, prior to
washing, fixation and visualisation by immunofluorescence
microscopy. As expected, control untransfected A549 cells,
incubated with anti-HA antibodies, and IFITM3-HA cells that
were not incubated with anti-HA antibodies, showed no labelling
(Fig. 8A and C). IFITM1-HA expressing cells acted as a positive
control and showed strong cell surface labelling (Fig. 8B). By
contrast, most IFITM2-HA and IFITM3-HA cells showed little, if
any, labelling. However, approximately 25% of IFITM3-HA cells
and 10% of IFITM2-HA cells (calculated from 30 random fields of
view at 40X magnification) showed intracellular, punctate
labelling (Fig. 8D and E). Since the cells were labelled prior to
fixation, this intracellular labelling suggested that, in some cells,
the IFITM2-HA and IFITM3-HA proteins are trafficked to the
cell surface where an externally exposed HA epitope could bind
antibody, prior to internalisation into intracellular organelles. The
lack of labelling in the majority of cells, which express the IFITM
proteins, indicates the labelling is not due to non-specific fluid
phase uptake of antibody. Together, we conclude that, in a
Figure 5. Trypsin cleavage of HA-tagged IFITM1. A) Predicted trypsin cleavage sites in hu IFITM1 CTD (Model 3, Fig. 1). B) IFITM1-HA cells were
treated with exogenous trypsin for 5 to 30 mins at 37uC. The trypsin was inactivated with soybean trypsin inhibitor, the cells were lysed and the
cellular proteins separated by SDS-PAGE. After transfer, proteins were identified with anti-IFITM1-NTD (i) and anti-HA (ii) antibodies. VDAC was used
as a loading control (iii). Control samples were untreated (UN), or treated with SBTI-inactivated trypsin (IN). In the overlay image, red represents anti-
IFITM1-NTD labelling and green represents anti-HA labelling (iv).
doi:10.1371/journal.pone.0104341.g005
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fraction of A549 cells, the CTDs of both IFITM2-HA and
IFITM3-HA proteins are, at least transiently, exposed on the cell
surface.
Previous results have suggested that IFITM2 and 3 are localised
to endosomes (Fig. 2, 4 and [6]). The exposure of CTD HA-tags in
the lumen of these organelles may result in their cleavage by
endosomal/lysosomal proteases. This hypothesis is supported by
western blots that showed low levels of HA-labelling for IFITM2
and 3 (Fig. 3). Moreover, when detected with anti-IFITM3-NTD,
IFITM2-HA appears to have 3 bands in the range of 12–17 kDa,
Figure 6. Biotin labelling and pulldown of untagged IFITM1. Untagged, wild type IFITM1 or IFITM1-Vstop expression plasmids were
transfected into HEK293T cells. After two days the cells were labelled with cell impermeable Sulfo-NHS-SS-Biotin prior to incubation with NeutrAvidin
agarose beads. A) Diagram to show the exposed CTD of IFITM1, with the targeted K122, or IFITM1-Vstop. B) Western blots probed with anti-IFITM1-
NTD; WCL – whole cell lysates, UB – material that remained unbound by NeutrAvidin, PD1 and PD2 – two rounds of elution of protein from the
NeutrAvidin beads. Gel i shows samples from cells labelled with biotin, gel ii shows unlabelled samples and gel iii shows samples from mock
transfected HEK293T cells that were treated with Sulfo-NHS-SS-Biotin. NB. The elution step detached some NeutrAvidin monomers from the beads.
These run at approximately 14 KDa and are seen as background bands in the western blots (labelled ‘NeutrAvidin’). Calreticulin was used as a loading
control and negative control for pulldown specificity. C) Western blot comparing the wild type IFITM1 (M1) with IFITM1-Vstop (Vstop), along with
mock transfected HEK293T cells. D) Western blots probed with anti-IFITM1-NTD for whole cell lysates (i) material that remained unbound to
NeutrAvidin (ii) and protein eluted from the NeutrAvidin beads (iii). As previously, NeutrAvidin monomers were eluted, and have the same molecular
weight at IFITM1-Vstop. This can be clearly seen in the pulldown blot due to the presence of a band in the unlabelled lane.
doi:10.1371/journal.pone.0104341.g006
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with the majority of the protein being of the lowest molecular
weight, consistent with this protein having lost its HA-tag. A
similar low molecular weight form was also seen for IFITM3-HA
(Fig. 3).
IFITM expressing A549 cells were co-stained with antibodies
against the NTD and the HA-tag. As IFITM proteins are
relatively short (less than 133 amino acids) co-staining for the NTD
and CTD should give apparent co-localisation. IFITM1-HA
expressing cells showed a high degree of overlap between the anti-
IFITM1-NTD and anti-HA antibodies (Fig. S6A). The overlap
was seen across multiple images as demonstrated by Mander’s
correlation coefficients M1 and M2. Furthermore, analysis of the
areas of different pixel colours demonstrated that around 70%
(61.8%) of pixels were detectable as yellow (Table S1).
By contrast, on IFITM3-HA expressing cells, a lower level of co-
localisation was seen with both NTD antibodies (Fig. 9B and Fig.
S6C). Importantly, clear red punctae were visible, suggesting that
in some organelles IFITM3 contains intact NTDs but lacks the
CTD HA-tag. This conclusion is supported by the quantification
of multiple images that demonstrate a lower Mander’s M1 and
M2, compared to IFITM1-HA, and show an excess of red pixels
(55% [61.4%]) for IFITM3-HA expressing cells (Table 2, 3 and
Table S1).
The anti-IFITM1-NTD antibody does not detect IFITM2-HA
as well as IFITM1-HA and IFITM3-HA (Fig. 3); we therefore
used the anti-IFITM3-NTD antibody for a similar investigation of
IFITM2-HA (Fig. 9A). When multiple images were quantified, the
results for IFITM2-HA and IFITM3-HA expressing cells were
largely equivalent, with 49% (61.1%) of pixels being red for
IFITM2-HA cells, compared to 46% (60.9%) for IFITM3-HA
cells (Table 2 and 3). The observed excess of red pixels for both
IFITM2-HA and IFITM3-HA indicates loss of the HA-tag,
consistent with the western blots (Fig. 3). Overall, the data suggest
a topology in which the HA-tagged CTDs of IFITM2 and
IFITM3 are exposed to the endosomal/lysosomal system.
Discussion
The membrane topology of the interferon-induced IFITM
proteins has been controversial. Initially it was suggested that both
the NTD and CTD are located on the extracellular face of
membranes and are connected by two transmembrane domains
and the CIL domain (Fig. 1, model 1) [1,15,17,18]. However
subsequent studies, demonstrating post-translational modification
of both the hu IFITM3 NTD and CIL domain by cytosolic
enzymes, led to the proposal of a model that placed the NTD, CIL
and CTD all within the cytoplasm (Fig. 1 model 2) [10,19]. The
same topology was also suggested for mu IFITM1 [20].
Here we present evidence that hu IFITM1, which localises
primarily to the plasma membrane, has a topology with the NTD
located in the cytoplasm and the CTD in the extracellular space
Figure 7. Immuno-gold labelling of A549 IFITM1-HA cell cryo-sections. Cryo-sections of the IFITM1-HA cells were labelled with anti-HA
antibodies and Protein A gold. A) Plasma membrane labelling. B and C) Plasma membrane and multi-vesicular body labelling. D) Plasma membrane
and Golgi apparatus labelling. Scale bars represent 200 nm.
doi:10.1371/journal.pone.0104341.g007
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(Fig. 1, model 3). Immunofluorescence microscopy showed that on
non-permeabilised cells the NTD is not accessible to antibody
labelling, whereas the CTD (through an HA-tag) is accessible. In
agreement, the majority of tagged IFITM1 was accessible to
cleavage by exogenous trypsin.
Our results also suggested that the HA-tag itself did not induce
the extracellular CTD topology since untagged IFITM1 could be
biotinylated at K122 using a cell impermeable biotin-labelling
reagent. However, while a large proportion of untagged IFITM1
could be biotin labelled and absorbed to NeutrAvidin beads, some
protein remained in the supernatant. We propose that the
unlabelled protein is that which resides in intracellular compart-
ments such as the Golgi and multi-vesicular bodies, as seen by EM
(Fig. 7), and that there could also be accessibility issues at the
plasma membrane due to the short length of the CTD.
Although not accessible on intact cells, the NTD of IFITM1 was
accessible to labelling with antibodies following detergent treat-
ment of cells and showed a very similar cellular distribution to that
seen with CTD anti-HA labelling. The NTD contains two
potential trypsin cleavage sites, but we saw no evidence of these
sites being accessible to exogenous trypsin. Thus our results are
consistent with a model recently proposed for murine and human
IFITM3 indicating a cytoplasmic NTD and CIL domain,
connected by an intramembrane hydrophobic domain (M1) that
does not fully span the membrane, and a second transmembrane
domain (M2) linking the CIL domain to an extracellular CTD
[21,22]. Our results with antibody labelling experiments indicate
that hu IFITM2 and 3 are likely to have the same topology,
suggesting this may be a common feature of human interferon-
induced IFITM proteins, and mu IFITM3. However, this model is
not consistent with published data on mu IFITM1 [20], in which
palmitoylation of a CTD cysteine (mu IFITM1 C103) suggested a
cytoplasmic location. This cysteine is not conserved in hu IFITM1,
perhaps indicating why there is an apparent difference between hu
and mu IFITM1 [20]. Whether palmitoylation of mu IFITM1 or
other non-human IFITM proteins influence protein topology and/
or its cellular distribution, as well as any possible effects on
functional activities, remains to be examined.
The model for mu IFITM3 [21] and proposed here for hu
IFITMs has important implications. Many studies of the IFITM
proteins have used tagged constructs. If these tags are at the C-
terminus they will reside in extracellular and lumenal spaces where
they may be exposed to proteolytic conditions. Indeed, our results
suggest that, even under normal culture conditions, IFITM-HA
Figure 8. Antibody feeding of IFITM expressing cells. Live A549-IFITM-HA cells were incubated with 5 mg/ml anti-HA at 37uC to allow
endocytosis of bound antibody molecules. Subsequently, the cells were washed, fixed, permeabilised and incubated with an anti-rat Alexa-488
conjugate. A) Control A549 cells show no specific staining. B) In IFITM1-HA cells the majority of labelling is at the plasma membrane. C) IFITM3-HA
cells that were not incubated with anti-HA antibody show no labelling. For IFITM2-HA and IFITM3-HA expressing cells (D and E) the majority of cells
are not labelled, however in both cases a minority of cells do show punctate labelling indicative of IFITM-mediated internalisation of anti-HA
antibodies. In D and E, the boxed region has been enlarged. All images were taken using the same microscope settings and adjusted uniformly. Scale
bars represent 15 mm.
doi:10.1371/journal.pone.0104341.g008
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expressing cells have cleavage products resulting from the loss of
the HA-tag or residues from the CTD itself. Western blots of A549
cells stably expressing IFITM1 show two bands when using the
anti-IFITM1-NTD antibody. The higher molecular weight band
is the HA-tagged form of the protein, while the lower weight band
is a cleaved form of the protein that has lost the HA-tag, and
possibly other residues from the CTD. Since this band is seen in
cells that were not treated with trypsin, we suggest that this C-
terminal cleavage may occur in the endosomal system. This
conclusion is supported by the observation that in A549 cells
expressing HA-tagged IFITM2 or 3, intracellular organelles can
be seen that contain IFITM2 or 3 with intact NTD epitopes but
lacking the CTD HA-tag (Fig. 9).
The potential for loss of the CTD or C-terminal tags will affect
the interpretation of cell localisation studies that rely on CTD
epitopes. IFITM3 has been localised to endosomal compartments
that co-label with markers for early and late endosomes
(transferrin, CD63, Rab proteins, LAMP1, LAMP2 and Lyso-
Tracker Red (as a marker for acidic compartments)
[4,9,12,27,28]), but IFITM2 has proved harder to localise.
Reliance on CTD epitope tags to determine the cellular
distribution of the protein may not reveal the full cellular content
of protein, and functionally important pools may be overlooked.
The relevance of the proposed topology to IFITM protein
function is unclear at this stage. To date, published work has found
that functionally important residues are located within the NTD
[27] and the conserved CD225 domain [19,29], comprising the
membrane interacting domains and the CIL loop, as well as the
second membrane domain that is proposed to interact with VAPA
[12]. Our data suggest the first membrane domain enters into, but
does not span, the lipid bilayers, perhaps allowing the protein to
induce membrane curvature. It could be further speculated that an
Figure 9. Co-staining with N- and C-terminal antibodies. Permeabilised IFITM2-HA (A) and IFITM3-HA (B) expressing cells were stained with
antibodies against the C-terminal HA-tag (green [Alexa-488]) and the NTD, using the anti-IFITM3-NTD antibody (red [Alexa-647]). Images are single
optical sections (0.25 mm thick) through the cells. Scale bars represent 15 mm. See also Table 2 and 3 for image analysis.
doi:10.1371/journal.pone.0104341.g009
Table 2. Image analysis of anti-IFITM3-NTD antibody and anti-HA antibody co-labelling.
Cell line Number of cells imaged Pearson’s R value Mander’s M1 Mander’s M2
IFITM2 57 0.73 (60.13) 0.85 (60.16) 0.86 (60.14)
IFITM3 49 0.72 (60.04) 0.75 (60.21) 0.77 (60.17)
Co-localisation analysis of multiple images, for each cell line, from two independent experiments. Pearson’s R-value represents the correlation in intensity between the
red (anti-IFITM3-NTD) and green (HA) channels. Mander’s correlation coefficients, M1 and M2, represent the overlap of red, in pixels that are green, and the overlap of
green, in pixels that are red, respectively. Error given is of the standard deviation.
doi:10.1371/journal.pone.0104341.t002
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extracellular CTD may allow IFITM proteins to interact with key
membrane components that are inaccessible on the cytoplasmic
face of the membrane.
In conclusion, our data, together with those recently published
for mu and hu IFITM3, provide a compelling case for hu IFITM
proteins having an intracellular NTD and CIL domain, and an
extracellular CTD. Whether all vertebrate IFITM proteins
conform to the same organisation and, if not, the functional
implications of other topologies, remain to be established.
Supporting Information
Figure S1 Tubulin co-staining on intact and permeabi-
lised IFITM cell lines. C-terminal domain HA-tagged
IFITM1-3 and A549 cell lines were co-stained intact, or following
permeabilisation, with an anti-HA antibody and an anti-tubulin
antibody. These antibodies were detected with Alexa-488 (green)
and Alexa-594 (red), respectively. A) Permeabilised IFITM-HA
cells show positive labelling for all IFITM proteins and tubulin. B)
Intact IFITM-HA cells show no labelling for tubulin, indicating
that the plasma membrane has remained intact and the antibody
does not have access to the cytoplasm. As previously, IFITM1-HA
can be labelled on intact cells, IFITM2-HA has no labelling and
only a minority of IFITM3-HA expressing cells shows plasma
membrane labelling. Nuclei were labelled with Hoechst. All
images are maximum projections of 0.25 mm optical sections taken
through the depth of the cells on a confocal microscope. All images
were taken using the same microscope settings and the levels
adjusted uniformly. Scale bars represent 15 mm.
(TIF)
Figure S2 Wheat germ agglutinin co-staining on intact
IFITM cell lines. IFITM-HA cell lines co-labelled with anti-HA
antibody, detected with Alexa-488 (green channel) and WGA-
Alexa-647 (red channel). Images are of a single optical section
(0.25 mm thick) through the middle surface of the cells. Scale bars
represent 15 mm.
(TIF)
Figure S3 Immunofluorescence of intact IFITM3 cells.
Intact IFITM3-HA cells stained with anti-HA antibody. A
minority (,1%) of the cells show some plasma membrane
labelling, although the vast majority do not. Labelling of
permeabilised cells showed that all cells express IFITM3-HA
(Fig. 2D) Scale bar represents 15 mm. The boxed region is
enlarged in the right hand panel.
(TIF)
Figure S4 qRT-PCR of A549 and HEK293T cells. qRT-
PCR of A549 and HEK293T cells to determine the expression
levels of any endogenous IFITM proteins. Each bar is labelled
with the mean number of RNA copies per cell with error bars
representing the standard deviation from n= 3 amplifications.
(TIF)
Figure S5 Trypsin cleavage and flow cytometry analysis
of IFITM1-HA. IFITM1-HA cells were treated with exogenous
trypsin for 10 and 30 mins at 37uC. The trypsin was inactivated
with soybean trypsin inhibitor, and cells fixed then labelled with
anti-HA antibody. The HA labelling was detected with anti-rat
Alexa-647 and the cells analysed by flow cytometry. A) Histograms
representing the fluorescence intensity of HA labelling. The black
line represents control A549 cells expressing no HA constructs.
The green line represents untreated IFITM1-HA cells. The blue
and red lines represent 10 and 30 mins of trypsin treatment,
respectively. B) Mean fluorescence intensity of HA labelling. Data
represent mean averages from n= 2 cleavages and error bars equal
standard deviation.
(TIF)
Figure S6 Co-staining with anti-IFITM1-NTD and anti-
HA antibodies. Permeabilised IFITM1-HA (A), IFITM2-HA
(B) and IFITM3-HA (C) expressing cells were stained with
antibodies against the C-terminal HA-tag (green [Alexa-448])
and the NTD, using the anti-IFITM1-NTD antibody (red [Alexa-
647]). Images are of single optical sections (0.25 mm thick) through
the middle the cell. Scale bars represent 15 mm.
(TIF)
Table S1 Image analysis of anti-IFITM1-NTD antibody
and anti-HA antibody co-labelling. Co-localisation analysis
of multiple images, for each cell line, from three independent
experiments. Pearson’s R-value represents the correlation in
intensity between the red (anti-IFITM1-NTD) and green (HA)
channels. Mander’s correlation coefficients, M1 and M2, represent
the overlap of red, in pixels that are green, and the overlap of
green, in pixels that are red, respectively. Relative areas of each
colour were calculated as described in materials and methods.
Error given is of the standard deviation.
(DOCX)
Acknowledgments
We thank members of the Marsh and Kellam labs for input into the
experiments described here and for critically reading the manuscript, Janos
Kriston-Vizi for advice on the co-localisation analysis and Alexander
Agrotis and Francisca Almeida for preliminary work on the trypsin
cleavage assay.
Author Contributions
Conceived and designed the experiments: SW MM. Performed the
experiments: SW SC IJW SES. Analyzed the data: SW SC IJW SES.
Contributed reagents/materials/analysis tools: SW SES PK. Wrote the
paper: SW MM.
Table 3. Image analysis of anti-IFITM3-NTD antibody and anti-HA antibody co-labelling.
Cell line Fields of view Yellow relative area Red relative area Green relative area
IFITM2 13 0.26 (60.07) 0.49 (60.11) 0.25 (60.09)
IFITM3 14 0.27 (60.04) 0.46 (60.09) 0.27 (60.09)
Relative areas of each colour were calculated as described in materials and methods. Red represents anti-IFITM3-NTD labelling, green represents anti-HA labelling and
yellow represents overlap of the two stains. Error given is of the standard deviation.
doi:10.1371/journal.pone.0104341.t003
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Abstract
Interferon inducible transmembrane proteins (IFITMs) are
broad-spectrum antiviral factors. In cell culture the entry of many
enveloped viruses, including orthomyxo-, ﬂavi-, and ﬁloviruses, is inhib-
ited by IFITMs, though the mechanism(s) involved remain unclear and
may vary between viruses. We demonstrate that Sindbis and Semliki
Forest virus (SFV), which both use endocytosis and acid-induced mem-
brane fusion in early endosomes to infect cells, are restricted by the
early endosomal IFITM3. The late endosomal IFITM2 is less restrictive
and the plasma membrane IFITM1 does not inhibit normal infection by
either virus. IFITM3 inhibits release of the SFV capsid into the cytosol,
without inhibiting binding, internalization, trafﬁcking to endosomes or
low pH-induced conformational changes in the envelope glycoprotein.
Infection by SFV fusion at the cell surface was inhibited by IFITM1,
but was equally inhibited by IFITM3. Furthermore, an IFITM3 mutant
(Y20A) that is localized to the plasma membrane inhibited infection by
cell surface fusion more potently than IFITM1. Together, these results
indicate that IFITMs, in particular IFITM3, can restrict alphavirus infec-
tion by inhibiting viral fusion with cellular membranes. That IFITM3 can
restrict SFV infection by fusion at the cell surface equivalently to IFITM1
suggests that IFITM3 has greater antiviral potency against SFV.
Keywords alphavirus, IFITM, interferon inducible transmembrane pro-
tein, restriction factor, Semliki Forest virus, SFV, virus entry, virus–host
interaction
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Human interferon inducible transmembrane pro-
teins (IFITMs) are a family of five, 15–17 kDa
membrane-associated proteins, of which three (IFITM1,
2 and 3) appear to function as broad-spectrum inhibitors
of viral replication. Although detailed studies are lacking
for most viruses, work on influenza A virus (IAV) has
suggested that IFITM3, in particular, inhibits viral entry
by interfering with endosomal, low pH-induced fusion
(1–4). However, the precise molecular mechanism(s)
for this inhibition remains unclear, and for some viruses
alternative modes of action have been proposed (5–7).
Alphaviruses, especially Semliki Forest virus (SFV) and
Sindbis virus (SINV), have been used extensively to study
viral entry into cells (8–11). These small (∼75 nm diam-
eter), positive sense, single-stranded RNA viruses were
amongst the first to be shown to use clathrin-mediated
endocytosis and endosomal low pH-dependent fusion to
enter cells (8,10). Despite the wealth of knowledge about
their entry, IFITM-mediated inhibition of alphavirus
infection has not been analyzed in any great detail,
although an overexpression screen has suggested IFITMs
inhibit Chikungunya virus infection but had less affect on
Venezuelan equine encephalitis virus (12). It has also been
suggested that low pH-induced fusion of SFV envelope
glycoprotein expressing cells (fusion from within) can
be inhibited by IFITM1 and IFITM3 (3). Nevertheless,
there is a view that alphavirus infection is not restricted
by IFITMs (13,14). Given the similarities, in terms of
structure and mode of entry, between alphaviruses and
flaviviruses, which are restricted by IFITMs (15–18), we
investigated whether SFV and SINV can also be restricted.
We show that normal infection by both SFV and SINV is
restricted by IFITM3 and, to a lesser extent, by IFITM2,
but not by IFITM1. The expression of IFITM3 does not
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Figure 1: Alphavirus infection is inhibited by IFITM proteins. A549 cells stably expressing HA-tagged IFITM1, 2 or 3 were
infected with SFV (A) or SINV (B) at the indicated MOI (pfu/cell) for 5.5–6 h prior to ﬁxation. Cells were then stained for the respective
viral envelope proteins and the proportion of infected cells counted using an Opera microscope system. Although SINV infection of
A549 cells was not as efﬁcient as SFV, IFITM3-HA expression inhibited infection by both viruses. IFITM2-HA expression had some effect
on SFV infection at lower MOI, but minimal effect on SINV infection. IFITM1-HA had no effect on either virus. These data are from a
representative experiment (n= 2–3) performed with triplicate wells in a 96 well plate. Each bar shows the mean infection percentage
for the three wells and the standard deviation.
affect SFV binding, internalization or entry into early
endosomes, which also contain IFITM3. Moreover, the
SFV E1 glycoprotein undergoes a characteristic low
pH-induced conformational change with similar kinetics
in both IFITM3-expressing and non-expressing cells.
However, release of the viral capsid protein into the cytosol
is inhibited in IFITM3-expressing cells.
SFV infection induced by low-pH fusion with the cell
surface was inhibited by the plasma membrane local-
ized IFITM1, but was equally restricted by IFITM3, even
though this protein is predominantly localized to intra-
cellular compartment and is present at only low levels on
the cell surface. Furthermore, a mutant of IFITM3, which
is localized to the plasma membrane (Y20A), inhibited
infection by plasma membrane fusion more potently than
IFITM1, but did not inhibit the endosomal route of infec-
tion.
Together our results show that (i) alphaviruses
are restricted by IFITMs, (ii) for SFV at least,
IFITM3-mediated restriction appears to affect viral
fusion and cytosolic delivery of the viral capsid, and (iii)
that IFITM1 and IFITM3 have different potencies for
inhibition of SFV infection.
Results
IFITMs can restrict alphavirus infection
To investigate whether IFITMs can restrict infection by
alphaviruses, we used A549 cells stably expressing human
C-terminally HA-tagged IFITM1, 2 or 3 (19,20). Cells were
infected with SFV or SINV at MOIs ranging from 0.1 to
1000 pfu/cell for 5.5–6 h, prior to immunolabelling for
newly synthesized viral envelope glycoproteins (E1/E2) as
a marker of infection. IFITM3-HA inhibited infection by
both viruses (Figure 1). At 1 pfu/cell, IFITM3-HA expres-
sion inhibited SFV infection by ∼95%. Though requiring
a higher MOI to see equivalent levels of infection, replica-
tion of SINV was also inhibited by IFITM3-HA. For both
viruses, IFITM3-HA restriction was less efficient at higher
MOIs (∼20% inhibition at 100 pfu/cell and<10% at 1000
pfu/cell for SFV, and ∼10% inhibition at 100 pfu/cell for
SINV). IFITM2-HA also inhibited SFV infection (∼50% at
1 pfu/cell) but had little activity against SINV. IFITM1-HA
had no activity against either virus.
These data indicate that IFITM3-HA, and to a lesser extent
IFITM2-HA, can restrict infection of A549 cells by two
different alphaviruses, and that the restriction can be sat-
urated with higher levels of input virus.
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IFITM3 endosomal localization and expression levels
impact antiviral activity
The A549 IFITM-HA cells used in Figure 1 were pro-
duced through single cell cloning of lentivirally trans-
duced cells. To further test IFITM3-mediated inhibition,
we used two additional sets of A549 stable cells pro-
duced using puromycin selection. One set (P1) was pro-
duced to stably express C-terminally HA-tagged IFITM1,
2 or 3, or an empty vector control. The other set (P2)
included cells expressing IFITM3-HA, IFITM3-HA with a
Y20A mutation and a GFP control. The Y20A mutation
disrupts a Yxxϕ type endocytosis signal in the IFITM3
N-terminal domain (NTD), causing accumulation of the
protein at the plasma membrane ((21), Figures S1 and 8B).
IFITM3-Y20A-HA allowed us to investigate the impor-
tance of endosomal localization for antiviral activity (see
Figures S1 and 3 for wild type IFITM3-HA localization).
These three sets of cells are denoted as: OS – the original
set produced by single cell cloning (Figure 1), and P1 and
P2 for the puromycin selected cells.
IFITM expression levels in all cells were analyzed by
western blot (Figure 2A). Antibodies against the NTDs
of IFITM1 or IFITM3 were used, as previously described
(20). The OS cells had the highest IFITM expression. P1
and P2 cells had expression levels similar to each other. OS-
and P1-IFITM2-HA had low expression, or poor detection
(detected by cross-reaction from the anti-IFITM3-NTD
antibodies), possibly as a consequence of localization
in more hydrolytic, late endosomal compartments (see
Figure 3).
P1- and P2-IFITM3-HA expressing cells inhibited
SFV in the range of 0.1 to 10 pfu/cell (Figure 2B),
but restriction was reduced compared to that seen in
OS-IFITM3-HA cells (compare Figures 2B with 1A).
At 1 pfu/cell, OS-IFITM3-HA showed ∼95% inhibition
while P1- and P2-IFITM3-HA cells showed ∼70% inhi-
bition. The reduced levels of restriction correlate with
the lower IFITM3-HA expression. P1-IFITM2-HA cells
showed some inhibition of SFV infection, though this was
lower than OS-IFITM2-HA and all IFITM3-HA cells. As
with OS-IFITM1-HA, P1-IFITM1-HA did not restrict
SFV infection. IFITM3-Y20A-HA, which localizes to the
plasmamembrane similarly to IFITM1-HA (Figure S1 and
(20)), also did not inhibit SFV infection, suggesting that
the endosomal localization of IFITM3 is essential for its
anti-SFV activity.
Previously, we noted that OS-IFITM3-HA restriction was
less efficient at high viral input (Figure 1). This effect was
also observed for the P1- and P2-IFITM3-HA cells. Thus,
IFITM3-mediated restriction can be saturated either by
increasing the amount of virus or lowering the level of
IFITM3-HA expression.
Unless otherwise indicated, all subsequent work was per-
formed with OS-IFITM-HA cells.
IFITM3 preferentially localizes to early endosomes
and IFITM2 to late endosomes
The majority of viruses restricted by IFITM3 are believed
to fuse with late endosomes where some studies have
suggested IFITM3 is localized (22,23). SFV by contrast,
has been shown to fuse in early endosomes at pH≤ 6.2
(8,11). Since IFITM3-HA more potently restricted SFV
and SINV than IFITM2-HA, and the endosomal localiza-
tion of the protein is necessary for its antiviral activity, we
investigated IFITM2-HA and IFITM3-HA localization.
Cells were co-immuno-labeled for the IFITM proteins
and markers of early and recycling endosomes [Early
Endosomal Antigen 1 (EEA1) and transferrin receptor
(TfR), respectively] or late endosomes and lysosomes
[CD63 and lysosomal associated protein 1 (LAMP1)].
IFITM3-HA showed more colocalization with TfR and
EEA1 than IFITM2-HA, while IFITM2-HA showed
more overlap with CD63 and LAMP1 than IFITM3-HA
(Figure 3). Image analysis showed that a significant
amount of both IFITM2-HA and IFITM3-HA did not
colocalize with each of the single endosome/lysosome
markers (Figure 3C, D). Given that early endosomes
are heterogeneous and neither EEA1 nor TfR mark the
entire early endosome population, and IFITM2-HA
and IFITM3-HA have somewhat overlapping distribu-
tions, we conclude that in fixed A549 cells IFITM3-HA
is associated more with early endocytic organelles and
IFITM2-HA more with later endocytic compartments.
The higher levels of early endosomal localization of
IFITM3-HAmay explain why this protein more effectively
inhibited SFV and SINV infection than IFITM2-HA,
and the plasma membrane-associated IFITM1-HA and
IFITM3-Y20A-HA proteins.
Trafﬁc 2016; 17: 997–1013 999
Weston et al.
Figure 2: IFITM3 expression levels affect SFV restriction. Two sets of A549 cells stably expressing IFITM-HAs (P1 and P2: See
Materials and Methods) were analyzed for IFITM expression levels and SFV restriction. A) Western blotting was used to analyze the
IFITM expression of all three sets of cells (OS= the original single cell clones used in Figure 1). A, 1, 2 and 3 denote A549, IFITM1,
IFITM2 and IFITM3, respectively. Antibodies against the IFITM1-NTD (which cross-react with IFITM3) or IFITM3-NTD (which cross-react
with IFITM2) were used to analyze IFITM expression. Tubulin was used as a loading control. Fluorescence intensity (int.) of the IFITM and
tubulin bands was quantiﬁed using LiCOR Odyssey software. IFITM band intensities were normalized to tubulin loading and arbitrarily
set relative to the highest band intensity on each blot (OS-IFITM3-HA in both cases). B) The P1 and P2 sets were infected with SFV
across a range of MOIs and analyzed for infection by immunoﬂuorescence, as in Figure 1. In line with lower IFITM expression, P1-
and P2-IFITM3-HA show reduced levels of SFV restriction compared to OS-IFITM3-HA (Figure 1). These data are from a representative
experiment (n= 2) performed with triplicate wells in a 96 well plate. Each bar shows the mean infection percentage for the three wells
and the standard deviation.
IFITM3 expression does not block SFV binding or
endocytosis
Having determined that IFITM3-HA can inhibit
alphavirus infection, and localizes to early endosomes,
we hypothesized that the inhibition of viral protein pro-
duction (the read out for Figures 1 and 2B) was due
to inhibition of viral entry into cells. In order to infect
a cell and replicate, alphaviruses need to deliver their
RNA-containing capsid into the cytosol. Initially the virus
must bind to the cell surface, prior to internalization
by clathrin-mediated endocytosis (CME). Once in the
endosomal system, the low pH environment triggers con-
formational changes in the envelope glycoproteins (E1/E2)
to drive fusion of the viral and endosomal membranes and
capsid release to the cytosol (24). We tested each of these
aspects of the SFV entry pathway to determine the stage at
which IFITM3 restricts infection.
Initially, we investigated whether IFITM-HA expression
affected virus binding to the cell surface. Equal amounts
of virus were added to IFITM-HA expressing A549 cells
for 1 h at 4 ∘C, and the amount of bound virus determined
by western blotting whole cell lysates for E1/E2. Similar
amounts of bound virus were detected in IFITM negative
A549 cells and cells expressing each of the three IFITM-HA
proteins (Figure 4A).
Next, to investigate whether IFITM3-HA affected SFV
endocytosis, we measured virus uptake using a protease
resistance assay (9). SFV was bound to the surface of
cells as previously, and the cells then warmed to 37 ∘C
for 5, 15 or 30min to promote endocytosis. After each
time point, the cells were placed on ice and treated with
subtilisin (25). Samples were lysed and analyzed for
E1/E2 by western blot. To quantify uptake, the band
intensities of E1 (bottom) and E2 (top) were measured
across multiple experiments. Although subtilisin failed
to remove ∼22% of the surface virus, there was a clear
increase in subtilisin resistant virus on warming the
A549 cells to 37 ∘C (Figure 4B). This peaked at 15min
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Figure 3: IFITM2 and IFITM3 are found in endosomal compartments. OS-IFITM2-HA and IFITM3-HA cells were ﬁxed,
permeabilized and stained using an anti-IFITM3-NTD antibody, and markers of early and late endosomes and lysosomes. A)
Example images of cells co-stained for IFITM and transferrin receptor (TfR) and visualized with AF488 (IFITM – green) and AF647
(TfR – magenta) by confocal microscopy. Confocal sections are displayed. B) Example images of cells co-stained for IFITM (AF488) and
LAMP1 (AF647) and imaged as in (A). Nuclei were detected with Hoechst staining. Scale bars represent 15 μm. C and D) Colocalizations
of IFITMs with early endosome markers, TfR and EEA1, or late endosome/lysosome markers, CD63 and LAMP1, were quantiﬁed. Data
are from three independent experiments using between 18 and 21 ﬁelds of view collected using a 63× objective lens. Quantiﬁcation of
overlapping pixels and signiﬁcance testing is described in Materials and Methods. IFITM3-HA shows more overlap with TfR and EEA1
than IFITM2-HA. Conversely, IFITM2-HA shows greater overlap with CD63 and LAMP1 than IFITM3-HA. There are pixels that contain
just IFITM protein or just cellular marker, suggesting the IFITMs are not limited to single compartments. Bars show the mean pixel area
and error bars are the standard deviation. ****p< 0.0001.
when> 75% of the virus was internalized (Figure 4C).
Very similar uptake was seen on IFITM3-HA cells. We
conclude that IFITM3-HA expression does not affect
either binding, or internalization of SFV into A549
cells.
Internalized SFV colocalizes with IFITM3
Since we observed that IFITM3-HA is associated with
early endosomes (Figure 3), we investigated whether inter-
nalized SFV entered IFITM3-HA positive endosomes.
As above, virus was bound and internalized into cells,
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Figure 4: SFV binding to and internalization into IFITM expressing cells A) SFV (200 pfu/cell) was added to A549 cells or
OS-IFITM expressing cells (A, M1, M2, M3) at 4∘C. After 1 h, the cells were washed and analyzed by western blotting for the viral
envelope proteins. Tubulin was used as a loading control. The results indicate similar levels of binding to all four cell lines. B) SFV
(200 pfu/cell) was allowed to bind to cells at 4∘C for 1 h. Endocytic uptake of virus was promoted by warming to 37∘C for 0, 5, 15 or
30min. Cells were then treated with subtilisin at 4∘C to remove surface-bound virus, leaving only internalized virus associated with the
cells. In each blot, controls of samples not treated with subtilisin were loaded to indicate the total cell-associated virus. C) Quantiﬁcation
of E1 and E2 subtilisin resistant band intensity. 3–4 independent experiments were performed. Band intensities of E1 (bottom) and
E2 (top) were determined and adjusted based on tubulin band intensity for each sample. A measure of total cell-associated virus was
determined by averaging band intensity for all untreated time points. The intensity of E1 or E2 at each treated time point was then
set as a proportion of this total. Band intensities were averaged across experiments and plotted to display the percentage of subtilisin
resistant E1 or E2 at each time point.
which were then fixed and immuno-labeled for E1/E2
and IFITM3-HA and analyzed by confocal microscopy
(Figure 5). As a control, these experiments were repeated
in A549 cells that were stained for EEA1 instead of
IFITM3-HA (Figure S2). When kept at 4 ∘C (t= 0) or
warmed for 5min, virus particles were seen as faint
puncta primarily around the cell edges, and there was
little overlap with IFITM3-HA or EEA1. After 10min at
37 ∘C, and at later time points, SFV staining appeared
as larger, increasingly bright, punctae. The increase in
EEA1 puncta intensity seen in Figure S2 was also seen in
mock-infected cells (data not shown), suggesting this may
be due to cooling and warming cells. A time-dependent
increase in the overlap between E1/E2 and IFITM3-HA
(Figure 5B) or EEA1 (Figure S3B) was detected over
multiple experiments.These data suggest that endocytosed
SFV was delivered to IFITM3-HA positive endosomes.
These observations were further confirmed by electron
microscopy (EM), which revealed that SFV particles were
internalized by CME (Figure S3). Subsequently, SFV par-
ticles were detected in multivesicular bodies that could
be co-labeled for SFV and IFITM3-HA (Figure S4), fur-
ther demonstrating that virus particles were delivered into
IFITM3-HA containing endosomes.
To confirm that we were investigating time points relevant
to infection, the kinetics of SFV capsid release in A549
cells were determined. SFV penetration of endosomes is
low pH-dependent. Thus, ionophores such as monensin,
that rapidly dissipate cellular low pH gradients, can be
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Figure 5: Internalized SFV colocalizes
with IFITM3. A) SFV (50 pfu/cell) was bound
to cells at 4∘C for 1 h. After washing, the
cells were warmed to 37∘C for the indicated
times, then ﬁxed and labeled for SFV E1/E2
and OS-IFITM3-HA (via the HA-tag) and visu-
alized with AF488 (green, E1/E2) and AF647
(magenta, HA). Confocal sections are dis-
played. E1/E2 labelling can be seen as small
puncta mainly around the cell periphery at 0
and 5min, with little overlap of SFV E1/E2 and
IFITM3-HA. At later time points (10min and
onwards) larger and brighter puncta become
visible closer to the nucleus, and overlap of
SFV E1/E2 and IFITM3-HA is seen, which
increases with time. Many IFITM3-HA posi-
tive, SFV negative puncta, can be seen sug-
gesting that not all IFITM3-HA containing
endosomes receive virus. By contrast, many
SFV positive puncta co-label for IFITM3-HA
at 20 and 30min. Nuclei were detected with
Hoechst staining. Scale bar represents 15 μm.
B) The overlap between green (SFV E1/E2)
and magenta (HA) pixels was quantiﬁed (see
Materials andMethods). A total of three inde-
pendent experiments were performed, and six
images taken at 63× magniﬁcation for each.
The average ratio of the relative area of over-
lapping pixels (green and magenta) to green
pixels from each experiment is plotted, with
the standard deviation used for the error bars.
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Figure 6: SFV is exposed to acidic pH in IFITM3 expressing cells. SFV (200 pfu/cell) was bound to A549 (lanes 1–12) or
OS-IFITM3-HA expressing cells (lanes 13–18) at 4∘C for 1 h. The cells were then washed and either kept at 4∘C (lanes 1–4) or warmed
to 37∘C to allow virus uptake (lanes 5–18), as indicated. In lanes 3–4, cells with bound virus were brieﬂy (3 min) treated with pH 5.5
medium at 37∘C, or in lanes 5–6, were warmed to 37∘C for 30min in medium containing baﬁlomycin A1 (Baf A). Subsequently, all
cells were placed on ice, lysed with 1% Triton X-100 and half of the lysate treated with trypsin at 37∘C as indicated. All samples were
then analyzed by non-reducing SDS-PAGE and western blotting for SFV E1/E2 and tubulin as a loading control. Following a pH 5.5 pulse
(lanes 3–4), or incubation at 37∘C (lanes 7–18), a high MW band corresponding to the acid-induced, trypsin-resistant, E1 homotrimer
(HT) was seen. This band was absent at 0 min (lanes 1–2) and in Baf A-treated samples (lanes 5–6), indicating it is the low pH-induced
form of E1.
used in time of addition experiments to determine when
incoming virus has passed through the pH sensitive stage
of entry (26). Virus particles were bound toA549 cells prior
to warming to promote uptake, as previously. Monensin
was added at times between 0 and 30min. When added
at 0min, monensin nearly completely abolished infec-
tion (Figure S5). However, when added at later times, an
increasing percentage of cells became infected. By 30min,
monensin addition had almost no inhibitory effect (Figure
S5), suggesting the majority of infectious virus had pen-
etrated the cells. Therefore, analysing SFV internalization
within the first 30min of warming is relevant to infection.
SFV is exposed to acidic pH in IFITM3 expressing cells
We next investigated whether the viral glycoproteins
received the appropriate low pH trigger to become fuso-
genic in IFITM3-HA expressing cells. The acid-induced
conformational changes in the E1/E2 complex generate a
homotrimeric (HT) form of E1 that is resistant to trypsin
digestion (27). Again, SFV was bound to cells and allowed
to internalize for 0, 5, 15 or 30min at 37 ∘C. As a positive
control, virus particles bound to cells at 4 ∘C were treated
with pH 5.5 medium for 3min at 37 ∘C to activate the
fusion protein directly at the cell surface. As a negative
control, cells were pre-treated with bafilomycin A1 (Baf
A; a vacuolar ATPase inhibitor) for 15min at 37 ∘C, prior
to binding and internalization of virus particles in the
presence of Baf A. After appropriate treatments, cells were
lysed and the lysates treated with trypsin, or not, and the
viral E1/E2 proteins analyzed by western blot. Samples
were not heated prior to SDS-PAGE as this can dissociate
the E1 HT. With 0min of internalization, the monomeric
forms of E1 and E2 were seen with the expected molecular
weights (MW) of ∼50 kDa (Figure 6, lane 1). After trypsin
treatment of samples kept at 4∘C, the E1/E2 bands were
undetectable (lane 2). Transient low pH treatment of
surface-bound virus induced the formation of a high MW
band that was resistant to digestion with trypsin (lanes 3
and 4), corresponding to the E1 HT.This trypsin-resistant,
high MW band was seen, with increasing intensity, when
virus was allowed to internalize into A549 cells for 5, 15
or 30min (lanes 7–12), but not when virus was internal-
ized into Baf A treated cells (lanes 5 and 6). When SFV
was internalized into IFITM3-HA expressing cells the
trypsin-resistant, high MW band appeared with kinetics
similar to those seen in IFITM-negative A549 cells (lanes
13–18). We therefore conclude that IFITM3-HA does not
interfere with acidification of endosomes, virus trafficking
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to these compartments, or the conformational changes
necessary for the viral glycoprotein to become fusogenic.
IFITM3 expression inhibits release of SFV capsid to the
cytosol
The final step in the SFV entry pathway is release of the
capsid into the cytosol. To determine whether IFITM3
affects this step, SFV particles were bound and internalized
into cells, which were then analyzed by immunofluores-
cence staining for the SFV capsid protein. Between 0 and
20min, in both A549 and IFITM3-HA cells, punctae of
virus were seen at the cell surface and subsequently within
endosomes (Figure 7A), as observed by E1/E2 labelling
(Figures 5 and S3). In general the labelling was weak, even
after treatment with Triton, presumably because the capsid
protein is poorly accessible when packed within virions.
At 40min in A549 cells, diffuse cytosolic fluorescence
was seen, which was further increased at 60min. This
cytosolic fluorescence was not seen following SFV uptake
into monensin-treated A549 cells, or in IFITM3-HA cells,
suggesting the diffuse fluorescence is from viral capsid
protein released into the cytosol. To develop a more
quantitative analysis of this capsid release, images were
analyzed over multiple experiments to determine the
mean cytosolic fluorescence intensity in each cell. This
quantification indicated that over time there is an increase
in the cytosolic capsid protein-associated fluorescence
in A549 cells, that is not seen in monensin-treated A549
or IFITM3-HA cells (Figure 7B). In addition, in these
latter cells the punctae of SFV staining appeared brighter
at later times, suggesting that non-fused virus particles
accumulated within endosomes (Figure 7A). Together
these observations indicate that IFITM3-HA expression
inhibits release of SFV capsid into the cytosol.
IFITM1 and IFITM3 can inhibit SFV infection by fusion
at the plasma membrane
Our data indicate that IFITM3 is primarily localized
to early endosomes and can block SFV capsid release
into the cytosol. We therefore investigated whether
IFITM3-mediated restriction could be bypassed by fusion
of SFV at the cell surface, and whether plasma membrane
localized IFITM1 (20) or IFITM3-Y20A (Figure S1) could
restrict entry at this site. Cells were pre-treated with Baf A
for 15min at 37∘C to inhibit SFV entry via the endocytic
route, prior to binding virus to the surface at 4∘C for 1 h.
The cells were then treated with pH 5.5 medium for 3min
at 37∘C to induce fusion at the plasma membrane, prior to
returning to pH 6.8 medium containing Baf A for 5.5–6 h
at 37∘C to allow production of E1/E2 proteins as a read out
for infection. As controls, cells with bound virus were given
a 3min pH6.8 pulse and treated with DMSO or Baf A.
Through the normal endocytic route (pH 6.8 DMSO),
between ∼65% and ∼80% of A549 cells (OS, P1 and P2),
were infected with SFV (5 pfu/cell), and infection was
inhibited by>90% with Baf A treatment (pH 6.8 Baf A;
Figure 8A). When cells were pre-incubated with Baf A
and transiently treated with low pH medium, ∼20–50%
of cells were infected (pH 5.5 Baf A; Figure 8A). The
Baf A pre-treatment step did not affect the result, since
pre-treatment with DMSOmedia, followed by Baf Amedia
for the infection period (pH 5.5 DMSO/Baf A) showed
similar results. This bypass of Baf A inhibition with pH 5.5
treatment is the level of infection by direct fusion at the
plasma membrane. It appeared that the three A549 cells
had different permissiveness to infection by plasma mem-
brane fusion.TheparentalOS-A549 cells were the least per-
missive to plasmamembrane fusion; the P1-A549 cells (sta-
bly transfectedwith an empty puromycin resistance vector)
were the most permissive, while the P2-A549 cells (stably
transfected with a GFP construct) were in the middle. We
speculate that the differentmanipulations of these cellsmay
be responsible for the variability.
Virus entering through the endocytic route infected OS-
and P1-IFITM1-HA cells, similarly to A549 controls, and
Baf A inhibited this. When virus bound to the surface of
both OS- and P1-IFITM1-HA cells was transiently treated
with pH 5.5 medium, the infection percentage was con-
sistently lower than that seen in similarly treated A549
cells (Figure 8A). In the OS set, the fact that A549 con-
trol cells were not easily infected by plasma membrane
fusion meant that inhibition by IFITM1-HA was modest.
However, in the P1 set, the difference between infection by
plasma membrane fusion of A549 and IFITM1-HA cells
was much greater, arguing that IFITM1-HA can inhibit
plasma membrane fusion to some extent.
Plasma membrane localized P2-IFITM3-Y20A-HA did
not restrict SFV infection through the endocytic route
(Figures 8A and 2B). However, when surface-bound virus
was low pH treated, P2-IFITM3-Y20A-HA inhibited
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Figure 7: IFITM3 expression inhibits SFV
capsid release. A) SFV (200 pfu/cell) was bound
to cells for 1 h at 4∘C prior to incubation at
37∘C for the indicated times. At each time point
the cells were ﬁxed and permeabilized with 0.1%
Triton-X100 and labeled with serum against the
SFV capsid, which was detected with AF594. Con-
focal sections are displayed. Following internaliza-
tion, virus particles were detected in cells, indi-
cated by the typical punctate association of virus
with endosomes. By 40min after warm-up diffuse
cytosolic ﬂuorescence was seen in A549 cells, indi-
cating release of the viral capsid protein to the
cytosol. In A549 cells treated with 10 μMmonensin,
and in OS-IFITM3-HA expressing cells, the staining
remains associated with puncta and the cytoso-
lic staining was not observed even at 60min after
warm-up. Nuclei were detected with Hoechst stain-
ing. Scale bar represents 15 μm. B) Quantiﬁcation
of cytosolic ﬂuorescence and signiﬁcance testing is
described in Materials and Methods. The data are
from three independent infections with 3–7 images
taken at each condition, with a total of at least
60 cells analyzed per cell line, per condition. Data
presented is the average ﬂuorescence intensity, nor-
malized to the background intensity at 0 min of
warming. *p< 0.05, **p< 0.01.
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Figure 8: IFITM1 and IFITM3 can inhibit SFV infection by fusion at the cell surface. A) OS-, P1- and P2-IFITM-HA cells
were infected by SFV through plasma membrane fusion. Cells were pre-treated with either DMSO or baﬁlomycin A1 (Baf A) prior to
addition of SFV (5 pfu/cell) for surface binding at 4∘C for 1 h (in the presence of DMSO or Baf A). Surface-bound virions were then
allowed to enter cells by endocytosis (pH 6.8) or fused directly at the cell surface (pH 5.5). pH 6.8 media containing DMSO or Baf A
(matched to the pre-treatment) was then added to the cells, which were incubated for 5.5–6 h at 37∘C to allow infection. As a control
for the Baf A pre-treatment, cells were instead pre-treated with DMSO, then incubated with Baf A containing media for the infection
period (pH 5.5 D/B). Cells were ﬁxed and infection determined by immunoﬂuorescence microscopy. Baf A inhibited infection through
the endocytic route (black bars compared to white bars). Low pH treatment resulted in bypass of Baf A inhibition, indicative of cell
surface fusion (green and magenta bars). The bars indicate the mean infection percentages from three independent experiments (each
containing triplicates for each sample) with standard deviation shown as the error bars. Statistical signiﬁcance was determined using
normalized infection values, comparing pH 5.5 DMSO/Baf A (green) or pH 5.5 Baf A (magenta) of A549 samples with IFITM samples, as
detailed in the Materials and Methods section. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001. B) OS-, P1- and P2-IFITM-HA
cells were labeled with anti-HA antibodies either intact (I) or following permeabilization (P), detected with AF647, and analyzed by
ﬂow cytometry to determine the relative levels of cell surface IFITM protein. As controls, cells were either incubated with no antibody
or secondary antibody only. The mean ﬂuorescence intensity (MFI), relative to the no antibody control for each cell line is displayed.
Plots are representative of 3–4 independent experiments.
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infection by ∼95% (Figure 8A). This inhibition is
greater than that seen for either OS- or P1-IFITM1-HA
(Figure 8A), even though P2-IFITM3-Y20A-HA expres-
sion levels were lower than those of IFITM1-HA
(Figure 2A).
Endocytic infection was low in all IFITM3-HA cells, with
OS-IFITM3-HA being the most restrictive (Figure 8A as
in Figures 1 and 2B). Baf A reduced this low level infection
to< 1%. Surprisingly, there was no increase in infection of
these cells following pH5.5 treatment of cell surface-bound
virus, and the infection was consistently lower than that
seen in all A549 cells (Figure 8A). Indeed, OS-IFITM3-HA
had the lowest infection percentages, even lower than
either OS- or P1-IFITM1-HA. IFITM3-HA also inhibited
SFV infection via plasma membrane fusion in the P1- and
P2- cells to a similar extent to that seen with IFITM1-HA.
It was interesting to see such potent inhibition of cell
surface fusion by IFITM3-HA since immunofluorescence
microscopy indicated that the majority of IFITM3-HA
is located in endosomal compartments (Figure 3) rather
than at the cell surface. To confirm these observations,
cells were stained either intact, or following permeabi-
lization, and analyzed by flow cytometry to determine
levels of each IFITM protein at the cell surface. Anti-
bodies against the C-terminal HA-tag were used as we,
and others, have shown the IFITM proteins to have
a type-II transmembrane topology with the C-terminal
domain facing the extracellular space (20,28,29).Themean
fluorescence intensity (MFI) of labeled OS-IFITM1-HA,
P1-IFITM1-HA and P2-IFITM3-Y20A-HAwas essentially
equivalent between intact and permeabilized cells, suggest-
ing the HA-tag is accessible at the cell surface (Figure 8B).
Conversely, for all three IFITM3-HA cases, significant
labelling was only detected when cells were permeabilized,
suggesting the majority of IFITM3-HA is in intracellular
pools (Figure 8B). TheMFI of intact IFITM3-HA cells was
slightly above background levels, suggesting some surface
IFITM3-HA (as we have previously observed (20)),
Overall, despite low levels of cell surface expression
(Figure 8B), IFITM3-HA inhibited SFV infection by fusion
at the plasma membrane to a similar or greater extent than
IFITM1-HA (Figure 8A). Presumably IFITM3-HA that
transiently transits the cell surface en route to endosomes
is responsible for this inhibition (20,21,30). From this, we
conclude that IFITM3-HA is a more potent inhibitor of
SFV fusion than IFITM1-HA.
Discussion
IFITM proteins restrict the replication of a wide range
of enveloped viruses, and at least one non-enveloped
virus (22,23). However, to date there is little evidence
that IFITMs restrict alphavirus infection. Here we show
that IFITM3, and to a lesser extent IFITM2, can inhibit
the replication of two alphaviruses in A549 cells. Using
SFV, we show that virus binding, endocytosis, delivery to
endosomes and exposure to acidic pH are unaffected by
IFITM3 expression. The viral envelope proteins undergo
an acid-dependent conformational change with similar
kinetics in IFITM3 expressing and non-expressing cells.
However, the viral capsid protein does not appear in the
cytosol of IFITM3 expressing cells. These results indi-
cate that IFITM3 restricts SFV infection by inhibiting
endosomal fusion and/or uncoating of the viral capsid.
To date the broad antiviral activity of IFITMs has been
largely seen through the use of retrovirus-based pseudo-
type reporter systems (22). However, for influenza A virus
(IAV) the inhibitory activity of IFITM3 has been better
characterized and appears to occur following virus endo-
cytosis and delivery to endosomes, but prior to detection of
the viral RNA in the nucleus (1). Nevertheless, the precise
mechanism(s) of IFITM3-mediated restriction remains
unclear. Based on lipid mixing assays, Desai et al. suggest
that IFITM3 inhibits IAV genome release from endosomes
after the formation of hemifusion intermediates (4). While
Li et al. suggest that IFITM proteins inhibit the initial lipid
mixing events leading to hemifusion, based on cell–cell
fusion experiments with IAV and the retrovirus JSRV (3).
Our experiments with SFV indicate that virus delivery to
acidic endosomes and the initial steps in the fusion reac-
tion, including low pH-induced conformational changes in
the viral envelope protein are unaffected by IFITM3. Nev-
ertheless, delivery of the capsid to the cytosol is blocked,
suggesting that IFITM3 inhibits membrane fusion or, pos-
sibly, uncoating after fusion has occurred.
It is interesting to note that IFITM1 did not inhibit endo-
cytic entry of either alphavirus since many other viruses
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show at least some sensitivity to this protein (22). Fur-
thermore, dengue virus, a type II fusion protein express-
ing virus, similar to alphaviruses, is restricted by IFITM1,
2 and 3 (17). We speculate endocytic uptake and fusion
with early endosomes allows SFV to escape inhibition
from the plasma membrane localized IFITM1, in this
system. However, why the endocytic route of alphavirus
entry is not inhibited by IFITM1, while other endocytosed,
low pH-dependent viruses (such as dengue) are inhibited,
remains unclear.
Previously the effect of IFITM protein expression on SFV
E1/E2-mediated fusion from within (cell–cell fusion facil-
itated by E1/E2 expressed on the cell surface and exposure
of cells to low pH medium) was reported (3). In that study
IFITM1 and IFITM3 were found to inhibit syncytium for-
mation. In agreement, we also see that both IFITM1 and
IFITM3 can inhibit infection by SFV, when virus is fused at
the cell surface. Immunofluorescence (Figure 3 and (20)),
EM (data not shown) and flow cytometry (Figure 8B) show
lower levels of IFITM3 at the cell surface than IFITM1.
It is therefore interesting that IFITM3 seems to be able
to inhibit infection by cell surface fusion to an equiva-
lent or greater extent than IFITM1 (Figure 8A). Further-
more, when IFITM3 is relocated to the plasma mem-
brane (IFITM3-Y20A) greater inhibition of infection was
seen compared to IFITM1 (Figure 8A). We conclude that
IFITM3 has greater potency for inhibiting SFV fusion
than IFITM1. Understanding this difference may provide
insights to the mechanism(s) underlying the ability of
IFITMs to restrict viral replication.
Finally, we observed that the antiviral action of IFITM3
can be saturated by increasing the amount of virus, and is
also influenced by the level of IFITM protein expression
(Figures 1 and 2). Type I interferon treatment of A549 cells
results in similar levels of IFITM expression as seen in the
P1 and P2 cell sets (data not shown).This ability to saturate
IFITM3 restriction could be explained if there is a level of
direct interaction between IFITM3 and SFV fusion sites.
Whether IFITM3 is recruited to sites of membrane fusion,
or is localized to specificmembrane domains conducive for
fusion, remains to be established.
With the wealth of experimental data on SFV mem-
brane fusion, using alphaviruses as a model may aid our
understanding of the molecular mechanism(s) underlying
IFITM-mediated inhibition of viral infection. Elucidating
these mechanisms may help to generate novel therapeutic
strategies that could be applied against a broad range of
both human and animal pathogens, and to further our
understanding of membrane fusion, a phenomenon that
underpinsmanymore biological functions than viral entry.
Materials and Methods
Cell lines and viruses
The previously described (19,20) original set (designated OS) of A549
cells stably expressing C-terminal HA-tagged human IFITM1, 2 or 3, were
cultured in Ham’s F-12 GlutaMAX media (all cell culture reagents were
from Life Technologies, unless otherwise stated), supplemented with 10%
(v/v) foetal calf serum [FCS (PAA)] and 1% (v/v) Penicillin/Streptomycin
(Pen/Strep, 10 000 units/mL, 10 000 μg/mL), as previously described (20).
The puromycin 1 (P1) set of cells, which consists of A549 cells sta-
bly expressing an empty puromycin resistance vector or C-terminal
HA-tagged IFITM1, 2 or 3, and the puromycin 2 (P2) set of cells, which
consists of A549 cells stably expressing GFP or C-terminal HA-tagged
IFITM3 or IFITM3-Y20A, were cultured in the same conditions. BHK-21
cells were cultured in Glasgow-MEM supplemented with 5% FCS, 1%
Pen/Strep and 10% (v/v) tryptose phosphate broth (Sigma).
SFV stocks were prepared as described (8). Briefly, BHK-21 cells were
infected with SFV at an MOI of 0.05 pfu/cell and cultured for 22 h
(h). Supernatants were collected and cleared of cellular debris by low
speed centrifugation and the virus concentrated by ultracentrifugation
(100,000× g for 2.5 h at 4 ∘C). Virus pellets were resuspended in TNbuffer
(100mM NaCl, 50mM Tris pH 7.6) and stored at −80∘C. Virus infectivity
was determined on BHK-21 cells by serial dilution plaque assay.
Sindbis virus (SINV)AR339 (a kind gift fromDr. PennyPowell, University
of East Anglia, Norwich, UK) stocks were prepared as for SFV.
Antibodies
Rabbit sera against the SFV envelope glycoprotein (E1/E2) and the
capsid protein were previously described (31). Rabbit anti-SINV sera
was provided by Dr. Penny Powell (University of East Anglia, Norwich,
UK). Rat anti-HA (clone 3 F10, Roche), mouse anti-HA (clone HA.11
16B12, Covance), rabbit anti-IFITM1-N-terminal-domain (NTD),
rabbit anti-IFITM3-NTD, mouse anti-tubulin, goat anti-rabbit Alex-
aFluor (AF)488, goat anti-rat AF647, goat anti-rabbit IRDye 680 and
goat anti-mouse IRDye 800 were all previously described (20). Mouse
anti-transferrin receptor (TfR, 1mg/mL, clone MEM-189, Abcam),
mouse anti-EEA1 (250 μg/mL, BD Biosciences), mouse anti-CD63 (32),
goat anti-rabbit AF594 and goat anti-mouse AF647 (both 2mg/mL, Life
Technologies). All antibodies were diluted as described below.
Viral infections
To infect A549 cells, virus was diluted to the required MOI in F-12 infec-
tion media [F-12 media supplemented with 0.2% (w/v) bovine serum
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albumin (BSA) and 10mM HEPES (both Sigma), pH 6.8], and incubated
with cells for 5.5–6 h at 37 ∘C. Infected cells were detected by immunoflu-
orescence staining, as described below, using antibodies against the viral
envelope glycoproteins. An Opera confocal microscope (Perkin-Elmer)
was used to image cells and the number of infected cells counted using
the COLUMBUS software (Perkin-Elmer).
Virus binding to the cell surface
SFV particles were bound to the cell surface to promote synchronous
internalization in the indicated experiments. Virus was diluted in 4 ∘C
bindingmedia [BM: RPMImediumwithout bicarbonate (Sigma), supple-
mentedwith 0.2%BSA, 10mMHEPES and 10mMMES (Sigma) at pH 6.8]
and added to cells at the indicated MOIs for 1 h with gentle shaking. The
cells were then rinsed twice with cold BM to remove unbound virus, prior
to any further treatment, as detailed below.
SFV internalization
SFV internalization into cells was analyzed by immunofluorescence and
EM (described below) or biochemically. For light microscopy analysis,
SFV was bound to cells at an MOI of 50 or 200 pfu/cell prior to treatment
with pre-warmed pH6.8 BM and incubation at 37∘C for the indicated
times. Cells were then fixed, permeabilized and stained for E1/E2 or the
capsid protein.
For the biochemical investigation of internalization, SFV (200 pfu/cell)
was bound to cells at 4∘C. The cells were then washed and warmed for
the indicated times, or left on ice. Surface-bound virus was removed by
treatment with subtilisin [2mg/mL in PBS (Sigma)] for 1 h at 4∘C with
gentle shaking. Subtilisin was inactivated by addition of 1mM PMSF in
PBS with 30mg/mL BSA. Cells were collected and washed with PBS
containing 0.2% (w/v) BSA to remove detached virus. Internalized virus
was then measured by western blot analysis of SFV E1/E2 in whole cell
lysates. Subsequently, the band intensities were quantified: A measure
of total cell-associated virus was determined by averaging the E1 or E2
band intensities at each time point, without subtilisin treatment. The E1
or E2 intensity at each subtilisin treated time point was then set as a
proportion of this averaged total, thus giving a percentage of subtilisin
resistant (internal) E1 or E2. All intensity values were adjusted based on
the tubulin loading control. These values were calculated and averaged
over 3–4 experiments.
SFV endosomal penetration
To determine the kinetics of endosomal penetration in A549 cells, 5
pfu/cell SFV was added and allowed to bind. Subsequently, F-12 infection
media, pre-warmed to 37∘C, containing DMSO or 10 μM monensin, was
added to cells (t= 0). At indicated time points between 3 and 30min,
DMSO media was replaced with F-12 infection media containing 10 μM
monensin. Cells were then incubated at 37∘C for 5.5–6 h, after which they
were fixed and analyzed for infection by immunofluorescencemicroscopy
for the E1/E2 proteins.
Immunoﬂuorescence staining and microscopy and ﬂow
cytometry
Immunofluorescence staining and microscopy was performed as previ-
ously described (20) with the exception that 0.1% Triton-X100 (Tx100,
Sigma) was used for permeabilization in experiments to detect the SFV
capsid protein.
For flow cytometry, cells were detached from plates using 5mM EDTA
and fixed in suspension with 3% formaldehyde for 15min at room tem-
perature. Formaldehyde was quenched with 50mM NH4Cl in 0.2% BSA
diluted in PBS (PBS/BSA) for 15min at room temperature. Samples were
then permeabilized with 0.05% saponin in PBS/BSA [permeabilization
buffer (PB)] or incubated with PBS/BSA alone for 30min at room tem-
perature, prior to labelling with rat anti-HA antibody for 1 h at room
temperature (either in PB or PBS/BSA as appropriate). Cells were washed
3× with the appropriate solution and labeled with goat anti-rat AF647 for
45min at room temperature. As controls, samples were incubated with no
antibodies, or incubated with only AF647. Cells were washed 3×with PBS
and subject to flow cytometry (LSR-II; BD Bioscience). Cells were gated
on forward and side scatter and analyzed for fluorescence intensity. Data
were processed using FLOWJO (v10.1r5) software (Tree Star).
Antibodies were used at the following pre-determined dilutions
form stocks (listed above): anti-HA 1:100, anti-IFITM1-NTD 1:200,
anti-IFITM3-NTD 1:200, anti-SFV E1/E2 1:500, anti-SFV capsid 1:500,
anti-SINV E1/E2 1:500, anti-TfR 1:200, anti-EEA1 1:200, anti-CD63
1:10 000 and anti-LAMP1 1:500. All secondary antibodies were used at
1:500.
Image analysis
Image analysis of colocalization between IFITM-HA and cellular markers
was performed using IMAGEJ software as previously described (20). For
the analysis of SFV E1/E2 colocalization with EEA1 or IFITM3-HA this
procedure was slightly altered. Confocal sections were acquired and the
multi-channel images of E1/E2 (green) co-stained with HA or EEA1
(magenta) were split into the component channels. These images were
processed with an ‘AND’ function to generate a new image containing
only pixels that are both green AND magenta (‘overlapping pixels’). A
threshold was set to remove background fluorescence, and the area of the
remaining pixels was quantified. These ‘overlapping pixels’ were removed
from the E1/E2 image, a threshold set, and the area of the remaining ‘green
pixels’ was quantified. Relative pixel areas were then used to calculate the
ratio between ‘overlapping pixels’ and ‘green pixels’ to determine the level
of overlap between E1/E2 and the cellular proteins.
To quantify the SFV capsid cytosolic fluorescence, confocal sections were
collected as displayed in Figure 7A and analyzed using IMAGEJ software
as follows: The channels containing the nuclei and capsid staining were
separated. Nuclei were segmented and any signal in the capsid channel
that fell within the nuclei area was assumed to be non-specific and
removed from the image. A threshold was then applied to these capsid
images to only detect virus puncta, which were similarly removed, and the
remaining signal was deemed to be cytosolic. Individual cells were then
segmented and the mean fluorescence in each cell calculated.
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Significance testing was performed using unpaired student’s T-tests and
GRAPHPAD PRISM software to compare the mean values of overlapping
pixels for colocalization or the difference between mean capsid cytosolic
fluorescence.
Electron microscopy
Epon section EM: 1000 pfu/cell SFV was added to cells grown on cov-
erslips and allowed to bind as above. Cells were subsequently washed
and warmed to allow internalization for the indicated times. The cover-
slips were fixed in EM-grade 2% paraformaldehyde/2% glutaraldehyde
(TAAB Laboratories Equipment, Ltd.) in 0.1 M sodium cacodylate, secon-
darily fixed for 1 h in 1% osmium tetraoxide/1.5% potassium ferricyanide
at 4∘C and then treated with 1% tannic acid in 0.1 M sodium cacody-
late for 45min at room temperature. Samples were then dehydrated in
sequentially increasing concentration of ethanol solutions, and embedded
in Epon resin. Coverslips were inverted onto prepolymerized Epon stubs
and polymerized by baking at 60∘C overnight. The 70 nm thin sections
were cut with a Diatome 45∘ diamond knife using an ultramicrotome
(UC7; Leica). Sections were collected on 1× 2mm formvar-coated slot
grids and stained with Reynolds lead citrate.
Immunolabelling EM: 5000 pfu/cell SFV was added to cells and allowed
to bind and internalize as above. As previously described (20), cells were
fixed with EM-grade 4% (w/v) paraformaldehyde in 0.1M phosphate
buffer pH 7.4, infused with 2.3 M sucrose, supported in 12% (w/v) gelatin
and frozen in liquid nitrogen. Ultrathin (70 nm) cryosections were cut at
−120∘C and picked up in 1:1 2.3 M sucrose: 2% methylcellulose. Sections
were labeled with primary antibody (mouse anti-HA 1:400), followed
by rabbit anti-mouse intermediate antibody (1:180, DAKO) and protein
A-gold. For double labelling experiments, sections were treated with
1% glutaraldehyde in PBS after the first protein A-gold incubation and
quenched in 15mMglycine before repeating the single labelling procedure
with the second primary antibody (anti-E1/E2) and a different sized
proteinA-gold, as described (33). Finally, sectionswere contrast stained in
1:9 solution of 4% uranyl acetate: 2% methylcellulose solution pH4.0. All
samples were imaged using a transmission electron microscope (Tecnai
T12; FEI) equipped with a charge-coupled device camera (SIS Morada;
Olympus).
Antibodies were used at the following pre-determined dilutions from
stocks (listed above): SFV E1/E2 1:50, mouse anti-HA 1:400.
SFV plasma membrane fusion
Cells, in a 96 well plate format, were pre-incubated with either DMSO or
100 nM bafilomycin A1 (Baf A) in BM for 15min at 37∘C. Cells were then
placed on ice and washed with cold BM containing DMSO or Baf A prior
to addition of 5 pfu/cell SFV to bind to the cell surface (in the presence
of Baf A or DMSO). The cells were washed to remove unbound virus and
treated with 37∘C BM (containing DMSO or Baf A) adjusted to pH 5.5 for
3min (or pH 6.8 as control), to trigger viral fusion at the cell surface. Cells
were subsequently incubated for 5.5–6 h in F-12 infectionmedia contain-
ing DMSO or Baf A. Control samples, pH 6.8 DMSO, were treated with
F12 infection media containing DMSO, allowing viral entry through the
normal endosomal route. Cells pre-treated with Baf A and pH6.8 media
were incubated with infection media containing Baf A, allowing endo-
cytosis but inhibiting low pH-induced viral fusion in endosomes. Cells
pre-treatedwith Baf A and given a pH 5.5 pulse were incubatedwith infec-
tion media containing Baf A to trigger fusion at the plasma membrane,
while inhibiting acidification of endosomes, such that the low pH trigger
was only received at the plasma membrane. Cells pre-treated with DMSO
and given a pH 5.5 pulse were incubated with infection media contain-
ing Baf A, to again block endosomal acidification and as a control for Baf
A pre-treatment. Infected cells were detected by immunofluorescence, as
described above, using antibodies against E1/E2. Three random epifluo-
rescence images, at 20×magnification, were taken for each well and ana-
lyzed for infection percentage using IMAGEJ software. Briefly, nuclei were
segmented to detect the total number of cells per field. The segmented
nuclei were super-imposed on the fluorescence channel marking infected
cells (E1/E2 stained cells) and a ring of 10 pixels was expanded around
each super-imposed nuclei. The E1/E2 fluorescence intensity within this
ring was used to score cells as infected or uninfected. The percentage of
infected cells was determined for each image and used to determine the
percentage of infected cells per well. All infectionswere carried out in trip-
licate wells, and the mean infection percentage calculated. In order to test
statistical significance of inhibition all infection percentages were set rel-
ative to the A549 pH6.8 DMSO condition within each cell line set (such
that OS-IFITMs were only compared to OS-A549, for example), thus giv-
ing a measure of the relative infection percentage induced by the pH 5.5
treatments. The difference in relative infection percentages was then ana-
lyzed across experiments using unpaired student’s T-tests in GRAPHPAD
PRISM software to compare the difference in relative infection percentage
from pH5.5 treatments in A549 controls against IFITM expressing cells.
SFV E1 trypsin insensitivity
Cells were initially pre-incubated with either DMSO or 100 nM Baf A in
BM as described for SFV plasma membrane fusion. Virus was added at
an MOI of 200 pfu/cell. Where indicated, cells with bound virus were
warmed to 37∘C to allow virus uptake (with Baf A as labeled), briefly
(3min) treated with pH 5.5 BM, or left on ice. Cells were lysed in 60 μL 1%
Tx100 in PBS for 15min on ice, and the nuclei removed by centrifugation.
40 μL of cell lysate were divided in two. One sample was mixed with 20 μL
trypsin [800 μg/mL in 1% Tx100 (Sigma)] and incubated for 10min at
37 ∘C, the other with 20 μL 1% Tx100. Both samples were then mixed
with 20 μL of soybean trypsin inhibitor [2mg/mL (Sigma)]. Finally, 6×
non-reducing Laemmli sample buffer (LSB) was added and an equal
volume of each sample was separated by SDS-PAGE and western blotted
for SFV E1/E2, as described below. Samples were not heated prior to
SDS-PAGE to maintain the E1 homotrimer.
Western blotting
Unless otherwise indicated, cell lysates were produced by incubating
cells with Tx100 lysis buffer [1% (v/v) Tx100, 150mM NaCl, 50mM
Tris–HCl at pH 8.0] containing 1× complete protease inhibitor cocktail
(Roche) for 15min on ice. Nuclei were removed by centrifugation and the
protein concentrations determined using the bicinochoninic acidmethod
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(Thermo Scientific). Equal amounts of protein for each sample were
mixed with 3× LSB containing 100mM dithiothreitol (unless otherwise
indicated). Samples were separated on 10% or 15% SDS-PAGE gels,
transferred to PVDFmembranes (Immobilon-FL,Millipore), and blocked
with 5% (w/v) milk powder (Marvel) in Tris-buffered saline (pH 7.4) with
0.05% Tween-20 (TBST) for 1 h at room temperature. The membranes
were incubated with primary antibodies overnight at 4 ∘C, washed with
TBST and probed with appropriate secondary antibodies conjugated to
Li-COR IRDye fluorophores at room temperature before imaging on a
Li-COR Odyssey system. Quantification of band fluorescence intensity
was performed using the ODYSSEY software.
Antibodies were used at the following pre-determined dilutions from
stocks (listed above): anti-SFV E1/E2 1:1000, anti-IFITM1-NTD 1:1000,
anti-IFITM3-NTD 1:500, anti-VDAC 1:300, anti-tubulin 1:1000. Both
Li-COR secondary antibodies were used at 1:10 000.
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Figure S1: IFITM3 Y20A localizes to the plasma membrane.
P2-IFITM3-HA (wild type; WT) and P2-IFITM3-Y20A-HA cells
were fixed, permeabilized and labeled with anti-IFITM1-NTD anti-
bodies (which cross-react with IFITM3) followed by AF488 (green).
The images were captured using an epifluorescence microscope. WT
IFITM3 was seen in intracellular compartments (also see Figure 3),
where as IFITM3-Y20A-HA was seen at the plasma membrane. Nuclei
were detected with Hoechst staining. Scale bar represents 15 μm.
Figure S1 – Associated with Figures 2 and 8. The figure displays the
localization of the IFITM3-Y20A mutant, compared to wild type. This
localization has been published by others, and is included here as a
demonstration of the plasma membrane localization of the mutant in this
system.
Figure S2: Internalized SFV colocalizes with EEA1.A) SFV (50 pfu/cell)
was bound to A549 cells for 1 h at 4∘C prior to warming for the indicated
periods to promote endocytic uptake. Cells were then fixed and labeled
for SFV E1/E2 and EEA1, and visualized with AF488 (green, E1/E2) and
AF647 (magenta, EEA1). Single confocal sections are displayed. As seen
in Figure 5, E1/E2 labelling at 0 and 5min was seen as small puncta.
At later time points following endocytosis, larger and brighter puncta
were seen. EEA1 and E1/E2 were seen to overlap from 10min, indicating
trafficking of SFV to early endosomes. The apparent increase in EEA1
intensity with time was also seen in mock-infected samples (data not
shown), and may be due to cooling and warming the cells. Nuclei were
detectedwithHoechst staining. Scale bar represents 15 μm.B)Theoverlap
between green (SFV E1/E2) and magenta (EEA1) pixels was quantified
over multiple experiments (see Materials and Methods). A total of three
independent experiments were performed, and six images taken at 63×
magnification. The average ratio of the relative area of overlapping pixels
(green andmagenta) to green pixels from each experiment is plotted, with
the standard deviation used for the error bars. Figure S2 – Associated
with Figure 5. This figure is equivalent to the data in Figure 5, but is
performed in the control A549 cells, stained for EEA1 and SFV, rather
than staining for IFITM3-HA as in Figure 5.
Figure S3: EM imaging of SFVuptake. SFV (1000 pfu/cell) was bound to
A549, or OS-IFITM3-HA expressing cells for 1 h at 4∘C prior to warming
for the indicated periods to promote endocytic uptake. Samples were fixed
and processed for Epon section EM, as detailed inMaterials andMethods.
Virus particles were seen at the plasmamembrane at 0min, then in coated
vesicles after 5min at 37∘C. By 20 and 30min, virus particles appear
in endosomal structures, but it was hard to distinguish viral particles
from other intraluminal vesicles. Figure S3 – Associated with Figure 5.
This figure displays Epon EM micrographs for SFV internalization to
complement the IF data of Figure 5.
Figure S4: Immuno-gold labelling of cryosections and EM imaging
of SFV uptake. SFV (5000 pfu/cell) was bound to cells and allowed
to internalize, prior to processing for cryosectioning and immunogold
labelling. A) Sections were labeled with antibodies against SFV E1/E2.
Viral particles were detected at the cell surface at 0min. By 30min
viral particles were found within multivesicular bodies in both A549
and OS-IFITM3-HA expressing cells. B) Sections were labeled for SFV
E1/E2 and the HA-tag. The primary antibodies were detected with 10 nm
colloidal gold (SFV) or 15 nm colloidal gold (HA) conjugated secondary
antibodies. There was minimal HA background detected in the A549
cells, whereas most HA labelling in the IFITM3-HA cells was associated
with multivesicular bodies, where SFV particles were detected following
30min at 37∘C. Scale bars represent 200 nm. Figure S4 – Associated with
Figure 5. This figure displays immuno-gold labeled cryosections and EM
micrographs for SFV internalization to complement the IF data of Figure 5
Figure S5: Kinetics of SFV penetration into A549 cells. SFV (5 pfu/cell)
was bound to A549 cells for 1 h at 4∘C prior to warming to 37∘C
with media containing DMSO or 10 μM monensin to allow endocytic
uptake. At time points between 3 and 30min, DMSO containing media
was replaced with media containing monensin. After 5.5–6 h infection,
the cells were fixed and analyzed for infection by immunofluorescence
microscopy. The data show the percentage of infected cells compared to
DMSO controls. Although monensin added at early time points effec-
tively inhibited infection, addition at 30min had almost no effect.Thedata
displayed are mean infection percentage from three independent infec-
tions (each containing duplicates of each sample) with standard deviation
between experiments as error bars. Figure S5 – Associated with Figures 4
and 5, 6 and 7. This figure details the results for the monensin time of
addition experiment to determine the time course for SFV passing the
pH-dependent step of entry.
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